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Artemisinin is herbal drug with a wide range of biological and physiological function. It is 
currently administered in the treatment against uncomplicated F.Palcifarum infections. It has 
also been shown to be cytotoxic against a variety of cancer cells. Despite the promise of many 
anti cancer drugs, drug induced cardiotoxicity has constantly threatened drug applicability 
especially in patients with co-morbities. Artemisinin has been shown to be cardioprotective, 
although the intracellular pathways remain to be elucidated.  
 
In this study, isolated perfused rat hearts were subjected to 35 minutes of ischaemia and 120 
minutes reperfusion or primary cardiac myocytes subjected to 120 minutes hypoxia and 120 
minutes reoxygenation where artemisinin (4.3µM) was administered in presence and absence 
of the PI3K inhibitor (wortmannin) (0.1µM), p70S6K inhibitor (rapamycin) (0.1µM), non 
selective nitric oxide synthase inhibitor (L-NAME) (100µM) and inducible nitric oxide 
synthase inhibitor (aminoguanidine) (100µM). At the end of the experiment, hearts underwent 
infarct size to risk ratio assessment via tri-phenyltetrazolium chloride staining or western blot 
analysis for p-Akt and p70S6K. Cardiac myocytes were assessed for either MTT analysis, 
cleaved-caspase 3 or for eNOS/iNOS or p-BAD activity using flow cytometry.  
In isolated hearts, artemisinin (0.1µM-100µM) showed a significant dose dependent decrease 
in infarct size (P<0.01-0.001 vs. I/R control). It was also shown to significantly improve 
cellular viability (66.5±6.3% vs. 29.3±6.1% in H/R, P<0.01) and decrease the levels of cleaved 
caspase-3 compared to the H/R control group (17.1±2.0% vs. 26.8±2.0% in H/R, P<0.001). 
Artemisinin was shown to confer protection via the activation of the PI3K-Akt-p70S6k cell 
survival pathway and presented an upregulation in p-eNOS and iNOS expression. Furthermore, 
co-administering artemisinin with doxorubicin showed artemisinin reverses I/R or H/R injury 
as well as doxorubicin-induced injury via the nitric oxide signalling pathway. Additionally, in 
HL-60 cells, the co-administration doubled artemisinins cytotoxicity while also implicating the 
nitric oxide pathway. This is the first study to shows that artemisinin ameliorates doxorubicin 
mediated cardiac injury whilst enhancing its cytotoxicity in HL-60 in a nitric oxide dependent 
manner. This study concluded that artemisinin was both anti apoptotic and protective against 
myocardial I/R injury via the PI3K-Akt-BAD/P70S6K and via the nitric oxide cell survival 
pathway as well as pro-apoptotic against HL-60 in a nitric oxide dependent manner. 
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0.43µM or EC80: 4.3µM). Data expressed as a % of mean stabilisation±SEM. artemisinin 
(4.3µM) *P<0.05 vs. I/R control, artemisinin (4.3µM) **P<0.01 vs. I/R control (n= 4-8). 
Figure 22. The effects of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM) on H/R 
in isolated perfused hearts subjected to 20 minutes of stabilisation, 35 minutes and ischaemia 
and 120 minutes reperfusion in the presence/absence of artemisinin (EC20: 0.042µM, EC50: 
0.43µM or EC80: 4.3µM). Data expressed as a % of mean stabilisation±SEM. (n= 4-8). 
Figure 23. The effects of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM) on CF in 
isolated perfused hearts subjected to 20 minutes of stabilisation, 35 minutes and ischaemia and 
120 minutes reperfusion in the presence/absence of artemisinin (EC20: 0.042µM, EC50: 0.43µM 
or EC80: 4.3µM). Data expressed as a % of mean stabilisation±SEM.*P<0.05 vs I/R control) 
(n= 4-8). 
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Figure 24. The effects of artemisinin (4.3µM) on infarct to risk ratios in isolated perfused rat 
heart model subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion in the presence/absence of artemisinin (4.3µM) which was administered 
throughout reperfusion. Results were expressed as Mean±SEM (***P<0.01 vs. I/R control) 
(n=6). 
Figure 25. Mean fold changes in the differential expression of miRNA-1 in hearts subjected to 
20 minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the 
presence/absence of artemisinin (4.3µM) where administered throughout reperfusion. Results 
were expressed as Mean±SEM. (*P<0.05 vs I/R Control) (n=3-4). 
Figure 26. Mean fold changes in the differential expression of miRNA-27a in artemisinin 
(4.3µM) treated hearts compared to I/R control. Hearts were subjected to 20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the presence/absence of 
artemisinin (4.3µM) administered throughout reperfusion. Results were expressed as 
Mean±SEM. (n=3-4). 
Figure 27. Mean fold changes in the differential expression of miRNA-133a in artemisinin 
(4.3µM) treated hearts compared to I/R control. Hearts were subjected to 20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the presence/absence of 
artemisinin (4.3µM) which was administered throughout reperfusion. Results were expressed 
as Mean±SEM (**P<0.01 vs. IR control) (n=3-4). 
Figure 28. Mean fold changes in the differential expression of miRNA-133b in artemisinin 
(4.3µM) compared to control. Hearts were subjected to 20 minutes stabilisation, 35 minutes 
ischaemia and 120 minutes reperfusion in the presence/absence of artemisinin (4.3µM) which 
was administered throughout reperfusion. Results were expressed as Mean±SEM (n=3-4).   
Figure 29. Mean fold changes in the differential expression of miRNA-155 in artemisinin 
(4.3µM) treated hearts compared to I/R hearts. Hearts were subjected to 20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the presence/absence of 
artemisinin (4.3µM) which was administered throughout reperfusion. Results were expressed 
as Mean±SEM (n=3-4).  
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Figure 30. % Effect of administration of artemisinin (Art) (4.3µM) on cleaved casapase-3 levels 
as analysed by Flow cytometry. Results were expressed as Mean±SEM (***P<0.001 vs 
Normoxia, *P<0.05 vs H/R) (n=4-6). 
Figure 31. % change in MTT reductase activity compared with control in isolated rat 
ventricular myocytes following H/R. Cardiomyocytes were subjected to 120 minutes hypoxia 
followed by 120 minutes of reoxygenation in the presence/absence of artemisinin (4.3µM). 
Results are expressed as Mean±SEM (***P<0.001 vs. Normoxic control and *P<0.01 vs. H/R) 
(n=6).  
Figure 32a. Dose response curve showing the effect of MTT cytotoxicity analysis on HL-60 
cells in response to treatment with increasing concentrations of artemisinin (1-1000µM). HL-
60 cells were incubated with artemisinin (1-1000µM) for 24 hours. Experiment was terminated 
by adding MTT solution and cells were further incubated for 2 hours until termination with 
lysis buffer. Plate readings were taken at 492nm and results analysed using the 4-parametric 
logistic analysis, Graphit software. Image of HL-60 control cells and artemisinin (0.4mM) cells 
shown below (Figure 32b). 
Figure 32b. HL-60 cells control vs artemisinin treated cells. Image shows HL-60 cells to the 
right incubated with artemisinin (0.4mM) for picture purposes and to the left is untreated HL-
60 control. 
Figure 32c. % change in MTT reductase activity compared to control in MTT cytotoxicity 
analysis of HL-60 cells in response to treatment with artemisinin (0.4mM). HL-60 cells were 
incubated with artemisinin (0.4mM) for 24 hours. Experiment was terminated by adding MTT 
solution and cells were further incubated for 2 hours until termination with lysis buffer. Plate 
readings were taken at 492nm and results analysed using the 4-parametric logistic analysis, 
Graphit software. 
Figure 33. Treatment protocol for infarct size assessment studies and ventricular myocytes 
studies respectively. 
Figure 34. Illustration of a typical western blot set up used to quantify protein.  
Figure 35. Assessment of PI3K-Akt cell survival pathway in Artemisinin mediated 
cardioprotection in isolated perfused heart model subjected to 35 minutes ischaemia followed 
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by 120 minutes reperfusion. Artemisinin (Art) (4.3µM) (EC20) was administered at 
reperfusion in the presence and absence of wortmannin (Wort) (PI3K inhibitor) (0.1µM) or 
rapamycin (Rapa) (mTOR inhibitor) (0.1µM). Wortmannin (0.1µM) or rapamycin (0.1µM) 
was also administered alone at reperfusion and subjected to same experimental protocol. 
Results are shown as Mean±SEM. (***P<0.001 vs IR, **P<0.01 vs Art and *P<0.05 vs Art) 
(n=6-8). 
Figure 36. % change in MTT reductase activity compared with control in isolated rat 
ventricular myocytes following hypoxia/reoxygenation protocol. For all drug treated groups 
except .Artemisinin (Art) (4.3µM) was administered at the start of reoxygenation with/without 
co-administering the inhibitors wortmannin (Wort) (PI3K inhibitor) (0.1µM) or rapamycin 
(Rapa) (mTOR inhibitor) (0.1µM). The inhibitors, wortmannin (0.1µM) or rapamycin (0.1µM) 
were also administered alone at reoxygenation and subjected to same experimental protocol. 
Values are mean ± SEM (***P<0.001 vs Norm, *P<0.05 vs Norm, **P<0.01 vs H/R, #P<0.05 
vs Art and ##P<0.01 vs Art) (n=6). 
Figure 37. % increase in Cleaved Caspase-3 activity comparedn to normoxia showing the effect 
administering Artemisinin (Art) (4.3µM) at the start of reoxygenation with/without co-
administering inhibitors wortmannin (Wort) (PI3K inhibitor) (0.1µM) and rapamycin (Rapa) 
(mTOR inhibitor) (0.1µM) . The inhibitors, wortmannin (0.1µM) or rapamycin (0.1µM) were 
also administered alone at reoxygenation and subjected to same experimental protocol. Values 
are Mean±SEM (***P<0.001 vs Norm, *P<0.05 vs H/R, # P<0.05 vs Art and ##P<0.01 vs Art) 
(n=4-6). 
Figure 38a. A representative blot of p-Akt and Total Akt from isolated rat heart tissue in 
response to the treatment with artemisinin (Art) (4.3µM), a combination of Art (4.3µM) and 
wortmannin (Wort) (0.1µM) (ie Art+Wort) and Wort (0.1µM) alone in the ischaemic 
reperfusion model. 
Figure 38b: Western blot demonstrating Phospho-Akt (Ser473) expression with artemisinin (Art) 
4.3µM and wortmannin (Wort) (PI3K inhibitor) (0.1µM) which abolishes expression induced 
by artemisinin. Wortmannin (0.1µM) was also administered alone at reperfusion and subjected 
to same experimental protocol as the artemisinin treatment. (**P<0.01 vs IR and ##P<0.05 vs 
Art)(n=4). 
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Figure 39a: Above is the representative blot of of p-p70S6K and T-p70S6K from isolated rat 
heart tissue in response to the treatment with artemisinin (Art) (4.3µM) and rapamycin 
(rapa)(0.1µM) in combination (artemisinin and rapamycin) (Art+rapa) and alone in the  
ischaemic reperfusion model.  
Figure 39b: Western blot demonstrating Phospho-p70s6k (Thr389) expression with artemisinin 
(Art) 4.3µM and rapamycin (Rapa) (mTOR inhibitor) (0.1µM) which abolishes expression 
induced by Artemisinin. Rapamycin (0.1µM) was also administered alone, at reperfusion and 
subjected to same experimental protocol. (***P<0.001 vs IR and *P<0.05 vs Art)(n=4). 
Figure 40. The assessment of phosphorylated BAD expression as analysed using flow 
cytometric analysis upon treatment with artemisinin (Art) (4.3µM) at reoxygenation following 
the hypoxia/reoxygenation protocol in the presence and absence of wortmannin (Wort)(PI3K 
inhibitor)(0.1µM0.vValues are expressed as MEAN±SEM (**P<0.01 vs Norm,##P<0.01 vs 
H/R,*P<0.01 vs Art)(n=6-8). 
Figure 41a: Hypothetical schematic representation of the artemisinin mediated 
cardioprotection in isolated cardiomyocytes and isolated perfused heart subjected to H/R injury 
and I/R respectively via the activation of the pro-survival signalling pathway PI3K-Akt kinase 
cascade and their targets BAD and p70S6K. PI3K-Akt is an important part of the RISK 
pathways identified by Hausenloy and Yellon (2003). Administering artemisinin (4.3µM) at 
reperfusion has is suggested to initiate cardioprotection by protecting against reperfusion-
induced cell death. The scheme portrays the important anti-apoptotic mechanisms that have 
been implicated in mediating cellular survival associated with the recruitment of these kinase 
cascades via the PI3K-Akt cascade shown to reverse the activation of caspases and proapototic 
protein BAD via the p70S6K upon administering artemisinin in different settings of I/R and 
H/R.  
Figure 42. An Image of isolated ventricular myocytes. 
Figure 43. The effects of artemisinin (4.3µM) in the presence and absence of non-selective 
Nitric oxide inhibitor, L-NAME (100µM) and aminoguanidine (100µM) on LVDP expressed 
as a percentage of mean stabilisation. Hearts underwent 20 minutes of stabilisation, 35 minutes 
ischaemia and 120 minutes of reperfusion in the presence/absence of artemisinin (4.3µM) ± 
inhibitors which were administered throughout reperfusion. Results presented are Mean±SEM 
(n=3-8). 
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Figure 44. The effects of artemisinin (4.3µM), L-NAME (100µM) and aminoguanidine 
(100µM) on H/R as a percentage of mean stabilisation. Hearts underwent 20 minutes of 
stabilisation, 35 minutes of Ischaemia and 120 minutes of reperfusion in the presence/absence 
of artemisinin (4.3µM) ± inhibitors. Art (4.3µM) was administered throughout the 120 minutes 
reperfusion with/without inhibitors (n=3-8). 
Figure 45. The effects of artemisinin (4.3µM) in the presence and absence of inhibitor, L-
NAME (100µM) and aminoguanidine (100µM) on CF (CF) expressed as a percentage of mean 
stabilisation. Hearts underwent 20 minutes of stabilisation, 35 minutes ischaemia and 120 
minutes of reperfusion in the presence/absence of artemisinin (4.3µM) ± inhibitors which were 
administered throughout reperfusion. Results presented are Mean±SEM (n=3-8). 
Figure 46. Assessment of nitric oxide survival pathway in artemisinin (Art) mediated 
cardioprotection in isolated perfused heart model subjected to I/R. Art (4.3µM) was 
administered at reperfusion in the presence and absence of either L-NAME (non selective nitric 
oxide inhibitor)(100µM) or aminoguanidine (Amg) (iNOS inhibitor)(100µM). Results are 
shown as Mean±SEM. ***P<0.001 vs. IR, *P<0.05 vs. Art, #P<0.05 vs. L-NAME, ##P<0.01 
vs. Art. (n=3-8). 
Figure 47. MTT reductase activity used in assessing cellular viability in isolated ventricular 
cardiomyocytes subjected to 2 hours of hypoxia and 2 hours of reoxygenation. Where Art 
(4.3µM) was administered in the presence and absence of L-NAME (100µM) and 
aminoguaninde (100µM). ### P<0.001 vs Norm, **P<0.01 vs H/R, *P<0.05 vs Art, #P<0.05 
vs H/R (n=3-8). 
Figure 48. Effect of administration of artemisinin (Art) (4.3µM) in the presence and absence 
of L-NAME (100µM) and aminoguanidine (Amg) (100µM) on cleaved caspase-3 levels as 
analysed by Flow Cytometry. ***P<0.001 vs Norm, *P<0.05 vs H/R, ##P<0.01 vs. Art, 
#P<0.05 vs. Art. (n=4-6). 
Figure 49. Effect of administering artemisinin (Art) (4.3µM) throughout reoxygenation in the 
presence and absence of L-NAME (100µM) on eNOS expressions as analysed using Flow 
Cytometry. ***P<0.001 vs Normoxia (Norm), **P<0.01 vs H/R, ##P<0.01 vs. Art. (n=4-6). 
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Figure 50: Effect of artemisinin (Art) (4.3µM) on iNOS expression in the presence and absence 
of L-NAME (100µM) and aminoguanidine (Amg) (100µM) analysed using FACS analysis. 
*P<0.05 vs. Normoxia (Norm), **P<vs. H/R, ##P< vs. Art (n=4-6) 
Figure 51a and 51b. Nitrite and Nitrate Standard Curves. Nitrite (left) and nitrate (right) 
standard curves were performed according to the OxiSelect™ in vitro nitric oxide colorimetric 
assay protocol showing a directly proportional increase in the absorbance and concentration of 
nitrite and nitrate in control samples respectively. Results expressed as Mean±SEM 
Figure 52. The effects of artemisinin, doxorubicin and the co-administration of artemisinin and 
doxorubicin on LVDP. Hearts underwent 20 minutes of stabilisation, 35 minutes of ischaemia 
and 120 minutes of reperfusion, during which the drugs were administered at the onset of 
reperfusion. Data is expressed as Mean±SEM. **P<0.01 vs. I/R control (n=4-8), *P<0.05 vs. 
I/R 
Figure 53. The effects of doxorubicin (1µM) in the presence/absence of artemisinin (4.3µM) 
administered at reperfusion in an isolated perfused heart model subjected to I/R. Results are 
shown as Mean±SEM. ***P<0.001 vs. IR, ###P<0.001 vs. Art, #P<0.05 vs. Art, $$$P<0.001 
vs. Dox. (n=3-8) 
Figure 54. MTT reductase activity used in assessing cellular viability in isolated ventricular 
cardiomyocytes subjected to two hours of hypoxia and two hours of reoxygenation. Dox (1µM) 
was administered in the presence/absence of Art, L-NAME (100µM) and aminoguanidine 
(100µM). ### P<0.001 vs. Norm, **P<0.01 vs. H/R, *P<0.05 vs. Art, ***P<0.001 vs. Dox, 
**P<0.05 vs. L-NAME (n=3-8) (D+A+L=Dox+Art+L-NAME and D+A+Ag= 
Dox+Art+aminoguanidine) (n=3-6) 
Figure 55. The effects of doxorubicin and inhibition of the nitric oxide pathway on cellular 
viability. Doxorubicin (1µM) was administered alone in the presence and absence of L-NAME 
(100µM) and aminoguanidine (100µM). ### P<0.001 vs. Norm, **P<0.01 vs. Dox, *P<0.05 
vs. H/R. (n=3-6). 
Figure 56. Effect of administering doxorubicin (Dox) (1µM), artemisinin (Art) (4.3µM), both 
drugs combined and in the presence and absence of L-NAME (100µM) and aminoguanidine 
(Amg) (100µM) on cleaved caspase-3 activity in isolated adult rat cardiomyocytes after two 
hours of hypoxia followed by two hours of reoxygenation (H/R) as analysed using Flow 
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Cytometry. Results are shown as Mean±SEM. ***P<0.001 vs. Norm, *P<0.05 vs. HR, 
***P<0.001 vs. H/R, ^^^P<0.001 vs. Dox, **P<0.01 vs. Art (n=4-6). (D+A+L=Dox+Art+L-
NAME) and (D+A+Ag=Dox+Art+Aminoguanidine). 
Figure 57. Effect of doxorubicin (Dox) (1µM), artemisinin (Art) (4.3µM), both drugs combined 
and in the presence and absence of L-NAME (100µM) and aminoguanidine (Ag) (100µM) on 
cleaved caspase-3 activity in isolated adult rat cardiomyocytes after two hours of hypoxia 
followed by two hours of reoxygenation (H/R) as analysed using Flow Cytometry. Results are 
shown as MEAN±SEM. ###P<0.001 vs. Norm, ***P<0.001 vs. H/R. (n=4-6). 
Figure 58a. Effect of administering doxorubicin (Dox) (1µM) and artemisinin (Art) (4.3µM) 
throughout reoxygenation in the presence and absence of L-NAME (100µM) on eNOS (Ser 
1171), expressions as analysed using Flow Cytometry. ***P<0.001 vs. Normoxia (Norm), 
**P<0.01 vs. HR, ###P<0.001 vs. Dox, ##P<0.01 vs. L-NAME (n=4-6) 
(D+A+L=Dox+Art+L-NAME).. 
Figure 58b. Effect of administering doxorubicin (1µM) throughout reoxygenation in the 
presence and absence of L-NAME (100µM) on eNOS expressions as analysed using Flow 
Cytometry. ***P<0.001 vs. Normoxia (Norm) (n=4-6). 
Figure 59a. Effect of doxorubicin (1µM) and artemisinin (Art) (4.3µM) on iNOS expression in 
the presence and absence of L-NAME (100µM) and aminoguanidine (Ag) (100µM) analysed 
using FACS analysis. *P<0.05 vs. Normoxia (Norm), **P<0.01 vs. H/R, ##P<0.01 vs. Dox. 
Data expressed as mean± SEM (n=4-6). 
Figure 59b. Effect of doxorubicin (1µM) on iNOS expression in the presence and absence of 
L-NAME (100µM) and Aminoguanidine (Ag) (100µM) analysed using FACS analysis. 
*P<0.05 vs. Normoxia (Norm) (n=4-6). 
Figure 60. The effects of artemisinin (0.4mM), doxorubicin (1µM), L-NAME (100µM) and 
various combinations of the three drugs on the cytotoxicity of HL-60 cancer cells. ***P<0.001 
vs. control, #P<0.05 vs. Art/Dox, ###<0.001 vs L-NAME Data presented as mean ±SEM 
(n=4). 
Figure 61: Hypothetical schematic representation of the adjunctive therapy using artemisinin 
and doxorubicin in isolated cardiomyotes and isolated perfused heart subjected to H/R injury 
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and I/R respectively via the downstream targets of PI3K-Akt kinase cascade, Nitric oxide. 
Administering Artemisinin (4.3µM) and doxorubicin (1µM) at reperfusion initiated 
cardioprotection by protecting against reperfusion-induced cell death in cardiomyocytes. The 
scheme portrays the important anti-apoptotic mechanisms that have been implicated in 
mediating cellular survival associated with the recruitment of nitric oxide shown to reverse the 
activation of caspases and increase nitrite and nitrate production. Doxorubicin (1µM) and 
artemisinin (0.4mM) nearly doubled doxorubicin cytotoxicity in HL-60 cell line. 
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ABBREVIATIONS         
Art        Artemisinin 
 
WORT                   Wortmannin          
 
L-NAME                Nw-Nitro-L-arginine methyl ester hydrochloride 
  
AMG or Ag           Aminoguanidine  
   
RAPA                 Rapamycin 
 
DMSO                 Dimethyl sulfoxide 
 
TBST                    Tris-buffered Saline Tween 20  
 
PI3-K                     Phosphatidylinositol 3-OH-kinase  
 
mTOR                   mammalian target of rapamycin                 
 
NO                    Nitric Oxide 
 
NOS                     Nitric oxide synthase 
      eNOS               endothelial nitric oxide synthase 
      iNOS               inducible nitric oxide synthase 
      nNOS             neuronal nitric oxide synthase 
 
GAPDH                Glyceraldehyde 3-phosphate dehydrogenase 
 
IC50                         half maximal inhibitory concentration 
 
EC20, EC50, EC80        20% effective concentration, 50% effective concentration 
(or half maximal effective concentration), 80% effective 
concentration  
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HR                      Heart rate 
 
LVDP                Left ventricular developed pressure 
 
CF                       Coronary flow 
 
TTC                   2,3,5-triphenyltetrazolium chloride 
 
KH buffer                    Krebs Heinsleit (KH) solution 
 
I/R                       Ischaemia-reperfusion# 
 
H/R                    Hypoxia/Reoxygenation 
 
MTT                   Thiazolyl blue tetrazolium bromide 
 
miRNA                     MicroRNA 
 
FACS                     Fluorescence Activated Cell Sorter 
 
PCR                     Polymerase chain reaction 
 
(qRT-PCR) or RT-PCR Quantitative real-time reverse transcription polymerase 
chain   reaction  
 
RB                        Restoration Buffer 
 
HL-60                  Human leukaemia cancer cell line HL-60 
 
p-Akt                     phospho-Akt 
 
p-p70S6 Kinase              phospho-p70S6K 




1.1 CARDIOVASCULAR DISEASE AND CORONARY HEART 
DISEASE 
A Cardiovascular Disease (CVD) is one of a variety of diseases of the heart and blood 
circulation. CVDs, including Coronary Heart Disease (CHD) and Cerebro-vascular Disease, 
are currently the leading cause of death globally, accounting for about 21.9% of total deaths at 
present and projected to increase by 26.3% by 2030 (Ali et al., 2010).  
The global burden of death as a result of CVD deaths worldwide is estimated to be more than 
all communicable diseases, maternal deaths, neonatal deaths and deaths due to nutritional 
disorders (Nichols et al., 2014). It is also estimated to be responsible for double the number of 
deaths caused by cancer and approximately half of all deaths in Europe. Medical advances such 
as surgeries and the use of therapeutics have led to significant decrease in mortality rates as a 
result of CVD (Anderson et al., 2007; Nichols et al., 2013). Research has also attributed the 
modest changes in mortality to cardiovascular health behaviour with emphasis on diet and 
weight, coupled with a reduction in the prevalence of smoking to be responsible for this 
improvements (Roger et al., 2012). Despite the noticeable decline in mortality, CVD remains 
accountable for over 4 million deaths in Europe alone yearly (Nichols et al., 2014). 
The prevalence of CHD and Cerebrovascular Accidents (also known as ‘strokes’ which result 
from a blood clot cutting off the blood supply to parts of the brain (Roger et al., 2012), has 
resulted in this condition being a serious health concern particularly in the western world, often 
leading to a large proportion of deaths and physical disabilities (Nichols et al., 2013). 
 
CHD in particular has the highest mortality rate of all diseases in the UK (Schünke et al., 2006) 
and the most common cause of premature death in the UK (BHF, 2012). Presently, one in six 
men and one in ten women die of CHD each year, with death rates more prevalent with age 
(NHS, 2014). CHD will be the leading cause of morbidity and mortality in the developing 
world in general by 2020 (Lopez and Murray 1997; Goldberg et al., 2004; Kloner and Rezkalla 
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2004). Although the mortality rate for CHD appears to be declining, morbidity rate appear to 
be on the rise with prevalence higher in lower socio-economic groups (BHF, 2012).  
One of the main subtypes of CHD is myocardial infarction (MI) (also known as a ‘heart 
attack’). MI is caused by the occlusion of one of the coronary arteries by atherosclerotic plaque 
formations (Reynold 2012). Coronary arteries bring blood and oxygen to the heart and a 
blockage in the arteries starves the heart of blood and oxygen, leading to cellular death (Cohn 
et al., 2000). CHD, angina (a sharp pain in the heart which may be explained as a result of 
lactic acid build), MIs and strokes have all been associated with atherosclerosis (Reynold, 
2012). Atherosclerosis is a condition whereby the arteries become narrowed due to a gradual 
build-up of fatty deposits (atheroma) along the arterial walls, causing it to narrow and thereby 
restricting blood flow (BHF, 2012) (as shown in Figure 1). 
 
Figure 1. The build-up of fatty deposits in atherosclerosis (CHF, 2013). 
Atheroma formed in the arterial wall may rupture and break away to form blood which may 
block the coronary artery and deprive the heart of oxygen rich blood. Studies have highlighted 
the importance of inflammatory cascades as mediators in the pathogenesis of atherothrombosis 
(Libby, 2002).  
1.2 ATHEROSCLEROSIS 
Atherosclerosis is a degenerative CVD in which the arteries become narrowed or blocked, often 
with fat, cholesterol, calcium, fibrin and cellular waste products (Anderson et al., 2007). This 
tends to restrict blood flow, causing insufficient delivery of oxygen and nutrients to meet the 
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hearts demand, a condition referred to as ischaemia – the atheromas in atherosclerosis cause 
functional constrictions or obstructions to blood vessel, a very common pathological condition 
in CVD (Anderson et al., 2007). 
Progressive atherosclerosis manifests itself as coronary artery disease, which could lead to 
angina, myocardial infarction or sudden death (Reynold, 2012; Anderson et al., 2007; Maganti 
et al., 2010). Currently, the most effective treatments for the management of these conditions 
are surgical interventions and the use of pharmacological agents, however there is no known 
cure (Anderson et al., 2007). 
The most common etiological factors responsible for myocardial infarction is the presence of 
an atherosclerosis plaque blocking the coronary arteries as seen in the Figure 2 (Asano et al., 
2003). This leads to the disruption of blood flow to the cardiac myocytes, causing the activation 
of an ischaemic cascade (Libby and Theroux 2005). During an ischaemic heart attack, lactic 
acid accumulates as a result of the switch from aerobic to anaerobic respiration during energy 
production by the myocytes, leading to an ischaemic region (Solani and Harris 2005). 
Consequently, Adenosine Triphosphate (ATP) levels become depleted, owing to the failure of 
Na+/K2+ ATP-dependent pumps to function, and an imbalance in intracellular ion concentration 
within the cell occurs causing a reversal in function of the sodium-calcium exchanger (Inserte 
et al., 2004). The resultant metabolic mismatch of ions and failure of the pumps causes a 
calcium overload, oxidative stress, ATP depletion leading to cell death (Javadov et al., 2009). 
                       
Figure 2. Cross-sectional view of a normal coronary artery, an artery thickened due to atherosclerosis and an 
artery with a blood clot induced as a result of atherosclerosis (NIH, 2014) 
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During the early stages of atherogenesis, leukocytes are recruited to the site of inflammation 
causing them to adhere to the endothelial wall (Libby 2002). Recruitment of the leukocytes is 
by the P and E-selectins that are upregulated in the process of atherogenesis resulting in the 
chronic inflammatory disorder (van Wanrooij et al., 2008). This interaction between the 
selectins slows down the blood leukocytes and causes the integrin leukocytes to bind to 
endothelial cell adhesion molecules leading to the recruitment of monocytes and lymphocytes 
(van Wanrooij et al., 2008). Monocytes within the sub-endothelial space activate matrix 
metaloproteinases (MMP) which degrade connective tissue within the matrix, thus inducing 
the release of macrophages which in turn release pro-inflammatory cytokines that cause 
monocytic proliferation and cytokine mediated progression of atherosclerosis (Libby 2002).  
Several risk factors have been identified in atherosclerosis, with some being potentially 
reversible, such as hypercholesterolemia, hypertension, cigarette smoking, obesity and 
physical inactivity while other risk factors include age, ethnicity, family history, diabetes and 
gender (Libby, 2000, Schonbeck et al., 2000, Collins et al., 2000). 
1.3 MYOCARDIAL INFARCTION 
As previously mentioned, myocardial infaction has been reported to occur with angina in acute 
coronary syndrome. Coronary artery disease and atherosclerosis are reported to have strong 
associations as both arteries share the same systemic environment (Bando et al., 2015). 
Myocardial infarction (MI) (also known as heart attack) refers to the irreversible necrosis of 
the heart due to prolonged ischaemia (Zafari et al., 2015). This condition is often mistaken with 
cardiac arrest however in MI the prolonged limitation of blood flow to the heart is accompanied 
by chest pain and discomfort with the symptoms starting slowly as opposed to the sudden 
cardiac arrest, MI results in damage to the heart muscles and eventually heart failure/cardiac 
arrest if symptoms are not relieved (AHA, 2014). Heart attack is however a common cause of 
cardiac arrest and often requires cardiac pulmonary resuscitation (CPR) which is an emergency 
response to keep blood flowing to the heart until help comes (Anderson et al., 2007; AHA 
2014).  
Major advances have recently been made in understanding the pathogenesis of acute coronary 
syndromes such as angina and MI (Grundy 1999). The most effective treatments for the 
management of these conditions presently are surgical interventions and the application of drug 
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therapy such as aspirin (an anti-platelet), warfarin (an anticoagulant), statins (which lower 
cholesterol levels), beta blockers and angiotensin converting enzyme (ACE) inhibitors are all 
widely accepted means of managing CHD and its various manifestations (Anderson et al., 
2007). Ultimately, patients with MI will require reperfusion treatments i.e. medical treatment 
that restores blood flow to the blocked arteries following occlusion (Verma et al., 2002; Kloner 
and Rezkalla 2004).  
1.4 ISCHAEMIA 
As previously mentioned, heart disease arises through injury to cardiac tissue by an imbalance 
of blood supply, causing an insufficiency in oxygen and nutrients required to satisfy myocardial 
demand and this phenomenon is referred to as ischaemia (Rosenfeldt et al., 2006). 
If ischaemia persists within the myocardium for a significant duration of time, it results in a 
spectrum of clinical syndromes which are characterised with metabolic and ultrastructural 
changes that led to irreversible injury (Eltszchig and collard 2004). These distinct alterations 
to cells such as cellular swelling, disruption of oxidative phoshorylation, decline of intracellular 
pH, decrease in levels of ATP, lactic acid build up, altered metabolism and free radical 
mediated injury, which may all occur if the onslaught is prolonged (Allen et al., 2008; Lichtig 
and Brooks 1974; Halestrap et al., 2004; Buja 2005). 
1.5 REPERFUSION 
Reperfusion as described in many studies, is a medical intervention administered to reduce 
ischaemic injury to tissues (Kloner and Rezkalla 2004; Yellon and Haunsenloy 2013). This 
treatment has resulted in years of success and is still an effective way of managing ischaemia 
and, in the long run, curbs mortality (Kloner and Rezkalla 2004). Although early reperfusion 
remains the best strategy to reduce ischaemic injury, restoration of blood flow to the ischaemic 
organ often causes a subsequent burst of reactive oxygen species (ROS), inflammatory 
mediators and the exacerbation of the ischaemic injury known to cause injury in the affected 
organ (Yellon and Haunsenloy 2013; Silachev et al., 2014; Shim 2010). Reperfusion is a well 
documented critical procedure employed to salvage reversibly damaged myocytes, by 
reintroducing coronary flow (CF) to the blocked artery and reperfusing the ischaemic 
myocardium (Verma et al., 2002). Early and successful myocardial reperfusion using either 
thrombolytic therapy or primary percutaneous coronary intervention are proven to be the most 
effectively used strategies of managing myocardial infarction and improving the clinical 
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outcome (Yellon and Haunsenloy 2007). However, this timely reperfusion to an ischaemic area 
as indicated can produce two variable effects on the myocardium, i.e. in an attempt to salvage 
a great amount of the myocardium and thus decreasing cardiac related morbidity and mortality, 
it also results in a paradoxical cardiomyocyte dysfunction, a phenomenon commonly termed 
“reperfusion injury” (Buja 2005; Verma et al., 2002; Yellon and Haunsenloy 2007). 
Despite its benefits, negative attributes resulting from reperfusion injury have been shown to 
include arrhythmias, enzymatic release, myocardial stunning followed by reversible and/or 
irreversible cell damage (Kalogeris et al., 2012). Free radicals are also generated in ischaemia 
as well as reperfusion (Zweir and Talukder 2006, Kalogeris et al., 2012). Previous studies have 
established that progression of myocardial injury is enhanced by neutrophils in our immune 
system and mast cells which accumulate at the site of injury during ischaemia injury and 
reperfusion injury (Jordan et al., 1999: Jeroudi et al., 1994). ROS and Reactive Nitrogen 
Species (RNS) are believed to encourage ischaemic injury as well as reperfusion injury 
(Tompkins et al., 2006). An experimental model of 3 weeks chronic exposure to hypoxia in 
Sprague Dawley rats was shown to promote the generation of ROS in vivo which was 
accompanied by hypoxia induced cardiopulmonary changes. Lung xanthine oxidase was 
shown to be elevated from day one of exposure to hypoxia which was followed by vascular 
thickening and ventricular hypertrophy that contributed to the development of cardiac 
pulmonary hypertension (Hoshikawa et al., 2001). In ischaemic conditions ATP is broken down 
to purine hypoxanthine via oxidation or proteolytic cleavage, thus reducing xanthine 
oxidoreductase to xanthine oxidase which in turn results in the formation of ROS and hydrogen 
peroxide (Pritsos, 2000). Xanthine oxidoreductase is an enzyme usually present in the 
myocardium as a rate-limiting step in purine degradation to uric acid (Jankov et al., 2008).  
The generation of free radicals in the mitochondria have been associated with free radical 
scavengers such as superoxide dismutase and glutathionine peroxidase (Poyton et al., 2009, 
Venditti et al., 2013).  Superoxide dismutase is an enzyme existing as a free radical scavenger 
in a normal functioning myocardium. However when the enzyme cleaves as a result of stress 
induced from both ischaemia and reperfusion, the production of ROS is increased (Venditt et 
al., 2013). 
Other factors that have been linked to myocyte necrosis include ROS, dysregulation of 
mitochondrial Ca2+ homeostasis, mitochondrial fragmentation and cytochrome c release in the 
myocytes (Hom et al., 2009, Webster, 2012,). These factors play a key role in pathologies and 
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are extremely damaging to the myocardium, despite their independent roles in disease, 
mitochondrial matrix Ca2+ overload can lead to the enhanced generation of ROS, triggering the 
opening of the permeability transition pore, and release of cytochrome c which leads to 
apoptosis (Brookes et al., 2004). 
The sustained injury is often reversible since the myocardium can normally tolerate brief 
periods (of up to 15 minutes) of severe or total ischaemia without resultant cardiomyocyte 
death; this is often encountered in the clinical situations of angina, vasospasm and angioplasty 
and is not associated with concomitant myocyte cell death (Yellon and Baxter 2000). 
Increasing the duration and severity of ischaemia leads to greater cardiomyocyte damage 
(Verma et al., 2012). 
Despite the return of blood flow to an ischaemic region, cardiac stunning often follows. Cardiac 
Stunning is a process whereby the contractile function of a section of the myocardium is 
affected, resulting in a visible reduction in heart contraction (Pomblum et al., 2010). Evidence 
has shown that free radical damage occurs upon reintroducing flow and thus myocardial 
stunning is viewed as a sub lethal form of oxyradical-mediated reperfusion injury (Bolli 1990). 
Studies have also shown that the generation of these oxyradicals which causes the sarcoplasmic 
reticulum dysfunction, also leads to calcium overload, which in turn exacerbates the damage 
initiated by the oxygen species (Pomblum et al., 2010). Although myocardial stunning is 
spontaneously reversible, studies continue to investigate and focus on the benefits and the 
mechanism of stunning, though reperfusion therapies have proven by far more relevant in terms 
of attenuating myocardial ischaemia/reperfusion injury (Pomblum et al., 2010). 
Reperfusion, which is also a potent stimulus for neutrophil activation and accumulation, results 
in marked endothelial cell dysfunction, changes in intracellular calcium homeostasis (which 
play an important role in the development of reperfusion injury), altered myocardial 
metabolism (which in turn may contribute to delayed functional recovery) and production of 
more oxygen free radical (Verma et al., 2002). These effects are characterised as reperfusion 
injury which is also associated with microvascular dysfunction such as impaired endothelium, 
leukocyte plugging in capillaries and plasma protein extravasation in post capillary venules 
(Carden and Granger 2002). 
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1.6 OXYGEN-DERIVED FREE RADICALS 
ROS are a group of chemically reactive ions, radicals and molecules derived from oxygen 
(Hancock et al., 2001). Free radicals are constituently present within cells and can be produced 
by a number of mechanisms the majority is formed within the mitochondria during 
reoxygenation forming such molecules as superoxide anion an oxygen derived free radical 
(Bollisetty and Jaimes 2013; Stowe and Camara 2009) . 
Male Sprague Dawley rat hearts that are chronically exposed to hypoxia show increased levels 
of xanthine oxidase hypoxanthine, a pathway known to generate oxidative stress in vivo. 
Hoshikawa et al. (2001) measured lung phosphatidylcholine hydroperoxide in the hypoxia-
exposed rats as a marker of oxidative stress of the lung tissue and showed hypoxia led to an 
increase in ROS (Hoshikawa et al., 2001). 
During normal physiological conditions within the myocardium, xanthine oxidoreductase is 
present principally in the dehydrogenase form and acts as rate-limiting step in purine 
degradation to uric acid (Jankov et al., 2008). However within ischaemic conditions ATP is 
broken down to the purine hypoxanthine, a substrate for xanthine oxidoreductase, and 
reversible oxidation or irreversible proteolytic cleavage causes the conversion of xanthine 
oxidoreductase to xanthine oxidase which is responsible for the detrimental formation of ROS 
and hydrogen peroxide (Pritsos 2000).  
Prior to ischaemia the myocardium will contain endogenous free radical scavengers such as 
superoxide dismutase which exhibit strong antioxidant capacity preventing ROS mediated 
injury (Rahman 2007, Rodrigo et al., 2013). Changes during ischaemia and reperfusion cause 
these enzymes to be unable to withstand the higher ROS stress and therefore are able to produce 
adequate protection from the increased ROS production (Rahman 2007). Oxygen-derived free 
radicals are formed to destructive levels during the reoxygenation of the ischaemic region of 
the myocardium (Zweier et al., 1994). Prior studies have demonstrated reoxygenation leads to 
a significant increase in oxygen derived free radicals that have many effects, one being the 
inhibition of contractile function in the heart (Zweier and Talukder 2006). However ROS does 
possess functional attributes within the body and participates in a range of different roles such 
as hormone biosynthesis, cell signalling and microbial killing (Rada and Leto 2008). The 
balance between the production and scavenging of ROS leads to homeostasis. However the 
accumulation of ROS is well documented in cellular damage (Stowe and Camara 2009).  
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A study using wild type mice and tumor necrosis factor receptor-associated protein 1 (TRAP1) 
knock out mice, (TRAP1 is an essential mitochondrial chaperone which is induced in rat hearts 
following I/R) showed upon 12 hours ischaemia and 1 hour reperfusion (I/R injury). TRAP1 
overexpressed hearts were shown to generate decreased levels of ROS and ameliorate 
myocardial dysfunction causing delays in mPTP opening (Zhang et al., 2015).  
Llacuna (2009) also showed the the generation of ROS increased over time, with significantly 
levels of ROS detected upon 30 minutes ischaemia, levels of oxidative stress peaked after 1 
hour in this study male C57BL/6 mice subjected to partial hepatic ischaemia. With prolonged 
levels of ischaemia, endogenous protective proteins/genes may be compromised thus the use 
of antioxidant based strategies to preserved the level of managanese superoxide dismutase 
(MnSOD) protective genes which has been shown to improve the integrity of the liver (Llacuna 
et al., 2009). 
Research has also shown that exogenous ROS scavengers and antioxidants can decrease the 
amount of ROS available in cells, thus attenuating the detrimental effects of ROS in vitro. 
Conversely, lowering the levels of oxidative stress may sometimes be beneficial in organisms 
where ROS is responsible for cellular signalling. The balance of ROS and antioxidants in this 
situation is optimal (Poljsak et al., 2013). 
1.7 METABOLISM CHANGES 
Research has been able to establish the precise sequence of biochemical events leading to 
myocyte cell death including the metabolic derangement (Ferrari et al., 1998). During 
ischaemia, the increased rate of glycolysis causes the accumulation of lactic acid thus causing 
the intracellular pH to drop significantly (Kalogeris et al., 2012). With a rapid decrease in the 
amount of adenosine triphosphate (ATP) available, the Na+/K+ ATPase is inhibited leading to 
a rapid rise in intracellular [Na+] leading to changes in Ca2+ in the cell  (Halestrap et al., 2007). 
1.8 CALCIUM OVERLOAD 
The high levels of intracellular Ca2+ is caused as a result of the activity of Na+/Ca2+ antiporter 
being inhibited (which usually pumps Ca2+ out of the cell) (Halestrap et al., 2007). Calcium 
overload is stimulated following ischaemia immediately after reoxygenation and has been 
shown to lead to the development of cellular contracture and death (Vaselle 2004). 
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Changes in the level of Ca2+ regulation has been shown to be critically important in both the 
mechanical dysfunction and arrhythmogenesis associated with congestive heart failure. 
Cytosolic calcium overload can result from Ca2+ influx across the sarcolemma via the cation 
channels opening, the actiavation of the Na+/H+ exchanger causing an influx of Na+ , or through 
the inactivation of the Na+/K+ -ATPase or the Na+/Ca2+ exchanger. This leads to the release of 
calcium from the sarcoplasmic recticulum or other endogenous stores. The Ca2+ overload is 
often accompanied by hyperactivation and, consecutively, hypercontracture in cells. In tissue 
however, the process does not end there hypercontracture will lead to cell rupture thus 
increasing Ca2+ overload as shown in Figure 2b (Piper 2000). 
                
Figure 2b. Schematic diagram of the mechanistic overview of the calcium paradox (Piper 2000). 
 
Abnormally high levels of calcium have been shown to have a number of different negative 
effects such as the activation of calcium dependant proteases and phospholipases that are able 
to cause significant damage to the sarcolemma and may even lead to cellular death (Shigekawa 
and Iwamoto, Halestrap et al., 2007).  
 
1.9 CELL DEATH 
Cell death is an essential process within the body to allow for the removal of cells whose 
activities are no longer required this can be due to age or through injury (Fulda et al., 2010). 
Cell death can be divided into categories namely, necrosis, apoptosis and autophagy (Fulda et 
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al., 2010). Studies have recently investigated the relationship between myocardial ischaemic 
injury and the major modes of cell death, such as oncosis and apoptosis. 
1.10 NECROSIS 
This form of ATP independent cell death is characterised by the swelling of the organelles and 
entire cell after which the cell membrane becomes more permeable with the release of cellular 
contents causing extensive tissue injury which is associated with an intense inflammatory 
response (Proskuryakov et al., 2003).  Necrosis is stimulated by stress such as ischaemia 
which evokes a large necrotic death of the cardiomyocytes (Fulda et al., 2010). What was 
thought to be one of the defining features of necrosis is the cells which undergo this process do 
by a chance occurrence however; recent studies have shown that necrosis is an active form of 
cell death with clear signs of regulation (Berghe et al., 2014, Okada and Mak 2004). 
Studies have defined the existence of two different oxidation-mediated necrotic pathways, an 
ATP-dependent apoptosis blockade, and the ATP independent process which involves the 
interactions of multiple regulatory factors (Sancho et al., 2006). A study using cultured mouse 
proximal tubular cells showed that the extent of cell death was proportional to the amount of 
ATP content and independent of mechanism of cell death, with an increase in cell death 
expected with decreased availability of ATP (Lieberthal et al., 2013). However apoptosis is the 
active process (ATP dependent) while necrosis is an organised primary cell death process 
independent of ATP (Apraiz et al., 2012). 
1.11 APOPTOSIS 
Is defined as a caspase dependent programme cell death (Fulda et al., 2010). It occurs under 
physiological conditions however it is most desirable under pathological circumstances (Apraiz 
et al., 2011). Typical morphological characteristics that accompany apoptosis or programmed 
cell death include plasma membrane blebbing, cell shrinkage, chromatin condensation and 
fragmentation (Vermeulen et al., 2005). It is also accompanied by changes in caspases which 
trigger apoptotic cell death in cells and tissues (Vanden Berghe et al., 2010) 
As previously mentioned, during apoptosis, caspases are cleaved and PARP (a nuclear enzyme 
that is activated by DNA strand breaking) inactivated, which preserves cellular ATP despite 
significant DNA damage (Abraham 2011, Roos and Kaina 2006). Altered intracellular calcium 
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levels may also regulate oncotic cell death leading to cells swelling to an abnormally high size 
due to the failure of the permeable membranes ionic pumps (Fink and Cookson 2005). 
Plasma membrane (PM) blebs are dynamic cell membrane protrusions which are normally 
initiated by a combination of events usually extracellular triggers that involve local disruption 
of membrane actin cortex interactions, leading to rapid protrusion of the PM as a result of the 
cell internal hydrostatic pressure (Fackler and Grosse 2008; Charras 2008). During the final 
stages of apoptosis, marked changes in cell morphology occur such as contraction and 
membrane blebbing, this has now been recently linked to caspase mediated activation of ROCK 
1 (rho-associated coiled coil containing protein) (an effector protein responsible for the 
regulation of the actomyosin cytoskeleton which promotes contractile force generation and 
plays a role in cell motility, metastasis and angiogenesis) (Coleman 2001). Blebs have thus 
been implicated in cellular injury, apoptosis, cytokinesis, and cell movement in healthy 
cultured cells at particular stages of cell movement (Barros et al., 2003; Rath and Olson 2012). 
 
It has been suggested in the past that ischaemia alone can trigger apoptosis after prolonged 
occlusion without reperfusion (Borutaite and Brown 2003). However, more recently, it is 
proposed that myocardial apoptosis and necrosis are primarily triggered during reperfusion 
(Zhoa and Johansen 2002). It is a highly regulated process therefore a target for 
pharmacological inteventions (Fulda et al., 2010). Apoptosis is characterised by a series of 
regulated biochemical process that leads to programmed cell death as seen in Figure 3. 
Figure 3. A general overview of the apoptotic pathways (Dabbagh and Rajaei 2013). 
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This process of apoptosis is initiated by the presence of stimuli such as ROS and hydrogen 
peroxide which distinguishes it from necrosis which is thought to be traditionally stimulated 
via acute cellular injury (Elmore 2007). Apoptosis can be divided into two main pathways 
intrinsic and extrinsic (Park et al., 2015). The extrinsic pathway involves the activation of a 
death receptor located in the extracellular surface of the cell by apoptotic stimuli (Elmore 2007) 
(as shown in Figure 3). The extrinsic pathway is a major pathways for caspase activation with 
apoptosis initiated via death signal ligation in the cell membrane, a death inducing signalling 
complex (DISC) is formed after Fas-associated death domain (FADD) and procaspase-8 as 
illustrated in Figure 4 (Keoni and Brown 2015). 
 
The intrinsic death pathway is however managed by the mitochondrial action in response to G 
protein-coupled receptors stimulated by environmental stresses like deoxyribonucleic acid 
(DNA) damage leading to the release of cytochrome c, nutrient deprivation, hypoxia, and intra-
mitochondrial proteins such as apoptosis inducing factor, second mitochondrial derived 
activator of caspades and endo nuclease G (Borutaite et al., 2003; Fan et al., 2013). The 
collective factors described earlier proceed to influence the activity effectors caspades like 
caspase 3 and execute the apoptotic cell death (Elmore 2007). Cytochrome c, has also been 
shown to binds with Apaf-1 and ATP in the cytosol form a complex known as the apoptosome 
this triggers the initiation of pro-caspase 9 (Keoni and Brown 2015)(shown in Figure 4). In the 
intrinsic apoptotic pathway, caspase activation is shown to be closely associated with the 
permeabilisation of the outer mitochondrial membrane by proapoptotic members of the B-cell 
lymphoma protein-2 (Bcl) family, mitochondrial lipids, proteins and components of the 
permeability transition pore usually in response to proapoptotic signals or cytotoxic stimuli that 
cause the disruption of the outer mitochondrial membrane. With the disrupted membrane, 
mitochondrial apoptogenic proteins such as cytochrome c, Second mitochondria-derived 
activator of caspase/direct inhibitor of apoptosis-binding protein (Smac/DIABLO), Omi/HtrA2 
(mitochondrial serine protease that is released into the cytosol during apoptosis to antagonize 
inhibitors of apoptosis), apoposis inducing factor (AIF) and endonuclease G found between the 
inner and outer mitochondrial membranes are released. Upon reaching the cytosol, these 
apoptogenic proteins trigger the cell death by promoting caspase activation or by acting as 
caspase-independent death effectors (Fulda and Debatin 2006). 
 
Caspases are synthesised as inactive proenzymes activation by apoptosis causes the cleavage 
of essential cellular substrates, including poly (ADP-ribose) polymerase and lamins, thus 
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participating heavily to the distinctive morphological changes seen within apoptosis. The 
caspase family main activating factor is cytochrome c release by the mitochondria through 
apoptotic stimuli (Borutaite et al., 2003). Caspases involved in apoptosis in humans that have 
been classified as initiators or effectors, the initiators include caspase 2, caspase 8, caspase 9 
and caspase 10) while the effectors are caspase 3, caspase 6 and caspase 7) (Wesche et al., 
2005). The release of cytochrome c triggers caspase-3 activation via the apoptogenic proteins 
forming an apotosome complex (Fulda and Debatin 2006). Caspase-3 is then activated by 
caspase-9 thereby causing cellular and biochemical events of apoptosis to occur (Fulda and 
Debatin 2006). 
Several caspase inhibitors however have been identified to decrease apoptosis, in sepsis 
lethality apoptosis for example it is used as a potential therapeutic target (Wesche et al., 2005). 
Caspase inhibitors are also commercially available, examples include Boc-D-fmk and Z-VAD-
fmk, which function by inhibiting the activation of certain initiator or effector caspases 
however they are required in very high toxic concentration to be effective (50µM) (Caserta et 
al., 2003, van Noorden 2001). Other non-toxic options do exist for example Q-VD-OPh 
(quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) which is a true 
pancaspase inhibitor and is effective at significantly lower concentrations (50µM) which is 
non-toxic in vivo but capable of crossing the blood–brain barrier (van Noorden 2001, Chauvier 
et al., 2007). These inhibitors cause a decrease in matrix metalloproteinase (MMP) and 
generation of ROS, this mitochondrial amplification loop of caspase activity is suggested to be 
an important response to cardiotoxic treatment (Fulda and Debatin 2006). 
A study has tested the effectiveness of Q-VD-OPh during reperfusion by inducing stroke in 
both male and female poly ADP ribise polymerase (PARP) (protein involved in DNA repair) 
knockout mice, results however showed Q-VD-OPh only significantly reduced infarct size in 
PKO and wild type, stroke-induced females, with no effect observed in males (Liu et al., 2008). 
Mocanu et al. (2000) also investigated the effectiveness of non-selective caspase inhibitor (Z-
VAD·fmk), caspase-8 inhibitor (Z-IETD·fmk), caspase-9 inhibitor (Z-LEHD·fmk) and 
caspase-3 inhibitor (Ac-DEVD·cmk) following I/R injury. Results showed a decrease in infarct 
size with drug treatment during early reperfusion which was accompanied by a decrease in the 
levels of caspases during reperfusion thus suggesting caspase inhibition during early 
reperfusion protects myocardium against lethal reperfusion injury as shown in Figure 4. (15) 
P a g e  | 16 
 
 
Figure 4. A cell-centric view of apoptosis and apoptotic cell death inducing strategies (Apraiz et al., 2011) 
Bcl-2 (B cell ymphoma 2), Bcl-xL,(B cel ymphoma extra large),Bax (apoptosis regulator Bax aso known as B-cl2 
ike protein 4), VDAC (voltage-dependent anion channel), GD3 (acidic glycosphingolipid ganglioside),TBID 
(truncated BH3-interacting domain death agonist), Smac/Diablo (Second mitochondria-derived activator of 
caspase/direct inhibitor ofapoptosis-binding protein), APAF (Apoptotic protease activating factor 1), 
ICAD/CAD( Inhibitor of  Inhibitor of Caspase-activated DNase/Caspase-activated DNase compex) 
The extrinsic and intrinsic apoptotic processes are both accompanied by similar biochemical, 
morphological and common phosphotidylserine externalisation processes (Apraiz et al., 2011). 
These processes occur due to the increase in intracellular Ca2+, although not unique to apoptosis 
alone (may also occur during cytochrome c release, caspase activation or DNA fragmentation) 
has been shown to inhibit translocase activity and activate a scramblase (a non- specific, 
bidirectional lipid molecule) which leads to spontaneous distribution of phospholipid in the 
plasma membrane (Apraiz et al., 2011).  
The apoptotic signal in the extrinsic pathway is triggered by a ligand binding to a 
complimentary cell surface receptor the tumour necrosis factor receptor (TNFR) which 
activates the TNF cell death pathway. Depending on the scenario, other death receptors such 
as CD95/Fas/Apo1 activated by the Fas ligand or the death receptor 4 and 5 (DR4/5 activated 
by the Apo2 ligand (Apo2L) otherwise known as TNF-Related Apoptosis-Inducing Ligand 
(TRAIL) may also bind to their respective ligands and induce cell death (Apraiz et al., 2011). 
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These adaptor proteins however require the death effector domain in order to recruit and 
activate the cell death effectors, initiators such as caspase 8 and 10. Ligand mediated death 
receptor activation does not always induce apoptosis however caspases are considered prime 
mediators of apoptosis (Apraiz et al., 2011). 
Intrinsic pathway for example are associated with mitochondrial damage, recent research has 
also implicated the involvement of other organelles such as the endoplasmic recticulum, 
nucleus and lysosomes (Danial and Kosmeyer 2004, Ferri and Kroemer 2001). This process is 
primarily driven as a result of damage from Ca2+ release leading to impaired oxidative 
phosphorylation and opening of the mitochondrial permeability transition pore. The membrane 
permeability leads to the release of pro-apoptotic proteins such as apoptotic inducing factor 
(AIF), endonuclease G, Smac/DIABLO, Bax and Bak and HtrA2/Omi (Elmore 2007, de Bruine 
and Medema 2008). Bak and Bax are both members of the pro-apoptotic Bcl-2 family of protein 
however Bcl-2 proteins do no operate at a mitochondrial level only (Danial and Kosmeyer 
2004, Brunelle and Letai 2009). Intrinsic apoptotic pathways may also be triggered by the 
nucleus triggered intrinsic pathways primarily involving DNA damage where protein-
modifying enzyme poly (ADP-ribose) protein (PARP)-1 plays a vital role (Ha and Snyder 
2000). It is proposed that PARP-1 mediated cell death is as a result of energy depletion as well 
as AIF translocation from the mitochondria (Ha and Snyder 2000). 
1.12 CYTOCHROME C 
Cytochrome c is principally recognised within the mitochondria as a key constituent of ATP 
synthesis however this molecule can be released into the cytosol and trigger programmed cell 
death (Apraiz et al., 2011). Cytochrome c release and cytochrome-c mediated apoptosis are 
managed by an intricate network of different molecular systems the most predominant the Bcl-
2 family (Ow et al., 2008). Cytochrome c release in the mitochondrial intermembrane space is 
a significant contributing factor of apoptosis within the majority of cells throughout the body. 
It can therefore be judged that the release of this molecule is as important to the process of 
apoptosis as the activation of caspases. 
When cytochrome c is present within the cytosol, it binds to Apaf-1, and induces the 
oligomerisation of Apaf-1·cytochrome c complex in a dATP/ATP-dependent manner (Jiang 
and Wang 2000; Liu et al., 1996; Zou et al., 1997). This allows for the recruitment of the 
initiator caspase, caspase-9, to the complex which induces procaspase-9 auto-activation (Mei 
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et al., 2010; Zou et al., 1999). Activated caspase-9 has been shown to specifically cleave 
downstream caspases such as caspase-3 and caspase-7 that constitute major caspase activity in 
apoptotic cells (Mei et al., 2010; Thornberry & Lazebnik 1998; Brentnall et al., 2013).  
In recent years, the role of the mitochondria in apoptotic cell death has been much debated. It 
is believed that the mitochondria of apoptotic cells undergo permeability transition (Fulda et 
al., 2010; Fan et al., 2013; Marchetti et al., 1996). The mitochondrial permeability transition 
pore (mPTP) as it is formally defined is a nonspecific channel located in the inner 
mitochondrial membrane (imm) (Halestrap and Brenner 2003). The molecular composition of 
this structure is still debated but it is believed by some to have three core components a voltage-
dependent anion channel adenine nucleotide translocator, cyclophilin D exhibits peptidyl-
prolyl cis-trans isomerase activity (Javadov et al., 2009). After an ischaemic episode, the 
process of reperfusion has been experimentally shown to lead to the opening of mPTP via 
oxidative stress which is followed by the loss of ionic homeostasis and ultimately death by 
necrosis (Halestrap et al., 2004).  
The metabolism and ionic homeostasis of the heart are greatly perturbed leading to the opening 
of the mPTP. Reperfusion alone can not induce significant mPTP opening however causes 
myocardial stunning does. This is suggested to occur as a result of the increased injury caused 
by the free radical damage (Halestrap and Pasdois, 2009). mPTP located in the inner 
mitochondrial matrix opens as a result of calcium triggered conformational changes (Javadov 
et al., 2009; Halestrap and Richardson 2015). A high concentration of Ca2+ in the matrix, 
followed by high oxidative stress and high adenine nucleotide depletion (characteristics 
assoiated with the irreversible ischaemia-reperfusion injury) have been shown to collectively 
lead to the opening of the mPTP as shown in Figure 5 (Halestrap and Richardson 2015).  
 
Proteins such as the Bcl-2 family and hexokinases associated with the outer mitochondrial 
membrane (omm) have been shown to regulate the mPTP opening via their interactions with 
inner mitochondrial proteins such as the imm Adenine Nucleotide Translocase (ANT), 
phosphate carrier (PiC) and FoF1 ATP synthase at contact sites (Murphy et al., 2005; Crow et 
al., 2004). Membrane potential may independently affect the opening of Ca2+ opening thus 
suggesting that mPTP is a voltage gated pore (Halestrap and Richardson 2015). Cells exposed 
to excessive amounts of Ca2+ undergo mPTP and then necrosis (He and Lemasters 2002). 
Pathological conditions such as I/R and heart failure have been associated with altered levels 
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of cardiomyocyte Ca2+ homeostasis , this is suggested to occur as a result of the inadequate 
oxygen available to the cardiac tissue thus causing a decrease in ATP levels too (Javadov et al., 
2009). This altered Ca2+ homeostasis (Ca2+ overload), oxidative stress from reperfusion injury 
combined with other factors such as high phosphate and low adenine nucleotide concentrations 
induce the formation of nonspecific mPTP imm (Javadov et al., 2009; Halestrap and 
Richardson, 2015). mPTP is clearly critical in regulating cell death, recent genetic studies have 
shown VDAC is an essential component of mPTP and attributed a regulatory (rather than 
structural) role to ANT while phosphate carriers were shown to play critical roles in mPTP 
formation thus questioning the molecular identity of the pore (Javadov et al., 2009). Cardiac 
pathology condition such as I/R have shown the inhibition of mPTP opening by analogs of 
cyclosporine A or sanglifehrin A which are responsible for the mediation of ROS accumulation 
via mitochondria targeted antioxidants (Javadov et al., 2009). Opening of mPTP causes 
uncoupling of the mitochondria and swelling of the matrix which leads to rupturing of the omm 
and ultimately cell death (Javadov et al., 2009) as shown in Figure 5.  
 
Figure 5. Showing the involvement and role of CyP-D, ANT, PiC and FoF1 ATP synthase and that of the outer 
mitochondrial proteins in regulating the opening of mPTP activity at contact sites. Figure also shows the 
involvement of the outer and inner mitochondrial protein in regulating the pore as well as the presence of outer 
membrane protein, VDAC at this contact site which may be more important for their role in the creatine 
phosphate shuttle (Halestrap and Richardson 2015). 
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1.13 STRATEGIES IN MI 
Reperfusion is undoubtedly key in the management of MI as it leads to a reduction in morbidity 
and mortality rates, however, this process is time dependent. By decreasing the time of onset 
of symptoms to reperfusion and choosing optimal reperfusion strategies, it will undoubtedly 
enhance survival for patients (Zhang and Huo 2011). 
1.14 CARDIOPROTECTION 
Endogenous protective mechanisms have been demonstrated in several animal models and in 
isolated human cardiomyocytes. In ischaemic preconditioning, repeated short cycles of 
ischaemia (mechanical occlusion) and reperfusion are administered prior to the onset of 
ischaemia and have been shown to limit myocardial injury and provide the myocardium with 
resistance to subsequent ischaemic insult (Skyschally et al., 2008; Tomai et al., 1999). It is 
considered post conditioning when the brief periods of ischaemia and reperfusion occur after 
the onset of reperfusion. Post conditioning has been shown to protect the myocardium and 
significantly reduce infarct size in several studies (Skyschally et al., 2008; Zhoa 2009). 
As previously mentioned, the myocardium is the source of innate endogenous protective 
mechanisms that are shown to be stimulated during reperfusion and to exert beneficial effects. 
However, they are very often found to be insufficient in preventing the deleterious effects of 
reperfusion injury itself. Viable endogenous protective mechanisms include adenosine 
production, opening of ATP-sensitive potassium channels (KATP), as well as release of nitric 
oxide (Verma et al., 2002). 
Research has shown that the protective effects of preconditioning are transient and last for 
greater than 2 hours however despite the promise of preconditioning and post conditioning, the 
experimental findings cannot be directly extrapolated to humans due to the fact that no clinical 
study can meet the conditions of experimental studies on preconditioning in which infarct size 
is the end-point (Tomai et al., 1999). 
1.15 PRECONDITIONING  
Ischaemic preconditioning was first described in 1986 by Murrey et al. and involves episodes 
of sub lethal ischaemia which is able to delay necrosis upon myocytes during a subsequent 
lethal ischaemic insult. The studies were done on a canine model with 4 consecutive periods 
of 5 minutes coronary occlusion which were shown to decrease infarct size by nearly 75% 
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when accompanied by a 40 minutes occlusion (Tomai et al., 1999). On a cellular level the 
underlying mechanism is still elusive however preconditioning does result in the activation of 
several different receptor families such as delta-opioid, alpha-adrenergic (Banerjee et al., 
1996), bradykinin and adenosine (Mullane & Bullough 1995). Stress signals seem to play a 
prominent role in ischaemic preconditioning through the activation of signalling molecules 
such as mitogen-activated protein kinases, protein kinase C elevated synthesis of numerous 
protective proteins and the opening of ATP-sensitive K+ channels (Tomai et al., 1999; Healy 
et al., 2015). 
Ischaemic preconditioning induces protection against I/R injury however, ischaemic 
preconditioning requires direct interference with the target tissues blood supply, limiting its 
clinical utility and feasibility because the process can be mechanical and/or pharmacological 
(Healy et al., 2015). Preconditioning in one tissue, such as the kidneys, has been shown 
experimentally to confer protection on distant organs such as the heart (Przyklenk et al., 1993).  
Pre-conditioning has however been shown to be feasible only during electric cardiac 
procedures thus encouraging the search for pharmacological cardioprotective agents that will 
target the reperfusion phase (du Toit et al., 2009). 
 
1.16 POST CONDITIONING 
Brief episodes of ischaemia within the early stages of reperfusion termed as post conditioning. 
This process has been suggested to be just as effective as preconditioning and has been shown 
to protect against I/R injury. Post conditioning perfomrend immediately or within 30 minutes 
after reperfusion is referred to as rapid post conditioning whereas it is considered delayed pos 
conditioning if post conditioning is performed hours or days later (Zhoa 2009). One study 
assessed the beneficial effects and showed post conditioning limits infarct size and improves 
endothelial function in isolated rat hearts subjected to I/R injury (Galagudza et al., 2004). 
Another study showed post conditioning showed a decrease in infarct size by 44% comparable 
with the protective effect of preconditioning (Zhoa et al., 2003). 
The protective mechanism of post conditioning in the myocardium has been confirmed by 
several studies (Zhoa and Vinten-Johansen 2006), in pigs (Iliodromitis et al., 2000) as well as 
in human trials (Straat et al., 2003). The protection offered as a result of pre-conditioning/post-
conditioning is potent, but limited to a narrow therapeutic time window (Simon 2014). In 
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animal experiments, a complex signal transduction cascade was identified which results 
specifically in a reduction of reperfusion injury, this prosurvival kinases are called the RISK 
(reperfusion injury salvage kinase) pathway (to be discussed in later sections). There is 
evidence that also shows that both ischaemic pre- and post-conditioning protects the 
myocardium against subsequent myocardial injuries in patients with coronary artery disease 
(Skyschally et al., 2008).  
1.17 PHARMACOLOGICAL AGENTS IN MI 
Mechanism of pharmacological pre-conditioning, which implores the use of pharmacological 
agents to counteract the burst in ROS and Ca2+ overload are also effective strategies in limiting 
ischaemic injury (Alvarez et al., 2014). Pharmacological agents such as adenosine, a non 
selective adenosine receptor agonist resulted in the same infarct size reduction as was observed 
in preconditioned hearts in rabbit hearts this study by Liu et al. (1999) was the first to show 
adenosine’s therapeutic potential (Sivaraman and Yellon, 2013). Following the success of 
animal studies, the acute myocardial infarction study of adenosine (AMISTAD) proceeded to 
investigate the effect of adenosine in a randomised population of 236 patients treated with 
thrombolysis, results showed 33% relative reduction in infarct size in the group that received 
adenosine and 67% reduction in infarct size amongst patients with anterior myocardial 
infarction (MI) however for this study infarct sizes was determined by single-photon emission 
computed tomography (SPECT) and the end point was a reduction in clinical events 
(Sivaraman and Yellon, 2013). Efficacy of this study was limited to patients with anterior MI, 
however an increase in adverse clinical events was present in patients with non anterior 
myocardial infarction, this is a limitation of the first study as it only evaluated clinical events 
as the end point. The AMISTAD II study studied 2,118 patients with evolving ST-segment 
elevation in myocardial infarction patients undergoing reperfusion therapy and found no 
significant difference in the primary end point between placebo group (17.9%) and the 
adenosine treated groups (16.3%) (Ross et al., 2005). The negative results observed were 
suggested to be from administering AMP579 for an average time of 0.37 hours prior to 
reperfusion whereas in animal studies, evidence for infarct size reduction with AMP579 is 
robust in terms of timing, dosage, and duration of administration. Another explanation for the 
negative results is that an infusion was given with no bolus dose which suggests that the 
concentration of AMP579 was likely not sufficient at the point of reperfusion and for several 
hours after. A2b activity has been shown to play a crucial role in cardioprotection by AMP579 
however, A2b is shown to be a low-affinity receptor that requires a high dose of agonist to result 
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in activity this suggests a negative result may be as a result of the blood concentration of 
AMP579 varying greatly in patients as Ross et al. (2005) stated, steady state concentration of 
the drug was achieved only in 4 to 6 hours. With several adenosine receptor subtypes being 
investigated, such as A1, A2a, A2b, and A3 subtypes, there is a great potential in their possibility 
of reducing the side effects of adenosine and produce better outcomes (Sivaraman and Yellon, 
2013).  
 
As mentioned earlier, therapy for MI is myocardial reperfusion by mechanical or 
pharmacological preconditioning. Animal studies have shown pharmacological agents such as 
bradykinin and adenosine administered prior to reperfusion limit infarct size whereas clinical 
trials have shown administering glucose–insulin-K+-therapy (GIK) 10-11hrs after the onset of 
symptoms drastically improved the clinical outcome of patients by 62% (Quintana et al., 2003). 
However due to the unequivocal positive results GIK is not currently used in clinical practice 
(Doenst et al., 2011). 
The Pol-GIK-trial (Polish- GIK trial) showed in a low-risk MI patient population, study had to 
be terminated prematurely due to the increase in mortality in GIK-treated patients (Dirksen et 
al., 2007). There were substantial differences between different studies particularly with regard 
to the time at which symptoms appear and start of treatment, and regarding the composition of 
the GIK cocktail and the duration of treatment. At present clinical studies support the 
effectiveness of insulin-glusoce infusion in diabetic and acute MI patients admitted to a surgical 
intensive care unit for at least 3 months but treatment needs to be accompanied by meticulous 
glucose regulation. Whether this effect can be effectively translated into routine practice is 
questionable (van der Horst et al., 2002) 
Positive results have been obtained with clinical trials using agents such as CSA (cyclosporine 
A). CSA administered at the onset of reperfusion was established as a pharmacological 
inhibitor which has the ability to prevent mPTP opening and reduce myocardial infarct (MI) 
size in animal models of acute ischaemia reperfusion injury (Ong et al., 2015). This has 
improved the translatability of mPTP inhibition and as a novel therapeutic approach in the 
clinical setting however, CSA is not a specific mPTP inhibitor (Ong et al., 2015). 
Other drugs such as levosimenden with its KATP channel-opening properties administered as a 
pre-treatment has been shown to effectively reduce infarct size where it was proposed that pre-
treatment with levosimenden could be useful before elective cardiac surgery while the post 
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treatment may be useful in acute coronary artery events (du Toit et al., 2009). Clinical trials 
recommended administering levosimendan a day prior to surgery (preoperative therapy 
initiation), this significantly improved the heart parametres in patients undergoing cardiac 
surgery. Study concluded the unique inotropic and cardioprotective properties of levosimendan 
if administered prior to surgery can provide sustained effects for several days which can help 
reduce complications in the postoperative period (Toller et al., 2015). 
Research has shown that adenosine, opiates and bradykinins are endogenously released in cells 
and acts on cell membrane receptors. Results from these studies suggested that selective 
pharmacological antagonists of the δ-or κ-opioid receptor are important triggers/mediators of 
protective response in both acute and delayed preconditioning. All these agents have been 
shown to block IPC and activate the G-protein coupled pathways resulting in a potent 
protective effect (Gross 2003).  
In addition to opioids having potent cardioprotective effects in various animal models, clinical 
studies using isolated human atrial trabeculae that have undergone hypoxic preconditioning 
showed by administering the δ-opioid agonist, DADLE protects the atrial tissue from I/R injury 
(Tomai et al., 1999). Opioid receptors are thought to play important roles in protecting the 
human myocardium during times of stress (Gross 2003). Results from both animal and human 
studies suggest the stimulation of δ- or κ-opioid receptors produce both acute and delayed 
cardioprotective effect (Gross 2003). Same way pharmacological agents have been associated 
with cardioprotection, other agents have been associated with drug induced cardiotoxicity. 
1.18 DRUG INDUCED CARDIOTOXICITY 
As it is becoming apparent that different drugs have the ability to cause serious adverse effect 
or even death (Force and Kerkela 2008). Drug induced cardiotoxicity has become a critical 
factor that needs meticulous attention when administering drug in treating different 
pathologies. Cancer patients seem to survive a lot longer due to the efficacy of drug treatment 
especially the anthrayclines however treatment is usually hampered by drug induced 
cardiomyopathies especially with popular anthracyclines such as result of drug induced 
cardiotoxicity as popular presented upon treatment with popular doxorubicin (Gharanei et al., 
2014). Cardiotoxic risks are therefore a major concern especially with the potential of 
artemisinin as a possible chemotherapeutic agent (Crespo-Ortiz and Wei 2011, Nam et al., 
2007, Lai et al. 2013) 
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In an attempt to establish links in the differential expression of apoptosis-related miRNAs in 
the cardiomyocytes subjected to I/R injury we investigated the expression profiles of certain 
popular miRNA’s such as miRNA1, miRNA27a, miRNA133a, miRNA133b and miRNA155 
against artemisinin treated cardiomyocytes. 
1.19 MICRO RNAS (miRNAS) 
Currently, there is a limited understanding regarding miRNA-mediated apoptotic pathways in 
myocardial injury. Although several studies have showed miRNAs to be important regulators 
of apoptosis and cardiac injury. Depending on the nature of the targeted genes, miRNAs can 
either be pro-apoptotic or anti-apoptotic (Yang et al., 2009). 
Research has shown a large class of small noncoding RNAs which are ~22 nucleotides in length 
in animals, known as miRNAs, function as important regulators of several biological processes 
by modulating gene expression (Salic and Windt, 2012; van Rooj 2011). These miRNAs are 
produced by two RNase III proteins- Drosha and Dicer (Ha and Kim 2014). Their main function 
is post-transcriptional gene regulation upon perfect complementarity based on G•U pairing 
between the target 3′-untranslated region (UTR) and the first 8 nucleotides of miRNA (He and 
Hannon 2004). They also play a major role in many other biological processes such as 
embryogenesis and differentiation, organ development and function, cancer, immunity and 
infection and toxicology/xenobiotics response (He and Hannon 2004). The functional 
characterisation of miRNAs is dependent on the identification of miRNA target genes. The 
dysregulation of miRNAs is related to a variety of disease particularly cancer where they are 
known to play dual functions as both tumor suppressor and oncogenes (Ha 2011; Ha and Kim 
2014). They are believed to be readily circulating in blood, hence the proposition of miRNAs 
as novel biomarkers of disease state, especially for the detection and identification of cardiac 
injury allowing them to emerge as regulators of ischaemia reperfusion (Weiss et al., 2012).  
Recently miRNAs have been implicated in the pathogenesis of cardiovascular diseases (such 
as heart failure, apoptosis and hypertrophy) and their altered expression profiles are currently 
being developed as novel diagnostic and therapeutic markers against cardiovascular disease 
and cancer (Ha et al., 2011; Salic and Windt, 2012; Papageorgiou et al., 2012, Port and 
Sucharov, 2010). 
A study showed, the differential expression of miRNA-1 is closely related with I/R injury in a 
rat model (Tang et al., 2009) and is well documented to be a biomarker for predicting acute 
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myocardial infarction in humans (Salic and Windt, 2012; Tang et al., 2009). miRNA-27a plays 
a pivotal role in the pathogenesis of cardiac hypertrophy and dysfunction and often implicated 
in cancer (Wang et al., 2011; Mertens-Talcott et al., 2007). Both human and rat models 
subjected to I/R injury, left ventricular dilation or myocardial fibrosis presented 
downregulation in miRNA-1 and miRNA-133 thus promoting myocyte hypertrophy which 
could lead to heart failure (Rooij et al., 2008). 
1.20 MEDICINAL HERBS AND CARDIOPROTECTION 
Extract from medicinal herbs are frequently used in attenuating ischaemia reperfusion injury. 
Extracts such as Psidium guajava L. and Limonium wrightii have expressed cardioprotective 
effects in isolated perfused rat hearts where they significantly attenuated ischaemic injury and 
improved myocardial dysfunction after reperfusion (Yamashiro et al., 2003). These drugs are 
believed to function via their radical-scavenging actions (Yamashiro et al., 2003).  
Other traditional herbal drugs have been evaluated in terms of heart failure and myocardial 
energy metabolism and these studies have suggested that cardiac function in patients with heart 
failure can be improved by inhibiting energy production from fatty acid metabolism and/or 
glucose metabolism (Apostolova and Victor 2015, Vogel et al., 2005. This was found to be a 
common feature of the herbal medicines studied in this study, as they mostly contain a multi-
sugar which can be metabolised into single sugar units of sugar that can be beneficial to the 
myocardium and potentially produce the cardioprotective effects (Ma et al., 2011).  
Other antioxidants have also been screened from medicinal plants such as ethanolic extracts 
from Curcuma longa L-EtOH Phyllanthus emblica L-EtOH and Piper rostratum Roxb-
EtOH for protection against doxorubicin induced cardiotoxicity in patients receiving 
doxorubicin treatment which showed a dose dependent cardioprotectiveness (Wattanapitayakul 
et al., 2005). Various other herbal extracts have proved highly effective in curing/managing a 
variety of diseases. Drugs such as aspirin and digitalis have also become a mainstay in the 
treatment of acute/recurrent pericarditis and several cardiovascular disorders respectively 
(Imazio and Adler 2013; Juneja et al., 2012). 
Chinese medicinal plants such as Carthamus tinctorius L. (safflower), are widely used in 
clinical practice in managing angina pectoris. The anti-ischaemic effects of the purified version 
of C. tinctorius (ECT) has also been investigated extensively both in vivo and in vitro (Mohanty 
et al., 2012). More recent discoveries of Chinese herbal drugs such as artemisinin and their 
P a g e  | 27 
derivatives have also proven a mainstay therapy against a variety of diseases especially malaria 
in chloroquine resistant countries and has shown much potential in attenuating myocardial 
injury (Sun et al., 2007). However, artemisinin has been proven to attenuate I/R injury and post 
infarct myocardial remodelling in rats by down regulating NF-kB pathway after MI. Recently, 
artemisinin was also found to suppresses cardiac hypertrophy in primary cultured rat cardiac 
myocyte via the nuclear factor (NF)-κB signalling pathway, by inhibiting genes involved in the 
pathogenesis of myocardial hypertrophy and heart failure (Xiong et al., 2010). 
1.21 ARTEMISININ 
Artemisia annua Linn is a Chinese medicinal plant, extracted and purified from the sweetworm 
wood (Shen et al., 1984). Artemisinin is the active ingredient which contains an endoperoxide 
moiety (Bilia et al., 2014; Krishna et al., 2008; Crespo-Ortiz and Wei 2012). The endoperoxide 
moiety in the artemisinin’s structure has enabled it to become the primary drug of choice 
presently against the P.falciparum and P.vivax malaria parasites (Nakase et al., 2008). 
Artemeether (a derivative of artemisinin) has been shown to be effective as Quinine in the 
treatment of cerebral malaria in children (van Hensbroek et al., 1996). 
Artesunate, artemether and arteether are the more widely used derivatives which are used for 
oral, intramuscular, rectal and intravenous administration (van Agtamael et al., 1999). They are 
mostly used in malaria treatment, where they are universally converted to dihydroartemisinin 
(DHA) in the body, an active metabolite (Melendez et al., 1991).   
Artemisinin’s have a wide range of biological functions as demonstrated in recent years ranging 
from anti-malarial, anti-tumour, anti-viral and anti-inflammatory activities (Lai et al., 2005).  
1.22 ARTEMISININ AND DERIVATIVES 
The artemisinin’s (artemisinin, DHA and arteether) however have been first reported to display 
immunosuppresiveness in vivo in the 1980’s, where they were reported to suppress the antigen-
specific IgM- and IgG-mediated antibody responses and other humoral responses in mice 
(Tawfik et al., 1990; Sun et al., 1991; Shen et al., 1984). Further studies have also shown their 
ability to exert anti-inflammatory action against other disease conditions such as bowel disease 
(Yang et al., 2012). 
Due to the artemisinin’s potent anti-inflammatory and immunomodulatory effects in the 
treatment if rheumatoid arthritis and systemus lupus erythematosus, these therapies provide 
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more efficacious, specific and less toxic effects in the short and long term compared to the 
standard therapies thus offering much promise (Kell 2009; Yang et al., 2012; Choy and Panayi 
2001). 
Artemisinin’s have also been implicated in allergic inflammation (Ho et al., 2013). Artesunate 
was proposed to attenuate experimental allergic asthma via the inhibition of the PI3K/Akt 
signalling cascade and NF-κB activation in 6 to 8 week old female BALB/c which were 
sensitized and challenged with ovalbumin to develop airway inflammation (Cheng et al., 2011; 
Ho et al., 2013). 
1.23 ANTI-VIRAL ACTIVITY OF ARTEMISININ 
There has been a strong demand for alternative anti-viral agents with mechanisms of action 
different from the current anti-cytomegalovirus (CMV) therapies. Presently used anti-CMV 
agents such as ganciclovir, foscarnet, and cidofovir, target the viral DNA polymerase (Efferth 
et al., 2008). Although very efficient in targeting the DNA, elongation in the viruses results in 
a dose dependent adverse effect leading to drug resistance, bone marrow suppression  in 
patients, tetragenicity and so on (Mocarski et al., 2007; Harter & Michel, 2012). Artemisinin 
yet proves itself as an agent with versatile pharmacological effects with its artemisinin’s 
bioactivity and that of its semisynthetic derivative artesunate, which has demonstrated even 
broader versatility. Artesunate amongst other effects has been shown to inhibit viruses, such as 
human cytomegalovirus (HCMV) and some of the Herpesviridae family (herpes simplex virus 
type 1 and Epstein-Barr virus), hepatitis B virus, hepatitis C virus and bovine viral diarrhoea 
virus as shown in Figure 7 (Efferth et al., 2008). 
1.24 ANTI-INFLAMMATORY AND AUTOIMMUNE EFFECTS OF 
ARTEMISININ 
Autoimmune diseases such as multiple sclerosis and rheumatoid arthritis are both lifelong 
disabilities accompanied with a reduced life expectancy. The high safety and tolerability profile 
of artemisinin and its derivatives adds to their attractiveness as a chosen therapy in a variety of 
clinical setting (Efferth et al., 2008). There is increasing evidence that artemisinin and its 
derivatives have immunosuppressive effects (Hou et al., 2014). 
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1.25 ARTEMISININ AS AN ANTIMALARIAL AGENT  
Nearly two billion people are at risk of developing malaria all over the world and an estimated 
one million die of the disease annually from malaria related illnesses (Wang et al., 2010). 
Despite substantial advancements in antimalarial treatment, concerns were growing with the 
use of popular quinines and quinoles in the treatment of malaria (Hara et al., 2007). 
 
In the 1960’s, Chinese scientists demonstrated that artemisinin (Qinghaosu) could clear the 
blood of malarial parasites more quickly than any other drug (Dondorp et al., 
2011).  Qinghoasu was widely used all over China during the 1980s and it took nearly a decade 
before it reached the global stage (Dondorp et al., 2011). The worldwide adoption of the 
artemisinin as efficient treatment to malarial parasite has contributed to significant reductions 
in morbidity and mortality due to malaria in many parts of the world including parts of Africa 
(Uhlemann and Fidock 2012).  
Presently, the artemisinin's and their derivatives are widely administered as the mainstay 
combination therapy against malaria parasites due to their rapid eradication of the parasite, 
efficiency in treating otherwise resistant parasites and clearance at various stages of the 
parasites development as shown in Figure 6 (Krishna et al., 2006). This has led to continuous 
efforts in developing newer derivatives of artemisinin's with higher efficacy for anti-malarial 
treatment that will overcome potential drug resistance (Ho et al., 2014). 
Previous experimental models claim anti-malarial action of artemisinin involves the formation 
of free radicals via cleavage of the endoperoxide bond (-c-o-o-c) in artemisinin’s structure to 
form a carbon based free radical intracellularly which results in the formation of free radical 
oxygen species (ROS) leading to death of the Plasmodium parasites (Lai et al., 2005; We et al., 
2014). Wang et al. (2010) suggested that the artemisinin’s effect as an antimalarial drug is 
through its direct and specific mitochondrial activation. In order to prevent parasites from 
developing resistance to this drug WHO called for a halt in the administration of artemisinin 
as a single pill and requested pharmaceutical companies to sell the drugs as combination 
treatments and not monotherapies (Krishna et al., 2006 Nosten and White 2007). 
1.26 ARTEMISININ COMBINATION TREATMENTS 
Artemisinin based combination treatments (ACTs) are now generally accepted as the best 
treatments for uncomplicated falciparum malaria (Nosten and White 2007). However recently, 
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there have been reports on the emergence of partial resistance in western Cambodia to 
artemisinin, which requires tighter and stricter measures to be placed (Uhlemann and Fidock 
2012). Adhering to the strict rules of the WHO in administering artemisinin will help prevent 
parasite resistance. Additional interventional control measures such as optimal deployment, 
coverage, and midcourse adjustment of containment strategies also remain essential (Dondorp 
et al., 2012). 
1.27 ANTIMALARIAL CARDIOTOXICITY  
Another major concern, which has constantly had the global stage, is the threatening 
cardiotoxicity with the use of a variety of antimalarial drugs (Hara et al., 2006). Effectiveness 
of drugs such as quinines in treating severe malaria in children has been challenged due to poor 
compliance and over 40% fatality (Achan et al., 2011; PrayGod et al., 2008). Parasites have 
been reported to have developed resistance to existing antimalarial drugs which leds to 
drawbacks in the attempt to eradicate malaria (Mwai et al., 2009). Quinines have presented 
cardiotoxic risks such as impaired left ventricular contractility, heart failure and increased risk 
of death (Lipshultz et al., 2004; PrayGod et al., 2008). 
It is well established that different antimalarial drugs present associated neurotoxicity and 
cardiotoxicity in experimental models (Balint, 2001; Kinoshita et al., 2010). With the ACT 
however no study has reported significant cardiac effects at therapeutic doses (van Vugt et al., 
1999; Gupta et al., 2005). A more recent study even showed artemisinin’s cardioprotective 
effect in the myocardium by showing its ability to alleviate myocardial injury and attenuate 
post infarct myocardial remodeling after MI (Sun et al., 2007; Gu et al., 2012). 
1.28 ANTI-CANCER ACTIONS OF ARTEMISININ 
Besides the known action in anti-malarial treatments, artemisinin and its derivatives artesunate 
and dihydroartemisinin have shown potent in vitro and in vivo anti-cancer activity against a 
variety of cancer cell lines (Hou et al., 2008, Singh et al., 2011). The observed pleiotropic 
effects in cancer cells with artemisinin treatment include apoptosis, inhibition of angiogenesis, 
growth inhibition via cell cycle arrest and the disruption of cell migration (Firestone and Sundar 
2009). 
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1.29 TARGET RECEPTORS IN CANCER 
Iron is essential in cell growth and proliferation in both in normal and cancer cells (Heath et 
al., 2013). Cancer cells take up a large amount of iron in comparison to non-tumouric cells, 
with some cancer cells shown to express 5-15 times more transferrin receptors compared to 
normal cells (Nakase et al., 2007, Singh et al., 2001 and Lai et al., 2005) which give rise to the 
selective cytotoxicity of the agents (Crespo-Ortiz et al., 2011 and Lai et al., 2005). Iron 
successfully binds to the transferrin (a glycoprotein attached to iron molecule) which in turn 
binds to the transferrin receptor (TfR), an important step in cellular uptake, pumping iron out 
of cells and re-using the TfR (Daniels et al., 2012). Cancer cells divide uncontrollably due to 
the multiple signals received and over expressed transferrin receptors (TfR) which are usually 
upregulated on cellular surfaces of several cancer types (Wang et al., 2010). 
Artemisinin has been shown to readily conjugate with TfR enabling the internalisation of 
artemisinin with the receptor bound transferrin leading to the formation of free radicals which 
can kill tumour cells (Oh et al., 2009; Lai et al., 2005). Artemisinin-tagged transferrin is highly 
selective and potent and ferrous iron is shown to enhance the anti-cancer efficacy of the 
artemisinin’s up to about ten-fold (Efferth et al., 2004; Lai et al., 2005). 
     
Figure 6. The different pharmacological actions of artemisinin (Ho et al., 2014) 
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1.30 ANTICANCER AND CARDIOTOXICITY 
Anthracyclines are one of the most effective anticancer treatments ever developed but their use 
is hampered by their cumulative dose limiting cardiotoxicity (Ng et al., 2006). Drug induced 
cardiotoxicity is very common in cancer therapy and is emerging as a critical issue amongst 
cancer survivors (Rachi et al., 2010). Drug induced cardiomyopathies ranging from 
arrhythmias, myocardial infarction to heart failure (Adao et al., 2013).  
 
Anthracyclines such as doxorubicin are quite efficient in killing cancer cells however treatment 
is often accompanied with chronic side effects which may even be developed years after 
terminating therapy (Kalyanaram et al., 2002). It is also well documented that anthracylines 
may exacerbate co-morbid effects in patients suffering from heart disease and may be 
responsible for a considerable amount of morbidity and mortality in patients (Adao et al., 2013; 
Daniels et al., 2012). 
1.31 ANTICANCER ACTIVITY OF DOXORUBICIN 
Doxorubicin is a widely used antineoplasmic drug, effective in a wide range of cancers both 
haematological and solid tumours (Ichikawa et al., 2014; Shi et al., 2011). Doxorubicin has 
well documented cumulative and dose dependent cardiac toxicities (Zhang et al., 2009; 
Ichikawa et al., 2014). Cardiotoxicity is a major limiting factor in anticancer therapy (Yeh et 
al., 2004). Manifestations of doxorubicin range from decreased left ventricular developed 
pressure (LVDP) to irreversible cardiac dysfunction, which occurs in more than a third of 
patients (Ramond et al., 2008; Kumar et al., 2012). Toxicity which may be acute or chronic 
cardiomyopathy, both leading to cardiac dysfunction, myopathy and eventually heart failure or 
death (Wallace 2003; Yeh et al., 2004).  
The mechanisms of doxorubicin induced cardiotoxicity have been studied extensively and the 
primary mechanisms responsible for the efficacy of doxorubicin in killing rapidly dividing 
cancer cells is shown to be related to DNA damage. Studies have suggested that the observed 
oxidative damage in the myocardium seen upon doxorubicin administration is due to iron-
mediated ROS activity (Ichikawa et al., 2014). Specifically, the reduction of doxorubicin 
activity by nicotinamine adenine dinucleotide (NADH) dehydrogenase in mitochondrial 
respiratory complex I, to form the superoxide radical (Volkova and Raymond 2011). This is the 
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widely accepted primary mechanism of doxorubicin toxicity, though iron chelator studies 
contradict this theory (Shi et al., 2011). Studies have also shown mitochondrial DNA lesions, 
dysregulation for calcium handling, adrenergic dysfunction and selective inhibition of 
cardiomyocyte-specific gene expression to play a pivotal role in doxorubicin induced 
cardiotoxicity (Zhang et al., 2009).  
It is suggested that cardiomyocytes may be much more sensitive to oxidative stress caused by 
doxorubicin due to their high reliance on oxidative substrate metabolism (Volkova and Rusell 
2011). The pathogenesis and prevalence of doxorubicin induced cardiotoxicity remains 
problematic thus encouraging more studies to detect, prevent and treat/manage the condition 
(Volkova and Rusell 2011). 
Clinical trials in the past have administered doxorubicin in combination with dexrazoxane (a 
cardioprotective drug) and it was shown to reduce the cardiotoxic effects of doxorubicin. 
Dexrazoxane acts by diminishing tissue damage resulting from extravasation of doxorubicin in 
cells (Jordon et al., 2009). However, dexrazoxane has since been withdrawn from the market 
due to the signs of it causing acute myelogenous leukaemia in paediatric patients and secondary 
malignancies in older patients (Tebbi et al., 2007). Prior to that the clinical implementation of 
dexrazoxane labelled it as the first and only proven antidote in anthracycline extravasation 
(Jordon et al., 2009). 
Dexrazoxane has been shown to reduce cardiotoxicity in adults and children with a range of 
tumor types (Swain and Vici 2004). However, cancer occurs mostly in elderly people and its 
predisposition increases with advancement in age (Eschenhagen et al., 
2011).  Pharmacological improvements in cancer therapy has led to an increase in long life 
expectancy for many patients, however, treatment related comorbidities have become an issue 
especially in long term cancer survivors (Bovelli et al., 2011). Clinical trials investigating 
cancer treatments however, presently under-represent vulnerable groups such as the older 
patients and patients with significant comorbidities. Given their mechanism of action, oncology 
patients are generally susceptible to drug induced cardiotoxicity, coupled with age, 
comorbidities, concomitant medication and prior exposure to chemotherapy and radiotherapy. 
The magnitude and risk of adverse effects increases amongst these group of patients thus 
raising the need to develop new cancer therapies that target treatment at a more molecular level 
(Eschenhagen et al., 2011).  
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Adjuvant chemotherapy using the monoclonal antibody, trastuzumab which targets HER2 has 
been shown to significantly improve patient survival rates however trastuzumab, when given 
in combination with anthracyclines, has been associated with asymptomatic and symptomatic 
left ventricular dysfunction which may lead to significant cardiac morbidity leading to the 
premature discontinuation of trastuzumab therapy (Nohria 2013). Some of these studies remain 
ambiguous and inconclusive while some adjunctive therapies used result in a decrease in the 
cytotoxic effects of the anthracycline, making it less efficient for the purpose it was initially 
administered for hence the intensified pressure to develop a cardiotoxic free anthracycline 
(Simunek et al., 2008). 
Cardiac toxicity is one of most feared side effects of anticancer agents, so the gain in life 
expectancy due to anticancer therapy might be countered by increased mortality due to cardiac 
problems such as heart failure, myocardial ischaemia, arrhythmias, hypertension, 
thromboembolism and generally poorer life expectancy as a result as other has been previously 
pointed out (Bovelli et al., 2010). Doxorubicin, a potent and effective anti-cancer agents is 
associated with adverse cardiac effects, including cardiomyopathy and progressive heart failure 
(Doyle et al., 2005). It has also been shown to have other off target effects which may lead to 
serious consequences in non dividing cells such as the brain, with the effects reported to be less 
severe in bone marrow cells due to their rapidly dividing nature (Minotti et al., 2004). Although 
cardiomyocytes divide, they have a limited capacity to regenerate and off targets effects that 
affect the heart may lead to serious life threatening conditions (Minotti et al., 2004). In a study 
by Gharanei et al. (2013), doxorubicin was shown to cause a time dependent reduction in the 
haemodynamic function of the heart as well as cause an increase in the infarct size to risk ratio 
in both naïve and I/R setting. 
1.32 CELL SIGNALLING PATHWAY 
Cellular homeostasis is key to regulating normal cellular functions, it has previously been 
shown to be dependent on the ability of cells to perceive and respond to stimulus appropriately. 
Extracellular and intracellular signals are translated in the cell and converted to cellular 
response such as cell division, cell cycle arrest or apoptosis. This is shown to occur via a 
complex network of signaling cascades which regulate cellular activities such as cellular 
survival metabolism, growth, proliferation, apoptosis and cell migration. These signals are 
transmitted to the cells first via cell surface receptors for appropriate ligand binding leading to 
conformational changes and subsequent phosphorylation/dephosphorylation of proteins that 
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result in the activation or inhibiton of downstream effectors of that pathway. This is presented 
as a response depending on the activated/inhibited pathway (Engelmann et al., 2006). It is 
paramount to investigate cellular signalling associated with drug effects in order to understand 
their applicability.  
1.33 REPERFUSION INJURY SIGNALLING KINASE (RISK) 
Studies by Hausenloy et al. (2005) have established that the recruitment of prosurvival kinases, 
Akt and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) commonly termed 
RISK pathway, confers powerful cardioprotection against myocardial I/R injury making the 
pro survival kinases, important targets for cardioprotection. Further studies have that the shown 
RISK pathway involves the activation of PI3K/Akt or extracellular regulated kinase 
(Hausenloy et al., 2007). PI3K/Akt and ERK 1/2 are parallel branches of the RISK pathway 
that are not independent of each other. Treatment in rat heart models subjected to I/R injury 
and treatment with ERK1/2 inhibitor, PD98059 has previously been shown to lead to the 
phosphorylation and activation of Akt (Hausenloy et al., 2004). 
 
PI3K-Akt pathway is a popular cell survival pathway that has been shown to catalyse the 
phosphorylation of inositol-containing lipids, known as phosphatidylinositol’s which are 
converted to phosphatidylinositol-3, 4, 5-trisphosphate, an important second messenger 
molecule. Previously, implicated in cell growth, survival, motility and metabolism in normal 
and cancer cells (Courtney et al., 2010; Oudit and Penninger, 2009; Ye et al., 2010). The 
cardioprotective role of PI3K-Akt pathway has also been shown in the myocardial I/R setting 
(Jonassen et al., 2004; Mangi et al., 2003; Tsuruta et al., 2002) and in preconditioning setting 
(Hausenloy and Yellon 2003). Upon activation of the PI3K cell survival pathway, its 
downstream targets are phosphorylated. This includes the serine/threonine kinase Akt (also 
known as PKB). The translocation of Akt occurs on Thr 308 on the membrane, which is 
necessary for Akt activation to occur. However, studies have shown that for maximal activation 
of this pathway, an additional phosphorylation at Ser473 by the rapamycin-insensitive mTOR 
complex is required (Sarbassov et al., 2008).  
Activation of the RISK pathway, can promote cell survival by phosphorylating pro survival 
molecules such as Akt, endothelial nitric oxide synthase (eNOS) and p70S6K (Hausenloy et 
al., 2004; Mocanu and Yellon 2003). These studies also showed a decrease in the activation of 
apoptotic proteins such as p53, caspases and members of the Bcl family, BIM, BAD and BAX. 
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Another important pathway, responsible for normal cell proliferation, survival and 
differentitation is the Mitogen-activated protein kinase (MAPK). Although it is not part of the 
RISK pathway, it is related to the extracellular signal-regulated kinase (ERK) pathway. 
ERK/MAPK pathway has led to the development of several pharmacological inhibitors used 
in the treatment of cancer. MAPK/ERK are shown to be activated by the Raf serine/threonine 
kinases. The MAPK/ERK kinase (MEK) 1/2 dual-specificity protein kinases, has been shown 
to activate ERK1/2 an important signalling pathway for cytoprotection (Roberts and Der 2007). 
 
1.34 DOWNSTREAM TARGETS OF PI3K-AKT PATHWAY LEADING 
TO THE ACTIVATION OF THE NITRIC OXIDE PATHWAY 
Signaling dynamics are often influenced by a feedback mechanism. The RISK pathway 
explains signalling through either the PI3K–Akt and/or the MEK1/2–Erk 1/2 cascades will lead 
to the inhibition of apoptosis by inactivating caspases 3 and 9, inactivating pro-apoptotic 
proteins BIM, BAX, BAD and p53 as well as activation of endothelial nitric oxide synthase 
(eNOS) which in turn produces nitric oxide (a ubiquitous molecule linked with homeostasis 
and pathology) (Hausenloy et al., 2003). Nitric oxide is a well-known cardioprotective 
molecule generated via the cGMP/PKG pathway, it is also a major player in the RISK 
(reperfusion injury salvage kinase) and SAFE (survivor activating factor enhancement) 
cardioprotective pathways. Tamareilli et al. (2011) reported the RISK and SAFE pathway 
interact in rats exposed to I/R injury where SAFE pathway inhibitor (AG490) was shown to 
abolish cardioprotection by blocking both Akt and GSK-3β phosphorylations, whereas RISK 
inhibitors (wortmannin or U0126) abolished cardioprotection and blocked STAT-3 
phosphorylation. 
Bose et al. (2005) investigated Glucagon-like peptide 1 (GLP-1), (a gut hormone that 
stimulates insulin secretion) in isolated perfused rat hearts which were previously shown to 
activate anti-apoptotic signaling pathways such as PI3K pathway and MAPK in pancreatic and 
insulinoma cells. Using infarct size as an end point, this study showed GLP-1 added before the 
onset of ischaemia demonstrated a significant reduction in infarction compared with the valine 
pyrrolidide (an inhibitor of its breakdown) This protection was abolished using GLP-1 receptor 
antagonist exendin (9-39), cAMP inhibitor Rp-cAMP, PI3K inhibitor LY294002, and p42/44 
MAPK inhibitor UO126 and results confirmed that GLP-1 protects against myocardial 
infarction in the isolated and whole rat heart models via a multitude of prosurvival kinases.  
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Hussein et al. (2013) also showed that nitric oxide plays an important role in cardioprotection 
against myocardial I/R injury upon administering 2-C-IBMECA (an A3 adenosine receptor 
agonist) which conferred protection via the PI3K-Akt cell survival pathway and the MEK1/2-
ERK1/2. 2-CL-IBMECA administered throughout reoxygenation significantly reduced 
apoptosis, necrosis, cleaved-caspase 3 activity and increased in BAD expression. The 
cytoprotective effect was abolished by co-administration of IBMECA with the kinase inhibitors 
wortmannin and UO126 thus implicating the two pathways in cellular survival. 
 Endogenous nitric oxide is present in normal cellular homeostasis, however it may also be 
generated during ischaemia from both enzymic and non-enzymic sources (Jugdutt 2003). 
Ischaemia- reperfusion, triggers the release or burst of ROS which is followed by a cascade of 
endothelial dysfunction, decreased endothelial nitric oxide synthase (eNOS) and nitric oxide 
(Jugdutt 2003). The release of the free radicals, ROS converts nitric oxide into the detrimental 
peroxynitrite thus contributing to reperfusion injury. However nitric oxide is shown to have a 
ubiquitous role (Andreadou et al., 2015). It is also accompanied by the release of cytokines and 
increase in inducible nitric oxide synthase (iNOS) and excessive nitric oxide production 
(Jugdutt 2003). eNOS derived nitric oxide is shown to be beneficial whereas iNOS 
overexpression may lead to the production of peroxynitrates resulting in cardiotoxicity (Jugdutt 
2003). iNOS upregulation has been implicated in cytoprotective studies in treatments resulting 
from the upregulation of PI3K pathway (Smart et al., 2006). With the role of nitric oxide in 
preconditioning also well documented, administering nitric oxide prior to ischaemia decreases 
the possibility of I/R injury by decreasing peroxynitrite formation this suggests nitric oxide 
may be protective against I/R injury. Knowledge of using nitric oxide in late ischaemic 
preconditioning has been used towards the development of novel anti-ischaemic 
therapy,however role of nitric oxide in post conditioning is not precisely known (Jugdutt 2003; 
Andreadou et al., 2015).  
Studies using cultured endothelial cell from adult male Sprague Dawley rat subjected to I/R 
injury followed by insulin treatment showed that an increase in insulin, led to the 
phosphorylation of eNOS via the PI3K-Akt pathway resulting in an increase in nitric oxide 
production and a decrease in infarct size also implicating the nitric oxide generated via eNOS 
as an anti-apoptotic mediator of cellular survival in this model (Gao et al., 2002). As well as 
nitric oxide syntheisis via the PI3K-Akt pathway, other downstream target such as p70S6K 
have been implicated and shown to protect the myocardium by inactivating BAD expression 
(Steelman et al., 2011). Studies have also associated pro-survival pathways with unrestricted 
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cellular proliferation and decreased sensitivity to apoptotic-inducing agents (Steelman et al., 
2011).  
Previously, PI3K-Akt pathway has been shown to promote cell survival by suppressing Bax (a 
pro-apoptotic member of the Bcl-2 family) translocation from cytoplasm to mitochondria.  
Apoptotic triggers can lead to the translocation of the Bcl-2 proteins to the outer mitochondrial 
membrane. The interactions between pro-survival and anti-apoptotic proteins can distort the 
balance between cell survival and cell death (Indran et al., 2011). 
Mitochondria are considered decisive elements for cell death via their interactions with protein 
kinases and nitric oxide against apoptosis, autophagy, and necrosis (Heusch et al., 2008). In a 
study investigating the involvement of the RISK and SAFE pathway using GH-releasing 
hormone (GHRH), inhibitors of PI3K/Akt and STAT-3 were administered to investigate the 
cardioprotective effects of GHRH. This resulted in a receptor mediated activation of the RISK 
pathway via which the phosphorylation of BAD, eNOS, PKC and GSK occurred. These 
downstream targets have been shown to inhibit the opening of the mitochondrial transition pore 
which leads to cardioprotection (Penna et al, 2013). Another study revealed that Na2S therapy 
activated the Erk1/2 arm of the RISK pathway which leads to cardioprotection in the setting of 
diabetes (Lambert et al., 2014). 
Nitric oxide is a downstream targets of the PI3K-Akt cell survival pathway and is produced by 
the endothelial nitric oxide synthase (eNOS) which is a fundamental determinant of 
cardiovascular homeostasis (Andreadou et al., 2015).Three isoforms of nitric oxide synthase 
(NOS) are known to synthesize nitric oxide in the myocardium. eNOS and neuronal NOS 
(nNOS) are both constitutively expressed isoforms, regulated by cystolic concentrations of 
calcium and cofactors BH4, magnesium and NADPH. The third isoform, inducible NOS 
(iNOS), is a calcium-independent synthase and thought to be dependent upon protein 
transcription (Abu-Soud et al., 2000). The nitric oxide isoform eNOS is known to initiate a 
cascade of molecular events leading to cardioprotection (Kukreja and Lei 2007).  
Nitric oxide has been shown to mediate anti hypertrophic effects (Kapakos et al., 2011). A 
study showed treatment with nitric oxide precursor L-arginine attenuated cardiac hypertrophy 
in hypertensive rats and also shown to improve ventricular function (Heusch et al., 2008). 
Cardiac hypertrophy has been associated with eNOS in angiotensin II deficient mice (Brede at 
al., 2003) whereas iNOS-overexpressing mice have been associated with mild left ventricular 
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hypertrophy, contractile dysfunction, and alterations in respiratory chain complexes (Heusch 
et al., 2008). 
1.35 CELL SIGNALLING PATHWAYS ASSOCIATED WITH 
ARTEMISININ INDUCED CARDIAC PROTECTION IN I/R AND 
WITH ADJUNCTIVE THERAPY 
Previous research have shown that artemisinin elicits the formation of free radicals via the 
cleavage of the endoperoxide bond in its structure in both anti-malarial and anti-cancers studies 
(Golan et al., 2011).  
Several pathways have been implicated in a variety of systems with both artemisinin and its 
derivatives. Artemisinin is believed to involve a diverse array of signalling molecules, 
considering it can elicit broad-spectrum inhibitory effects on several major signalling pathways 
such as MAPK, Wnt, β-catenin, NF-κB, PI3K pathway and so on (Mirshafiey et al., 2006; Xu 
et al., 2007; Hou et al., 2009; Ho et al., 2012; Cheng et al., 2013; Li et al., 2013).  
For example, several studies have shown artemisinin can abrogate metastasis via the NF-κB 
pathway (Weifeng et al., 2010; Lai et al., 2013; Sun, et al., 2011). Ho et al. (2012) showed 
artemisinin was a viable treatment on allergic asthma and suggested its anti oxidative effects 
were via the upregulation of iNOS. 
In a rheumatoid arthritis model also, artesunate suppressed tumour necrosis factor (TNF)-α-
induced production of interleukins, interleukin 1-beta (IL-1β), interleukin-6 (IL-6) and 
interleuking-8 (IL-8) resulting in the inhibition of pro-inflammatory cytokines, inhibition of 
Akt, NF-κB and p38 MAPK (Xu et al., 2007). Artesunate in addition to increasing the 
expression of E-cadherin caused movement of β-catenin from the nucleus to the plasma 
membrane causing apoptosis and reduced tumour growth via the Wnt pathway (Li et al., 2008). 
Experimental studies have suggested that artemisinin limits injury in I/R although the 
associated intracellular pathways remain to be elucidated (Sun et al., 2007).  
 
Pharmacological agents previously discussed have been used to initiate cardioprotection when 
administered during reperfusion .These studies have also confirmed the activation of one both 
or these pro-survival kinase cascades that comprise the RISK pathway (as shown in Figure 7a) 
(Mocanu et al., 2005; Baines et al., 1999, Diaz 2000, Gordon et al., 2003). 
P a g e  | 40 
   
Figure 7a. Activation of pro-survival PI3K–Akt and Erk 1/2 kinase cascades that make up RISK pathway 
(Hausenloy and Yellon 2003) 
Figure 7a show the two two branches of the anti-apoptotic pathway of cellular survival “RISK 
pathway” a term coined by Hausenloy and Yellon (2003). 
Figure 7b. Activation of pro-survival RAS-ERK and PI3K–mTOR which respond to extracellular and 
intracellular signal leading to cellular survival, proliferation, metabolism and motility (Mendoza et al., 2011). 
The Ras-extracellular signal-regulated kinase (Ras-ERK) and PI3K-Akt signaling pathways 
shown to either act independently or may intersect to regulate each other. The two pathways 
are responsible for controlling cell survival and providing compensatory mechanisms that may 
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positively or negatively regulate each other (Mendoza et al., 2011). The intensity and duration 
of the pathway activations are regulated by the strength of the stimulus and feedback loops 
which are responsibe for the cross-talks between pathways (Mendoza et al., 2011). 
The activated ERK phosphorylates cytoplasmic signaling proteins p46 such as the P90 
ribosomal S6 kinase. The nuclear targets involved with the ERK pathway includes the ternary 
complex factor (TCF) transcription factors, which play a major role in inducing the expression 
of immediate early genes which produce c-Fos and c-Myc that are responsible for inducing 
late-response genes that promote cell survival, cell division, and cell motility. The Ras-ERK 
signaling described here can trigger cell cycle arrest (Mendoza et al., 2011). 
The PI3K-mTOR pathway on the other hand regulates the cellular process by directly recruiting 
the growth factor receptors or indirectly recruiting docking proteins such as insulin receptor 
substrate or GRB2-associated binder (Mendoza et al., 2011). This pathways generates 
phosphatidylinositol 3, 4, 5 triphosphate (PIP3), which recruits Akt that is activated by 3-
phosphoinositide-dependent kinase 1 (PDK1) and a second mTOR complex mTORC1, which 
consists of the Ser/Thr kinase mTOR, this is a known as scaffolding protein regulatory-
associated protein of mTOR (RAPTOR). This leads to the phosphorylation of eukaryotic 
initiation factor 4E (eIF4E)-binding protein (4E-BP) and p70S6K. Both responsible for 
promoting cell growth and division (Mendoza et al., 2011). 
1.36 ISCHAEMIA REPERFUSION AND ARTEMISININ 
Previously, Sun et al. (2007), have shown that artemisinin decreases myocardial injury in the 
rat heart model of ischaemia reperfusion injury. Studies have also described artemisinin as a 
major player in a variety of pathophysiological conditions such as antimalarial therapy 
(Krishna et al., 2006), anti-viral activity (Harter & Michel, 2012), anti-inflammatory responses 
(Mirshafiey et al., 2006), cytotoxicity in cancer cells (Ho et al., 2012) and so on. Artemisinin 
is therefore a drug with great potential to be used in a variety of clinical settings, without the 
risk of cardiotoxicity or exacerbation of cardiovascular events (Kinoshita et al., 2010).  
Gu et al. (2012) and Sun et al. (2007) studied artemisinin in the popular off target organ (heart) 
and showed the cardioprotective potential in a post infarct myocardial remodeling model and 
in I/R setting. Hara et al. (2007) also showed the K+ ion changes that occur in the normal 
myocardium may instigate cardiac arrhythmias which they also suggested may affect vascular 
tone in the ischaemic myocardium however treatment with artemisinin resulted in the inhibition 
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of the delayed rectifier K+ current, a voltage-gated K+ current suggesting artemisinin regulates 
malfunctions of the potassium channel which may alleviate cardiac arrhythmia.  
1.37 AIM AND HYPOTHESIS 
Given the important findings that artemisinin has cardioprotective and anti-hypertrophic 
properties. This study hypothesised that artemisinin’s cardioprotectivenesss may be associated 
with the recruitment of the PI3K-Akt cell survival pathway, (an important target of 
cardioprotection and a branch of the reperfusion injury salvage kinase (RISK) pathway), 
mediated via the recruitment of pro-survival kinases such as Akt, p70S6K, nitric oxide and 
BAD. The current study therefore aimed to examine:  
(a) the effect of artemisinin in naïve hearts and in stressed conditions; 
(b) the intracellular signalling pathways associated with artemisinin-mediated 
cardioprotection in isolated perfused hearts and isolated ventricular cardiomyocyte 
models subjected to I/R and H/R injury respectively; 
(c) the differential expression of miRNA upon artemisinin treatment in I/R heart; 
(d) the intracellular signalling pathways associated with co-administering artemisinin 
and doxorubicin in isolated perfused hearts and in isolated ventricular 
cardiomyocytes subjected to I/R or H/R injury respectively; 
(e)  the effect of artemisinins treatment on HL-60 cancer cells, when co-administered 
with doxorubicin and associated pathways. 
In summary, the study aimed to investigate cell signalling pathway associated with 
artemisinin’s cardioprotection in I/R and H/R setting while specifically investigating 
pro-survival kinases PI3K-Akt, its downstream targets such as nitric oxide, p70S6K 
and apoptotic markers such as caspase 3. In addition to that, the study investigated 
the potential of artemisinin as an adjuvantive therapy in ameliorating doxorubicin 
induced cardiotoxicity and its cytotoxicity against HL-60 cancer cell line and 
associated intracellular signalling. 




Adult male Sprague Dawley rats (350-400g) were obtained from Charles River (Margate, UK) 
and kept at the institutional animal house to acclimatise while having free access to food and 
water at all times. The care and use of animals were in accordance with the Guidance on the 
Operation of the Animals (Scientific Procedures Act 1986). The study was carried out upon 
obtaining ethical approval from Coventry University Research ethics committee which was 
regularly assessed throughout the project 
 




de]indeno[4,5,-h]-2-h]-2-benzopyran-3,6,9-trione (Wortmannin) (Selective irreversible PI3K 
inhibitor), 27-epoxy-3H-pyrido[2,1-c] [1,4]oxaazacyclohentriacontine-1,5,11,28,29 
(4H,6H,31H)- pentone (Rapamycin) were purchased from Tocris (Bristol, UK), Nw-Nitro-L-
arginine methyl ester hydrochloride (L-NAME) (Non-specific inhibitor of Nitric Oxide) and 
Aminoguanidine hydrochloride (Selective inducible nitric oxide inhibitor) both supplied from 
Sigma-Aldrich (Poole, UK) and dissolved in dimethyl sulfoxide (DMSO) making sure the final 
concentration of DMSO was less than 0.02% as this does not affect haemodynamics or infarct 
size (data not included) which is then stored at -20 °C. Thiazolyl blue tetrazolium bromide 
(MTT) was purchased from Sigma (Poole, UK). Cleaved Caspase-3 (Asp175) Antibody (Alexa 
Fluor® 488 Conjugate), p-AKTser473, total AKT, p-p70S6 Kinase (Thr389), total p70s6k, p-
BADser136,  total-BAD, GAPDH, iNOS, phospho-eNOS (Thr 495), eNOS Horse radish peroxide 
(HRP) conjugated Rabbit monoclonal antibodies and antibiotin were purchased from New 
England Biolabs (Hertfordshire, UK). SuperSignal West Femto® enhanced chemoluminescent 
substrates were purchased from Pierce (UK). Nitric oxide Assay was purchased from Cell 
Biolabs,Inc (San Diego,USA), the reagents, equipments and primers used for miRNA isolation 
were all purchased from Applied Biosystems, UK: mirVana™ miRNA isolation kit (Ambion, 
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Applied Biosystems, UK),Applied Biosystems MicroRNA Reverse Transcription Kit and 
primer assay set for U6 snRNA, rno-miR-1, hsa-miR-27a, hsa-miR-133a, hsa-miR-133b and 
hsa-miR-155 (Applied Biosystems, UK),TaqMan MicroRNA primer Assays (Applied 
Biosystems, UK) and SYBR Greeen PCR Master Mix (Applied Biosystems, UK). HL-60 cells 
were obtained from European Collection of Cell Cultures (ECACC). 
2.3 ISOLATED PERFUSED RAT HEART MODEL 
Following sacrifice by cervical dislocation, the hearts were rapidly excised and placed in ice 
cold Krebs Heinsleit (KH) solution (118.5 mM NaCl, 25 mM NaHCO3, 4.8mM KCl, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 12 mM Glucose, 1.7mM CaCl2.2H2O) <4 oC and pH 7.4 as described 
previously (Hussain et al., 2014). 
2.4 HEART PERFUSION PROCEDURE 
The aorta was cannulated and retrograde perfusion with KH buffer. The pH of the KH buffer 
was maintained at 7.4 by gassing continuously with 95% O2 and 5% CO2 maintained at a 
temperature of 37 ± 0.5oC using a water-jacketed heat exchange coil and pH 7.4.  
The isolated perfused heart model also known as the Langendorff model measures cardiac 
function in an ex-vivo model at a constant diastoic pressure of 8-10mmHg. The Langendorff 
model has evolved since 1895 when Oscar Langendorff first pioneered the technique as a 
means understanding the underlying physiology of the heart in terms of its contractile function, 
coronary blood flow and cardiac metabolism (Bell et al., 2011). In most recent studies this 
model has been used to probe pathophysiology of ischaemia/reperfusion and other disease 
states as well as study the impact of pharmacological agents and their impact on intracellular 
signalling and in molecular biology and genetics (Bell et al., 2011).  In a normal in vivo heart, 
the coronary system relies on the pressure within the heart to pump blood. Whereas the 
Langendorff model pumps directly into the coronary system allowing constant pressure within 
the heart, while maintaining a steady ejection of KH buffer via the heart chambers. This allows 
the system to maintain pressure and flow while maintaining contractile activity (Bell et al., 
2011; Cheung et al., 2000). 
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2.5 MEASUREMENT OF INDIVIDUAL PARAMETERS: LVDP, HR 
AND CF 
The left atrium was then removed and a water-filled latex balloon was inserted into the left 
ventricle. The balloon was then inflated to a constant diastolic pressure of 8-10mmHg. This 
allows left ventricular developed pressure (LVDP) to be measured. A physiological pressure 
transducer was connected to a bridge amp and a power lab (AD Instruments Ltd, Chalgrove, 
UK) which allows the LVDP, Heart rate (HR) using ECG leads. Coronary flow (CF) was 
measured at regular intervals by collecting the perfusate at the distal end of the perfusion 
cannula. Hearts maintained a steady state of CF, HR and left ventricular developed pressure.  
The experiment was conducted for 175 minutes in total. In the normoxic experiments the 
isolated hearts were perfused for 155 minutes with KH buffer after 20 minutes stabilisation.   
Figure 8a. Langendorff trace showing left ventricular developed pressure and HR 
In the ischaemia/reperfusion studies, hearts were allowed to stabilise for 20 minutes followed 
by 35 minutes ischaemia and 120 minutes reperfusion. The anterior descending left coronary 
artery was ligated to induce regional ischaemia (Figure 8c). This was performed using a hooked 
6-0 silk surgical suture and forceps and piercing through the heart thus ligating the flow to the 
left coronary artery forming a snare with the thread. The thread was passed through a pipette 
tip and the snare tightened to initiate ischaemia (Figure 8c). At the onset of reperfusion, the 
flow of KH buffer was reintroduced via the removal of the pipette tip thus releasing the snare. 
Reperfusion was conducted for 120 minutes (Figure 8a). Below is a schematic diagram of the 
langendoff set up (Figure 8b) and Figure 10 shows an outline of the experimental protocol in 
both the normoxic and I/R protocol. 
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Figure 8b. Schematic diagram of a Langendorff set-up showing perfusion with Krebs buffer solution which is 
oxygenated at the top. Cannula at the bottom of the reservoir inserted into the aorta of the excised heart and 
perfusion is maintained at a constant pressure and flow. Adapted from 
<http://www.sciseek.com/search/images&search=langendorff&type=images> 
Due to the transient ischaemia, myocardial blanching becomes visible at the site of the snare 
and ischaemia is accompanied by a reduced flow through the heart, a drop in LVDP and HR. 
2.5.1 Drug Treatments used in the langendorff protocol 
To profile the effect of artemisinin on infarct size to risk, hearts were subjected to 20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion where artemisinin 0-100µM 
was added into the heart throughout the period of reperfusion (120 minutes) in the I/R studies. 
In order to establish the effective pharmacological concentrations the EC20, EC50 and EC80 
values were calculated as 0.042µM, 0.43µM and 4.3µM. These values were used in the 
presence and absence of PI3-K inhibitor, wortmannin (0.1µM), inducible Nitric Oxide 
Synthases (iNOS inhibitor), aminoguanidine (100µM), Non-selective Nitric Oxide Synthases 
(NOS) inhibitor, L-NAME (100µM) and mTOR inhibitor, rapamycin (0.1µM) (Hussain et al., 
2011).  
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2.5.2 Experimental groups: 
2.5.2.1 I/R treated group 
EC80 being the most cardioprotective concentration was used for the subsequent experiments 
with the inhibitors of PI3k-Akt, p70S6K, non-selective NOS (L-NAME) and selective iNOS 
(aminoguanidine). Hearts were randomly assigned to different drug treatments and allowed to 
stabilise for 20 minutes while being perfused with KH buffer, then subjected to 35 minutes 
ischaemia followed by 120 minutes repefusion where the different drug ± inhibitor 
combinations are administered as shown in Figure 10. One group was treated with artemisinin 
(4.3µM) ± wortmannin (0.1µM) or with wortmannin (0.1µM) alone which was administered 
throughout the period of reperfusion. Another group was treated with artemisinin (4.3µM) ± 
rapamycin (0.1µM) or with rapamycin alone (0.1µM) administered throughout reperfusion. 
Third group was treated with artemisinin (4.3µM) ± L-NAME (100µM) or with L-NAME 
(100µM) alone which was administered throughout the period of reperfusion and the last group 
was treated with artemisinin (4.3µM) ± aminoguanidine (100µM) or with aminoguanidine 
(100µM). 
Upon completing the I/R studies, the left coronary artery was re-ligated in preparation for 
staining the heart with 1ml of 0.2% Evans blue in saline, allowing differentiation between 
viable and tissue at risk. After staining, the hearts were weighed and stored at -20oC for later 
analysis.  
2.5.2.2 Normoxic treated group 
Whereas in the normoxic study, hearts were allowed to stabilise for 20 minutes followed by 
155 minutes perfusion. The following procedures were carried out: For normoxic control 
group, hearts were stabilised for 20 minutes followed by perfusing with KH buffer for 155 
minutes. In the artemisinin treated group, hearts were stabilised for 20 minutes with KH buffer 
only followed by perfusing with artemisinin (4.3µM: the concentration which proved most 
cardioprotective from our previously described experiments). 
Upon completing the treatment protocols, hearts were weighed and stored at -20 °C for 2, 3, 5-
Triphenyl-2H-tetrazolium chloride (TTC) staining or the left ventricle was dissected free.  
 
2.5.3 Triphenyltetrazolium Chloride Analysis 
The hearts were then cut transversely into slices approximately 2 mm thick and incubated at 
37°C in 1% triphenyltetrazolium chloride (TTC) solution in phosphate buffer for 10–12 
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minutes and fixed in 10% formaldehyde for at least 4 hours to enhance the staining prior to 
analysis.  
Thereafter, the heart slices were removed from formaldehyde and placed between two Perspex 
sheets which were compressed with bulldog clips thus maintaining pressure. The heart slices 
were traced onto acetate film and were traced unto the film using different coloured markers to 
differentiate between the viable, at risk and infarct tissue (Figure 8d). The at risk tissue stained 
red and the infarct tissue appeared pale (Figure 9). 
Figure 8c. Image showing a cannulated heart, snare being tightened and ischaemia induced followed by 
staining with Evans blue followed by transverse slicing of the heart for further analysis. Image adapted from 
Bell et al., 2011 
 
Figure 8d. Heart slices placed between two Perspex sheets compressed with bulldog clips (Downey, 1998) 
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2.5.4 Quantifying Results: Infarct size/Risk % Assessment 
The acetate film was scanned into a computer to allow calculation of Infarct to risk ratio from 
the differenciated tissues traced. Areas of viable, at risk and infarct tissue were measured using 
the Image Tool program as developed by the University of Texas Health Science Centre at San 
Antonio, Version 8.1 (UTHSCSA).  
Figure 9. Hearts slices showing the differenciated areas or infarct, risk and viable tissue (Downey, 1998) 
These values were then used to calculate the % infarct to risk ratio. The percentage of 
infarct/risk tissue was calculated for each slice. An average reading for infarct/risk percentage 
for each heart was obtained by averaging the percentages of the individual slices. However, the 
infarct size was calculated as a percentage of the area at risk (area at risk being the area that 
correlates with the entire myocardial perfusion bed distal to the occluded coronary artery) 
(Redford et al., 2012). This is reported to be the most vital, reliable and reproducible way of 
assessing infarct size and has thus been used by several studies in understanding mechanisms 
behind common diseases and also towards developing and evaluating the most appropriate 
treatment strategies against them (Redford et al., 2012). Different hearts are individualistic 
therefore different in size and in terms of haemodynamics and electrophysiology too. Diverse 
morphological differences therefore exist between the hearts sampled, particularly when 
measuring infarct size, this is considered a crucial limitation of the technique hence recent 
studies evaluate infarct size as a percentage of area at risk. However by measuring infarct size 
as a percentage of the area at risk, calculating infarct size thus accounts for variability within 
the groups in terms of dissimilarities in the actual size of the heart and size of the area occluded 
(ischaemia induced) (Graham et al., 2001). This is the most accepted way of determining the 
actual infarct size and may be used for prognosis and evaluation of drug efficacy especially in 
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studies aimed at reducing infarct size or in studying genetic manipulation on the ischaemic 
tolerance of the myocardium (Graham et al., 2001; Liu et al., 2002). 
 
TTC has been shown to stain viable tissue around infarction within hours of infarction whereas 
the more conventiona histological stain which target firbrous scars in disease conditions may 
require several days from time of infarction to euthanising the animal (Redford et al., 2012). 
Thus assessing infarction based as a percentage of area at risk using TTC staining has been 
shown to be an effective way of investigating diseased conditions (Redford et al., 2012). 
The area at risk is thus a potential source of variation in infarct analysis so this study quantified 
it to eliminate possible variabilities and also calculated the significant difference between the 
experimental groups. 
The data obtained was statistically assessed using the SPSS software package. The following 












Figure 10. An outline of the experimental protocol for infarct size assessment in the I/R and Normoxic group 
showing the different treatments and time 
 
2.6 ADULT RAT VENTRICULAR MYOCYTES ISOLATION 
2.6.1 Preparations of buffers and reagents 
Adult ventricular rat myocytes were isolated from Sprague Dawley rats (350-400g) by 
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the hearts were placed in ice cold KH buffer before mounted on a modified Langendorff 
apparatus and perfused with modified calcium free Krebs buffer containing (in mM); 116 NaCl, 
5.4  KCl, 0.4 MgSO4.7H20, 10 glucose, 20 taurine, 5 pyruvate, 0.9 Na2HPO4. 12H2O and 25 
NaHCO3 dissolved in RO water. The buffer was then oxygenated with 95% O2 and 5% CO2 
and maintained at 370C, pH 7.4 using NaOH. 
2.6.2 Isolation of adult rat cardiomyocytes 
The hearts were then perfused for 5 minutes with the calcium free buffer to clear the vessels of 
blood. Hearts were then perfused with a modified KH buffer and collagenase digestion buffer 
with low calcium concentration containing Collagenase 0.075% (Worthingtons Type II) and 
4.4M CaCl2, pH 7.4) at a rate of 7.5ml/min. During perfusion with collagenase the effluent was 
collected and re-used throughout experiment. 
Following digestion, the hearts were removed from the apparatus and cut transversely into a 
basal and apical section. The position of the scission, at the mid-line from base to apex, was 
judged carefully in order to retain most of the right coronary and left anterior descending 
arteries in the basal section thus trimming and discarding the atria away. The ventricles were 
sliced and mechanically dissociated. The tissues were then incubated for 10 minutes in 25ml 
of digestion buffer in an orbital shaker and oxygenated with 95% O2 and 5% CO2.  Thereafter, 
the suspension was passed through a nylon mesh with a pore size 400µm and centrifuged at 
400 rpm for 2 minutes and the supernatant removed. The pelleted cells were re-suspended in 
restoration buffer (RB) (in mM 116 NaCL , 5.4 KCL , 0.4 MgSO4 , 10 glucose ,20 taurine, 5 
Pyruvate, 0.9 NaHPO4 , 5 Creatine , 2% BSA, 50µM CaCl2  and 1% Penstrep pH 7.4 at 37o C) 
where the calcium concentration was gradually brought to 1.25 mM to avoid calcium overload. 
The viability of the isolated myocytes was assessed throughout by visualising the cells under a 
light microscope. Digested hearts with a cellular viability of below 70% were excluded. The 
isolated myocytes were incubated in RB (at 37 oC, 5% CO2 for 24 hours before being used 
(Maddock et al., 2002). Following treatment the isolated cells then underwent quantitative 
analysis using Fluorescence Activated Cell Sorter (FACS) or cellular viability assay using MTT 
reductase. 
2.6.3 Principle behind FACS analysis 
Protein expression within cell populations are assessed using fluorescently labelled antibodies 
and other fluorescent probes which can easily identify cellular patterns (Alvarez et al., 2010). 
The flow cytometer provides high-dimensional quantitative measurement of light scatter and 
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fluorescence emission properties of cellular populations. In a typical analysis, cells are which 
are stained with fluorochrome-conjugated antibodies bind to the cell surface and intracellular 
targets. Within the flow cytometer, these cells are passed sequentially through laser beams 
which excite the fluorochromes thus measuring the emitted light, which is proportional to the 
antigen density (Aghaeepour et al., 2013). The flow cytometry set-up consists of a laser, 
electronics to amplify and process signals, optical system which focuses different coloured 
light unto the detectors, computer and a flow cell (Alvarez et al., 2010). Multiparameter flow 
cytometry was then developed by Paul Mullaney (also at Los Alamos) where he combined and 
improved the measurement of volume, light scatter and fluorescence into one.  
In the current study, FACS was used for the analysis of cardiomyocytes after having undergone 
hypoxia/reoxygenation and different treatment protocols.  In this study, intracellular staining 
for Caspase-3 using Alexa Fluor® 488 conjugate was used to detect myocyte cleaved caspase-
3 expression, iNOS and eNOS expessions were also estimated following drug treatment. Flow 
cytometry is a well-known technique that can analyse and measure physical characteristics of 
cells as they flow in a stream of fluid through an electronic detection devise equipped with a 
beam of light. This allows analysis of physical and chemical characteristics of thousands of 
cells in a short space of time. The main components of the present day flow cytometry 
technique are the (1) flowing saline stream which is the fluid that transports cells through the 
beam of light, (2) the optic system which consists of lasers that illuminate the particles using 
different coloured light, filters and focuses the appropriate lights unto detectors and (3) lastly 
the electronic system that converts the detected light into electronic signals to be processed by 
computer software.  
Fluorescence tagged antibodies can bind to a specific target proteins in a cell and can be used 
to investigate the levels of relative protein expression in a specific sample preparation. This 
fluorescent marker called fluorochrome fluoresces when hit by light. The molecule is excited 
when light of a certain wavelength loses energy and emit light of a longer wavelength excited 
emission. This allows the optical filters to separate lights of different wavelengths. 
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Figure 11. Fluorescein Isothiocynate, a small sized protein that conjugates to protein through the isothiocynate 
group. Fluorescence emitted is proportional to binding site for the fluorescent compound. 
Light emitted can then be detected and converted into electronic signals by a computer which 
will give a readout of the specific fluorescence intensity detected in the sample, which 
corresponds to level of fluorescence tagged anti-bodies bound to the cell or the sample 
population investigated. The relative fluorescence value obtained corresponds to the relative 
protein levels in the sample of interest that were targeted by the anti-body of interest. The 
fluorescence intensity emitted is directly proportional to the binding sites for the fluorescent 
compound on the cell. So the more binding sites there are, the more fluorescence is emitted, 
and the higher the fluorescence intensity as illustrated in Figure 11. 
2.6.4 Experimental Protocol for isolated cardiac myocytes using FACS analysis 
The isolated myocytes were counted using a haemocytometer and resuspended in restoration 
buffer (RB) to a density of 100,000 cells/ml. 1ml of the cells was pooled to be used as normoxic 
control while the remaining cells were centrifuged and the pellet re-suspended in Esumi 
hypoxic buffer (in mM 137 NaCl, 12 KCL, 0.49 MgCl2  0.9,CaCl2, 4 HEPES,20 Na lactate, 10 
deoxy-D-glucose). The myocytes were then incubated in a hypoxic chamber, Galaxy 48R (New 
Brunswick) for 2 hours with atmosphere 5% CO2 95% N2 at 37oC. Following incubation under 
hypoxic conditions, the myocytes were centrifuged at 500rpm for 5 minutes and the pellet was 
resuspended in restoration buffer. The myocytes were then assigned to the different treatment 
groups: artemisinin (4.3µM), artemisinin (4.3µM) ± wortmannin (0.1µM), wortmannin 
(0.1µM), artemisinin (4.3µM) ± rapamycin (0.1µM), rapamycin (0.1µM). The concentrations 
of inhibitors used are based on concentrations used in previous unpublished results of previous 
investigations in the lab. The myocytes then underwent reoxygentaion for 2 or 4 hours. Upon 
completing reoxygenation the cells were then assessed either for cellular viability using MTT 
(Thiazolyl blue tetrazolium bromide) or flow cytometric analysis for the assessment of p-
BADser136, iNOS, eNOS or cleaved caspase-3 activity as described below. 
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2.7 QUANTITATIVE ANALYSIS OF p-BAD (Ser136), T-BAD, iNOS, 
GAPDH, p-eNOS (Ser 1177) AND eNOS (Ser 1177) BY FACS ANALYSIS 
Following the different treatments myocytes were harvested and centrifuged at 1200 rpm for 2 
minutes. The supernatant discarded while the pellet was resuspended in Phosphate Buffer 
Saline (PBS) and fixed with 3% formaldehyde for 10 minutes at room temperature. The fixed 
cells were then put on ice for 1 minute before centrifuging at 1200rpm for 2 minutes and the 
supernatant discarded. 250 µl of ice cold methanol (90%) was added and the samples incubated 
on ice for 30 minutes before being washed twice in incubation buffer (0.5% BSA in PBS) 
following a 10 minutes (at 37°C) incubation of the samples each time followed by 
centrifugation of the samples (at 1200rpm, 2 minutes). 
FACS was used to assess the differential protein levels. For p-BAD (ser136) and T-BAD analysis, 
the samples were probed for 1 hour with either p-BAD (ser136) or T-BAD rabbit monoclonal 
antibody diluted at 1:100 dilution in incubation buffer followed by incubation in Alexa Fluor® 
488 goat anti-rabbit IgG antibody at a dilution of 1:1000 for 1 hour. For iNOS and GAPDH, 
the samples were also probed for 1 hour with iNOS or GAPDH rabbit monoclonal antibody 
diluted at 1:100 dilution in incubation buffer followed by incubation in Alexa Fluor® 488 goat 
anti-rabbit IgG antibody at a dilution of 1:1000 for 1 hour. For p-eNOS and e-NOS the samples 
were also probed for 1 hour with p-eNOS (Ser 1177) and eNOS (Ser 1177) rabbit monoclonal antibody 
diluted at 1:100 dilution in incubation buffer followed by incubation in Alexa Fluor® 488 goat 
anti-rabbit IgG antibody at a dilution of 1:1000 for 1 hour. 
At the end of the incubation period, the cells were centrifuged and the supernatant was removed 
the cells resuspended in 500µl PBS and analysed using flow cytometer (Becton Dickinson, 
Oxford, UK) on the FL1 channel to count 10,000 events  (Vermes et al., 2002; Hussain et al., 
2014).  
2.8 QUANTITATIVE ANALYSIS OF CLEAVED CASPASE-3 
ACTIVITY 
Cleaved caspase-3 (Asp175) Antibody (Alexa Fluor 488 conjugate) purchased from New 
England Biolabs (Ipswich, UK) was used to detect the cleaved caspase-3 a pivitol effector 
caspase in apoptotic signalling (Sakamaki and Satou 2009). Activation of caspase-3 requires 
P a g e  | 55 
proteolytic processing of its inactive zymogen into p17 and p12 fragments. The antibody 
detects endogenous levels of large fragments of cleaved caspase-3 (Sakamaki and Satou 2009). 
At the end of the experimental protocol the cells were harvested from a 24 well plate and 
transferred to a labelled 1.5 ml microfuge tubes containing treated cells and controls were 
centrifuged at 1200 rpm for 2 minutes. The pellet was then resuspended in Phosphate Buffer 
Saline (PBS) and fixed with 3% formaldehyde for 10 minutes at room temperature. 
The cells were then fixed on ice for 1 minute before centrifuging at 1200 rpm for 2 minutes 
following aspiration of the supernatant. 250 µl of ice cold methanol (90%) was added and the 
samples incubated on ice for 30 minutes. Myocytes were subsequently washed with incubation 
buffer twice (0.5% BSA in PBS) and blocked with incubation buffer for 10 minutes and spun 
again at 1200 rpm for 2 minutes (at 37°C). The cells were then fixed for 10 minutes at 37oC 
and put on ice for 1 minute before centrifuging at 1200 rpm for 2 minutes following aspiration 
of the supernatant. 250 µl of ice cold methanol (90%) was added and the samples incubated on 
ice for 30 minutes before being washed twice in incubation buffer (0.5% BSA in PBS) 
following a 10 minutes (at 37°C) incubation of the samples each time followed by 
centrifugation of the samples (at 1200rpm, 2 minutes). The antibody was prepared to 1:100 
final dilution in incubation buffer.  The cells were then incubated in incubation in Alexa 
Fluor® 488 goat anti-rabbit IgG antibody at a dilution of 1:1000 for 1 hour in the dark at room 
temperature. The cells were then spun at 1200 rpm for 2 minutes and washed with incubation 
buffer twice. At the end of the incubation period, the cells were centrifuged and the supernatant 
discarded. The pellet was then resuspended in 500µl PBS and analysed using flow cytometer 
(Vermes et al., 2002). Samples were then analysed using the flow cytometer (FACS, Becton 
Dickinson, Oxford, UK) on FL-1 channel and set up to count to 10,000 events. 
2.9 CELLULAR VIABILITY ASSAY BASED ON MTT REDUCTASE 
ACTIVITY USING ISOLATED VENTRICULAR 
CARDIOMYOCYTES 
After 2 hours of hypoxia/reoxygenation respectively, the cells were subjected to MTT assay to 
measure succinate dehydrogenase activity. This assay measures the ability of NADPH-
dependent cellular oxidoreductase enzymes within viable cells to reduce MTT tetrazolium dye 
from yellow to purple (as shown in Figure 12, Figure 13). Cells were placed into a 96 well flat-
bottomed microtitre plate with 50 µl of cells (containing 1 x 10-4 cells.ml-1) per well. 10 wells 
were used as control and contained 100µl of restoration buffer. Other wells were used for the 
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different treatment groups which contained 50µl of cells and 50µl of drug treatment. Drugs 
used for this study were diluted with restoration buffer to a final concentration of 4.3µM in the 
artemisinin treated group, 0.1µM in wortmannin treated groups, 0.1µM in rapamycin treated 
groups, 100µM in L-NAME treated group and 100µM in aminoguanidine treated group.  
 
The total number of cells was calculated in order to determine the volume of RB to resuspend 
the cells in and obtain 10,000 cells per ml, this was determined using a nucleo counter 
(Chemometec, Sartorius, and Surrey, UK). 1ml of cells was stored for normoxic control and 
1ml for hypoxia/reoxygenation control. 6 wells were used for each concentration of the 
experimental groups used.  Cells were then incubated for 2 hours under hypoxic conditions. 
Drugs were administered at the start of reoxygenation and cells were incubated for an 
additional 2 hours with 20µl of MTT (MTT solution consisting of 5mg.ml-1 in PBS (10g for 
10-4 cells/well) was added at reoxygenation except for the blanks which contains restoration 
buffer and MTT solution.  Cells were incubated in the dark at 370C for 2 hours. Upon 
completing the 2hours reoxygenation, myocytes were subsequently lysed with 100µl of lysis 
buffer (20% SDS in 50% dimethylformamide) and incubated on an orbital shaker and incubated 
overnight at 37o C. Calorimetric analysis of the plate was done to measure the fluorescence 
emission at 450nm (Thermo Scientific, UK) using a plate reader (Anthos 2001). 
Figure 12. The principle behind the formation of formazan from NADPH-dependent cellular oxidoreductase 
enzymes within viable cells which reduces MTT tetrazolium dye from yellow to purple. Adapted from (NBSBio, 
2010).  
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Figure 13.  MTT assay showing a yellow tetrazole in the first two columns (control) which was reduced to 
purple formazan showing the proportion of living cells in the wells. Adapted from 
http://www.nature.com/nprot/journal/v3/n3/images/nprot.2007.517-F1.jpg 
The absorbance was measured for the different treatment groups. The effect of the artemisinin 
treatment was obtained by subtracting the absorbance from the control values.  Graphs were 
made using the mean absorbance of the drug treated group as a percentage of the mean 
absorbance of the control group.   
2.10 CYTOTOXICITY ASSAY BASED ON MTT REDUCTASE 
ACTIVITY USING HL-60 CELL LINE 
Human leukaemia cancer cell line HL-60 was obtained from the European Collection of Cell 
Cultures (ECACC). The cells were cultured in RPMI 1640 media without L-Glutamine 
(Biosera, Ringmer, UK) which was supplemented with 10% fetal bovine serum, 2mM L-
glutamine, HEPES and 0.1% antibiotic solution (100 U/ml penicillin, 0.1mg/ml streptomycin; 
Invitrogen Paisley,UK). The cells were maintained at 37°C under a humidified atmosphere and 
5% CO2. Cell viability was measured using an electronic counter (NucleoCounter ®) and 
culture plastics purchased from Thermo Scientific (Roskilde, Denmark). 
In the MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay a yellow 
tetrazole was reduced to purple formazan which was proportional to the amount of living cells, 
thus determining the number of viable cells incubated per plate. Incubation was at 37°C and its 
duration was based on results of assay optimization experiments from previous experiments in 
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the lab (data not presented). HL-60 cells (1x104cells/well) were plated in 96-well flat-bottomed 
microtitre plates, and treated with varying concentrations of Artemisinin (10-1000µM), 
Artesunate (0-60µM) and Dihydroartemisinin (0-60µM) for 24 hours. At the end of the 
incubation period, the cells were terminated by adding MTT solution (20µl of 5mg/ml MTT to 
each well) and further incubated for 2 hours at 37°C. 100µl of lysis buffer (20% sodium dodecyl 
sulfate in 50% dimethyl formamide) was then added to each well containing treatment and 
control samples. 
The plates were incubated overnight to solubilise the cells. The absorbing intensity of each well 
was determined at 492nm using a plate reader (Anthos 2001). This measures the percentage of 
cell growth calculated using the following formula;  
% Cell Growth = (average absorbance of treated wells for Artemisinin/average absorbance of 
untreated control wells) x 100%. 
The experiment was repeated three times and IC50 values for artemisinin was estimated using 
the 4-parametric logistic analysis (Grafit Software, Erithacus, UK). The mean calculated IC50 
value was then used in subsequent experiments in the chapters to follow. 
Dose–response titration was plotted for artemisinin, artesunate dihydroartemisinin to yield 
concentrations of half-maximal inhibition (IC50).  
Using MTT assay in cancer cells is a widely accepted method of measuring cell proliferation. 
It determines the number of live cells per well as a percentage of control thus allowing accurate 
representation of drug exposure to cancer cells. Despite its limitation it is a rapid and cheap 
way of assessing cellular proliferation calometrically and it is proven to be valid, accurate and 
easily reproducible method of analysis. 
Detection sensitivity however varies widely among different cell types, depending on the 
metabolic activity of the cell type being tested. Typically HL-60 cells proliferate quickly and 
are easy to culture. Due to these reasons and the widely available validation of MTT assay 
using HL-60 cancer cells by many researchers, this study chose to use HL-60 cells.  
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2.11 NITRIC OXIDE ASSAY USING THE OXISELECT™ IN VITRO 
NITRIC OXIDE CALORIMETRIC ASSAY 
Nitric Oxide is an important mediator in the pathogenesis of several diseases (Isenovic et al., 
2011; Raij 2006). Reactive nitrogen intermediates (RNI) and reactive oxygen intermediates 
(ROI) especially, have been shown to damage cells by inactivating the metabolic enzymes and 
damaging important cellular components which exacerbate diseases such as ischaemia, 
atherosclerosis, inflammatory diseases and cancer (Rahman et al., 2012; Isenovic et al.,  
2011). At the moment, the concept of oxidative stress does not include ‘nitrosative stess’ which 
includes RNI such as nitric oxide (NO), peroxynitrite and, recently, to S-nitrosothiols which 
have been shown to react with proteins, carbohydrates and lipids, with consequent alterations 
to intracellular and intercellular homeostasis, leading to possible cell death and regeneration 
(Rahman et al.,2012). 
 
Figure 14. Schematic representation of nitric oxide and nitric oxide intermediates and their effects on normal 
cellular homeostasis to cell death. Adapted from <http://file.scirp.org/Html/8-7300384/9f214aba-c126-45e5-
874d-3721fd603aa4.jpg> 
Due to the extremely short half-life and difficulty in quantification of NO, total NO is measured 
as the sum of the oxidized nitrate and nitrite (Bryan and Grisham 2007) which offers valuable 
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information regarding NO bioavailability and metabolism. Nitrate in the sample is converted 
to nitrite by nitrate reductase enzyme. The OxiSelect™ quantitatively measures this using the 
Greiss reagents, a coloured azo dye which absorbs at 540nm. 
2.11.1 Experimental protocol using the Nitric Oxide assay 
Adult ventricular rat myocytes were isolated from Sprague Dawley rats by enzymatic 
dissociation method as in the previous protocols. Myocytes were counted using a 
haemocytometer and resuspended in restoration buffer (RB) to a density of 100,000 cells/ml.  
2.11.2 Preparation of Samples 
Samples are filtered through with 10kDa MWCO ultrafilter to reduce protein interference and 
turbidity. 
2.11.3 Preparation of standards 
Reagents are prepared according to manufacturer’s instructions. With unused stock aliquoted 
and frozen to avoid multiple freeze thaw cycles. 
Nitrite and nitrate standards were prepared by making a dilution series of concentration range 
0-140µM from a standard 14mM of the nitrite and nitrate provided in the kit in restoration 
buffer. Potential interference was prevented by diluting the nitrate and nitrite standard in the 
same buffer as the samples, although this can compromise sensitivity. 
2.11.4 Assay Protocol 
Nitrate levels in the samples were measured by subtracting nitrite only from total nitrite and 
nitrate. 
Nitrate= Total nitrite + nitrate -Nitrite only 
2.11.5 Measurement of Nitrite only 
 50µL of nitrite standards, samples or blanks were added to a 96 well plate 
 50µL of PBS was added to each of the wells 
 50µL of Griess Reagent A was added to each well 
 Plate was incubated at 10 minutes, this allowed the colour to develop and absorbance was 
read at 540nm on a microplate reader 
Concentration of nitrite was calculated by comparing sample absorbance to standards 
Negative Control without nitrate were subtracted 
Each nitrite standard and sample was assayed in duplicate 
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2.11.6 Measurement of Total/Nitrate via Nitrate Reduction 
 50µL of nitrate standard, samples or blanks to the 96 well plate 
 Enzyme reaction mixture was prepared for the number of tests to be performed 
 Appropriate volume of diluted enzyme cofactor is added (1:100 dilution in deionized 
water) and vortexed 
 50µL of the enzyme reaction mixture is added to the wells containing the sample/nitrate 
and covered with foil  
 Plates are then incubated for 1 hour at room temperature on an orbital shaker 
 50µL of Greiss Reagent A is added and vortexed followed by Gneiss Reagent B 
 Plate is incubated for a further 10 minutes for colour development 
 Absorbance is then read at 540nm 
The sample’s absorbance is then calculated by comparing the Nitrate and standard curve. 
 
2.12 WESTERN BLOTTING  
2.12.1 Introduction to Western blotting 
Western blotting, also called immunoblotting is a commonly used analytic technique used to 
detect identify and quantify fractioned proteins based on its molecular weight, charge and 
conformation. The protein is extracted from an extract of tissue or cell homogenate. Proteins 
are separated based on the size by gel electrophoresis and transferred unto a PVDF membrane 
by immunoblot transfer (Mahmood and Yang 2012). The proteins then adhere to the membrane 
in the same pattern as they have been separated due to interactions of charges. They are then 
probed with specific primary and secondary antibody of the protein of interest. The membrane 
is then developed for the visualization of specific protein bands to measure the relative density 
of each protein. The size of the tagged protein is detected by imaging which then determines 
the accurate molecular weight of the target protein. The molecular weight of which corresponds 
to a band on the marker weight marker used. However the effectiveness of this technique can 
be limited to high levels of nonspecific background staining which can limit the identification 
and/or quantification of band intensity (Olle et al., 2005). 
2.12.2 Tissue Preparation 
At the end of the Langendorff experiment, tissues were harvested for western blot analysis. 
The hearts collected underwent 20 minutes stabilisation, 35 minutes ischaemia and varying 
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reperfusion times (10 minutes, 20 minutes, 60 minutes and 120 minutes) in the presence and 
absence of artemisinin and the inhibitors. This reperfusion times are based on established 
protocols used in our lab, with 10 minutes reperfusion sample ran in the cell signalling studies. 
Upon completing the experimental protocol, the hearts were removed from the Langendorff 
apparatus and the left ventricles were cut off using a sterile scalpel which was then snap frozen 
in liquid nitrogen and stored at -80°C for further analysis. 
2.12.3 Protein Extraction  
Proteins were extracted from the stored frozen samples. Approximately 60mg of the frozen 
ventricular tissue sample was placed in a sterile cryogenic vial containing 250 μl of cold 
suspension buffer (100 mM NaCl, 10 mM Tris, 1 mM EDTA, (pH 8.0), 2 mM Sodium 
pyrophosphate, 2 mM sodium fluoride, 2 mM β-glycerophospahte, 0.1 mg/ml PMSF, Roche 
Complete™ protease tablet followed by high speed centrifugation using IKA Labortechnik T25 
homogeniser at 11,000rpm at 4oC for 10minutes). The supernatant were assessed for protein 
concentration using the Nanodrop spectrophotometer ND1000 (Thermo Scientific, UK) at 
280nM. The samples were then diluted with an equal volume of sample buffer (312mM Tris-
Cl pH6.8, 50% Glycerol, 0.15% Bromophenol Blue, 2.5% SDS) followed by heating for 5mins 
at 95oC and centrifuging for 30secs at 5000rpm. The remaining of the undiluted protein samples 
were stored at -80°C as stock protein concentrations.  
2.12.4 Gel electrophoresis  
60 µg of protein sample was loaded unto Biorad 4-15% Tris/Glycine precast gradient gels 
(Biorad, Hertfordshire, UK). The gel was then attached to the Mini-PROTEAN 3 electrode 
assembly system (Biorad PowerPac 3000) with the short plates facing inwards and run at 130 
volts for 90 minutes. The electrode assembly was then placed into the clamping frame and 
securely closed. The inner chamber is then lowered into the Mini Tank which was placed in the 
Biorad mini protean III system (Bio-Rad, UK) which separates out the samples.  
Approximately 125 ml of running buffer (glycine 14.42 g/l, SDS 1.0 g/l, Tris 3.0 g/l) was added 
to the inner chamber of the system and about 200 ml added to the outer chamber. The plastic 
combs were removed to expose the wells and samples loaded into the appropriate wells using 
gel loading tips (Fischer). A protein molecular marker (Cell Signalling Technologies, UK) with 
bands of specific molecular weight was also loaded to one of the wells for identification of the 
target protein. The gel was then run by attaching electrical leads from the Mini-PROTEAN 3 
apparatus to the Power-Pac using the Power-Pac 3000 at 130 volts for 90 minutes. 
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2.12.5 Protein transfer  
The gels were then transferred to a Polyvinyl Di fluoride (PVDF) membrane using the Trans-
Blot Turbo transfer packs (Bio-Rad, UK) assembled in accordance to the manufacturer’s 
guidelines. Turbo transfer mixed molecular weight transfer settings were selected on the 
transfer system to transfer at 25V, 1.3 A for 7 minutes when using two gels.  
2.12.6 Immunoblot Transfer Procedure 
The PVDF membrane was washed in Tris-buffered Saline Tween 20 (TBST) and incubated 
with blocking buffer (5% milk in (TBS) Tween 20 TBST) for an hour facing upwards. The 
membrane was washed 3 times in TBST and then incubated overnight on an orbital shaker at 
4oC with the primary antibody phospho-AktSer473 or phospho-p70S6K (Thr 389) rabbit monoclonal 
antibody at a dilution of 1:1000 for 12-14 hours.  
After the incubation, the membrane was washed 3 times in TBST and then incubated in a 
1:2000 dilution of Anti-rabbit antibody HRP linked IgG and HRP linked anti-biotin antibody 
orbital shaker at room temperature for 1 hour. The membrane was washed again 3 times in 
TBST before imaging.  
Upon capturing the images of the relative changes in density, the blots were then stripped of 
the phospho-antibody (p-Akt (Ser 473) or p-p70S6k (Thr 389)) by boiling in water for 5 minutes and 
membranes re-probed for T-Akt or T-p70S6K by incubating in (5% milk in TBST) for an hour, 
then incubated overnight on an orbital shaker at 4oC for Totals (T-Akt and T-p70s6k) at a 
dilution of 1:1000. After the overnight incubation, the membrane was washed 3 times in TBST 
and then incubated in a 1:2000 dilution of Anti-rabbit antibody HRP linked IgG and HRP linked 
anti-biotin antibody. Immunoblots were detected on the Biorad™ ChemiDoc imaging system 
as done earlier. 
2.12.7 Quantification of band density using Chemiluminescent Phospho-imagery 
The immunoblots were used to detect the proteins by using the enhanced chemiluminescence 
substrates. Membranes were placed on a piece of acetate sheet with 1 ml of Super Signal West 
Femto (Fischer Sceintific, Loughborough,UK) which was prepared by combining reagent A 
and B in 1:1 dilution and was added on top of the membrane prior to use while keeping it away 
from light. The solution was spread over the entire surface of the membrane with excess 
substrate dripped off. The membrane was then placed into the using the Biorad™ ChemiDoc 
imaging system (Bio-Rad, UK). Using the Bio-Rad Quantity One software the membrane is 
exposed for 10-30 seconds allowing the proteins bands to be visualised. Band density was 
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analysed by taking into account background exposure for the blot using Image J (N.I.H, 
Bethesda, USA) and accurately identifying the target protein. 
2.13 miRNA PROTOCOL 
2.13.1 Evaluation of miRNA profile of the isolated perfused heart tissue following 
Artemisinin treatment 
2.13.1.1 qPCR for the determination of miRNA expression in the myocardium. 
Hearts were subjected to the different treatments as described in the isolated perfused rat 
heart model with the exception of inserting the latex balloon for haemodynamics readings. 
Following the Langendorff perfusion, the left ventricle was dissected and chopped into 
smaller pieces and transferred into 2ml RNase/DNase free microfuge tubes containing 
500ml of RNA later solution (Ambion life technologies, Paisley, UK) which was then 
stored in a – 20 ºC freezer until use. 
 
Quantitative reverse transcriptase PCR was used to analyse the expression of cardiac injury 
specific miRNAs (miR-1, miR-27a, miR-133a and miR-133b) and a miRNA involved in 
cancer development miR-155.  
2.13.1.2 miRNA extraction from isolated ventricular tissue following Artemisinin treatment 
in the isolated perfused heart model 
miRNA was extracted using the Mirvana™ miRNA Isolation kit (Ambion, Applied 
Biosystems, UK) in accordance with the manufacturer´s instructions. The homogeniser 
(IKA Overtechnical T25) was cleaned with with with RNase/DNase free ethanol (Fischer, 
UK), ZAP solution and RNase free H20 (Ambion Life Technologies Paisley, UK). The 
RNA later solution in which the sliced ventricles were placed was discarded and 1 ml of 
lysis buffer (Ambion Life Technologies Paisley, UK) solution was added to the tissue 
which was placed in ice. The samples were then homogenised using the IKA Overtechnical 
T25 in ice, making sure that the samples remained cool to prevent denaturation of the 
RNAs by over homogenising. 30 μl of miRNA homogenate additive (Ambion Life 
Technologies Paisley, UK) was added to the tissue lysate, vortexed and incubated on ice 
for 10 min. 
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Using the extraction hood, 300µl of chloroform (Ambion, UK) was added to the microfuge 
tube containing the tissue lysate.  The samples were then vortexed and miRNA 
Homogenate Additive was added, vortexed again and centrifuged at 12,000 rpm at room 
temperature.   The upper phase (containing RNA) was transferred to new RNAase free 
microfuge tubes while the lower phase (containing chloroform and phenol) was carefully 
discarded. The sample was subsequently spun for 5 min at 10,000g using (mikro 200R 
Hettich Zentrifuge). Some RNAase free H2O is heated on a heating block at 95 ºC for 
elution. The upper phase which has been transferred into a new RNAase free tube (while 
noting the volume transferred each time for the different sample). 
1.25 x volumes of 100% RNAase free ethanol (EtOH) was added to the aqueous phase 
collected (ie. to 500 μl of upper phase collected; 625 μl of EtOH was added). The mixtures 
were centrifuged through a spin column into a collection tube for 15 seconds at 12,000 
rpm at room temperature. Maximum volume filtered at a time was 700 μl so the process 
was repeated until all of the mixture is filtered. The effluent was discarded and the spin 
column was washed with 500 µl of Wash Solution 1 (Ambion, UK) which was filtered 
through the filter cartridge and then centrifuged for 15 seconds at 12,000rpm at room 
temperature. The flow through was discarded. Next, 500μl of wash solution 2/3 was added 
to the spin column and centrifuged for 15 seconds at 12,000 rpm at room temperature. The 
last wash was repeated at the same speed. The filter was then spun with the emptied 
collection tube for 1 min at 12,000 rpm to remove any residual fluid and a new filter placed 
in a newly marked collection tube. 
50 μl of 95 °C warm RNase free water (Ambion, UK) was added to this new spin column 
and incubated for 1 min. The spin column/ collection tubes were centrifuged for 20 seconds 
at 12,000rpm, at room temperature. The flow through contained the extracted miRNA 
which was collected and stored in – 20 ºC freezer. 
2.13.2 Quality control 
The quantity and quality of RNA obtained was measured using the nanochip bioanalyser 
(Quiagen) and nanodrop-1000 spectrophotometry (NanoDrop Technology, Delaware, USA).   
Nanochip Bioanalyser (Qiagen). 
The nanochip bioanalyser (Qiagen) was used to assess RNA quality, 1μl of RNA (~250ng) was 
used. The RNA electrodes were thoroughly cleaned with RNA RNAZap (Ambion, UK) and 
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Deionised water. The samples to be run and the RNA 6000 Ladder were heated to 70°C for 2 
minutes to thaw and placed on ice until use. The filtered gel matrix was then prepared by adding 
550μl of RNA matrix into a spin filter and centrifuged at 1500 × g for 10 minutes. 65μl of the 
eluate and 1μl of RNA dye is then added to the RNAase-free tubes and placed on ice which 
was then centrifuged at 13,000 × g for 10 minutes. 9μl of this gel dye mix was used to prepare 
the RNA 6000 nanochip in the chip priming station (which is located on well C4). Upon 
priming the chip, an extra 9μl was then added into each well of the chip marked with a G (that 
is well A4 and B4). 5μl of RNA 6000 Nano Marker was then placed into the remaining 13 
wells of the chip with1μl of each sample and 1μl of RNA 6000 Ladder added to the appropriate 
wells on the chip. The chip was then vortexed for 1 minute and used for the Eukaryotic total 
RNA Nano assay. 
2.13.3 Nanodrop-1000 spectrophotometry  
Nanodrop-1000 spectrophotometry (NanoDrop Technology, Delaware, USA). Was used at an 
absorbance of 280 nM to determine the RNA integrity number (RIN). This ensures high purity 
levels from the extracted RNA. The eluate which contained the RNA was collected and stored 
at -20°C for RT-PCR and qPCR. 
2.13.4 Reverse transcription reaction 
Quantitative polymerase chain reaction, also called quantitative real-time reverse transcription 
polymerase chain reaction (qRT-PCR) or RT-PCR. A widely used technique used to detect, 
amplify and quantify specific sequences in a DNA molecule.  The technique involves 
conversion of RNA into complementary DNA (cDNA) using reverse transcriptase. The cDNA 
is then used as a template for exponential amplification using PCR. For each cycle run, RNA 
levels are duplicated. The amplified RNA can then be quantified using the computer software. 
To convert RNA template into a complementary DNA (cDNA), 500 ng miRNA was reverse 
transcribed for U6 snRNA, rno-miR-1, hsa-miR-27a, hsa-miR-133a, hsa-miR-133b and hsa-
miR-155 using the Applied Biosystems MicroRNA Reverse Transcription Kit and primer assay 
set (Applied Biosystems, USA) according to the manufacturer's instructions. miRNA 
expression patterns were assessed by reverse transcription MicroRNA Assays (Applied Bio 
systems) followed by QP using the different stem-loop primers.  
DNA/RNA free microfuge PCR tubes were labelled and the following was added: 
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For each RT reaction 0.3µl of 100 mM dNTPs, 1.5µl of MultiScibe™ Reverse Transcriptase, 
3µl of 10x RNase buffer, 0.3μl of RNase Inhibitor and 0.5µl of the different TaqMan miRNA 
primers x 6 = 3µl TaqMan RT PCR miRNA primer mix (making a total of 8.1µl of RT PCR 
Master mix master mix) . A total volume of 30µl for the reaction, 21.9µl being nuclease water 
which was added to each well. 
For each RT reaction below were the reagents used; 
  1x reaction 10x reaction 
1 100 mM dNTPs                0.3µl   3.00 μl 
2 Multi Rev Trans 1.5µl   15.00 μl 
3 10x RT buffer 3.00 μl 30.00 μl 
4 RNAse inhibitor               0.3 μl 3.00 μl 
5 U6 0.50 μl 5.00μl 
6 miR-1 0.50 μl 5.00 μl 
7 miR-27a 0.50 μl 5.00μl 
8 miR-133a 0.50 μl  5.00 μl 
9 miR-133b 0.50 μl 5.00μl 
 Total vol master mix            8.1µl  
Table 1. Concentration of reagents used in RT Reaction 
- RNAase free H2O: To make Vt uptill 30 μl - 8.1 μl= 21.9 μl 
- Each sample will have a different miRNA concentration and therefore will need a 
specific volume of miRNA and water to each sample RT PCR reaction 
The 6 primer sets used are: U6, miR-1, miR-27a, miR-133a, miR-133b and miR-155, all from 
Ambion life sciences (Paisely, UK).  
To convert RNA template into a complementary DNA (cDNA), Quantitative real-time reverse 
transcription polymerase chain reaction (qRT-PCR) was performed with the following setup; 
16 °C for 30 minutes, 42 °C for 30 minutes and 85 °C for 5 minutes. This exponentially 
amplifies the RNA with duplication of RNA with each cycle. 
2.13.5 Real-Time PCR reaction 
miRNAs expression patterns were assessed by reverse transcription with TaqMan MicroRNA 
Assays (Applied Biosystems) followed by real time PCR..  
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Real Time PCR was performed using a standard real time PCR protocol on the 7500 HT Real 
Time PCR sequence detection system (Applied Biosystems, USA). The 7500 Fast Real Time 
PCR sequence detection software SDS software version 1.4 (Applied Biosystems, UK) was 
used to record the amplification of DNA  in real time by optics and imagining system using 
SYBR Green fluorescent dye incorporation to double stranded DNA. A 20μl reaction mixture 
containing 100 ng cDNA, specific Applied Biosystems miRNA primer assays and SYBR green 
PCR Master Mix was used in the Real Time PCR reaction. A non-template control was included 
in all experiments. 
 
For the Real Time PCR reaction 0.5µl of each primer set (Applied Viosystems primer assays) 
10µl 2xSYBR green  PCR Master Mix (SYBR MM) and 6.5μl nuclease free water making a 
total of 17μl volume of the non-template controls with 3.0μl of cDNA for the experimental 
group. Each 20 μl reaction contained the following: 
  




SYBR MM 10 µl 
H2O 6.5 μl 
Table 2: The volumes of reactions needed for real time PCR reactions  
 
The order is adding the reagents to reduce tip wastage are: 
a) RNase free H2O 
b) Master mix "mix" (Primers and SYBR MM) 
c) cDNA 














Real Time PCR reaction was performed using the following setting; 50 °C for 2 minutes, 95 
°C for 10 minutes, followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute.  
Programme: 
1) 2 min 50 ºC 
2) 10 min 95 ºC 
3) 15 sec 95 ºC 
4) 1 min 60 ºC 
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5) repeat 3) and 4) 40 times 
 
2.13.6 Quantifying miRNA results: 
The ΔΔ cycle threshold (CT) values for the artemisinin treated group which was then compared 
with the control group. U6 was used as an internal reference to normalise other primers. 
2.13.6.1 Statistical analysis: 
Fold changes in the miRNA expressions were assessed for statistical differences using ANOVA 
(GraphPad Prism version 5 and SPSS). All values were expressed as mean ± SEM. P-values of 
≤0.05 were considered statistically significant. The relative amount of miRNA was calculated 
with the CT values for the different primers in relation to the CT values of U6 snRNA using 
the following formula; miRNA data was then analysed using the comparative ΔΔCT method 
(Sandhu, 2010). 
X0/R0 = 2CTR-CTX 
Where; 
 X0 = original amount of target miRNA 
R0 = original amount of U6 snRNA 
CTR = CT value for U6 snRNA, and 
CTX = CT value for the target miRNA. 
               
2.14 STATISTICAL ANALYSIS ACROSS TECHNIQUES USED:  
The percentage of infarct/risk ratio, % of cell viability, cleaved caspase-3 levels, eNOS (Ser 1177), 
iNOS, the relative changes in phosphorylated proteins and miRNA expressions were all 
expressed as MEAN±SEM. Hearts treated with artemisinin, the different inhibitors and the 
control groups were tested for group differences in infarct size, cellular viability and protein 
expression using the SPSS software package-One Way analysis of variance (Anova) with LSD 
post hoc test.  Physiological parameters (Haemodynamics) were assessed using Two Way 
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Chapter 3 
3 PROFILING ARTEMISININ: ROLE OF 




Artemisinin is described as a sesquiterpene trioxane lactones used as anti-pyretic treatment for 
fever and flu in ancient China (Ho et al., 2014). Artemisinin is used especially in malaria 
treatment which is converted in the body to the active metabolite, dihydroartemisinin (DHA) 
(Zhu et al., 1983 and Melendez et al., 1991). 
Artemisinin has a wide range of biological functions ranging from anti-malarial, anti-tumour, 
anti-microbial and anti-inflammatory activities (Bilia et al., 2014 and Lai et al., 2005). Malaria 
remains one of the major threats to human health, in developing countries especially affecting 
early two billion people are at risk all over the world and an estimated one million die of the 
disease annually (Wang et al., 2010).  
It is however well established that antimalarial drugs especially the quinines and quinolones 
present associated neurotoxicity and cardiotoxicity in experimental models (Balint, 2001; 
Kinoshita et al., 2010; Hara et al., 2007). Several cardiotoxic effects such as impaired left 
ventricular contractility, heart failure and increased risk of death (Lipshultz et al., 2004 and 
Kinoshita et al., 2010) have been associated with the different antimalarial treatments such as 
halofantrine. Although very effective in treating multidrug resistant P falciparum, Ter Kuile et 
al. (1993) reported the first death related to halofantrine cardiotoxicity. Another patient case 
study evaluation revealed 74% of fatal events occurring within 24 hours of administering 
halofantrine (Bouchard et al., 2009; Ter Kuile et al., 1993). The use of antimalarial drugs for 
therapeutic reasons was thus limited due to the drug resistance and associated neurotoxicity 
and cardiotoxicity observed across the different treatments. 
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However, aside from its current use as an anti-malarial drug, the artemisinin's (artemisinin and 
its derivatives) have also shown a potential in treating several infections such as 
trypanosomiasis and leishmania, inhibit several viruses, such as human cytomegalovirus and 
other members of the Herpes viridae family (herpes simplex virus type 1 and Epstein-Barr 
virus), cancers and inflammation (Efferth et al., 2008; Mishina et al., 2007; We et al., 2014). 
All these findings made the artemisinin’s interesting and important to review especially as a 
potential anti-cancer therapy. 
Recent research has shown the artemisinin's express cytotoxic effects against a variety of 
cancer cells by inducing cell cycle arrest at various stages of the cell division depending on the 
cancer cell line (Yoon et al., 2012) by promoting apoptosis and preventing tissue invasion, 
angiogenesis and metastasis (Ho et al., 2014; Crespo-Ortiz and Wei, 2011; We et al., 2014). 
The adverse cardiotoxic effects presented by the popular antimalarial drugs are also common 
amongst traditional cancer therapy drugs (Dudgeon et al., 2002 Although quite efficient in 
killing cancer cells often exarcerbate co-morbid effects in patients suffering from heart disease 
(Daniels et al., 2012).  
Anti-cancer therapy has seen much development over the years, resulting in improvement of 
life expectancy across patients of different cancer types (Ibrahim et al., 2013). However, with 
this advancement, patients are now surviving long enough for the prevalence of adverse 
cardiovascular effects posed by some of the cancer therapies to become evident (Bowles et al., 
2012; Chen et al., 2012; Yeh et al., 2004). This poses a need for the development of effective 
treatments that reduce drug induced cardiotoxicity and protect the myocardium from injury 
damage (Broder et al., 2008).   
Cancer cells contain high levels of required iron for proliferation; however this makes it an 
ideal target for artemisinin by causing the release of ROS which has been shown to trigger 
apoptosis via oxidative stress (Efferth 2005; Crespo-Ortiz and Wei, 2011). A study using HL-
60 cell lines have shown artemisinin induced damage is related to early and rapid generation 
of ROS which was found to activate apoptosis (Michaelis et al., 2010).  
ROS induced stress has been shown to increase mitochondrial oxidative stress (Cui et al., 2012 
and Dai et al., 2014). As mentioned in chapter 1, increase in ROS in tissues as a result of 
reperfusion injury can damage macromolecules within the tissue which eventually causes 
myocardial cell death (Banerjee et al., 2008; Palcher et al., 2007). This process is shown to be 
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primarily mitochondrial mediated causing abnormal increase in calcium and several other 
cellular deregulations (Wang 2001). The complex roles of the mitochondria in apoptosis 
involve several mitochondrial proteins which activate different apoptotic signals that leads to 
mitochondrial swelling (Du et al., 2000; Verhagen et al., 2000). Mitochondria swelling can 
cause the outer mitochondrial membrane to rupture and release cytochrome c into the cytosol 
forms complexes known as apoptosomes (Montaigne et al., 2012). Apoptosomes comprise of 
procaspase-9 which are cleaved to caspase-9 which activates caspase-3 promoting apoptosis 
(Yuan et al., 2011). There is now evidence showing, artesunate a derivative of artemisinin 
activates mitochondrial apoptosis in breast cancer cells via iron catalysed lysosomal ROS 
generation (Brady et al., 2010). Apoptosis being a tightly regulated cell deletion process, plays 
an important role in various cardiovascular diseases, such as myocardial infarction, reperfusion 
injury andother coronary diseases leading to heart failure.  
The irreversible damage to cardiac tissue caused as a result of myocardial ischaemia 
reperfusion injury sustained during ischaemia and reperfusion has been shown to activate 
apoptosis although the exact time at which this occurs is unclear (Kalogeris et al., 2012; Palcher 
et al., 2007).  Studies have however confirmed that in addition to apoptosis caused as a result 
of ischaemic injury, increase in apoptosis is observed with reperfusion treatment. This is due 
to additional stress inflicted on the already weakened cells, to rapidly recover after being 
severely compromised during ischaemia (Zhoa et al., 2002). Studies have shown the elderly 
population are more prone to developing ischaemic heart disease as well as other diseases due 
to the decrease in function of cells as a result of aging (Stern et al., 2003; Simanek et al., 2011). 
Substantial evidence has also shown that the presence of comorbidities such as ischaemic heart 
disease in diseases such as cancer compromises therapeutic advances in oncology (Tashakkor 
et al., 2013). The prevalence of comorbidities is particularly high in the elderly population, 
with 80% of this population having three or more chronic conditions at a time (Caughey et al., 
2008). In this review by Caughey et al. (2008), comorbidities have been associated with a 
decline in many health outcomes as well as with an increase in mortality rates. A significant 
number of studies have also identified the correlation between the incidences of cancer and 
increase in age, while reporting improvements in life expectancy as a result of medical and 
pharmacological interventions (Crivellari et al., 2000; Simanek et al., 2011). More cancer 
patients are reported to survive cancer upon treatment however these cancer survivors are 
identified to be at greater risks of developing cardiovascular diseases which may act as a 
potential hazard when providing appropriate treatment to these cancer patients (Tashakkor et 
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al., 2013). Studies have reported this population of cancer survivors are more likely to develop 
secondary malignancies such as ishaemic heart disease partly because of their age but more 
significantly as a result of drug induced cardiotoxity from the anthracycline therapy (Gharanei 
et al., 2013, Tashakkor et al., 2013). Presently administered cancer treatment such as 
doxorubicin which is a first line treatment against a wide range of cancers including 
haematological malignancies, solid tumours and soft sarcomas (Tacar et al., 2013). Although 
doxorubicin is extremely effective in treating these cancer types, its use is limites as it has been 
shown to exacerbate myocardial injury particularly in patients with underlying ischaemic heart 
disease, this has been reported as a threefold increase in the rate of cardiomyopathy in the 
elderly population (Doyel et al., 2005). This population of patients with pre-existing 
conditions/comorbidities are very often under represented in studies. With the possibility of 
both conditions (ishaemic heart disease and cancer) to co-exist at the same time in patients 
undergoing cancer treatment it is imperative to study both conditions at a cellular level in terms 
of apoptosis which may lead to death. 
 
Lee and Gustafsson (2009) have implicated apoptosis in the pathogenesis of a variety of 
cardiovascular diseases and also reported that the inhibition of apoptosis is cardioprotective 
and can prevent the development of heart failure. With this knowledge the inhibition of cardiac 
apoptosis therefore holds promise as an effective therapeutic strategy for cardiovascular 
diseases (King and Kang 2010). 
Advancements have been made in the clinical development using miRNA as therapeutic targets 
and biomarkers of cardiovascular diseases (Olson 2014). miRNA’s are small non coding RNA 
molecules, found to freely circulate in plasma and are responsible for regulating gene 
expression by recognizing complementary messengers (Dimmeler et al., 2010; Corsten et al., 
2010). miRNAs play important regulatory roles in homeostasis and disease not just in the 
cardiovascular system (Corsten et al., 2010). Many studies have explored the diagnostic 
potential in a selection of miRNA’s and have identified peculiar miRNA expression profiles 
that correlate with a variety of pathological conditions such as hypertrophy, heart failure, and 
arrhythmias (Schroen et al., 2009; van Rooij et al., 2006). miRNA found freely circulating in 
blood are easily detected suggesting the potential of being useful disease biomarkers 
(Dimmeler et al., 2010). In the cardiovascular system, miRNA’s are generally considered to act 
as intracellular mediators required for maintaining normal cardiac function (Wang and Yang 
2012). Deregulation in the expression profiles of the miRNA molecules are associated with 
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cardiovascular diseases such as pathological cardiac hypertrophy and heart failure in humans 
and mouse models of heart diseases (Salic and Windt 2012; Wang and Yang 2012). 
miRNA-1 and miRNA-133 is the most abundantly expressed miRNA in the heart (Basser et 
al., 2014). D'Alessandra et al. (2010) showed that circulating muscle-derived miRNAs might 
be useful biomarkers of acute myocardial infarction. They have also been found to regulate 
various processes ranging from normal physiological conditions to stressed and to even diseased 
conditions thus rendering them as potentially novel biomarkers for disease onset (Schlutz et 
al., 2014; Kondkar and Abu-Amero 2015). Recent studies have identified circulating 
microRNAs as possible novel biomarkers that may be used in the diagnosis of acute myocardial 
infarction (Li et al., 2013). Prior to miRNAs B-type natriuretic peptide (BNP) and cardiac 
troponin have been thoroughly used in studies investigating heart failure and acute myocardial 
infarction (Jiang et al., 2014). BNP is a useful biomarker in emergency setting with serum level 
associated with age, race and body mass index whereas cardiac troponin is a prognostic 
indicator of acute MI where serum level is shown to elevate with conditions such and 
hypertension and ketoacidosis (Li et al., 2013). However, more recent have suggested miRNAs 
to be more sensitive and reliable biomarkers in sub-clinical myocardial injury (Li and Zhang 
2015). Li et al. (2014) investigated the expression of plasma miRNA-1 and cardiac troponin T 
in early diagnosis of patients with acute myocardial infarction where they showed that miRNA 
is more specific and sensitive in early diagnosis compared to cardiac troponin T however it is 
not superior. 
miRNAs can potentially be used for the early detection and identification of diseases (Zhoa et 
al., 2010; Jiang et al., 2014). With vascular diseases being prevalent worldwide, early 
assessment and ability of miRNAs to clearly show the stages of diseases alone or in association 
with previous biomarkers such as BNP, have emerged with more sensitive and increased 
diagnostic powers (Jiang et al., 2014).  
Studies have further suggested that miRNA-1 and miRNA-133 for example which is released 
into blood during cardiac tissue injury is upregulated in response to tissue injury otherwise 
associated with pro-apoptotic effects (Tang et al., 2009; Ho et al., 2011). miRNA-1 in adult 
cardiomyocytes and skeletal muscle is known to regulate apoptosis, by targeting the synthesis 
of (heat shock protein-60) HSP-60, (heat shock protein-70) HSP-70, and Bcl-2 (B cell 
lymphoma-2, an apoptosis regulator) (Yang et al., 2007). HSPs are a family of proteins 
produced in response to stress (Yang et al., 2007). Some genes are aberrantly expressed in 
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infarcted hearts, miRNA’s such as miRNA-1 which is consistently dysregulated in ischaemic 
hearts and miRNA-27a which is highly expresses in breast cancer cells (Tang et al., 2009; Wu 
et al., 2011; Mertens-Talcott et al., 2007). Researchers found that overexpression of these 
miRNA’S could trigger increased sensitivity to I/R injury or even trigger cell death or in the 
case of miRNA-27a its suppression decreases the number of breast cancer cells through the 
inhibition of cell cycle traverse and increased apoptosis (Wu et al., 2011;Liu et al., 2009). In 
this study we therefore detected the expression profile of popular miRNA’s associated with 
ischaemia reperfusion or cancer in naïve and artemisinin treated cardiomyocytes. 
At present there is renewed interest in developing anti-cancer therapies from medicinal herbs 
which have been found to be generally safer than first line therapies currently being 
administered in treatment. The artemisinin's stand out as a family of bioactive molecules with 
high potency against several cancer cells (Ho et al., 2012). Studies have shown the artemisinin's 
offer a promising alternative due to their established safety record in anti-malarial treatment 
and the promising effect against 55 different cancer cell lines including breast cancer, 
leukaemia, prostate, ovarian and so on (Efferth et al., 2003; Lai et al., 2013; Tin et al., 2012; 
Chadwick et al., 2010; Zhou et al., 2008; Crespo-Ortiz and Wei 2011). These studies 
emphasised the important role of artemisinin as an effective and possibly potent anticancer 
treatment with much promise. Coupled with the findings by Sun et al., (2007) who showed 
artemisinin at high micromolar concentrations to be cardioprotective against myocardial 
ischaemia/reperfusion (I/R) injury in rats and further suggested the mechanism may be related 
to its functions of antioxidation and scavenging free radicals. 
For decades now, it is well established that most of the widely used cancer limited in use due 
to their dose dependent cardiotoxicity (Harake et al., 2012). As previous limited studies have 
revealed the potential of artemisinin to be cardioprotective against myocardial I/R injury (Sun 
et al., 2007). However no study is yet to establish the intracellular signalling via which this 
occurs. The cardiovascular system is undoubtedly a complex well organised system where 
signal transduction plays an important role in its normally physiology as well as 
pathophysiology (Wheeler-Jones 2005). It is therefore imperative to investigate the artemisinin 
mediated cardioprotection suggested by Sun et al. (2007) and in subsequent chapters we 
investigated the intracellular signalling associated with the cardioprotection, as no study has 
established that to our knowledge. Furthermore, previous studies have revealed the importance 
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of prosurvival kinases especially Akt, in hearts recovering from ischaemia reperfusion injury 
(Whittington et al., 2013).  
Aims of the study: In this chapter however, we aimed to establish the effect of artemisinin in 
naïve isolated perfused hearts as well as in stressed conditions and in isolated cardiomyocyte 
subjected to I/R and H/R respectively. We furthermore, investigated the differential expression 
of certain miRNA upon treatment with artemisinin as well as investigating artemisinin’s 




benzodioxepin-10(3H)-one (Artemisinin) purchased from Tocris (Bristol, UK), which is 
dissolved in dimethyl sulfoxide (DMSO) and stored at -20 °C. Thiazolyl blue tetrazolium 
bromide (MTT) was purchased from Sigma (Poole, UK). Cleaved Caspase-3 (Asp175) 
Antibody (Alexa Fluor® 488 Conjugate) purchased from New England Biolabs (Hertfordshire, 
UK). mirVana™ miRNA Isolation kit equipments and primers used for miRNA Isolation were 
all purchased from Applied Biosystems, UK (Ambion, Applied Biosystems, UK),Applied 
Biosystems MicroRNA Reverse Transcription Kit and primer assay set for U6 snRNA, rno-
miR-1, hsa-miR-27a, hsa-miR-133a, hsa-miR-133b and hsa-miR-155 (Applied Biosystems, 
UK), TaqMan MicroRNA Assays (Applied Biosystems, UK) and TaqMan Universal PCR 
Master Mix purchased from (Applied Biosystems, UK). Human Leukamia cells (HL-60) were 
obtained from the European Collection of Cell Cultures (ECACC) 
3.2.2 Animals 
Adult male Sprague-Dawley rats 350-400g were obtained from Charles River (Margate, UK) 
for this study. Animals received humane care in accordance with the Guidance on the Operation 
of the Animals (Scientific Procedures Act 1986) and were sacrificed by cervical dislocation.  
The study was carried out upon obtaining ethical approval from Coventry University Research 
ethics committee which was regularly assessed throughout the project. 
3.2.3 Isolated perfused rat heart model 
Briefly following sacrifice, the hearts were rapidly excised and placed on a langendorff set-up 
where it is retrogradely perfused with KH buffer as described in detail in chapter 2. 
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The pH of the KH buffer was maintained at 7.4 by gassing continuously with 95% O2 and 5% 
CO2 maintained at a temperature of 37 ± 0.5oC using a water-jacketed heat exchange coil. 
A latex balloon inserted into the left atrium which is inflated to constant diastolic pressure of 
8-10mmHg in the left ventricle is used to measure left ventricular developed pressure (LVDP). 
A physiological pressure transducer was connected to a bridge amp and a power lab (AD 
Instruments Ltd, Chalgrove, UK) allowing the LVDP, HR (HR) and CF (CF) was measured at 
regular intervals while collecting the perfusate at regular intervals. Hearts maintained a steady 
state of LVDP, HR and CF. 
The langendorff experiment was conducted for 175 minutes in total. In the normoxic 
experiments, the isolated hearts were perfused for 155 minutes with KH buffer after 20 minutes 
stabilisation. 
Hearts were randomly assigned to the following different treatment groups. In the normoxic 
treatment groups: 
a) hearts perfused with KH buffer alone (Normoxic control) for 155 minutes after 20 
minutes stabilisation.  
b) hearts perfused with KH buffer and Artemisinin (Normoxic drug treatment; 10nM-
100µM) (Artemisinin was administered throughout 155 minutes of perfusion) 
In the Ischaemia/reperfusion (I/R) studies, hearts were allowed to stabilise for 20 minutes 
followed by 35 minutes ischaemia and 120 minutes reperfusion. The anterior descending left 
coronary artery was ligated to induce regional ischaemia. Upon completing the 35 minutes of 
simulated ischaemia, the flow of KH buffer was reintroduced for 120 minutes (Figure 10).  
In the Ischaemic control group, after 20 minutes of stabilisation, ischaemia was induced for 35 
minutes and drug treatment administered during reperfusion for 120 minutes. Hearts were also 
randomly assigned to the following different treatment groups; 
a) hearts that underwent I/R were perfused with KH buffer alone (I/R control)  
b) hearts that underwent I/R were perfused with KH buffer and artemisinin treatment (I/R 
drug treatment; artemisinin (10nM-100µM) was administered throughout reperfusion). 
At the end of the experiment, the hearts were incubated in triphenyl tetrazolium chloride (TTC) 
solution (1% in phosphate buffer) for 10–12 minutes and fixed in 10% formalin for at least 4 
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hours to enhance the staining prior to analysis. The dye stains any risk tissue bright red and 
infarct tissue pale/whitish or was frozen in RNA later (Applied Bio systems, UK) for miRNA 
analysis. 
The heart slices were then treaced unto acetate film and scanned into a computer to allow 
calculation of I/R% as areas of viable, risk and infarct tissue measured using the Image Tool 
program as developed by the University of Texas Health Science Centre at San Antonio, 
Version 8.1 (UTHSCSA). 
 
Figure 15. Protocol for Infarct/risk ratio analysis and tissue collection for miRNA analysis 
3.2.4 Evaluation of miRNA profile in isolated perfused heart tissue following drug 
treatment 
50 mg of heart tissue was snap frozen in snap frozen in RNALater, (after subjected to the 
different treatments as described in the isolated perfused rat heart model). miRNA was 
extracted using the Mirvana™ miRNA Isolation kit (Ambion, Applied Biosystems, UK) in 
accordance with the manufacturer´s instructions. 
cDNA was then made by reverse transcribing 500 ng miRNA for U6 snRNA, rno-miR-1, hsa-
miR-27a, hsa-miR-133a, hsa-miR-133b and hsa-miR-155 using the Applied Biosystems 
MicroRNA Reverse Transcription Kit and primer assay set (Applied Biosystems, UK) 
according to the manufacturer's instructions.  
miRNAs expression patterns were assessed by reverse transcription TaqManR MicroRNA 
Assays (Applied Biosystems) followed by qPCR using the different stem-loop primers.  
Real Time PCR was performed using a standard TaqMan Universal PCR Master Mix (Applied 
Biosystems, USA) protocol on the 7500 HT Real Time PCR sequence detection system 
(Applied Biosystems, USA). The SDS software version 1.4 was used to record the 
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amplification of DNA using SYBR Green fluorescent dye to double-stranded DNA (Applied 
Biosystems, UK).  
Upon completing the Real Time PCR reaction the ΔΔ cycle threshold (CT) values for the 
Artemisinin treated group was compared with the control group. U6 was used as a reference to 
normalise other primers. 
Fold changes in the miRNA expressions were assessed for statistical differences using the 
Students t-test (GraphPad Prism version 5). All values were expressed as mean ±SEM. A P-
value of P≤0.05 was considered statistically significant. miRNA data was then analysed using 
the comparative ΔΔCT method (Sandhu, 2010). 
The relative amount of miRNAs were calculated with the CT values for the different primers 
in relation to the CT values of U6 snRNA using the following formula; 
X0/R0 = 2CTR-CTX 
Where; 
 X0  = original amount of target miRNA 
R0  =  original amount of U6 snRNA 
CTR =  CT value for U6 snRNA, and 
CTX =  CT value for the target miRNA. 
3.2.5 Adult Rat Ventricular Myocytes Model 
Adult ventricular rat myocytes were isolated from Sprague Dawley rats (350-400g) by 
enzymatic dissociation method as described in chapter 2. The isolated myocytes were incubated 
in RB (at 37 oC, 5% CO2 for 24 hours before being used. 
Control sample was pulled aside for the normoxic group. The rest of the myocytes then 
underwent reoxygenation for 2 hours. Upon completing reoxygenation, the isolated 
cardiomyocyte underwent quantitative analysis using Fluorescence Activated Cell Sorter 
(FACS) to assess cleaved caspase-3 activity, iNOS or eNOS (Ser1177) expression or using MTT 
reductase (Thiazolyl blue tetrazolium bromide) for assessment of cellular viability.or flow 
cytometric analysis for the assessment of cleaved caspase-3 activity as described below. 
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3.2.6 Assessment of cleaved-caspase 3 activity by FACS 
Isolated cells were harvested, washe and incubated in inubation buffer as described in chapter 
2. The antibody was prepared to 1:100 final dilution in incubation buffer. The cells were then 
incubated in incubation in Alexa Fluor® 488 goat anti-rabbit IgG antibody at a dilution of 
1:1000 for 1 hour in the dark at room temperature. The cells were then spun at 1200 rpm for 2 
minutes and washed with incubation buffer twice. At the end of the incubation period, the cells 
were centrifuged and the supernatant discarded. The pellet was then resuspended in 500µl PBS 
and analysed using flow cytometer (Vermes et al., 2002). Samples were then analysed using 
the flow cytometer (FACS, Becton Dickinson, Oxford, UK) on FL-1 channel and set up to 
count to 10,000 events. Histograms were then plotted to record the levels of cleaved Caspase-
3 activity. Please refer to methods chapter 2 for detailed description of the technique. 
3.2.7 MTT cell viability assay using isolated cardiomyocytes: 
Following 2 hours of hypoxia, cardiac myocytes were harvested and subjected to MTT assay 
to measure MTT reductase activity. This assay reduces the initial yellow tetrazole to purple 
formazan, which quantifies the proportion of viable cells incubated per plate. Cell densities 
were initially calculated to 100,000 cells/ml. The cells were then placed into a 96 well plate 
with 100 µl of cells (1 x 10-5 cells.ml-1) per well. Normoxic control and Hypoxia reoxygenated 
untreated cells were isolated while the remaining myocytes were treated with artemisinin 
(4.3µM) throughout the 2 hours of reoxygenation. 20µl of MTT (MTT solution is 5mg.ml-1 in 
PBS (10g for 10-4 cells/well) was added to all the wells and incubated in the dark at 370C for 2 
hours. 100µl of lysis buffer (20% SDS in 50% dimethylformamide) was then added and 
incubated overnight at 37o C. Calorimetric analysis of the plate was done to measure the 
fluorescence emission at 450nm on the NanoDrop 2000c UV-Vis Spectrophotometer (Thermo 
Scientific, UK). 
3.2.8 MTT cell viability assay using HL-60 cell line: 
Human leukaemia cancer cell lines HL-60 were obtained from the European Collection of Cell 
Cultures (ECACC). The cells were cultured in RPMI 1640 media without L-Glutamine 
(Biosera, Ringmer, UK) and supplemented with 10% fetal bovine serum, 2mM L-glutamine, 
HEPES and 0.1% antibiotic solution (100 U/ml penicillin, 0.1mg/ml streptomycin from 
Invitrogen). The cells were maintained at 37°C under a humidified atmosphere and 5% CO2. 
Cell viability was measured using an electronic counter (NucleoCounter ®). HL-60 cells were 
counted on the nucleocounter, 50µL of the cells containing (1x105cells/well) was plated in 96-
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well flat-bottomed microtitre plates and treated with varying concentrations of artemisinin (10-
1000µM) for 24 hours. At the end of the incubation period, the cells were terminated by adding 
MTT solution (20µl of 5mg/ml MTT to each well) and further incubated for 2 hours at 37°C. 
100µl of lysis buffer (20% sodium dodecyl sulfate in 50% dimethyl formamide) was then added 
to each well containing treatment and control samples.  
Incubation was at 37°C and its duration was based on results of assay optimization experiments 
from previous experiments in the lab (data not presented in this study). The plates were 
incubated overnight to solubilise the cells. The absorbing intensity of each well was determined 
at 492nm using a plate reader (Anthos 2001). This measures the percentage of cell growth 
calculated using the following formula;  
% Cell Growth = (average absorbance of treated wells for artemisinin/average absorbance of 
untreated control wells) x 100%. 
The experiment was repeated three times and IC50 values for artemisinin were estimated using 
the 4-parametric logistic analysis (Grafit Software, Erithacus, UK). The mean calculated IC50 
value was then used in subsequent experiments in the chapters to follow. 
Dose–response titration was plotted for artemisinin (1-1000µM) to yield concentrations of half-




The data obtained was expressed as % of infarct/risk ratio, % of area at risk/ventricular volume, 
% of cell viability, % cleaved caspase-3 levels, the relative quantitative changes in 
phosphorylated proteinssuch as iNOS and eNOS and miRNA expressions were all expressed 
as MEAN±SEM. The different groups were tested for group differences using the SPSS 
software package - One Way analysis of variance (ANOVA) with LSD post hoc test.  
Physiological parameters (haemodynamics) were also assessed using a one way ANOVA for 
each time point. Fold changes in miRNA study were assessed for statistical difference using 
student t-test. P values of P<0.05 were considered statistically significant. 
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3.3 RESULTS  
3.3.1 Exclusion Criteria 
For this chapter two hearts were excluded from this experiment, one was due to poor 
stabilization at the beginning of the experiment and the other due to very high flow rate which 
may be indicative of a tear in the aortic wall or may be an incompetent valve. Another rat was 
also excluded due to low viability of live cells following isolation (≤70%) in the cellular 
viability studies. All other groups have been used. 
 
3.3.2 Profiling the effects of artemisinin treatment on haemodynamics in isolated 
perfused hearts under normoxic conditions 
Normoxic hearts were allowed to stabilise for 20 minutes followed by perfusion with KH buffer 
for 155 minutes. Artemisinin treated hearts were stabilised for 20 minutes followed by 
artemisinin treatment with EC80: 4.3µM for 155 minutes (Figure 2). 4.3µM is the dose 
calculated using I/R heart where the cardioprotective effects were more significant compared 
to the untreated control group (Figure 20b and 20c) (where 80% drug response is seen). 
Left ventricular developed pressure (LVDP), Heart rate (HR) and CF (CF) haemodynamic 
parameters were assessed throughout the time period of the experiments detailed above. 
The artemisinin (4.3µM) treated normoxic hearts remained relatively stable in terms of LVDP 
when compared to the normoxic control hearts throughout reperfusion. The artemisinin 
(4.3µM) treatment alone did not appear to have a significant effect on LVDP when compared 
to control but the artemisinin (4.3µM) treatment was slightly higher, although not significantly 
different from the control in LVDP when perfused with artemisinin (4.3µM) for 155 minutes, 
as illustrated in Figure 16. 
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Figure 16. The effects of artemisinin (4.3µM) on LVDP in isolated perfused hearts under normoxic conditions 
expressed as a percentage of mean stabilisation. Hearts were subjected to 20 minutes of stabilisation and were 
perfused for 155 minutes in the presence/absence of artemisinin (4.3µM). Results presented are Mean±SEM 
(n=6).  
3.3.2.1 The effects of artemisinin (4.3µM) treatment on HR in isolated perfused hearts 
under normoxic conditions  
Artemisinin (4.3µM) treated group, compared to time matched normoxic control showed a 
progressive increase in HR (P<0.001). Artemisinin (4.3µM) treatment caused a significant 
increase in the HR, this is noticeable 10 minutes into treatment with artemisinin (4.3µM) 
(97.2±2.7% vs. 111.6±9.7%, P<0.05, Figure 17). The effect became more pronounced at the 
later stages of the treatment when compared with the control group (at 125 minutes: 91.0 ± 
1.9% vs. 115.6 ± 10.8% respectively, P<0.001, as seen in the following Figure 17. 
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Figure 17. The effects of artemisinin (4.3µM) on HR in isolated perfused hearts under normoxic conditions 
expressed as a percentage of mean stabilisation. Hearts were subjected to 20 minutes of stabilisation and were 
perfused for 155 minutes in the presence/absence of artemisinin (4.3µM). Results presented are Mean±SEM 
(P<0.05 vs. Normoxic Control, **P<0.01 vs. Normoxic Control, ***P<0.001 vs. Normoxic control) (n= 6). 
3.3.2.2 The effects of artemisinin (4.3µM) treatment on CF in isolated perfused hearts 
under normoxic conditions  
CF was also recorded by collecting the effluent at regular intervals of 5 minutes for 1 minute. 
CF in the artemisinin treated group compared to the normoxic time matched control showed a 
very similar pattern, however artemisinin (4.3µM) treatment led to a significant (P<0.05) 
increase in CF at 5 minutes and 10 minutes of perfusion with artemisinin (4.3µM) (92.1±4.3% 
vs. 104.7±3.5% in artemisinin treated hearts at 5 minutes of drug perfusion) and (93.8±2.5% 
vs.103.8±4.0% in artemisinin treated hearts at 10 minutes of drug perfusion). Most significant 
increase in CF was observed at 170 minutes (i.e. 120 minutes into the treatment with 
artemisinin (4.3µM) when compared with untreated normoxic control (at 155 minute of drug 
perfusion; 88.3 ± 2.7% vs. 97.6± 2.2%, P<0.01, Figure 18).  
Drug administration 
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Figure 18. The effects of artemisinin (4.3µM) on CF in isolated perfused hearts under normoxic conditions 
expressed as a percentage of mean stabilisation. Hearts were subjected to 20 minutes of stabilisation and were 
perfused for 155 minutes in the presence/absence of artemisinin (4.3µM). Results presented are Mean±SEM 
(n=6) 
3.3.3 Effects of artemisinin treatment on infarct size in isolated perfused hearts in 
normoxic conditions 
Infarct size was calculated as a percentage of the area at risk. This is reported to be the most 
vital, reliable and reproducible way of assessing infract size and has been used by several 
studies in understanding mechanisms behind these common diseases, and also towards 
developing and evaluating the most appropriate treatment strategies (Redford et al., 2012). 
Different hearts are different in size and in terms of haemodynamics and electrophysiology of 
the heart. Diverse morphological differences therefore may exist between the hearts sampled 
particularly when measuring infarct size may, this may be a crucial limitation of this technique. 
However by measuring infarct size as a percentage of the area at risk, (area at risk being the 
area that correlates with the entire myocardial perfusion bed distal to the occluded coronary 
artery) calculating infarct size thus accounts for variability within the groups in terms of 
dissimilarities in the actual size of the heart and size of the area occluded (ischaemia induced) 
(Graham et al., 2001). This is the most accepted way of determining the actual infarct size and 
may be used for prognosis and evaluation of drug efficacy especially in studies aimed at 
reducing infarct size or in studying genetic manipulation on the ischaemic tolerance of the 
myocardium (Graham et al., 2001; Liu et al., 2002). 
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TTC is used to assess infarction based on the percentage of area at risk, this is an effective way 
of investigating diseased conditions (Redford et al., 2012). 
The area at risk is thus a potential source of variation in infarct analysis so this study quantified 
it to eliminate possible variabilities and also calculated the significant difference between the 
experimental groups. 
Treatment with artemisinin (4.3µM) for 155 minutes was compared to untreated time matched 
control hearts. Administration of artemisinin (4.3µM) significantly decreased the infarct size 
when compared to the untreated control (8.93±1.16% vs. 6.58±0.23%, P<0.05, Figure 18) 
 
Figure 19. Infarct to risk ratios in the isolated rat hearts subjected to 20 minutes of stabilisation followed by 
155 minutes perfusion with KH buffer in the presence/absence of artemisinin (4.3µM). Results were expressed 
as Mean±SEM (*P<0.05 vs. normoxic control) (n=6) 
3.3.3.1 The effect of artemisinin on isolated perfused hearts subjected to I/R injury 
The cardioprotective effect of the increasing concentrations of artemisinin (0-100µM) was 
investigated in order to establish the concentration at which artemisinin is most protective while 
monitoring the effect on its different effects on the haemodynamic parameters observed as well 
as on infarct size. 
3.3.3.2 The effect of artemisinin (0-100µM) treatment on (%) area at risk/ventricular 
volume in isolated perfused rat hearts subjected to I/R injury. 
All the hearts in this group were allowed to stabilise for 20 minute while perfused with KH 
buffer, hearts where then subjected to 35 minutes ischaemia followed by 120 minutes 
reperfusion with artemisinin (0-100µM). At the end of the reperfusion period, the left coronary 
artery was re-occluded and stained with Evans blue which was injected into the left ventricle 
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to stain the ischaemic area and risk area. The Evans blue stains the non-ischaemic tissue blue 
while the ischaemic area/ infarcted region becomes pale. The area at risk (ischaemic area) was 
quantified for each heart to ensure the values do not vary significantly between the groups 
(Figure 20a). This allows for better assessment and quantification of the % of infarcted tissues 
as well as for more reliable quantification of drug treatment. Quantifying infarct size as a 
percentage of area of risk between the groups corrects for variability in heart sizes and induced 
ischaemia between the different hearts and aso the groups. Administering artemisinin at 
0.01µM concentration compared with I/R showed no significant difference (42.0± 4.6% vs. 
37.9±3.1% respectively, Figure 20a). The % area at risk/left ventricular volume for the 
increasing concentrations of artemisinin also showed no significant difference to control and 
between the groups (Figure 20a).  





























Figure 20a. Area at risk expresses as a percentage of the left ventricular volume. Hearts were subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the presence/absence of artemisinin 
(0-100µM). Results were expressed as Mean±SEM 
3.3.3.3 The effect of artemisinin (0-100µM) treatment on Infarct size to Risk ratio (%) in 
isolated perfused rat hearts subjected to I/R injury 
For the infarct size analysis, hearts were stained with TTC. The hearts were treated with 
artemisinin over a wide range of significantly lower concentration's (0-100µM) than previously 
tested by Sun et al., 2007. Upon reperfusion at 0.1µM, artemisinin started showing a significant 
infarct sparing effect when compared to untreated time matched I/R control (46.9±1.5% vs. 
55.8±1.7% I/R, P<0.01,Figure 20b). There was a gradual decrease in infarct size with 
increasing concentration of artemisinin, with results being highly significant compared to 
control. With an increased concentration of artemisinin of up to about 10µM, infarct size 
significanty decreased by up to 20% compared to I/R control (35.7±3.5% vs. 55.8±1.7% I/R, 
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P<0.001, Figure 20a). Artemisinin (0.1µM-100µM) showed a significant dose dependent 
decrease in infarct size (P<0.01-0.001 vs. I/R control) when compared to untreated time 
matched I/R control. 
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Figure 20b. The effects of artemisinin (0-100µM) on infarct size to risk ratios in isolated perfused rat heart 
model of I/R. Hearts were subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion in the presence/absence of artemisinin (0-100µM). Results were expressed as Mean±SEM 
(**P<0.01 vs. I/R control, ***P<0.001 vs. I/R control) (n=4-8) (Artemisinin=Art) 
The infarct sizes were used to construct a dose response curve and the EC20, EC50 and EC80 
values were calculated with these values used for the subsequent experiments. EC20 value was 
calculated as 0.0042µM using the values from the concentrations above and as shown in the 
log graph below. EC50 calculated as 0.43µM and 4.3µM as EC80, as in Figure 20c. 
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Figure 20c. Dose response curve used to calculate the EC20, EC50 and EC80 values as 0.042µM, 0.43µM and 
4.3µM using values from Figure 20a. Graphs shows the effect of increasing artemisinin concentration (0-
100µM) on infarct size to risk ratios in isolated perfused rat heart model of I/R. Hearts were subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the presence/absence of artemisinin 
(0-100µM)(n=4-8)  
Figure 20c shows the log dose response curve based on the infarct size to risk ratio (%) of 
hearts subjected to the experimental protocol of 20 minutes stabilisation, 35 minutes ischaemia 
and 120 minutes reperfusion. 
 
The haemodynamic data for the individual concentrations 1µM, 10µM, and 100µM is not 
included. However, the haemodynamic effects for EC20 (0.042µM), EC50 (0.43µM) and EC80 
(4.3µM) are depicted in the Figures 21-23. 
3.3.3.4 The effects of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM) treatment 
on LVDP in isolated perfused hearts subjected to I/R 
Isolated rat hearts were stabilised for 20 minutes followed by 35 minutes ischaemia and 155 
minutes reperfusion where artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM) was 
administered throughout reperfusion. The LVDP drastically dropped during ischaemia and 
increased upon reperfusion in all groups. Reperfusion generally attenuates the fall in LVDP 
caused by myocardial ischaemia. This occurs as a result of re-establishing flow by removing 
the ligation in both the control and artemisinin group during reperfusion. 
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There was no significant change in LVDP during stabilisation and ischaemia between all 
groups. Treatment with the different concentrations of artemisinin (EC20:0.042µM, EC50: 
0.43µM or EC80:4.3µM) at reperfusion generally caused no significant difference in LVDP 
compared to I/R. However, towards the end of reperfusion, at 120 minutes, treatment with 
artemisinin at EC20:0.042µM concentration, resulted in an increase in LVDP compared to time 
matched control (P<0.05). This increase in LVDP was noticeable until 175 minutes (90.0±3.0% 
vs 70.7±2.9%, P<0.01, Figure 21). Treatment with artemisinin, 4.3µM and 0.43µm revealed a 
slight increase in LVDP compared to IR control, although this was not significant. 
 
  
Figure 21. The effects of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM) on LVDP in isolated 
perfused hearts subjected to 20 minutes of stabilisation, 35 minutes and ischaemia and 120 minutes reperfusion 
in the presence/absence of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80:4.3µM). Data expressed as a % 
of mean stabilisation±SEM. artemisinin (4.3µM) *P<0.05 vs. I/R control, artemisinin (4.3µM) **P<0.01 vs. I/R 
control (n= 4-8). 
3.3.3.5 The effects of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM) treatment 
on HR in isolated perfused hearts subjected to I/R 
HR remained relatively stable with a slight increase in the drug treated group compared to 
untreated time matched I/R control, although did not reach statistical significance.  
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Figure 22. The effects of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM) on HR in isolated perfused 
hearts subjected to 20 minutes of stabilisation, 35 minutes and ischaemia and 120 minutes reperfusion in the 
presence/absence of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM). Data expressed as a % of 
mean stabilisation±SEM. (n= 4-8). 
Baseline values of HR in all groups were similar in the different treatment groups during 
stabilisation as well as during ischaemia. During reperfusion when artemisinin (EC20: 0.042µM, 
EC50: 0.43µM or EC80: 4.3µM) was added showed no significant difference to the untreated 
control groups. 
The effects of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM) treatment on CF in 
isolated perfused hearts subjected to I/R. 
CF dropped during ischaemia and upon reintroducing KH buffer, CF values were shown to 
increase again almost to stabilisation readings. However, treating hearts with artemisinin 
0.43µM and 0.042µM upon reperfusion at these two concentrations revealed changes to CF 
were not significant compared to untreated time matched I/R control. Artemisinin 4.3µM 
treated hearts showed a significant decrease in CF compared to I/R control at 160 minutes into 
reperfusion with artemisinin (81.7±2.8% vs. 87.1±3.2% in I/R control respectively, P<0.05, 
Figure 23). 
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Figure 23. The effects of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM) on CF in isolated perfused 
hearts subjected to 20 minutes of stabilisation, 35 minutes and ischaemia and 120 minutes reperfusion in the 
presence/absence of artemisinin (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM). Data expressed as a % of 
mean stabilisation±SEM.*P<0.05 vs I/R control) (n= 4-8). 
 
The infarct size in the artemisinin (4.3µM) treated group compared to I/R controls also 
subjected to 20 minutes stabilisation, 35 minutes of regional myocardial ischaemia followed 
by reperfusion for 120 minutes showed artemisinin significantly decreased infarct size (38.0 ± 
2.5 % vs. 55.8±1.7% in I/R, P<0.001, Figure 24). 
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Figure 24. The effects of artemisinin (4.3µM) on infarct to risk ratios in isolated perfused rat heart model 
subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the 
presence/absence of artemisinin (4.3µM) which was administered throughout reperfusion. Results were 
expressed as Mean±SEM (***P<0.01 vs. I/R control) (n=6).   
3.3.4 The differential expression of miRNA levels in isolated rat hearts upon I/R 
followed by treatment with artemisinin (4.3µM)  
Studies have shown the importance of miRNA’s in gene regulation with their deregulation 
being a common feature in a variety of diseases. More recently their expression in a variety of 
setting are emerging important biomarkers in cardiomyopathies (Chhabra et al., 2009). Certain 
miRNAs that have previously been linked with myocardial injury and cancer were investigated 
in this study in order to evaluate their expression in I/R setting of isolated rat hearts treated in 
the presence/absence of the potential anti-cancer drug artemisinin (4.3µM). Hearts were 
subjected to same treatment protocol as the isolated rat heart experiments (20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion) where artemisinin (4.3µM) 
was administered throughout reperfusion, following successful miRNA extraction with high 
purity levels. miRNA expression patterns were assessed using reverse transcription followed 
by qPCR and Real time PCR. Fold change in the differential expressions of miRNA-1, miRNA-
27a, miRNA-133a, miRNA-133b and miRNA-155 were assessed. 
As shown in the Figure 25, miRNA-1 was abundantly expressed in the untreated heart 
subjected to I/R setting whilst treatment of hearts with artemisinin (4.3µM) during reperfusion 
caused significant decrease in the expression levels of miRNA-1 compared to I/R control 
(0.5±0.3% vs. 51.3±11.0%, P<0.05, Figure 25). Treatment with artemisinin (4.3µM), expressed 
a nearly 100-fold decrease in miRNA-1 expression. 
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Figure 25. Mean fold changes in the differential expression of miRNA-1 in hearts subjected to 20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the presence/absence of artemisinin (4.3µM) 
where administered throughout reperfusion. Results were expressed as Mean±SEM. (*P<0.05 vs I/R Control) 
(n=3-4) 
Hearts subjected to I/R showed an increase in miRNA-27a while hearts treated with artemisinin 
(4.3µM) showed a significant (P<0.01) decrease compared to I/R. The trend observed showed 
an abundant expression of miRNA-27a in the untreated heart subjected to I/R, whereas 
expression of miRNA-27a was very low in artemisinin (4.3µM) treatment hearts, over 20-fold 
decrease compared to I/R control (0.8±0.3% vs. 12.6±0.2% in I/R, P<0.01, Figure 26).  
 
           
Figure 26. Mean fold changes in the differential expression of miRNA-27a in artemisinin (4.3µM) treated hearts 
compared to I/R control. Hearts were subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 
minutes reperfusion in the presence/absence of artemisinin (4.3µM) administered throughout reperfusion. 
Results were expressed as Mean±SEM. (n=3-4) 
miRNA-133a was significantly downregulated (9-fold decrease) in artemisinin (4.3µM) treated 
cells compared to non-treated I/R control (19.5±3.6% vs. 174.9±13.3% in I/R control, P<0.01, 
Figure 27). D’Alessandra et al., (2010) showed upregulation of miRNA-133a to increase in 
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Figure 27. Mean fold changes in the differential expression of miRNA-133a in artemisinin (4.3µM) treated 
hearts compared to I/R control. Hearts were subjected to 20 minutes stabilisation, 35 minutes ischaemia and 
120 minutes reperfusion in the presence/absence of artemisinin (4.3µM) which was administered throughout 
reperfusion. Results were expressed as Mean±SEM (**P<0.01 vs. IR control) (n=3-4) 
miRNA-133b was also upregulated in the isolated perfused rat hearts subjected to I/R. 
Expression of miRNA-133b decreased nearly 10 fold in the artemisinin (4.3µM) treated hearts 
(3.8±2.2% vs. 40.0±3.8% in I/R, Figure 28) although results did not reach significance when 
compared to the untreated time matched control. 
 
 
               
Figure 28. Mean fold changes in the differential expression of miRNA-133b in artemisinin (4.3µM) compared to 
control. Hearts were subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in 
the presence/absence of artemisinin (4.3µM) which was administered throughout reperfusion. Results were 
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The expression level of miRNA-155 in the isolated perfused rat hearts subjected to I/R was 
downregulated by treatment with artemisinin (4.3µM) throughout reperfusion. Artemisinin 
(4.3µM) treated hearts showed a nearly 10 fold decrease compared to control (0.5±1.3% vs. 
1.2±0.4%, P<0.05 in I/R, Figure 29)  
 
Figure 29. Mean fold changes in the differential expression of miRNA-155 in artemisinin (4.3µM) treated hearts 
compared to I/R hearts. Hearts were subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 
minutes reperfusion in the presence/absence of artemisinin (4.3µM) which was administered throughout 
reperfusion. Results were expressed as Mean±SEM (n=3-4)  
3.3.5 Effect of artemisinin (4.3µM) on cleaved caspase-3 activity in myocytes subjected 
to Hypoxia/Reoxygenation (H/R) 
In order to assess the cytoprotective effects of artemisinin in adult rat ventricular myocytes, 
changes in the levels of cleaved caspase-3 were measured via flow cytometry. Results from 
H/R show a significant increase in levels of cleaved caspase-3 compared to normoxic control 
26.8±2.0% vs. 8.8±1.2%, P<0.001, Figure 30) Administration of artemisinin (4.3µM) 
throughout reoxygenation resulted in a significant decrease in the levels of cleaved caspase-3 
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Figure 30. % Effect of administration of artemisinin (Art) (4.3µM) on cleaved casapase-3 levels as analysed by 
Flow cytometry. Results were expressed as Mean±SEM (***P<0.001 vs Normoxia, *P<0.05 vs H/R) (n=4-6). 
3.3.6 Changes in levels of MTT reductase activity with drug treatment following 
Hypoxia/Reoxygenation (H/R) in ventricular myocyte 
Isolated cardiac myocytes were subjected to 120 minutes of hypoxia and 120 minutes of 
reoxygenation where artemisinin (4.3µM) was administered throughout reoxygenation. 
Following H/R, cells were subjected to MTT assay which measures the cellular effects of 
artemisinin by measuring the changes in the level of MTT reductase activity which determines 
cellular viability in the isolated adult rat ventricular myocytes. 
Cells subjected to H/R showed a significant (P<0.001) decrease in cell the viability compared 
to normalised normoxic cells 29.3±6.1% vs. 100.0±0.0% in Normoxia respectively, Figure 31). 
Administration of artemisinin (4.3µM) throughout reoxygenation significantly improved cell 
viability compared with H/R group (66.5±6.3% vs. 29.3±6.1% respectively, P<0.01, Figure 
31).  
 
Figure 31. % change in MTT reductase activity compared with control in isolated rat ventricular myocytes 
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reoxygenation in the presence/absence of artemisinin (4.3µM). Results are expressed as Mean±SEM 
(***P<0.001 vs. Normoxic control and *P<0.01 vs. /HR) (n=6).  
3.3.7 Changes in levels of MTT reductase activity with drug treatment following 
Hypoxia/Reoxygenation (H/R) in HL-60 cells 
The cytotoxic effects of the increasing concentration of artemisinin was investigated in order 
to determine a concentration at which artemisinin causes significant cytotoxicity. Artemisinin 
caused a dose-dependent decrease in the viability of HL-60 cells. The IC50 of artemisinin was 
calculated using the graphit programme as 401.9µM (0.4mM) (Figure 32a). This concentration 
(0.4mM) caused a significant reduction in the number of viable cells when compared to 
untreated time matched control in HL-60 cells (57.2%±3.2% vs. 100.0±0% in Control, 
P<0.001, Figure 32c).  
 
Figure 32a. Dose response curve showing the effect of MTT cytotoxicity analysis on HL-60 cells in response to 
treatment with increasing concentrations of artemisinin (1-1000µM). HL-60 cells were incubated with 
artemisinin (1-1000µM) for 24 hours. Experiment was terminated by adding MTT solution and cells were 
further incubated for 2 hours until termination with lysis buffer. Plate readings were taken at 492nm and results 
analysed using the 4-parametric logistic analysis, Graphit software. Image of HL-60 control cells and 
artemisinin (0.4mM) cells, n=6 shown below (Figure 32b) 
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Figure 32b. HL-60 cells control vs artemisinin treated cells. Image shows HL-60 cells to the right incubated 
with artemisinin (0.4mM) for picture purposes and to the left is untreated HL-60 control. 
 
 
Figure 32c: % change in MTT reductase activity compared to control in MTT cytotoxicity analysis of HL-60 
cells in response to treatment with artemisinin (0.4mM). HL-60 cells were incubated with artemisinin (0.4mM) 
for 24 hours. Experiment was terminated by adding MTT solution and cells were further incubated for 2 hours 
until termination with lysis buffer. Plate readings were taken at 492nm and results analysed using the 4-
parametric logistic analysis, Graphit software. Results are expressed as Mean±SEM (n=6) 
 
3.4 DISCUSSION 
3.4.1 Reperfusion and CHD 
CHDs are a number one cause of death globally, claiming 7.3 million lives in 2001 and 
responsible for three-quarter of all deaths worldwide (Gaziano et al., 2009). Several anticancer 
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trastuzumab (a monoclonal antibody used in combination with chemotherapy, hormone 
blockers, or lapatinib in the treatment of metastatic breast cancer). Pathogenesis of 
anthracycline-associated toxicity is well-documented, with their different mechanisms known. 
This has raised the need to develop pharmacological mediation that will alleviate the drug 
induced toxicity (Sparano et al., 2002). There is an imperative need to develop a 
drug/adjunctive therapy to anti-cancer treatment that do not exarcerbate cardiac injury 
particularly in cancer patients who may have underlying ischaemic heart disease. Ischaemic 
heart disease is one of the prevalent manifestations of CHD often resulting as a consequence 
of oxygen and nutrient deprivation to parts of the heart which leads to severe tissue damage 
which may also lead to death (Palcher et al., 2007; Hadjipanayi and Schilling 2013). Several 
clinical interventions are used to currently limit or prevent the extent of a cardiac event from 
occurring (Niccoli et al., 2014). Ultimately, however patients with CHD will require 
reperfusion treatments. Reperfusing the tissue is an effective approach to managing ischaemia 
and in the long run curbs mortality (Xu et al., 2014). In spite of its clinical benefits, concerns 
have been raised as to the effectiveness of reperfusion treatments due to injury caused as a 
result of this mediation to cells/tissues (Yellon et al., 2000). 
With research in the past showing that by restoring blood flow to the deprived ischaemic area 
by either therapeutic means or surgical procedures (an effective mechanism of salvaging 
reversible cardiac injury), reperfusion poses a potential risk of early patient mortality in the 
patients receiving the treatment (Collard et al. 2001; Lee et al. 1995). While the blood flow 
relieves ischaemia, it may also result in cardiac damage, oxidative stress and complications 
called reperfusion injury (Gibson et al. 2009). Hence, the effect was termed as the double edged 
sword (Braunwald and Kloner 1985). Reperfusion injury maybe accompanied by several 
irreversible pathologies such as microvascular injury (stunning) and cellular damage known as 
reperfusion injury (Braunwald and Kloner 1985). Limiting the impact of I/R injury is of vital 
importance given the death figures relating to cardiovascular related mortality in the world. 
3.4.2 Artemisininin alleviates myocardial injury 
There is evidence in a myocardial model of I/R injury using Wistar rats that artemisinin 
possesses some cardioprotective effects that can salvage cardiac myocytes by limiting infarct 
size development (Sun et al., 2007). Artemisinin, also known as Qinghaosu, is an active 
component of the Chinese medicinal herb Artemisia annua (sweet wormwood) (Efferth et al., 
2008) which is a popular treatment for flu and fever in ancient china (Crespo-Ortiz and Wei 
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2012).  Artemisinin is presently administered as combination therapy against malarial 
infections worldwide (Dondorp et al., 2010 and Pasvol 2005). Studies have also shown 
artemisinin to be effective against pathophysiological conditions such as parasitic infections, 
viral infections, autoimmune diseases and a variety of cancer types (Harter and Michel, 2012; 
Mirshafiey et al., 2006; Ho et al., 2012; Hou et al., 2008; Xu et al., 2007).   
In our results we were able to show that artemisinin confers protection in a dose dependent 
manner by alleviating the induced myocardial I/R injury. Artemisinin was shown to be 
cardioprotective in this model of I/R at concentrations as low as 0.1µM where it significantly 
attenuates the development of myocardial infarction in isolated perfused rat hearts.  
Our results are consistent with the findings of Sun et al., (2007), which showed artemisinin at 
10µM and 100µM alleviated myocardial infarction in Wistar rats which, they speculated could 
be associated with its functions of anti-oxidation and scavenging of free radicals although this 
was not shown in their paper. No intracellular signalling pathways were actually investigated 
in Sun’s paper. Their data showed 10µM and 100µM significantly improved myocardial 
function and increased blood flow after ischaemia which was concurred in our study where we 
observed an increase in CF at 105 minutes into reperfusion with artemisinin (4.3µM) when 
compared to the untreated control. Interestingly, Sun et al.,(2007) showed an increase in LVDP 
compared to non-treated I/R control whereas LVDP in our artemisinin (4.3µM) treated hearts 
showed no significant difference. However, administering artemisinin at lower concentrations 
of 0.43µM showed slight increase in LVDP towards the end of drug treatment however this 
increase was not significant in comparison to the control. A significant increase in LVDP was 
observed with 0.042µM artemisinin administration compared to non-treated IR control towards 
the end of reperfusion. This can be explained as a result of the anticholinergic effects of 
artemisinin which may evoke anticholinergic mediated tachycardia in isolated guinea pig atrial 
cells (Hara et al., 2007). Dose dependent acute effects of artemisinin in heart subjected to I/R 
remain relatively unaffected in our studies. Changes in HR and CF as well as artemisinin 
treatment (EC20: 0.042µM, EC50: 0.43µM or EC80: 4.3µM E) resulted in no significant 
differences between the treatment groups. Artemisinin appears to bring about its effect without 
significantly altering haemodynamics as observed with results from 4.3µM and 0.43µM 
concentrations of artemisinin. It has been suggested clinically that, enhancement of vagal tone 
with administering anticholinergic drugs can lead to atrial fibrillations with the documented 
effect being variable or even spontaneous (Chen and Tan 2007). Although artemisinin is shown 
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to have minimal side effects, functional studies have reported changes in action potential and 
inotropic responses thus suggesting it may have possible cardiac influences (Hara et al., 2007). 
Which was represented in our normoxic hearts whereby perfusing the hearts with artemisinin 
4.3µM, showed an increase in HR with a time lag of 10 minutes upon drug administration for 
the drug to reach the heart and show a response. The drug administration revealed a gradual 
increase which became more pronounced towards the end of the treatment. CF was also 
significant increased at some time points i.e. upon perfusion and towards the end of artemisinin 
treatment. This effect although not previously reported may be explained in terms of the 
diuretic effect the artemisinin’s, sodium artesunate, an artemisinin derivative has been shown 
to have diuretic effects as well as natriuretic effects in patients with malaria (Zaki et al., 2011). 
Arteether, another artemisinin derivative shown to have no cardiovascular effects in rats has 
been shown to have minor diuretic effects (Kar et al., 1989). Our findings agree with this study 
by showing no significant effect on LVDP throughout artemisinin (4.3µM) administration. 
Diuretic therapy however has important antianginal effects and as a result of this effect on 
intravascular volume it is used in the treatment of high blood pressure (Parker et al., 1996). 
Short acting diuretic effects are however shown to have effects on HR variability in patients 
with heart failure (Parker et al., 1996; Tomiyama et al., 1999) which disagrees with our findings 
as this was observed in the normoxic hearts. Diuretics have been associated with increase in 
HR resulting in tachycardic episodes (Tomiyama et al., 1999). This suggests a possible increase 
in HR may be observed due to the HR variability caused by the diuretic effect of artemisinin.  
However in dogs, artemisinin derivatives, artesunate and artemeether administered over a 3 
month period while demonstrating a spectrum of toxic changes was followed by a decrease HR 
in the experimental dogs (Yin et al., 2014). Efferth and Kaina (2010) however have explained 
considerable toxicities may be found in animal studies but not in human studies. This is 
however as a result of drug differences such as mode of administration can lead to better drug 
safety and profiles. By adminstering artemeether or arteether intramuscularly, Efferth and 
Kaina (2001) observed no effect on the variety of haemodynamic parameters. Artemisinin and 
its derivatives are reported to be well tolerated and relatively safe in different models (Hara et 
al., 2007). 
Since time immemorial, herbs have been shown to be used for medicinal purposes. Claims 
have been on the earliest reference of earliest reference of use of medicinal herbs as a cure for 
a disease was found in Ebers Papyrus (2600 BC), other references date back to herbs in Rig 
Veda (period estimate between 3500-1800 BC). Medicinal plants/herbs are widely used and 
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have been shown to possess antiplatelet, hypolipidemic, anti-inflammatory, hypoglycemic and 
hypotensive actions in a variety of setting such as congestive heart failure, systolic 
hypertension, angina pectoris, atherosclerosis, cerebral insufficiency and arrhythmia. 
Chinese herbal plant Carthamus tinctorius L. (safflower), is widely used in preventing and 
treating cardiac disease in clinical settings where it is shown to alleviate ischaemic injury in 
vivo and in vitro. Other medicinal plants include Sini Decoction (SND) administered against 
myocardial I/R injury where it is shown to ameliorate mitochondrial oxidation injury in Kun 
Ming mice where cardioprotection was presented as limiting mitochondrial swelling, lactic 
acid content of myocardium and increase in the expression of Mn SOD miRNA with SND 
treatment (Zhoa et al., 2008). A study by Cheng et al. (2005) showed the inhibition of lipid 
peroxidation, augmentation of endogenous antioxidants and improving myocardial metabolism 
upon administering Curcumin against myocardial injury in rat models of myocardial I/R injury. 
Curcumin presented decrease in infarct size and the aforementioned mediations. 
3.4.3 Differential expression of miRNAs in response to I/R and treatment with 
artemisinin.  
Vast amount of studies have shown apoptosis to be mediated via several pathways including 
the intrinsic and extrinsic pathways (Li et al., 2013) As previously mentioned, there is therefore 
a need for reliable, specific and sensitive biomarkers that can detect sub-clinical acute cardiac 
drug induced injury (Li et al., 2013; Jiang et al., 2014). Studies have identified unique miRNA 
signatures in disease conditions such as chronic cardiovascular diseases where such as 
atherosclerosis serum levels of miRNA were quantitatively measured using PCR in peripheral 
bood samples of pre-atheroscelerotic patients and marked changes were reported. Jiang et al. 
(2015) suggested by integrating specific patterns of miRNA with BNP or cardiac troponin, 
diagnosis of cardiovascular disease will significantly improve. 
Caspases and mitochondrial involvement are also well researched in terms of cellular 
signalling, survival and death. However, until recently very little was known about miRNA-
mediated apoptotic pathways in myocardial injury. Several studies have showed miRNAs to be 
important regulators of apoptosis and in cardiac injury. Depending on the nature of the targeted 
genes, miRNAs can either be pro-apoptotic or anti-apoptotic, although over 93% of known 
miRNAs in vertebrae have been shown to have at least one target gene related to cell death and 
survival (Yang et al., 2009). 
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Promising evidence has also shown the importance of the role of miRNAs in cardiovascular 
disease (Ha 2011; Xiao and Chen 2010). Elevated levels of biomarkers in the blood do not 
diagnose underlying mechanisms of diseases but are however good indicators of myocardial 
damage (Salic and Windt 2012). Recently, miRNA’s such as miRNA-21, miRNA-92 and 
miRNA-101 are being characterised and used as biomarkers in several cardiomyopathies which 
are deregulated in dilated cardiomyopathy (Ikeda et al., 2007). Deregulation of miRNA-208 
expression is also associated with a poor clinical outcome and therefore represents a potential 
prognostic marker of human dilated cardiomyopathy (Satoh et al., 2010). It is well established 
that the expression of many miRNAs changed significantly in diseased myocardium with 
studies showing altered expression of miRNA-1 and miRNA-133 to be associated with human 
heart failure (Care et al., 2007; Yang et al., 2007). 
In our study we investigated the role of miRNA-1 in modulating artemisinin induced cell 
survival and differential expression in response to I/R injury. miRNA-1 can act as both a pro 
and/or anti-apoptotic factor in cardiac I/R injury (Gidlof et al., 2011; and Tang et al., 2009). 
miRNA-1 is closely related with I/R injury in a rat model (Tang et al., 2009) and has been well 
documented to be a biomarker for predicting acute myocardial infarction in humans too where 
an upregulation in miRNA-1 is seen in patients with myocardial infarction (Ai et al., 2010). 
Over-expression of miRNA-1 has been shown to increase in response to oxidative stress.  In 
our I/R control group however, levels of miRNA-1 were evidently upregulated compared to 
the cardioprotective drug treatment (artemisinin), previous studies have shown 
cardioprotective drugs to express a decreased level of miRNA-1 compared to control which 
was significantly higher in our result as well as previous studies(Tang et al., 2009; Wu et al., 
2011). Cheng et al., (2010) showed a 200 fold increase in the level of miRNA-1 in Sprague 
Dawley rats with the introduction of Triton-100, a compound primarily administered to induce 
cellular necrosis (Cheng et al., 2010). This suggests administering cardiotoxic drugs may lead 
to upregulation of miRNA-1 which agrees with previous finidngs. Treatment with artemisinin 
in our results showed a significant 4-fold decrease in the expression of miRNA-1. Research by 
Xu et al., (2007) showed decreased levels of miRNA-1 favours cardiomyocyte survival which 
corresponds to the effect seen in the different models upon administering artemisinin. miRNA-
1 has been well implicated in the induction of apoptotic or necrotic cell death in different organs 
and in circulating blood plasma (Wu et al., 2011). We can therefore postulate the decrease in 
the expression of miRNA-1 levels observed in our study may be associated with the 
cardioprotection offered by artemisinin.  
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miRNA-27a has been shown to play a pivotal role in the pathogenesis of cardiac hypertrophy 
and dysfunction as implicated in previous studies (Divakaran and Mann 2008; Nishi et al., 
2010; Da Costa Martins and De Windt 2012). miRNA-27a has also previously been implicated 
in a variety of cancer types such as breast cancer, pancreatic cancer, prostrate cancer, leukaemia 
and so on (Mertens-Talcott et al., 2007; Liu et al., 2009; Fletcher et al., 2012; Zhoa et al., 2011; 
Ma et al., 2010). Upregulation of miRNA-27a has been shown to induce caspase-dependent 
and independent apoptosis in human embryonic kidney cells (Chhabra et al., 2009). 
Upregulation in the levels of miRNA-27b in Smad4 (gastrointestinal malignancy-specific 
tumor suppressor gene) knockout mice has been shown to also induce cardiac hypertrophy and 
heart failure while its supersession led to the inhibition of the hypertrophic cell growth (Wang 
et al., 2011). miRNA-27a is often implicated in breast cancer as an oncomiRNA (Mertens-
Talcott et al., 2007). It has previously been implicated in human gastric adenocarcinoma where 
its downregulation was shown to confer sensitivity of drugs on gastric cancer cells (Liu et al., 
2009). miRNA-27a levels were partially downregulated by administering artemisinin although 
data did not reach statistical significance. Down regulation of miRNA-27a also suppresses the 
growth, colony formation and migration of pancreatic cells, prostate cancer and various other 
cancer types (Fletcher et al., 2012; Zhoa et al., 2011; Ma et al., 2010).  
It is evident that in cardiomyocytes apoptosis is a key event in I/R studies and interventions are 
constantly being developed to salvage the situation. By administering artemisinin in this study, 
we have been able to limit myocardial injury which suggests artemisinin has a great potential 
as a therapeutic agent against myocardial I/R injury. We also investigated the differential 
expression of certain miRNAs in the cardiomyocytes subjected to I/R injury and upon treatment 
with artemisinin. Some miRNAs have been implicated in cardiovascular disease such as 
miRNA-1 shown to reduce myocardial infarction through repressing certain apoptotic genes 
and up-regulating anti-apoptotic genes. Pro-apoptotic miRNAs such as miRNA-133a are 
important potential targets too (He et al., 2011). In another study, circulating miRNA-1, 
miRNA-133a, miRNA-499, and miRNA-208a were found to increase in patients with acute 
MI (Sodha et al., 2009). This is similar to the expression patterns which we detected in miRNA-
1 and miRNA-133a in rats subjected to acute myocardial injury. 
miRNA expression varies among tissues; miRNA-1, miRNA-133a, and miRNA-133b are 
strongly expressed in the heart and skeletal muscle and are regarded as cardiac-specific 
miRNA’s (Lopez-Neblina et al., 2005; Chen et al., 2006). Both miRNA-1 and miRNA-133 
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have been shown to play a crucial role in regulating cardiac hypertrophy both in vivo and in 
vitro are highly expressed in the heart muscle (Dong and Yang 2011).  
miRNA-133b on the other hand is a versatile pro-apoptotic molecule (Ratovitski 2013). It is 
currently being explored as a therapeutic target for anti-cancer treatment with increased 
expression of THP1 macrophages (Human monocytic cell lines) and HL-60 (HeLa cells) 
following innate immune activation by members of the Toll-like receptor (TLR) family (Arcila 
2010). With the potential of artemisinin as a possible anti-cancer therapy we anticipated a 
decrease in. Expression levels of miRNA-133b in our artemisinin treated heats did show a 
decrease in miRNA-133b expression however results did not reach significance when 
compared to the controls. 
miRNA-155 has been shown to be consistently up-regulated during acute myocarditis in both 
humans and mice models (Corsten et al., 2012). miRNA-155 has been associated with heart 
failure, inducer of pathological cardiomyocyte hypertrophy, down modulates inflammatory 
cytokine production and mediate inflammatory response (Seok et al., 2014) which agrees with 
our I/R hearts. Artemisinin treated hearts interestingly, reversed the miRNA-155 expression by 
10 fold compared to I/R control. Similarly, Seok et al., (2014) in their experimental mouse 
model of cardiac hypertrophy showed loss of miRNA-155 prevents progression of heart failure 
and extends the survival in mice. Our results suggest artemisinin down-regulates miRNA-155 
which has been shown to suppress cardiac hypertrophy in response to stressors and by 
therapeutically inhibiting endogenous miRNA-155. Previous studies have established 
artemisinin has the ability to suppress cardiac hypertrophy in primary cultured rat cardiac 
myocyte by activating genes involved in the pathogenesis of cardiac remodeling and heart 
failure (Xiong et al., 2010). 
Nazari-Jahantigh et al., 2012 showed miRNA-155 targets Bcl6 (ordinarily an unstimulated 
macrophage) which promotes pro-inflammatory activation. miR-155 has been shown to 
mediate the suppression of Bcl6 (ordinarily an unstimulated macrophage)which causes the 
progression of atherosclerosis by influencing macrophages to atherogenic activation which is 
vital for associated inflammatory response (Nazari-Jahantigh et al., 2012). Therefore miRNA-
155 up-regulates inflammatory macrophages amplifying vascular inflammation and other 
coronary heart diseases. These findings agree with the outcomes from our results. 
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3.4.4 Artemisinin 4.3µM improves cell viability of cardiomyocytes subjected to 
hypoxia/reoxygenation (H/R) injury. 
In this study, the isolated cardiomyocytes were subjected to 2 hours of hypoxia and 2 hours of 
reoxygenation where artemisinin (4.3µM) was administered throughout the reoxygenation 
period. Following H/R, the cells were subjected to MTT assay which gives an indication of cell 
viability (Stockert et al., 2012). 
Administering artemisinin (4.3µM) at reperfusion showed improvement in myocyte viability 
following H/R, this is indicative of the potential of artemisinin to salvage H/R induced injury 
in adult ventricular myocytes. Additionally, artemisinin has the ability to attenuate and prevent 
cell damage in response to ischaemic and hypoxic injuries according to our study. Xiong et al., 
(2010) similarly showed artemisinin blocked angiotensin II-induced cardiac hypertrophy in 
vitro in a concentration-dependent manner thus inhibiting cell damage. The effect of 
artemisinin on cardiac hypertrophy was blocked after IκB-α which was silenced by transfection 
of cardiomyocytes with IκB-α siRNA. The study suggests artemisinin could be an effective 
preventive and therapeutic agent against cardiac hypertrophy and heart failure by inhibiting 
NF-κB signal pathways (Xiong et al., 2010). 
3.4.5 Artemisinin attenuates myocardial injury in cardiomyocytes subjected to H/R 
injury by reducing the level of cleaved caspase-3 activity.  
It is well established that ischaemia results in necrotic tissue and/or apoptosis (Iliodromitis et 
al., 2007; Morin et al., 2009). Cleaved caspase-3 is a pivitol effector caspase in apoptotic 
signalling (Sakamaki and Satou 2009; Lu and Chen 2011). Studies have shown that activation 
of caspase-3 maybe as a result of mitochondrial oxidative stress which causes it rupture and 
release cytochrome c into the cytosol forming complexes known as apoptosomes (Montaigne 
et al., 2012; Cui et al., 2012 and Dai et al., 2014).  
Our study showed treatment with artemisinin (4.3µM) protects the heart by salvaging myocytes 
committed to apoptotic pathways. Artemisinin (4.3µM) significantly improved cell viability in 
isolated adult rat cardiomyocytes compared to the non-treated H/R group control. Hypoxia has 
been shown to stimulate cellular shrinkage which has been previously identified as a feature of 
ischaemic caspase-dependent cell death (Shinzawa and Tsujimoto 2003). This explains the 
effects seen in the H/R group and may suggest artemisinin is a potential scavenger that reverses 
this effect. 
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Cardiomyocyte death occurs during ischaemia however more myocytes maybe damaged as a 
result of reperfusion injury as has been shown in previous studies (Baines et al., 2011; 
Braunwald and Kloner 1985). This explains the effects seen in the I/R hearts and H/R groups. 
These studies validate that the hearts have successfully undergone ischaemia and reperfusion. 
Administration of artemisinin causes a significant decrease in cleaved caspase-3 activity. With 
apoptosis being a reliable marker of cellular injury, evaluating therapeutic agents such as 
artemisinin using cleaved caspase-3 is imperative especially with artemisinin’s potential. 
Treatment with artemisinin during reperfusion has shown much promise in terms of 
cardioprotection against I/R in isolated rat hearts therefore investigating the effect of cleaved 
caspase-3 in isolated cardiomyocytes re-affirmed artemisinin’s anti-apoptotic potential in 
isolated cardiomyocytes subjected to H/R injury. 
3.4.6. Artemisinin is potent against HL-60 cancer cells 
Many reports on artemisinin show potent cytotoxic effect in a variety of cancer cells (Crespo-
Ortiz and Wei 2012, Qaderi et al., 2013. Due to artemisinin and its derivatives structurally 
possessing an endoperoxide bridge, it is thought to lead to the production of free-radical species 
which in turn explains its cytotoxicity in cancer cells (Beekman et al., 1996). 
As an additional study, we investigated the anti-cancer activity of artemisinin in HL-60 cells. 
Artemisinin was established as a potent anti-cancer drug at 0.4mM, the IC50 which shows 
strong evidence that artemisinin induces apoptosis in HL-60 cells. Our results are in agreement 
with the study by Jones et al., (2009) who showed artemisinin–acridine hybrids display 
promising antitumour activity in HL-60 by inducing cell death by apoptosis. Artemisinin linked 
to acridine was shown to enhance antitumour activity in the HL-60 leukaemia cell line 
(Lipinski et al., 2000). The apoptotic effect of artemisinin in cancer cells has been associated 
with internalisation of iron which explains artemisinin’s selective toxicity towards cancer cells 
(Lipinski et al., 2000). Cytotoxicity is increased in cancer cells with high cellular iron content 
as this makes the tumour cells more sensitive to oxidative stress (Lipinski et al., 2000 and 
Efferth et al., 2003). This effect is absent in normal non-tumouric cells. Efferth et al., (2004) 
reported very minimal cytotoxicity as a result of artemisinin treatment in normal non cancer 
cells. However Efferth et al., (2004) also suggested that other iron-related genes may also be 
involved in the cellular response and carcinogenesis of the artemisinin’s such as mitochondrial 
aconitase and ceruloplasmin (ferroxidase) which were are identified as important targets of the 
cellular response to artemisinin's’s when administered with ferrous iron (Efferth et al., 2004). 
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Observed cytotoxicity was potentially as a result of artemisinin treatment as well as oxidative 
stress which accounts for the high rise in ROS production (Barrera 2012). 
Willoughby (2002) also showed Artemisinin at 0.3mM significantly down-regulated the 
expression of CDK2 and CDK4 (both important modulatory proteins in cell division) on 
LNCaP prostate cancer. In cancer cells, CDKs are overactive, causing unregulated proliferation 
in a variety of cancer types (Yoon et al., 2012). This suggests artemisinin has the capacity to 
change the function of certain transcription regulators leading to the selective loss of CDK4 
gene expression (Willoughby 2002). In Human colon cancer (HT29) the artemisinin’s have 
been found to activate the BAX family to induce the release of cytochrome c, leading to 
apoptosis in cancer cells (Riganti et al., 2009).  
In our study we have shown artemisinin’s important function as an anti-apoptotic/pro-survival 
agent in cardiac cells subjected to I/R injury and also as a pro-apoptotic agent against HL-60 
cancer cells. In this study we observed artemisinin as an effective chemopreventative agent 
against HL-60 cancer cells, with other studies claiming its cytotoxicity against several other 
cell lines (Hou et al., 2008). We also observed artemisinin’s anti-apoptotic function in cardiac 
cells where it expresses cardioprotective properties in both healthy and I/R hearts. In HL-60 
cancer cells artemisinin was shown to decrease cellular viability whereas in isolated 
cardiomyocytes despite simulated myocardial injury as a result of induced I/R or H/R 
artemisinin was shown to improve viability and salvage injured myocytes by preventing a 
multitude of processes from occurring which may trigger cell death. Studies have shown anti 
apoptosis and cellular survival serve to counteract programmed cell death in cells and the two 
processes are never mechanistically distinct (Portt et al., 2010). However, artemisinin in our 
study was revealed to have a dual but conflicting function in cardiomyocytes and in HL-60 
cells, artemisinin is suggested to activate apoptotic signalling complexes that initiate death in 
HL-60 cancer cells as well as capable of salvaging the injured myocardium. This signifies the 
importance of artemisinin and its potential particularly in cancer patients with underlying 
ischaemic heart disease. 
3.5 CONCLUSION 
With novel research on artemisinin, we can conclude artemisinin offers a promising remedy in 
combating a variety of human diseases beyond malaria. Our results showed artemisinin has the 
potential to salvage cells marked for apoptosis and reverse the effect of myocardial injury also.  
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Results show artemisinin decrases infarction, increases viability, decreases caspase-3 activity 
in isolated perfused hearts and cardiomyocytes subjected to I/R injury. Hearts treated with 
artemisinin upon reperfusion/reoxygenation revealed a decrease in the expression of miRNAs 
associated with apoptosis/myocardial injury. Results from HL-60 cells also confirmed 
artemisinin’s selective cytotoxicity against HL-60 cancer cells. Artemisinin was observed to be 
pro-apoptotic in HL-60 cancer cells and anti-apoptotic in the myocardium thus suggesting 
artemisinin’s vital importance particularly in cancer patients with underlying comorbidities 
such as ischaemic heart disease where artemisinin has the potential to be used as an anti-cancer 
agent without causing drug induced cardiotoxicity. Further studies were conducted to 
investigate cell signalling pathways associated with the observed cardioprotection which will 
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4 ARTEMISININ ATTENUATES MYOCARDIAL 
ISCHAEMIA REPERFUSION INJURY VIA 
RECRUITMENT OF THE PI3K-AKT-P70S6K/BAD 
CELL SURVIVAL PATHWAY. 
4.1 INTRODUCTION  
Ischaemic heart disease (IHD) is a persistent public health burden due to its wide prevalence 
and high impact on morbidity and mortality worldwide (Chilton 2004; Hausenloy and Yellon 
2013; Silachev et al., 2014). IHD is characterised by a restriction in blood flow to the coronary 
arteries which is associated with oxidative stress, where the mitochondria act as a major source 
of ROS often resulting in acute or severe tissue injury, depending on the duration and 
magnitude of the ischaemic insult (Eltzshig and Eckle 2011; Kalogeris et al., 2012). Restoration 
of blood flow to an ischaemic organ which we have previously discussed in detail is in order 
to maintain tissue viability is accompanied with ‘reperfusion injury’ to the ischaemic organ 
(Yellon and Haunsenloy 2013; Silachev et al., 2014).  
Previous studies have shown artemisinin suppresses myocardial hypertrophy in response to 
aortic banding in Sprague Dawley rats and that artemisinin it decreases myocardial injury in 
the rat heart model of ischaemia reperfusion (I/R) injury as discussed in detail in previous 
chapter however the intracellular processes mediating this protection in the heart was not fully 
investigated (Xiong et al., 2010; Sun et al., 2007). Gu et al. (2012) have shown artemisinin is 
cardioprotective and inhibits ventricular remodelling via the inhibition of the NF-ĸB Pathway 
which results in inhibition of inflammation and prevents cardiac dysfunction. They further 
speculated artemisinin may inhibit MMP-2 and MMP-9 (inflammatory cytokines) expression 
levels although the mechanism remains unclear. (11). However, studies have suggested that the 
activation of the NFkB pathway is usually a causal effect in cardiac hypertrophy response (Gu 
et al., 2012). 
Artemisinin which has been shown to be effective in a variety of pathophysiological conditions 
such as malarial infections (Krishna et al., 2006), viral infections (Harter and Michel, 2012), 
inflammation (Mirshafiey et al., 2006) and cancer chemotherapy, in vitro and in vivo (Ho et 
al., 2012; Hou et al., 2008; Luo et al.,2014) is a drug with multiple potential.  
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However in anti-malarial and anti-cancer studies where interest in artemisinin lies, it has been 
shown to exacerbate the formation of free radicals by cleaving the endoperoxide bond within 
its structure (Ho et al., 2014; O’Neill et al., 2010). This has led to several investigations 
associating artemisinin with different signalling pathways such as MAPK, NF-κB, Wnt, β-
catenin, PI3K pathway in a range of different models and cell lines (Mirshafiey et al., 2006; 
Xu et al., 2007; Ho et al., 2012;Cheng et al., 2013; Li et al., 2013) . 
Studies have demonstrated that the recruitment of the PI3K-Akt cell survival pathway, also 
referred to as the RISK pathway, as an important target for cardioprotection which is mediated 
via recruitment of pro-survival kinases such as Akt, p70s6k, and BAD (Li et al., 2011; 
Hausenloy et al., 2005). Phosphorylation of down-streaming targets of Akt such as p70s6k is 
responsible for cell growth and proliferation (Courtney et al., 2010; Ye et al., 2010). Danial 
(2008) reported phosphorylation of BAD (Ser136), an anti-apoptotic protein and a downstream 
target of Akt, as an important mediator of cell survival, with a critical role in inhibiting the 
opening of the mPTP) along with eNOS, PKC and glycogen synthase kinase-3β (GSK) leading 
to cardioprotection (Davidson et al., 2006; Hausenloy et al., 2004). Conversely, Akt has also 
been implicated in cellular injury and caspase-dependent programmed cell death with caspase-
3 playing a pivotal role in the regulation of the cellular apoptosis in several models including 
stress-induced myocardial injury models in rats (Hussain et al., 2014; Baines et al., 2005; Fulda 
et al., 2010; Sakamaki and Satou, 2009). 
Given the important findings that artemisinin has cardioprotective and anti-hypertrophic 
properties, the current study aims to examine the intracellular signalling pathways associated 
with artemisinin-mediated cardioprotection in the isolated rat hearts and adult primary 
ventricular myocyte models of I/R injury.  
4.2 MATERIALS AND METHODS 
Chemicals: Artemisinin, Wortmannin, Rapamycin were purchased from Tocris (Bristol, 
UK) and dissolved in DMSO and stored at -20 °C. MTT was purchased from Sigma 
(Poole, UK). Cleaved Caspase-3 (Asp175) Antibody (Alexa Fluor® 488 Conjugate), p-
AKT (Ser473), total AKT, p-p70S6 Kinase (Thr389), total p70s6k, p-BAD (Ser136, total-BAD 
antibodies and secondary IgG HRP conjugated rabbit monoclonal antibodies were 
purchased from New England Biolabs (Hertfordshire, UK). SuperSignal West Femto® 
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enhanced chemoluminescent substrates was purchased from Fischer Scientific 
(Loughborough, UK) 
 
Adult male Sprague Dawley rats (350-400g) were obtained from Charles River 
(Margate, UK). Animals received humane care in accordance with the guidance on the 
operation of the animals (Scientific Procedures Act 1986). The study was carried out 
upon obtaining ethical approval from Coventry University Research ethics committee 
which was regularly assessed throughout the project.  
4.2.1 Isolated Perfused Heart Model 
Following sacrifice by cervical dislocation, the hearts were rapidly excised and placed in ice 
cold KH solution(118.5 mM NaCl, 25 mM NaHCO3, 4.8mM KCl, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 12 mM Glucose, 1.7mM CaCl2.2H2O)  at <4 oC  as described previously (Hussain 
et al., 2014). 
The aortic arch was removed, allowing cannulation of the aorta and subsequent retrograde 
perfusion with KH buffer, saturated with 95% O2, 5% CO2, maintained at a temperature of 37 
± 0.5oC and pH 7.4 using a water-jacketed heat exchange coil. 
The left atrium was removed and a latex balloon inserted and inflated to a constant diastolic 
pressure of 8-10mmHg. This allows LVDP to be measured. A physiological pressure transducer 
was connected to a bridge amp and a power lab (AD Instruments Ltd, Chalgrove, UK) which 
allows the LVDP, HR using ECG leads and CF to be measured at regular intervals. The 
perfusate was also collected at those intervals.  
During ischaemia/reperfusion studies the isolated hearts were allowed to stabilise for 20 
minutes followed by 35 minutes ischaemia and 120 minutes reperfusion. Upon subjecting the 
hearts to 20 minutes of stabilisation, the anterior descending left coronary artery is ligated to 
induce regional ischaemia. This was performed using a hooked 6-0 silk surgical suture and 
forceps and piercing the heart under the left coronary artery to form a snare with the thread. 
The thread was passed through a pipette tip and the snare tightened to initiate ischaemia. At the 
onset of reperfusion, the flow of KH buffer was reintroduced via the removal of the pipette tip 
thus releasing the snare. Reperfusion was conducted for 120 minutes (Figure 33). 
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Figure 33. Treatment protocol for infarct size assessment studies and ventricular myocytes studies respectively. 
 
4.2.1.1 Treatment protocol for the Isolated rat heart model 
The isolated hearts were allowed to stabilise for 20 minutes followed by 35 minutes of 
ischaemia and 120 minutes of reperfusion. At the onset of reperfusion, artemisinin EC80 at 
4.3µM was administered throughout the experiment with the inhibitors of PI3k-Akt and 
p70S6K. Hearts were randomly assigned to different drug treatments. One group was treated 
with artemisinin (4.3µM) ± wortmannin (0.1µM) or with wortmannin (0.1µM) alone, which 
was administered throughout the period of reperfusion. Another group was treated with 
artemisinin (4.3µM) ± rapamycin (0.1µM) or with rapamycin alone (0.1µM) administered 
throughout reperfusion. Figure 33 illustrates an outline of the experimental protocol. No effects 
where seen in haemodynamics with the drug treated hearts when compared to control hearts. 
Upon completing the experiment the left coronary artery re-ligated in preparation for staining 
the heart with 1ml of 0.2% Evans blue in saline, allowing differentiation between viable and 
tissue at risk. After staining, the hearts were weighed and stored at -20oC for later analysis. The 
hearts were then cut transversely into slices approximately 2 mm thick and incubated at 37°C 
in 1% TTC solution in phosphate buffer for 10–12 stminutes and fixed in 10% formaldehyde 
for at least 4 hours to enhance the staining prior to analysis.  
Drug 
administration 
(Art ± Inhibitor) 
Drug 
administration 
(Art ± Inhibitor) 
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Thereafter, the heart slices were removed from formaldehyde and placed between two Perspex 
sheets which were compressed with bulldog clips. The heart slices were traced onto acetate 
film using different coloured markers to differentiate between the viable, at risk and infarct 
tissue. The at risk tissue stained red and the infarct tissue appeared pale. 
 
The acetate film was scanned into a computer to allow calculation of Infarct to risk ratio from 
the differentiated tissues traced. Areas of viable, at risk and infarct tissue were measured using 
the Image Tool program as developed by the University of Texas Health Science Centre at San 
Antonio, Version 8.1 (UTHSCSA). 
4.2.2 Adult Rat Ventricular Myocytes Isolation 
Ventricular rat cardiomyocytes were isolated from Adult male Sprague Dawley rats (350-400g) 
by enzymatic dissociation method (Maddock et al., 2002; Hussain et al., 2014). 
Following digestion as decribed in detail in chapter 2, the isolated myocytes were incubated in 
RB for MTT, caspase 3 and FACS analysis (at 37 oC, 5% CO2 for 24 hours before being used 
(Maddock et al., 2002) 
4.2.2.1 Treatment protocol for the isolated ventricular rat heart model  
The RB suspended myocytes were then incubated in a hypoxic chamber, Galaxy 48R (New 
Brunswick) for 2 hours with atmosphere 5% CO2 95% N2 at 37oC and the pellet resuspended 
in RB. The myocytes were then assigned to the different treatment groups: artemisinin 
(4.3µM), artemisinin (4.3µM) ± inhibitor of PI3K (wortmannin) (0.1µM), wortmannin 
(0.1µM), artemisinin (4.3µM) ± inhibitor of mTOR/p70S6K (rapamycin) (0.1µM), rapamycin 
(0.1µM). The myocytes then underwent reoxygenation for 2 hours. Upon completing 
reoxygenation the cells were then assessed either for cellular viability using MTT or flow 
cytometric analysis for p-BAD (Ser136) or cleaved caspase-3 activity as described below. 
4.2.3 Quantitative analysis of cleaved caspase-3 activity and BAD (Ser136) by FACS 
analysis  
Isoated cardiomyocytes were resuspended in PBS and fixed with 3% formaldehyde for 10 
minutes at room temperature washed in incubation buffer (0.5% BSA in PBS as described in 
detail previously. For p-BAD (Ser136) and T-BAD analysis, the samples were probed for 1 hour 
with either p-BAD (Ser136) or T-BAD rabbit monoclonal antibody diluted at 1:100 dilution in 
incubation buffer followed by incubation in Alexa Fluor® 488 goat anti-rabbit IgG antibody at 
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a dilution of 1:1000 for 1 hour. For the analysis of cleaved caspase-3 activity, the cells were 
incubated for 1 hour in cleaved caspase-3 (Asp175) secondary rabbit monoclonal antibody (Alexa 
Fluor ® 488 conjugate) (New England Biolabs, Hertfordshire,UK) diluted at 1:1000 . At the 
end of the incubation period, the cells were centrifuged and the supernatant was removed the 
cells resuspended in 500µl PBS and analysed using flow cytometer (Becton Dickinson, Oxford, 
UK) using the on the FL1 channel to count 10,000 events (Vermes et al., 2002; Hussain et al., 
2014).  
4.2.4 Cell viability assay based on MTT reductase activity 
The cells were harvested as described previously and subjected to MTT assay to measure 
succinate dehydrogenase activity. 50µl of cells (containing 1 x 10-4 cells.ml-1) were used per 
well and for contained 100µl of restoration buffer. Other wells were used for the different 
treatment groups which contained 50µl of cells and 50µl of drug treatment. Drugs used for this 
study were diluted with restoration buffer to a final concentration of 4.3µM in the artemisinin 
treated group, 0.1µM in wortmannin treated groups and 0.1µM in rapamycin treated groups 
similar to previous experiments which were administered at reoxygenation. 6 wells were used 
for each concentration of the experimental groups used. Cells were the incubated for 2 hours 
under hypoxic conditions. Drugs were administered at the start of reoxygenation and cells were 
incubated for an additional 2 hours with 20µl of MTT (5mg.ml-1 in PBS) which was added to 
all the wells and incubated in the dark at 370C. 100µl of lysis buffer (20% SDS in 50% 
dimethylformamide) was then added and cells incubated overnight at 37o C. The absorbances 
of the plates were measured on a plate reader at 450nM (Thermo Scientific, UK).  
4.2.5 Western Blotting 
Following the protocol previously described in chapter 2, 60µg of the sample was loaded onto 
Biorad 4-15% Tris/Glycine precast gradient gels (Biorad, Hertfordhsire, UK). The gel was then 
attached to the Mini-PROTEAN 3 electrode assembly system (Biorad PowerPac 3000) and run 
at 130volts for 90 minutes (Figure 34). 
Following electrophoresis, the proteins were transferred unto a PVDF membrane using the 
Biorad Midi Trans-Blot® Turbo™ Transfer pack using the Biorad trans blot at 25V, 1.3 A for 
7 minutes when using two gels. The membrane was washed in TBST and incubated with 
blocking buffer (5% milk in TBST) for an hour. The membrane was washed 3 times in TBST 
and then incubated overnight on an orbital shaker at 4oC with p-Akt (Ser473 or p-p70S6K (Thr 389) 
rabbit monoclonal antibody at a dilution of 1:1000. After the overnight incubation, the 
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membrane was washed 3 times in TBST and then incubated in a 1:2000 dilution of Anti-rabbit 
antibody HRP linked IgG and HRP linked anti-biotin antibody Immunoblots were detected 
with the Super Signal West Femto (Fischer Scientific, Loughborough, UK) using the Biorad™ 
ChemiDoc imaging system (as shown in Figure 34).  
 
Figure 34: Illustration of a typical western blot set up used to quantify protein. Avaiable online from < 
http://www.antibodies-online.com/images/news/WesternBlotSetup.jpg> 
Band intensity was quantified using Quantity-One 1-D analysis software (Biorad, 
Hertfordshire, UK) for the p-Akt or p-p70s6k expressions  Upon capturing the images of the 
relative changes in density, the blots were then stripped of the phospho-antibody (p-Akt or p-
p70S6K) by boiling in water for 5 minutes and membranes re-probed for  T-Akt or T-p70S6K 
by incubating in (5% milk in TBST) for an hour, then incubated overnight on an orbital shaker 
at 4oC for Totals (T-Akt and T-p70s6k) at a dilution of 1:1000. After the overnight incubation, 
the membrane was washed 3 times in TBST and then incubated in a 1:2000 dilution of Anti-
rabbit antibody HRP linked IgG and HRP linked anti-biotin antibody. Immunoblots were 
detected on the Biorad™ ChemiDoc imaging system as done earlier. The relative changes in 
phosphorylated proteins were normalised to T-Akt and T-p70S6K expression. 
Statistical Analysis  
The percentage of infarct/risk ratio, % of cell viability and the relative changes in 
phosphorylated proteins were all expressed as MEAN±SEM. Hearts treated with artemisinin, 
the different inhibitors and the control groups were tested for group differences in infarct size, 
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cellular viability and protein expression using the SPSS software package-One Way analysis 
of variance (Anova) with LSD post hoc test.  Physiological parameters (Haemodynamics) 




There was no significant effect on the haemodynamic parameters with drug treated hearts as 
compared to control (data not shown). 
4.3.2 Exclusion Criteria 
We have excluded two rats from our experiment, one due to poor stabilization and the other 
due to very high flow rate which may be indicative of a tear in the aortic wall or may be an 
incompetent valve. Another rat was also excluded due to low viability of live cells following 
isolation (≤70%) in the cellular viability studies. All other groups have been used. 
4.3.3 Artemisinin confers protection from I/R via activation of the PI3K cell survival 
pathway in the isolated perfused heart model 
Administration of artemisinin (0-100µM) throughout reperfusion significantly (P<0.01-0.001) 
reduced infarct size by limiting myocardial ischaemia reperfusion injury as shown in chapter 
3. EC80 which was calculated as 4.3µM (the most effective cardioprotective concentration) was 
used in subsequent experiments as was illustrated in Figure 20c.  
 
To elucidate the mechanistic basis of artemisinin-induced protection of ischaemic reperfusion 
injury, we evaluated the role of the PI3K pathway. Artemisinin (at 4.3µM) which caused a 
significant (P<0.001) decrease in infarct size to risk ratio compared to the I/R control 
(38.0±2.5% vs.55.8±1.7% respectively, Figure 35). Wortmannin alone (at 0.1µM) had no effect 
on infarct size to risk ratio compared to control (51.9 ± 1.3% vs. 55.8 ± 1.7 % respectively, 
Figure 35). 
However, co-administration of artemisinin (4.3µM) with wortmannin (at 0.1µM) significantly 
(P<0.01) reversed artemisinin-induced infarct sparing effects compared to artemisinin (4.3µM) 
alone (48.7±1.1% vs. 38.0 ±2.5% respectively, Figure 35).  
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Figure 35. Assessment of PI3K-Akt cell survival pathway in artemisinin mediated cardioprotection in isolated 
perfused heart model subjected to 35 minutes ischaemia followed by 120 minutes reperfusion. Artemisinin (Art) 
(4.3µM) (EC80) was administered at reperfusion in the presence and absence of wortmannin (Wort) (PI3K 
inhibitor) (0.1µM) or rapamycin (Rapa) (mTOR inhibitor) (0.1µM) .Wortmannin (0.1µM) or rapamycin 
(0.1µM) was also administered alone at reperfusion and subjected to same experimental protocol. Results are 
shown as Mean±SEM. (***P<0.001 vs IR, **P<0.01 vs Art and *P<0.05 vs Art) (n=6-8). 
 
Rapamycin alone (at 0.1µM) did not have an effect on I/R compared to I/R control (53.9±1.6% 
vs 55.8 ± 1.7% respectively), but the co-administration of artemisinin (4.3µM) with rapamycin 
(0.1µM) upon reperfusion significantly (P<0.05) reversed the protective effects of artemisinin 
(47.0±1.4 % vs 38.0±2.5 % respectively, Figure 35).  
4.3.4 Artemisinin improves the viability of cardiomyocytes subjected to hypoxia/ 
reoxygenation injury via PI3K cell survival pathway 
The isolated cardiac myocytes were subjected to 2 hours of hypoxia and 2 hours of 
reoxygenation. Artemisinin (4.3µM) was administered throughout the reoxygenation period in 
the presence and absence of the PI3K inhibitor wortmannin (0.1µM). 
2 hours of hypoxia followed by 2 hours of reoxygenation significantly (P<0.001) decreased the 
viability of the cells 29.3±6.1 % H/R vs. 100.0±0.0% respectively, Figure 36). Administration 
of artemisinin (4.3µM) throughout reoxygenation significantly improved cell viability 
compared with H/R group (66.5±6.3% vs. 29.3±6.1 % respectively, P<0.01, Figure 36). 
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Figure 36: % change in MTT reductase activity compared with control in isolated rat ventricular myocytes 
following hypoxia/reoxygenation protocol. For all drug treated groups except artemisinin (Art) (4.3µM) was 
administered at the start of reoxygenation with/without co-administering the inhibitors wortmannin (Wort) 
(PI3K inhibitor) (0.1µM) or rapamycin (Rapa) (mTOR inhibitor)(0.1µM). The inhibitors, wortmannin (0.1µM) 
or rapamycin (0.1µM) were also administered alone at reoxygenation and subjected to same experimental 
protocol. Values are mean ± SEM (***P<0.001 vs Norm, *P<0.05 vs Norm, **P<0.01 vs H/R, #P<0.05 vs Art 
and ##P<0.01 vs Art) (n=6) 
Administration of wortmannin alone (0.1µM) above at reperfusion had no effect on cellular 
viability (33.7±3.8% vs. 29.3±6.1%, P>0.01 respectively, Figure 36). However, the co-
administration of artemisinin (4.3µM) with wortmannin (0.1µM) significantly (P<0.05) 
reversed the viability afforded to the cells by artemisinin (39.5 ±7.6% vs. 66.5 ± 6.3% 
respectively, Figure 36).  
Rapamycin alone (0.1µM) compared to H/R had a no significant effect on cellular viability 
(31.8±3.2 vs. 29.3±6.1% respectively, Figure 36). Co-treatment with the mammalian target of 
rapamycin (mTOR) inhibitor, rapamycin significantly (P<0.01) blocked the cytoprotective 
activity of artemisinin (4.3µM) (39.5±5.1% vs. 66.5±6.3% respectively, Figure 36). 
4.3.5 Artemisinin decreases Cleaved Caspase-3 activity in cardiomyocytes subjected to 
hypoxia reoxygenation injury 
To determine the cell signalling mechanisms via which artemisinin mediates its cytoprotective 
effects, isolated rat ventricular myocytes were subjected to 2 hours of hypoxia followed by 2 
hours of reoxygenation. Cells at reoxygenation were treated with artemisinin (4.3µM) alone 
and in the presence/absence of PI3K inhibitor, wortmannin (0.1µM) or mTOR inhibitor, 
rapamycin (0.1µM) from which we assessed the levels of cleaved caspase-3 via flow 
cytometric analysis. Results from H/R group show a significant (P<0.001) increase in the levels 
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of cleaved caspase-3 activity compared to normoxic control (26.8±2.0% vs. 8.8±1.2% 
respectively, Figure 37).  
 
Figure 37: % increase in Cleaved Caspase-3 activity compared to normoxia showing the effect administering 
Artemisinin (Art) (4.3µM) at the start of reoxygenation with/without co-administering inhibitors wortmannin 
(Wort) (PI3K inhibitor) (0.1µM) and rapamycin (Rapa) (mTOR inhibitor) (0.1µM) . The inhibitors, wortmannin 
(0.1µM) or rapamycin (0.1µM) were also administered alone at reoxygenation and subjected to same 
experimental protocol. Values are Mean±SEM (***P<0.001 vs Norm, *P<0.05 vs H/R, # P<0.05 vs Art and 
##P<0.01 vs Art)(n=4-6) 
The administration of artemisinin (4.3µM) at reoxygenation significantly (P<0.05) decreased 
cleaved caspase-3 activity when compared to H/R group (17.1±2.0% vs. 26.8±2.0% 
respectively, Figure 37). The treatment of the cells with 0.1µM wortmannin alone did not have 
an effect on cleaved caspase-3 activity compared to untreated time matched control (30.5±1.2% 
vs. 26.8±2.0% respectively, Figure 37). However, the anti-caspase 3 activity of artemisinin was 
significantly (P<0.05) reversed by co-administration of wortmannin (25.2±1.3% vs. 17.1±2.0% 
respectively, Figure 37). The treatment of cells with rapamcycin alone (0.1µM) also did not 
have an effect on cleaved caspase-3 activity compared to untreated time matched controls 
(31.3±1.5 vs 26.8±2.0% respectively, Figure 37). Whereas, anti-caspase 3 activity of 
artemisinin was significantly (P<0.001) reversed by co-treatment of artemisinin (4.3µM) with 
0.1µM rapamycin (31.3±1.5% vs 17.1±2.0% respectively, Figure 37). 
4.3.6 Artemisinin mediated cardioprotection involves upregulation of p-AKT (Ser473) in 
I/R treatment with artemisinin (4.3µM) in the presence and absence of 
wortmannin (0.1µM)   
Isolated perfused hearts were subjected to 35 minutes of ischaemia and reperfused for 10 
minute, where artemisinin (4.3µM) was perfused in the presence and absence of the PI3K 
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inhibitor, wortmannin.  Administration of artemisinin (4.3µM) significantly (P<0.01) 
upregulated p-Akt (Ser473) expression compared with time-matched controls (129.4±15.9% vs.  





Figure 38a: A representative blot of p-Akt and Total Akt from isolated rat heart tissue in response to the 
treatment with Artemisinin (Art) (4.3µM), a combination of Art (4.3µM) and wortmannin (Wort) (0.1µM) (ie 
Art+Wort) and Wort (0.1µM) alone in the ischaemic reperfusion model. 
Figure 38b: Western blot demonstrating Phospho-Akt (Ser473) expression with Artemisinin (Art) 4.3µM and 
Wortmannin (Wort)(PI3K inhibitor)(0.1µM) which abolishes expression induced by Artemisinin. Wortmannin 
(0.1µM) was also administered alone at reperfusion and subjected to same experimental protocol as the 
Artemisinin treatment. (**P<0.01 vs IR and ##P<0.05 vs Art)(n=4). 
  
The treatment of the hearts with wortmannin (0.1µM) alone did not have any effect on the level 
of Phospho-Akt (Ser 473) compared to untreated time matched control (6.4±4.4% vs. 26.8±11.4% 
respectively, Figure 38b). However, co-treatment of artemisinin (4.3µM) with wortmannin 
(0.1µM) showed a significant (P<0.01) decrease in the level of Phospho-Akt (Ser473) compared 
to artemisinin (4.3µM) alone (45.3±6.2% vs. 129.4±15.9% respectively, Figure 38b).  
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4.3.7 Artemisinin mediated cardioprotection involves the upregulation of 
phosphorylated p70S6K (Thr389) in I/R treatment with artemisinin (4.3µM), 
rapamycin (0.1µM)  
Hearts subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion 
with artemisinin and (4.3µM) and rapamycin (0.1µM) as previousy described. Proteins were 
extracted from ventricular tissue samples and were loaded unto gradient gels. Following 
electrophoresis, immunoblots of the different treatments and controls were detected and the 
relative changes in phosphorylated proteins following treatment were quantified. Artemisinin 
(4.3µM) showed a significant (P<0.001) upregulation in the level of phospho- p70S6K (Ser389) 
compared with time matched controls (76.0± 5.5% vs. 10.0±2.0% respectively, Figure 39). 
Treatment with rapamycin (0.1µM) alone at reperfusion had no effect on phospho-p70S6K 
(Thr389) levels compared to IR control (4.5±3.2% vs 10.0±2.0% respectively, P<0.05, Figure 39). 
However, co-treatment of artemisinin (4.3µM) with rapamycin (0.1µM) showed a significant 
(P<0.05) decrease in the level of phosphorylated p70S6K (Ser389) compared to artemisinin 
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Figure 39a: Above is the representative blot of of p-p70S6K and T-p70S6K from isolated rat heart tissue in 
response to the treatment with Artemisinin (Art) (4.3µM) and rapamycin (rapa)(0.1µM) in combination 
(artemisinin and rapamycin) (Art+rapa) and alone in the  ischaemic reperfusion model.  
Figure 39b: Western blot demonstrating Phospho-p70s6k (Thr389) expression with Artemisinin (Art) 4.3µM 
and rapamycin (Rapa) (mTOR inhibitor)(0.1µM) which abolishes expression induced by Artemisinin. 
Rapamycin (0.1µM) was also administered alone, at reperfusion and subjected to same experimental protocol. 
(***P<0.001 vs IR and *P<0.05 vs Art)(n=4). 
4.3.8 Artemisinin mediated cardioprotection involves upregulation of p-BAD (Ser136) 
Flow cytometric analysis was used to determine p-BAD (Ser136) in cardiomyocytes subjected to 
hypoxia reoxygenation injury where the effects of artemisinin (4.3µM) and wortmannin 
(0.1µM) were investigated alone and in combination.  Hypoxia/Reoxygenation resulted in a 
significant (P<0.001) decrease in p-BAD (Ser136) compared with the normoxic group (62.0± 
7.4% vs. 100.0±0.0% respectively, Figure 40). The treatment of the cells with artemisinin 
(4.3µM) caused a significant (P<0.01) increase in p-BAD (Ser136) levels compared to H/R 
control (106.9±8.8% vs. 62.0±7.4% respectively, Figure 40) whereas co-incubating artemisinin 
(4.3µM) with wortmannin (0.1µM) significantly (P<0.05) decreased the artemisinin dependent 
increase in p-BAD (Ser136) levels (77.3±2.1% vs. 106.9±8.8% respectively, Figure 40). Whereas 
administering wortmannin (0.1µM) throughout the reoxygenation phase had no significant 
effect on phospho-BAD (Ser136) levels compared with H/R control group (59.9±2.0% vs. 
62.0±7.4%, respectively, Figure 40). 
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Figure 40: The assessment of phosphorylated BAD expression as analysed using flow cytometric analysis upon 
treatment with Artemisinin (Art) (4.3µM) at reoxygenation following the hypoxia/reoxygenation protocol in the 
presence and absence of Wortmannin (Wort)(PI3K inhibitor)(0.1µM0.vValues are expressed as MEAN±SEM 
(**P<0.01 vs Norm,##P<0.01 vs H/R,*P<0.01 vs Art)(n=6-8). 
 
4.4 DISCUSSION  
It is well established that artemisinin possesses anti-parasitic, anti-cancer, anti-inflammatory 
and anti-viral properties (Ding et al., 2014; Ho et al., 2014; Mavoko et al., 2013; Maude et al., 
2010; Santos et al., 2002). There is some evidence in a myocardial model of I/R injury using 
Wistar rats suggesting artemisinin alleviates myocardial ultrastructure injury and possesses 
some cardioprotective effects that can salvage cardiac myocytes by limiting infarct size 
development (Sun et al., 2007) at 10µM and 100µM concentrations investigated, however, the 
signalling pathways mediating this protection were not established.  
In chapter 3, we have we investigated the concentration-dependent (0-100µM) effect of 
artemisinin on infarct size to risk ratio and EC80 (4.3µM) concentration, was used in this study 
as it was identified as the most effective concentration. This concentration of artemisinin was 
used to identify the intracellular signalling associated with artemisin and to further enhance the 
understanding on mechanisms by which artemisinin is cardioprotective in the isolated perfused 
rat heart model, isolated cardiomyocytes subjected to MTT, cleaved caspase 3 activity, FACS 
analysis and Western blotting.  
 
Previous studies have shown several cellular injuries occur as a result of drug induced 
cardiotoxicity which is a serious drawback amongst the most effective drugs ever developed 
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(Simanek et al., 2009). The heart is an important off target organ of drug toxicity and an 
imbalance between supply and demand within an ischaemic organ in experimental studies have 
been shown to cause profound tissue hypoxia or may lead to microvascular dysfunction 
(Eltzschig and Eckle 2011). In this study we investigated the effect of artemisinin which we 
have shown to alleviate myocardial I/R injury in a dose dependent manner while particulary 
focusing on the celluar signalling mediating this protection. Ischaemia and reperfusion injury 
have been shown to elicit tissue injury which contributes to a number of clinical manifestations 
including CHD, myocardial infarction and other pathologies which also remains a leading 
cause of death worldwide (Eltzschig and Eckle 2011, Kloner et al., 2004; Hausenloy and Yellon 
2013 and Ferdinandy et al., 2007). The ability of artemisinin to alleviate the simulated I/R 
injury by attenuating and preventing cellular damage proves artemisinin is an agent with great 
potential, given the potential promise from bench side to bedside.  
In establishing artemisinin’s association with PI3K-Akt cell survival pathway, we administered 
artemisinin (4.3µM) at the onset of reperfusion which significantly decreased myocardial 
infarct size development in a wortmannin-sensitive manner. Wortmannin is a potent, selective, 
cell-permeable and irreversible inhibitor of PI3K (Cheng et al., 2005).  The PI3K–Akt 
pathway has been shown to participate in several cellular processes by phosphorylating a 
diverse array of substrates, including apoptotic proteins (BAD, BAX, BIM, p53 and caspases), 
eNOS and PKC (Li and Sato 2011, Madrid et al., 2000 and Yang et al., 2009). We also 
investigated the downstream targets of Akt such as BAD and p70S6K. Administration of 
rapamycin, an mTOR selective inhibitor in combination with artemisinin (4.3µM), the 
previously observed cytoprotective effects of artemisinin were abolished implicating p70S6K 
in artemisinin mediated protection. 
It is well established that the activation of PI3K-Akt-p70S6K cell survival pathway is 
associated with the activation of pro-survival factors (via agents such as HMG-Co-A reductase 
inhibitors and G-protein-coupled receptor ligands, bradykinin and insulin-like growth factor-
1) and inhibition of pro-apoptotic factors (such as-BAX, BIM and p53 and kinases implicated 
in I/R injury such as p38 and JNK MAPK, PKA, Rho kinase and JAK-STAT) (Li and Sato, 
2001; Al khouri et al., 2005; Hausenloy and Yellon, 2004).  In the isolated rat heart model, 
infarct size was calculated in the different treatment groups and the physiological parameters 
monitored with the different treatments. Expression levels of phosphorylated proteins 
associated to the PI3K-Akt pathway and cardiomyocyte cell viability assessment were also 
P a g e  | 128 
investigated and compared. To our knowledge, this is the first study to show that artemisinin 
confers protection to the myocardium following I/R in ex vivo model of myocardial I/R and 
the associated cell signalling pathway of artemisinin-mediated cardioprotection. However, Gu 
et al. (2012) have shown artemisinin can inhibit ventricular remodelling and cardiac and 
improve cardiac function possibly by the interruption of the NF-kB pathway. 
We were able to show the involvement of the PI3K-Akt-BAD-p70s6K in both the isolated 
perfused heart model and isolated ventricular myocyte model. The co-treatment of artemisinin 
(4.3µM) with wortmannin (0.1µM) reversed the upregulation of p-Akt while rapamycin 
(0.1µM) reversed the expression of p70S6K thus confirming the involvement of PI3K-Akt-
p70S6K cell survival pathway in artemisinin’s cardioprotection. Hausenloy and Yellon (2004) 
have showed signalling through PI3-Akt-BAD pathway confers protection against I/R injury, 
through the activation of the serine–threonine kinase, Akt (Hausenloy and Yellon 2004) thus 
supporting our findings. Sun et al. (2013) also reported p-Akt in the mitochondria is responsible 
for inhibiting the release of cytochrome c as well as suppresses the activation of caspase-3 
thereby limiting the number of cells committed to apoptosis. 
Pharmacological agents such as resveratrol have been shown to utilise the same pathway by 
inhibiting the PI3K-Akt-p70S6K cell survival pathway in the human chronic myeloid leukemia 
K562 cell line (Sui et al., 2014). The PI3K/Akt signalling pathway is critical in cell 
proliferation, differentiation and survival and in the study by Sui et al. (2014) resveratrol was 
shown to inhibit proliferation and induce apoptosis in various types of cancer cell. Furthermore, 
studies in cardiomyocytes subjected to I/R injury showed activation of the PI3K-Akt-p70S6K 
and its downstream targets such as eNOS, BAD, GSK-3β, mTOR and so on conferred 
protection upon administering insulin to rat heart subjected to myocardial injury and oxidative 
stress thus inhibiting apoptosis and improving cardiac function (Yao et al., 2014). 
Cleaved caspase-3, being a pivitol effector caspase in apoptotic signalling has been associated 
with I/R and cellular damage leading to apoptosis (Sakamaki and Satou 2009; Lu and Chen 
2011). Studies have shown ROS induced stress is responsible for activating caspase-3 (Yuan et 
al., 2011). ROS induces mitochondrial oxidative stress which causes the outer mitochondrial 
membrane to rupture and release cytochrome c into the cytosol forming complexes known as 
apoptosomes which are cleaved into caspase-9 that activates caspase-3 eventually causing 
myocardial cell death (Banerjee et al., 2008; Yuan et al., 2011 Montaigne et al., 2012; Cui et 
al., 2012; Dai et al., 2014).  
P a g e  | 129 
Artemisinin (4.3µM) administered at reoxygenation resulted in a significant decrease in 
hypoxic injury and in the levels of activated cleaved caspase-3 suggesting the cytoprotective 
role of artemisinin in ventricular myocytes is caspase dependent. Artemisinin’s anti-caspase-3 
activity was reversed by co-treatment with wortmannin (0.1µM) suggesting artemisinin’s 
protection in the myocardium to be PI3K dependent. This thereby allowed us to extrapolate the 
existence of a novel link between PI3-Akt pathway and the anti-caspase-3 activity in 
artemisinin’s discerned effect. Previous studies have described Akt as a critical target in 
suppressing apoptosis in a PI3K dependent cell survival pathway (Sun et al., 2013; Abel and 
Doenst, 2011). 
Improvement in myocyte viability was also observed upon administering artemisinin (4.3µM) 
at reperfusion following H/R, showing its capacity to salvage H/R induced injuries in adult 
ventricular myocytes. Aremisinin treated cells presented an increase in MTT reductase activity 
which was reversed with administering wortmannin (0.1µM). 
Hausenloy and Yellon (2004) have shown the Reperfusion Injury Salvage Kinase (RISK) 
pathway to confer powerful cardioprotective responses which incorporates the anti-apoptotic 
pro-survival kinase signalling cascades, phosphatidyl-inositol-3-kinase (PI3K)–Akt and the 
p42/p44 extra-cellular signal-regulated kinases (Erk 1/2), both implicated in cellular survival. 
Our results have shown the up-regulation of pro-survival kinase PI3-Akt which have been 
confirmed by our western blot analysis to be implicated in the cytoprotection against 
reperfusion-induced injury in this study.  
PI3K-Akt pathway has also been shown to protect against stress induced apoptotis (Kang et al., 
2010; Faghiri and Bazan 2010). Activation of Akt has been associated with cell survival and 
phosphorylation of BAD at Ser136 (Datta et al., 1997; del Peso et al., 1997). Our results support 
this finding by showing an upregulation of p-BAD as well as Akt. BAD at Ser136 is one of the 
serine sites of phosphorylation which is responsible for neutralizing BAD's apoptotic function 
(Harada et al., 2001). BAD (Ser136) is also the preferred target substrate for Akt and p70S6 
kinases in the PI3K signalling pathway (Blume-Jensen et al., 1998; Eves et al., 1998 and 
Harada et al., 2001). Our results suggest the involvement of BAD (Ser136) in artemisinin’s 
cytoprotection which has been linked with the cell survival pathway PI3-Akt. Studies describe 
the translocation of BAD into the mitochondria which is usually accompanied by the release 
of cytochrome c which in turn initiates the cell death machinery initiating apoptosis (Mehic 
2012). It is therefore our understanding that Akt which has been previously reported to be 
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translocated into the mitochondria where it modulates cellular death or survival to be the major 
player involved in this cellular survival (Yang et al., 2009; Abel and Doesnt 2011).  
Our results also show artemisinin facilitates cell survival following I/R and H/R induced 
injuries by activating p70S6K, which is a functional target of Akt. Jonassen et al., 2004 has 
previously implicated p70S6K as a functional target of insulin activated Akt cell-survival 
signalling in their human cardiac derived Girardi model of I/R injury. Park et al. (2014) has 
also implicated protection from I/R injury by administering Cordycepin (3′-deoxyadenosine) 
isolated from Cordyceps militaris in adult Sprague Dawley rats via the activation of Akt/GSK-
3β/p70S6K cell signaling pathway. Cordycepin like artemisinin has been shown to exhibit 
many pharmacological functions including anticancer, anti-inflammatory, and antioxidant 
activities and is speculated to be an attractive therapeutic agent against I/Rinjury and other 
cardiomyopathies (Park et al., 2014). Brevik et al. (2015) has similarly with intermittent 
exogenous B-type natriuretic peptide during early reperfusion (intermittent 3×30 seconds 
infusion of BNP peptide in early postconditioning) confers protection via PI3K/Akt/p70s6k 
dependent signalling suggesting the pivotal role of in cardioprotective signalling. Therefore the 
phosphorylation of p70s6k and BAD in response to Akt activation by administering artemisinin 
throughout reperfusion suggestively identifies artemisinin as a putative target in the induction 
of artemisinin-induced cardioprotection. 
This study established the involvement of the anti-apoptotic pro-survival kinase signalling 
cascades, PI3K-Akt-BAD/p70S6K as being involved in artemisinin mediated cellular survival. 
Artemisinin was not only able to salvage the myocardium at risk, as observed by a reduction 
in infarct size but it also increased cellular viability and salvaged cells marked for apoptosis. 
Wortmannin and rapamycin inhibited the cardioprotective effects of artemisinin whereas no 
cardioprotective effect was observed indicating a role of PI3K-Akt/p70S6K in artemisinin 
mediated protection  
To our knowledge this is the first study to associate artemisinin’s cardioprotection to PI3K-
Akt-BAD/p70S6K and anti-caspase-3 pathways. It has shown the cardioprotective artemisinin 
when administered at reperfusion salvages damaged tissue. This is supported by several studies 
that have linked PI3K pathway to be important in cardioprotection such as Hausenloy  
&Yellon (2004) who showed that the activation of PI3K-Akt survival kinase pathway 
constitutes a common survival pathway resulting in a cardioprotective response during 
reperfusion (Shneyvays et al., 2005,Hussain et al., 2014 and Sun et al., 2013). The results from 
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the present study demonstrated treatment with artemisinin (4.3µM) significantly reduces 
infarct size and improves cellular viability when administered at reperfusion. Co-administering 
artemisinin with wortmannin or rapamycin abolished cardioprotection earlier observed by 
artemisinin alone. This thus shows the involvement of the recruitment of PI3K-Akt-
BAD/p70S6K pathway by artemisinin at reperfusion (shown in Figure 41).   
 
 
Figure 41: Hypothetical schematic representation of the Artemisinin mediated cardioprotection in isolated 
cardiomyocytes and isolated perfused heart subjected to H/R injury and I/R respectively via the activation of the 
pro-survival signalling pathway PI3K-Akt kinase cascade and their targets BAD and p70S6K. PI3K-Akt is an 
important part of the RISK pathways identified by Hausenloy and Yellon (2003). Administering Artemisinin 
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(4.3µM) at reperfusion has is suggested to initiate cardioprotection by protecting against reperfusion-induced 
cell death. The scheme portrays the important anti-apoptotic mechanisms that have been implicated in 
mediating cellular survival associated with the recruitment of these kinase cascades via the PI3K-Akt cascade 
shown to reverse the activation of caspases and proapototic protein BAD via the p70S6K upon administering 
Artemisinin in different settings of I/R and H/R.  
 
4.5 CONCLUSION 
This is the first study to show that artemisinin limits ischaemia reperfusion injury in the isolated 
rat heart and in cardiac myocytes via the recruitment of the PI3K-AKT-BAD/p70S6K cell 
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Chapter 5 
5 ARTEMISININ ATTENUATES MYOCARDIAL 
ISCHAEMIA REPERFUSION INJURY VIA 




The principal mechanisms for I/R injury involve ROS production and oxidative stress, with 
the major organs affected by this injury being the heart and lungs (Kozak 2007). During 
ischaemia, the vasculature of the heart becomes dysfunctional, as a result of coronary artery 
occlusion leading to an imbalance between myocardial oxygen supply and demand (Heusch 
2008). This results in an ischemic cascade that releases cellular metabolic wastes that make 
the heart more vulnerable leading to ischaemic injury (Kozak 2007). 
Reperfusion injury which also is an unavoidable clinical manifestation of myocardial injury 
has been shown to be associated with oxygen-derived free radicals mostly responsible for 
the observed injury (Annapurna et al., 2013). Drugs such as anthracyclines have been 
proven to have a double edged sword effect despite its effectiveness in treating cancers, it 
is shown to cause cardiomyopathy that could lead to more severe conditions or even death 
(Takemura and Fujiwara 2007). 
This occurs so frequently that it has spurred research so much towards developing strategies 
to limit ROS induced injuries. The mechanisms thought to be responsible for the observed 
cardiotoxic effects with certain drug treatments are oxidative stress, disruption of calcium 
homeostasis and mitochondrial dysfunction (Minotti et al., 2004). 
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Excess productions of free radicals from either endogenous or exogenous sources have 
been shown to play significant roles in tissue damage and disease (Pharm-Huy et al., 2008). 
There are also many substantial evidence from experimental studies that have associated 
oxidative stress and ischaemic heart disease (Bedard and Krause 2007; Rivera et al., 2010; 
Young and Woodside 2001; Zhang et al., 2012). 
Clinical observations have shown that there is an enhanced neutrophil mobilisation that 
leads to the release of highly reactive free radicals in patients suffering from ischaemia 
reperfusion injury (Peake and Suzuki 2004). These free radicals are known to cause tissue 
damage and increased production of nitric oxide, which is an effective mediator that 
reverses tissue injury (Kozak 2007).  
Nitric oxide signalling is believed to be a promising therapeutic approach against 
myocardial dysfunction (Zhang et al., 2012). Due to the versatile nature of nitric oxide, it 
reacts readily with other free radicals such as hydroxyl to form nitrite or with superoxide 
in the mitochondria to form peroxynitrite which decomposes to become hydroxyl radical 
and nitrogen dioxide, respectively (Kozak, 2007). This process is similar to oxidative stress 
that produces reactive oxygen species, popularly known as ‘nitrosative stress’ which 
constitutes the RNI such as nitric oxide, peroxynitrite and S-nitrosothiols (Palcher et al., 
2007). RNI have been shown to react with proteins, carbohydrates and lipids, thus resulting 
in alterations in the intracellular and intercellular homeostasis of cells which may possibly 
lead to cell death and regeneration (Rahman et al., 2012). These reactive species damage 
cells by inactivating the metabolic enzymes and damaging important cellular components 
which exacerbate diseases such as ischaemia, atherosclerosis, inflammatory diseases and 
cancer (Rahman et al., 2012; Isenovic et al., 2011).   
Nitric oxide is produced by the catalytic action of NOS on L-arginine (Palcher et al., 2007). 
NOS is primarily responsible for the conversion of L–arginine to nitric oxide free radical 
upon reaction with oxygen which is an NADPH dependent oxidation (Palcher et al., 2007). 
nNos, iNOS, eNOS are the different isoforms of NOS present in the human myocardium 
and are activated in response to ischaemia/hypoxia (Kelly et al., 1996). 
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Extracellular signals, such as shear stress, stimuli from vascular endothelial growth factor 
(VEGF), estrogen, sphingosine 1-phosphate, bradykinin, and aldosterone has been shown 
to modulate eNOS nitric oxide generation with Akt specifically inducing phosphorylation 
of Ser-1177 whereas phosphorylation of Thr-495 has been reported to down-regulate nitric 
oxide generation thus leading to cardioprotection (Chen et al., 2008). 
During ischaemia, nitric oxide has been shown to enter endothelial cells and upon 
reoxygenation, NOS is activated to produce high amounts of nitric oxide, thus producing 
cytotoxic effects (Palcher et al., 2007). The cytotoxicity attributed to nitric oxide is due to 
peroxynitrite, which is produced from the reaction between nitric oxide and superoxide 
anion (Palcher et al., 2007). Generating these free radicals may have effects ranging from 
subtle cellular signalling to more exaggerated oxidative injury that may result in 
committing cells to necrosis or apoptosis (Palcher et al., 2007).  
However, in most studies, nitric oxide has emerged as a very important intracellular 
messenger which is responsible for regulating virtually every critical cellular function 
(Gutierrez et al., 2009).  Nitric oxide is extremely important in regulating the vascular tone 
of endothelial vessels, thus playing an equally important role in the regulation of blood 
pressure, cardiac remodelling and cellular survival in cardiac hypertrophy and heart failure 
(Moncada and Higgs 1993; Wang et al., 1993; Zhoa et al., 1995). Limiting the incidences 
of ischaemia is therefore of vital importance, given that ischaemic heart disease is a leading 
cause of death in the industrialized world (Ferdinandy et al., 2007).  
NOS has been associated with both physiological and pathological processes in the body 
Drugs such as angiotensin-converting enzyme inhibitors and statins have the ability to 
restore or maintain endogenous production of nitric oxide in endothelial cells; this 
mechanism may explain part of their therapeutic efficiency (Palcher et al., 2007). 
Others studies have demonstrated that the Akt mediates the activation of eNOS in 
endothelial cells in response to shear stress, leading to increased nitric oxide production 
(Dimmeler et al., 1997). By inhibiting the PI3K/Akt pathway or mutation of Ser 1177 on the 
eNOS protein this decreases the Akt-dependent phosphorylation of the eNOS in vitro in a 
Ca2+ independent Manner (Dimmeler et al., 1997). This study confirms eNOS as a novel 
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Akt target and nitric oxide generation to be critical for vascular remodelling thus making 
its decreased bioavailability to mediate the pathophysiological changes in vascular 
morphology often associated with hypertension and atherosclerosis (Rudic et al., 1998). 
Artemisinin, a traditional herbal drug has also been shown to have anti-hypertrophic effect 
in response to aortic banding by alleviating myocardial ischaemia reperfusion injury and 
exerting an inhibitory effect on inducible nitric oxide synthase synthesis (Xiong et al., 
2010; Sun et al., 2007).  
In previous chapters’ we have shown, artemisinin to be cardioprotective against myocardial 
I/R injury via activation of PI3K/Akt cell survival pathway which is an established 
cytoprotective signalling pathways (Haunsenloy and Yellon 2007; Yao et al., 2014). 
Phosphorylation of Akt has been shown to promote nitric oxide synthesis which is an 
established inhibitor of mitogenic and hypertrophic activities in cells (Hussain et al., 2009; 
Ye et al., 2010). Studies have also administered NG-Nitro-l-arginine methyl ester (L-
NAME) treatment to chronically inhibit eNOS (Abu-Soud et al., 2000).  
In the past decade, significant advances have been made in identifying intracellular 
pathways involved in the mechanisms that influence cellular survival and death (Fulda et 
al., 2010). In this study we therefore aimed to determine involvement of the 
PI3K/Akt/iNOS-eNOS cell survival pathway in Artemisinin mediated cardioprotection. 
The comparative importance of the NOS isoforms, eNOS and eNOS-derived NO, initiate 
a cascade of molecular events leading to the activation of iNOS which is well linked to 
cardioprotection (Bolli et al., 1998). Thus investigating the Nitric Oxide pathway using 
non selective inhibitors of Nitric Oxide pathway L-NAME and a selective inhibitor of 
iNOS, Aminoguanidine in artemisinin mediated cardioprotection is vital in this study. 
5.1.1 Aim and objective 
The aim of this study was to determine whether administration of artemisinin (4.3µM) at 
reperfusion will reduced infarct size in isolated heart model, via improving cell viability in 
isolated cardiomyocytes following hypoxia reoxygenation (H/R) injury and whether the 
protective effect of artemisinin will be blocked when administered in combination with 
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inhibitors, L-NAME (100µM, non-specific nitric oxide inhibitor) and aminoguanidine 
(100µM, specific iNOS inhibitor).    
5.2 METHODOLOGY 
5.2.1 Animals 
Adult male Sprague Dawley rats (350-400g) were obtained from Charles River (Margate, 
UK). The care and use of animals were in accordance with the Guidance on the Operation 
of the Animals (Scientific Procedures Act 1986).  The study was carried out upon 
obtaining ethical approval from Coventry University Research ethics committee which was 
regularly assessed throughout the project. 
5.2.2 Preparation of drugs 
Artemisinin, L-NAME) (Non-specific inhibitor of Nitric Oxide) and Aminoguanidine 
hydrochloride (Selective inducible nitric oxide inhibitor) both supplied from Sigma-
Aldrich (Poole, UK) and dissolved in DMSO making sure the final concentration of DMSO 
was less than 0.02% as this does not affect haemodynamics or infarct size (unpublished 
paper) stored at -20 °C. MTT was purchased from Sigma (Poole, UK). Cleaved Caspase-3 
(Asp175) Antibody (Alexa Fluor® 488 Conjugate), iNOS, phospho-eNOS (Ser1177), eNOS 
Horseradish peroxide (HRP) conjugated Rabbit monoclonal antibodies and antibiotin were 
purchased from New England Biolabs (Hertfordshire, UK). SuperSignal West Femto® 
enhanced chemoluminescent substrates were purchased from Pierce (UK). Nitric oxide 
Assay was purchased from Cell Biolabs Inc (San Diego, USA). HL-60 cells were obtained 
from ECACC. 
5.2.3 Isolated perfused rat heart model 
Following sacrifice by cervical dislocation, the hearts were rapidly excised and placed in 
ice cold KH solution (118.5 mM NaCl, 25 mM NaHCO3, 4.8mM KCl, 1.2 mM MgSO4, 
1.2 mM KH2PO4, 12 mM Glucose, 1.7mM CaCl2.2H2O)  <4 oC  and pH 7.4 as described 
previously (Hussain et al., 2014). 
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The aortic arch was removed, allowing cannulation of the aorta and subsequent retrograde 
perfusion with KH buffer, saturated with 95% O2, 5% CO2, maintained at a temperature of 
37 ± 0.5oC and pH 7.4 using a water-jacketed heat exchange coil. 
The left atrium was then removed and a water-filled latex balloon was inserted into the left 
ventricle to a diastolic pressure of 8-10mmHg. This allows LVDP to be measured. A 
physiological pressure transducer was connected to a bridge amp and a power lab (AD 
Instruments Ltd, Chalgrove, UK) which allows the LVDP, HR using ECG leads. CF was 
measured at regular intervals by collecting the perfusate at regular intervals.  
The experiment was conducted for 175 minutes in total. During I/R studies the isolated 
hearts were allowed to stabilise for 20 minutes followed by 35 minutes ischaemia and 120 
minutes reperfusion. Details of technique in chapter 2. 
Artemisinin 4.3µM was administered throughout reperfusion in the presence and absence 
of either the non-selective NOS inhibitor L-NAME (100µM) or inducible Nitric Oxide 
Synthases (iNOS inhibitor) aminoguanidine (100µM). 
Upon completing the experiment the left coronary artery re-ligated in preparation for 
staining the heart with 1ml of 0.2% Evans blue in saline, allowing differentiation between 
viable and tissue at risk. After staining, the hearts were weighed and stored at -20oC for 
later analysis. The hearts were then cut transversely into slices, approximately 2 mm thick 
and incubated at 37°C in 1% TTC solution in phosphate buffer for 10–12 minutes and fixed 
in 10% formaldehyde for at least 4 hours to enhance the staining prior to analysis.  
The heart slices were then removed from formaldehyde and traced onto acetate film using 
different coloured markers to differentiate between the viable, at risk and infarct tissue. The 
acetate film was scanned into a computer to allow calculation of Infarct to risk ratio from 
the differentiated tissues traced. Areas of viable, at risk and infarct tissue were measured 
using the Image Tool program as developed by the University of Texas Health Science 
Centre at San Antonio, Version 8.1 (UTHSCSA). 
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5.2.4 Adult Rat Ventricular Myocytes Isolation 
Adult ventricular rat myocytes were isolated from Sprague Dawley rats (350-400g) by 
enzymatic dissociation method (Maddock et al., 2003, Hussain et al., 2014). Details of 
heart digestion with collagenase digestion buffer in chapter 2.  
 
Following digestion, the hearts were removed from the apparatus and the atria were 
trimmed away and discarded. The ventricles were mechanically disrupted by passing the 
tissue through a large bore Pasteur pipette. The tissues were then incubated for 10 minutes 
in 25ml of digestion buffer in an orbital shaker and oxygenated with 95% O2 and 5% CO2.  
Thereafter, the suspension was passed through a nylon mesh with a pore size 400µm and 
centrifuged at 400rpm for 2 minutes. The supernatant was discarded and the pelleted cells 
were re-suspended in restoration buffer (RB) (in mM 116 NaCL , 5.4 KCL , 0.4 MgSO4 , 
10 glucose ,20 taurine, 5 Pyruvate, 0.9 NaHPO4 , 5 Creatine , 2% BSA, 50µM CaCl2  and 
1% Penstrep pH 7.4 at 37o C) where the calcium concentration was gradually brought to 
1.25mM to avoid calcium overload. The isolated myocytes were incubated in RB (at 37oC, 
5% CO2 for 24 hours before being used (Maddock et al., 2002). 
 
Figure 42. An Image of isolated ventricular myocytes 
The cells were incubated in 15 mls of hypoxic buffer (12 mM KCL, 0.49 mM MgCl2, 0.9 
mM CaCl2, 4 mM HEPES, 10 mM Deoxyglucose and 20 mM lactate and placed into a 
hypoxic chamber pre-heated at 37 °C. Following incubation, the myocytes were 
centrifuged at 500rpm for 5 minutes and the pellet was resuspended in restoration buffer. 
The myocytes were then assigned to the different treatment groups: artemisinin (4.3µM), 
artemisinin (4.3µM) + L-NAME (100µM), L-NAME (100µM), artemisinin (4.3µM) + 
aminoguanidine (100µM) and aminoguanidine (100µM). The myocytes then underwent 
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reoxygenation for 120 minutes. Upon completing reoxygenation the cells were then 
assessed either for cellular viability using MTT (Thiazolyl blue tetrazolium bromide) or 
flow cytometric analysis for iNOS, eNOS (Ser 1177) or cleaved caspase-3 activity as described 
below. 
 
5.2.5 Cellular viability assay based on Thiazolyl blue tetrazolim bromide (MTT) 
reductase activity using isolated ventricular cardiomyocytes 
The isolated myocytes were counted using a using a nucleo counter (Chemometec, 
Sartorius, Surrey, UK) and resuspended in RB to a density of 100,000 cells/ml. 1ml of the 
cells was pipetted to be used as normoxic control while the remaining cells were 
centrifuged and the pellet re-suspended in Esumi hypoxic buffer (in mM 137 NaCl ,12 
KCL, 0.49 MgCl2  0.9,CaCl2, 4 HEPES,20 Na lactate, 10 deoxy-D-glucose). The myocytes 
were then incubated in a hypoxic chamber, Galaxy 48R (New Brunswick) for 120 minutes 
with atmosphere 5% CO2 95% N2 at 37oC.  
Some wells were used as control which contained 100µl of restoration buffer. The 
remaining wells were randomly allocated to the different treatment groups which contained 
50µl of cells and 50µl of drug treatment. Drugs used for this study were diluted with 
restoration buffer to a final concentration of 4.3µM in the artemisinin treated group, 100µM 
in L-NAME treated group and 100µM in aminoguanidine treated group. The drugs were 
administered at the start of reoxygenation and cells incubated for an additional 120 minutes 
with 20µl of MTT (MTT solution consisting of 5mg.ml-1 in PBS (10g for 10-4 cells/well) 
was added at reoxygenation except for the blanks which contains restoration buffer and 
MTT solution. The cells were then incubated in the dark at 37oC for 120 minutes. Upon 
completing the 120 minutes reoxygenation, myocytes were subsequently lysed with 100µl 
of lysis buffer (20% SDS in 50% dimethylformamide) and incubated on an orbital shaker 
and incubated overnight at 37o C. Calorimetric analysis of the plate was done to measure 
the fluorescence emission at 450nm (Thermo Scientific, UK) using a plate reader (Anthos 
2001). The absorbance was measured for the different treatment groups. The effect of the 
artemisinin treatment was obtained by subtracting the absorbance from the control values.  
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Graphs were made using the mean absorbance of the drug treated group as a percentage of 
the mean absorbance of the control group. 
5.2.6 Quantitative analysis for cleaved caspase-3, iNOS and eNOS (Ser 1177) using 
FACS analysis 
Following the cardiomyocyte isolation, the myocytes were harvested and centrifuged at 
1200 rpm for 2 minutes. The pellet was then resuspended in PBS and fixed with 3% 
formaldehyde for 10 minutes at room temperature. The cells were then put on ice for 1 
minute before centrifuging at 1200 rpm for 2 minutes following aspiration of the 
supernatant. 250 µl of ice cold methanol (90%) was added and the samples incubated on 
ice for 30 minutes before being washed twice in incubation buffer (0.5% BSA in PBS) 
following a 10 minutes (at 37°C) incubation of the samples each time followed by 
centrifugation of the samples (at 1200rpm, 2 minutes). The antibody was prepared to 1:100 
final dilution in incubation buffer for the analysis of cleaved caspase-3 activity or iNOS 
and eNOS.  
5.2.7 Quantitative analysis of cleaved caspase-3 activity 
Cleaved caspase-3 (Asp175) antibody (Alexa Fluor 488 conjugate) was used to detect the 
levels of activated caspase-3 in the different experimental groups. For the analysis of 
cleaved caspase-3 activity, the cells were incubated for 1 hour in cleaved caspase-3 (Asp175) 
secondary rabbit monoclonal antibody (Alexa Fluor ® 488 conjugate) (New England 
Biolabs, Hertfordshire,UK) diluted at 1:1000. At the end of the incubation period, the cells 
were centrifuged and the supernatant was removed the cells resuspended in 500µl PBS and 
analysed using flow cytometer (Becton Dickinson, Oxford, UK) using the on the FL1 
channel to count 10,000 events  (Vermes et al., 2002; Hussain et al., 2014). 
5.2.8 Quantitative analysis of iNOS, p-eNOS (Ser 1177) and eNOS  
To quantify iNOS levels, FACS analysis was used to assess the differential protein levels 
for iNOS and GAPDH. Following centrifugation, the harvested cells samples were probed 
for 1 hour with iNOS or GAPDH rabbit monoclonal antibody diluted at 1:100 dilution in 
incubation buffer followed by incubating in Alexa Fluor® 488 goat anti-rabbit IgG 
antibody at a dilution of 1:1000 for 1 hour. 
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For p-eNOS (Ser 1177) and T-eNOS the samples were also probed for 1 hour with p-eNOS 
and eNOS rabbit monoclonal antibody diluted at 1:100 dilution in incubation buffer 
followed by incubation in Alexa Fluor® 488 goat anti-rabbit IgG antibody at a dilution of 
1:1000 for 1 hour. 
At the end of the incubation period, the cells were centrifuged and the supernatant was 
removed the cells resuspended in 500µl PBS and analysed using flow cytometer (Becton 
Dickinson, Oxford, UK)  on the FL1 channel to count 10,000 events  (Vermes et al., 
2002; Hussain et al.,2014).  
5.2.9 Nitric oxide Assay using the OxiSelect™ In Vitro Nitric Oxide Calorimetric 
Assay 
The OxiSelect™ is a colorimetric assay was used to measure the amount of nitrate and 
nitrite in the isolated cardiomyocytes treated with artemisinin (4.3µM). Assay was carried 
out according to manufacturer’s instructions, details of which can be found in chapter 2. 
5.2.9.1 Experimental protocol using the Nitric Oxide assay 
Adult ventricular rat myocytes were isolated from Sprague Dawley rats by enzymatic 
dissociation method as in the previous protocols. The isolated myocytes were counted using 
a using a nucleo counter (Chemometec, Sartorius, Surrey, UK) and resuspended in 
restoration buffer (RB) to a density of 100,000 cells/ml. 
5.2.9.2 Preparation of Samples and standards 
Nitrite and nitrate standards were prepared by making a dilution series of concentration 
range 0-140µM from a standard 14mM of the nitrite and nitrate provided in the kit in 
restoration buffer. Potential interference was prevented by diluting the nitrate and nitrite 
standard in the same buffer as the samples. Triplicate wells were used for measuring the 
nitrate concentration. 
5.2.9.3 Measurement of Total/Nitrate levels 
Nitrate levels in the samples were measured by subtracting nitrite only from total nitrite 
and nitrate. 
P a g e  | 143 
Nitrate = (Total nitrite + nitrate) - Nitrite only 
50µL of nitrite standards, samples or blanks were added to a 96 well plate. Followed by 
50µL of PBS and 50µL of Griess Reagent A were added to each well. The plate was then 
incubated for 10 minutes allowing the colour to develop. Absorbance was then read at 
540nm on a microplate reader. 
Concentration of nitrite was calculated by comparing sample absorbance to standards. 
Negative controls without nitrate were subtracted from reading. Each nitrite standard and 
sample was assayed in duplicate 
5.2.9.4 Measurement of Total/Nitrate via Nitrate Reduction 
To measure nitrate levels. 50µL of nitrate standard, samples or blanks to the 96 well plate. 
Drug treated cells were subjected to artemisinin (4.3µM) treatment. 50µL of the enzyme 
reaction mixture prepared according to manufacturer’s instruction was then added to the 
wells containing the sample/nitrate and covered with foil. 
The Plates were then incubated for 1 hour at room temperature on an orbital shaker. 50µL 
of Greiss Reagent A followed by Greiss Reagent B were added and the plate was then 
incubated for a further 10 minutes for colour development. Absorbance was then read at 
540nm. The sample’s absorbance is then calculated by comparing the Nitrate and standard 
curve and comparing our drug treatment to control.  
Statistical Analysis 
Results were expressed as Mean ±standard error of mean (SEM) for infarct/risk ratio, cell 
viability, cleaved caspase-3 analysis, iNOS, p-eNOS (Ser 1177) and nitric oxide assay. Infarct 
size was tested for group differences using one way analysis of variance (ANOVA) with 
LSD post hoc tests. P values of P<0.05 were considered statistically significant. 
Haemodynamics: LVDP, HR and CF were assessed for statistical difference using two way 
ANOVA at the different time points. 
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5.3 RESULTS 
5.3.1 Exclusion Criteria 
We have excluded three rats from our experiment; two due to low viability of live cells 
following isolation (≤70%) and the other due to a rip in the ventricular wall while tightening 
the snare during ischaemia. All other groups have been included. 
5.3.2 Haemodynamics data for artemisinin treatments and inhibitors (L-NAME and 
aminoguanidine) 
There was no significant effect on the different parameters when comparing the different 
treatment groups.   
 
 
Figure 43. The effects of artemisinin (4.3µM) in the presence and absence of inhibitor, L-NAME (100µM) 
and aminoguanidine (100µM) on LVDP expressed as a percentage of mean stabilisation. Hearts underwent 
20 minutes of stabilisation, 35 minutes ischaemia and 120 minutes of reperfusion in the presence/absence of 
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artemisinin (4.3µM) ± inhibitors which were administered throughout reperfusion. Results presented are 
Mean±SEM (n=3-8). 
LVDP remained relatively stable throughout stabilisation and ischaemia with control 
showing a steady decline over time during reperfusion compared to the drug treatment 
which is however not significant. Drug treatments did not have a significant effect on LVDP 
when compared to control. 
 
 
Figure 44. The effects of Artemisinin (4.3µM), L-NAME (100µM) and aminoguanidine (100µM) on H/R 
(HR) as a percentage of mean stabilisation. Hearts underwent 20 minutes of stabilisation, 35 minutes of 
Ischaemia and 120 minutes of reperfusion in the presence/absence of Artemisinin (4.3µM) ± inhibitors. Art 
(4.3µM) was administered throughout the 120 minutes reperfusion with/without inhibitors (n=3-8). 
The H/R recorded was the number beats per minute (bpm) which showed no significant 
difference between the groups when compared with time matched controls. 
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Figure 45. The effects of artemisinin (4.3µM) in the presence and absence of inhibitor, L-NAME (100µM) 
and aminoguanidine (100µM) on CF (CF) expressed as a percentage of mean stabilisation .Hearts 
underwent 20 minutes of stabilisation, 35 minutes ischaemia and 120 minutes of reperfusion in the 
presence/absence of Artemisinin (4.3µM) ± inhibitors which were administered throughout reperfusion. 
Results presented are Mean±SEM (n=3-8). 
CF which was the amount of effluent (in mls) collected for duration of 1 minute at regular 
intervals of 5 minutes throughout the experiment. The results obtained were calculated as 
a percentage of mean stabilisation. CF recorded for the different treatment groups remained 
fairly regular throughout the experiment. 
5.3.3 Artemisinin confers protection from I/R via activation of the Nitric Oxide cell 
survival pathway in the isolated perfused heart model 
Administration of artemisinin (4.3µM) throughout reperfusion significantly (P<0.001) 
reduced infarct size by limiting myocardial ischaemia reperfusion injury (38.0±2.5% vs. 
55.8±1.7%, Figure 46).  
In order to evaluate the role of the nitric oxide pathway, a known cardioprotective pathway 
and also a downstream target of PI3K pathway. We administered artemisinin (4.3µM) with 
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non-selective nitric oxide inhibitor, L-NAME (100 µM), results showed a reversal in the 
artemisinin induced cardioprotection (44.7±0.9% vs. 38.0±2.5%, P<0.05 respectively, 
Figure 46). L-NAME alone (100µM) had no effect on infarct size to risk ratio compared to 
I/R control (52.0±1.5% vs. 55.8±1.7 %, P>0.05, respectively, Figure 46).  
Co-administering artemisinin (4.3µM) with a selective iNOS inhibitor, aminoguanidine 
(100µM) throughout reperfusion significantly (P<0.05) reversed artemisinin’s infarct 
sparing effects when compared to artemisinin (4.3µM) alone (48.3±1.4% vs. 38.0 ±2.5% 
respectively, Figure 46). Aminoguanidine alone (100µM) had no effect on I/R compared to 
I/R control (52.3±1.5% vs 55.8 ± 1.7% respectively, Figure 46).  
 
Figure 46. Assessment of nitric oxide survival pathway in artemisinin (Art) mediated cardioprotection in 
isolated perfused heart model subjected to I/R. Art (4.3µM) was administered at reperfusion in the presence 
and absence of either L-NAME (non selective nitric oxide inhibitor)(100µM) or aminoguanidine (Amg) 
(iNOS inhibitor)(100µM). Results are shown as Mean±SEM.***P<0.001 vs. IR,  *P<0.05 vs. Art, 
#P<0.05 vs. L-NAME, ##P<0.01 vs. Art. (n=3-8). 
5.3.4 Artemisinin improves the viability of isolated rat ventricular myocytes 
subjected to hypoxia/reoxygenation injury via nitric oxide signalling. 
Cardiac myocytes were subjected to 2 hours of hypoxia and 2 hours of reoxygenation where 
artemisinin (4.3µM) was administered throughout the period of reoxygenation in the 
presence and absence of the non selective inhibitor of nitric oxide, L-NAME or selective 
iNOS inhibitor, aminoguanidine (Amg) (100µM respectively). Isolated ventricular 
mycoytes were also subjected to H/R and no treatment with a drug for control purposes. 
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Normoxic cells compared to H/R control showed a significant (P<0.001) decrease in 
cellular viability (100.0±0.0% vs 29.3±6.1%, respectively, Figure 47). However, 
artemisinin (4.3µM) administered throughout reoxygenation significantly improved cell 
viability compared to the H/R group (66.5±6.3% vs. 29.3±6.1 % respectively, P<0.01, 
Figure 47). 
The non-selective inhibitor of nitric oxide synthase, L-NAME showed no significant effect 
on cellular viability when administered alone compared to H/R (47.0±7.1% vs. 29.3±6.1% 
respectively, Figure 47). However, by co-administering artemisinin (4.3µM) with L-
NAME (100µM) the artemisinin induced cytoprotection was significantly (P<0.05) 
reversed (48.1 ±5.5% vs. 66.5 ± 6.3% respectively, Figure 47).  
Aminoguanidine alone (100µM) however, did show significance when compared to H/R 
in terms of cellular viability (50.1±6.6% vs. 29.3±6.1%, P<0.05 respectively, Figure 47). 
The viability afforded to the cells by artemisinin similarly showed a significance (P<0.01) 
as previously described, in the presence of artemisinin (4.3µM) and aminoguanidine 
(100µM) however it was cellular viability was significantly decreased compared to 
artemisinin alone (46.4±6.2% vs. 66.5±6.3% respectively, P<0.05, Figure 47). 
 
Figure 47. MTT reductase activity used in assessing cellular viability in isolated ventricular 
cardiomyocytes subjected to 2 hours of hypoxia and 2 hours of reoxygenation. Where Art (4.3µM) was 
administered in the presence and absence of L-NAME (100µM) and aminoguaninde (100µM). ### P<0.001 
vs Norm, **P<0.01 vs H/R, *P<0.05 vs Art ,#P<0.05 vs H/R (n=3-8). 
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5.3.5 Artemisinin decreases cleaved caspase-3 activity in isolated ventricular 
cardiomyocytes subjected to H/R injury via the nitric oxide cellular survival 
pathway 
In order to determine whether artemisinin at reperfusion can attenuate caspase 3 activity, 
in an adult rat cardiomyocyte model of H/R injury artemisinin (4.3µM) was administered 
throughout reoxygenation following hypoxia. The study also investigated the role of nitric 
oxide synthase, eNOS and iNOS by administering inhibitors of nitric oxide, L-NAME 
(100µM) and aminoguanidine (100µM) respectively alone and in combination with 
artemisinin (4.3µM) during reoxygenation to determine the involvement of the nitric oxide 
pathway in the mediated cytoprotection observed. 
Isolated rat ventricular myocytes were subjected to 2 hours of hypoxia followed by 120 
minutes of reoxygenation. Cells at reoxygenation were then treated with artemisinin 
(4.3µM) alone and in the presence/absence of L-NAME (100µM) or aminoguanidine 
(100µM) from which we assessed the levels of cleaved caspase-3 via flow cytometric 
analysis. The normoxic group had a low level of activated caspase-3 while the H/R group 
showed a significant (P<0.001) increase in the levels of cleaved caspase-3 activity 
compared to the normoxic control (8.8±1.2% vs. 26.8±2.0%, respectively, Figure 48). 
Treatment with artemisinin (4.3µM) showed a significant (P<0.05) decrease in the levels 
of caspase-3 compared to H/R control (17.1±2.0% vs. 26.8±2.0%, respectively, Figure 48). 
Co-treatment of artemisinin (4.3µM) with L-NAME significantly (P<0.01) reversed the 
anti-caspase 3 effect of artemisinin (31.0±1.4% vs. 17.1±2.0%, respectively, Figure 48). 
Co-administering artemisinin (4.3µM) with aminoguanidine (100µM) when compared to 
artemisinin showed a significant decrease also (26.7±3.2% vs. 17.1±2.0%, respectively, 
P<0.05, Figure 48). However, treatment with L-NAME showed, L-NAME had no 
significant effect compared to H/R control (29.9±0.7% vs. 26.8±2.0%, P>0.05, Figure 48). 
No significant effect was observed with aminoguanidine administered alone throughout 
reoxygenation too compared to H/R control (28.0±2.1 vs. 26.8±2.0%, P>0.05, Figure 48). 
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Figure 48. Effect of administration of artemisinin (Art) (4.3µM) in the presence and absence of L-NAME 
(100µM) and aminoguanidine (Amg) (100µM) on cleaved caspase-3 levels as analysed by Flow Cytometry. 
***P<0.001 vs Norm, *P<0.05 vs H/R, ##P<0.01 vs. Art, #P<0.05 vs. Art. (n=4-6) 
5.3.6 Artemisinin mediates cardioprotection via upregulation and activation of 
eNOS (Ser1177) observed isolated ventricular cardiomyocytes subjected H/R. 
Following isolation, cardiomyocytes were subjected to 120 minutes hypoxia and 120 
minutes reoxygenation with artemisinin (4.3µM) treatment to determine the levels of p-
eNOS expression using FACS analysis. Untreated cardiomyocytes subjected to H/R 
showed a decrease in the expression of p-eNOS compared to the normalised normoxic 
control (46.3±2.0% vs. 100.0±0%, P<0.001, Figure 49). Upon treating the cardiomyocytes 
with artemisinin, a significant (P<0.001) increase in the level of p-eNOS compared H/R 
control was observed (156.3± 31.0% vs. 46.3±2.0% respectively, Figure 49). Co-treating 
cells with non selective nitric oxide inhibitor, L-NAME (100µM) with artemisinin (4.3µM) 
upon reoxygenation, significantly (P<0.01) downregulated eNOS expressed nitric oxide 
(59.6±8.1% vs. 156.3± 31.0%, Figure 49). Treatment with L-NAME (100µM) alone upon 
reoxygenation had no effect on p-eNOS expression compared to H/R control (51.0±10.6% 
vs. 46.3±2.0%, Figure 49).  
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Figure 49. Effect of administering artemisinin (Art) (4.3µM) throughout reoxygenation in the presence and 
absence of L-NAME (100µM) on (Ser 1177) expressions as analysed using Flow Cytometry. ***P<0.001 vs 
Normoxia (Norm), **P<0.01 vs H/R, ##P<0.01 vs. Art (n=4-6). 
5.3.7 Artemisinin treatment in isolated cardiomyocytes shows elevation in iNOS 
expressions. 
Isolated ventricular cardiomyocytes subjected to after 2 hours hypoxia, 2 hours 
reoxygenation presented a reduced level of iNOS compared to normoxic control (69.9 ± 
13.5 % vs. 100.0±0%, P<0.05, Figure 50). Whereas treatment with artemisinin (4.3µM) 
showed a significant (P<0.01) increase in the level of iNOS compared H/R control (150.4 
± 14.4% vs. 69.9 ± 13.5% respectively, Figure 50). Co-treating cells with L-NAME 
(100µM) and artemisinin (4.3µM) significantly (P<0.01) inhibited eNOS(Ser 1177) expression 
(71.5 ± 5.8 % vs. 150.4 ± 14.4%, Figure 50) however administering L-NAME alone had 
no effect on iNOS expression as compared to H/R control (72.8 ± 14.0 % vs. 69.9 ± 13.45 
%, Figure 50) 
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Figure 50: Effect of artemisinin (Art) (4.3µM) on iNOS expression in the presence and absence of L-NAME 
(100µM) and Aminoguanidine (Amg) (100µM) analysed using FACS analysis. *P<0.05 vs. Normoxia 
(Norm), **P<vs. HR, ##P< vs. Art (n=4-6) 
5.3.8 Increase in nitrite and nitrate levels in artemisinin treated cardiomyocytes 
The OxiSelect™ nitric oxide (Nitrite/Nitrate) assay is a simple, colorimetric assay that 
quantitatively measures nitric oxide in various samples by NO2-/NO3- (nitrite/nitrate) 
determination. Results show nitrate in the sample converted to nitrite by nitrate reductase 
enzyme which is detected with Griess Reagents as a colored azo dye product (absorbance 
540nm).  
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Figure 51a and 51b. Nitrite and Nitrate Standard Curves. Nitrite (left) and nitrate (right) standard curves 
were performed according to the OxiSelect™ in vitro nitric oxide colorimetric assay protocol showing a 
directly proportional increase in the absorbance and concentration of nitrite and nitrate in control samples 
respectively. Results expressed as Mean±SEM. 
 
Figure 51a and 51b show the absorbance of the nitrate and nitrite standard solutions with 
which the drug treated cardiomyocytes were measured. Table 4a shows the average of 
control and artemisinin treated cardiomyocytes (n=4-6). The concentration of nitrate within 
each sample was calculated by comparing the sample absorbance to the standard curve. 
Negative controls (without nitrate) were subtracted as shown in Table 4 thus showing the 
effect of artemisinin treatment in this assay. Data was collected for artemisinin treatment 
without inhibitors as the results were inconclusive and showed no obvious differences 
between treatments. 
 
Concentration (µM) Control Artemisinin 
0 0.19 0.20 
20 0.06 0.22 
40 0.17 0.34 
60 0.25 0.36 
80 0.32 0.34 
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100 0.29 0.43 
120 0.29 0.46 
140 0.18 0.51 
 
Table 4. Table showing the difference in mean absorbance of nitrate and nitrite in artemsinin treated cell 
lysate compared to standard control sample (n=4-6) 
 
5.4 DISCUSSION 
In the previous chapter, it was confirmed that by administering artemisinin at reperfusion, 
artemisinin significantly alleviated evidence of myocardial injury and improved cellular 
survival in the myocardial model of I/R and H/R respectively. This findings are supported 
by research by Sun et al. (2007) who showed artemisinin possesses some cardioprotective 
effects by limiting infarct size development (Sun et al., 2007). More recently, many 
researchers have reported artemisinin’s great potential against several cancer types (Yatuv 
et al., 2010; Lai and Singh 2006; Qadieri et al., 2013). However, this is under researched 
in terms of its effects in the heart, which is a popular organ target of toxicity in presently 
used anthracyclines (Toldo et al., 2013). The main finding of this study is establishing the 
downstream targets of the pathway PI3K-Akt-nitric oxide cell survival pathway in 
artemisinins’ mediated cardioprotection in cardiomyocytes and in HL-60 cells. 
Activating Akt can influence a variety of downstream targets that can have multiple effects 
on cellular function especially on kinases such as p70S6K, eNOS, and other downstream 
targets (Kane and Weiss, 2003; Jonassen et al., 2004).  Akt is known to activate pro-
survival factors as well as inhibit the activation of caspase 3, thus decreasing the number 
of cells committed to apoptosis (Sun et al., 2012; Hussain et al., 2013) 
By investigating myocardial injury, apoptosis and the cellular factors and signalling 
pathways that regulate apoptosis, this study may ultimately enable the development of ways 
of suppressing apoptotic cell death and understand in-depth the process of myocardial 
injury and how to certain therapies can alleviate it. I/R injury, myocardial infarction, heart 
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failure and drug induced cardiotoxicity are amongst the main causes of apoptosis and 
necrosis in cardiac myocytes (Zhou et al., 2014). 
The major finding of this chapter is that artemisinin significantly alleviates myocardial 
injury of simulated myocardial I/R and H/R. Results from the isolated perfused hearts 
showed that artemisinin decreases infarct size, improves myocyte viability and decreases 
cleaved-caspase-3 activity in isolated ventricular myocytes. From the different models 
investigated in this study, it was established that the cardioprotective properties of 
artemisinin were as a result of activation of nitric oxide following the induced 
ischaemic/hypoxic injury. 
Myocardial damage caused as a result of ischaemia and reperfusion therapy has been 
associated with free radical-induced myocardial damage, neutrophil accumulation, 
intracellular calcium overload, endothelial and microvascular dysfunction, and altered 
myocardial metabolism (Verma et al., 2002; Monassier 2008). Although not investigated 
in our I/R and HR studies, it explains the mechanism behind the induced damaged. The 
injury induced is as a result of the metabolic and functional changes occurring in the 
myocardium (Rosano et al., 2008). A decrease in ATP, creatine phosphate (CP) and changes 
in pH causes the proteins within cells to denature, subsequently resulting in an overall 
change in the working heart model (Kubes and Granger 1993; Wright et al., 1995). 
Studies have postulated that exposure to hypoxia favours an increase in the production of 
ROS in the mitochondria, activation of NADPH oxidase, xanthine oxidase/reductase, and 
nitric oxide synthase enzymes production as well as cellular hypertrophy (Araneda and 
Tuesta 2012). The production of nitric oxide during ischaemia has led to a lot of 
controversy in studying whether nitric oxide plays a protective or detrimental role in 
myocardial I/R injury (Ozaki et al., 2002; Kanno et al., 2000). Literature postulating that 
nitric oxide plays a ubiquitous role in modulating biological processes ranging from normal 
biological processes to pathophysiological extremes is extensive (Rakhit and Marber 
2001). Injury induced by I/R directly damages myocytes; this is attributed to altered nitric 
oxide formation (Bredt and Snyder 1994). Nitric oxide is known to affect diverse 
physiological and pathological processes within the biological system (Sharma et al., 
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2008). Recent findings do not support the controversy of the detrimental effects of nitric 
oxide. It is well established that nitric oxide plays an important role in maintaining cellular 
physiology and cytostasis (Ramirez et al., 2010). 
Furthermore, there is overwhelming evidence showing that nitric oxide is an important 
cardioprotective molecule via its vasodilator, antioxidant, antiplatelet, and anti-neutrophil 
actions making it essential for normal cellular homeostasis (Ferdinandy 2006). However, 
nitric oxide is only considered detrimental if when it combines with O2 it forms ONOO- 
(Palcher et al., 2007). This rapidly decomposes to generate highly reactive oxidative 
intermediates. iNOS has been shown to mediate anti-stunning and anti-infarct actions 
which have been elicited stimulus such as ischaemia (Bolli 2001). 
In normal physiological conditions, there is a critical balance between cellular 
concentrations of nitric oxide, O2, and superoxide dismutase, which favour nitric oxide 
production (Fulda et al., 2010). In conditions such as I/R, the formation of ONOO- is 
favoured. However, in order to induce preconditioning, which involves brief episodes of 
ischaemia, both NO and O2 synthesis are required (Ferdinandy and Schulz 2003). The 
overproduction of NO, O2´ and ONOO during subsequent episode of ischaemia and 
reperfusion is attributed to the cardioprotection observed in preconditioning in which 
model (Ferdinandy and Schulz 2003). 
In the different models evaluated by this study, L-NAME, a non selective inhibitor of nitric 
oxide synthase was administered alone and in combination with artemisinin. Several 
studies have shown L-NAME effectively blocks nitric oxide synthesis (Boultadakis and 
Pitsikas 2010; Minami et al., 1995; Klamer et al., 2001). In the isolated ventricular 
cardiomyocyte, L-NAME had no effect on infarct size whereas in combination with 
artemisinin, the cardioprotection observed with artemisinin were abolished. This present 
study was able to show artemisinin’s capacity in attenuating myocardial 
ischaemia/reperfusion injury while implicating the nitric oxide pathway. Studies have 
supported our findings by showing the administration of L-NAME in addition to flavonoids 
partially abolished the cardioprotection afforded by the flavonoids against I/R in rats, which 
suggests the role of nitric oxide in cardioprotection (Challa et al., 2010). This, supports that 
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an upregulatory effect on eNOS leading to increased nitric oxide production is 
cardioprotective as observed with artemisinin treatment. Evidence from Felaco et al. (2000) 
also supports that an increase in the levels of p-eNOS contributes to the mechanism of 
cardioprotection against I/R injury as we have also observed with artemisinin-treatment in 
cardiomyocytes. 
Furthermore, study by Bell and Yellon (2002) showed that by administering bradykinin in 
an isolated perfused rat heart model, the PI3K-Akt pathway is activated resulting in an 
increase in eNOS nitric oxide leading to an ultimately a decrease in infarct size and 
cardioprotection in the treated hearts.  
Gao et al. (2002) supported our findings by showing that administering insulin in vivo 
reduced myocardial apoptosis via the activation of p-eNOS and increased nitric oxide 
production through the PI3K-Akt pathway (Gao et al., 2002). Additionally, further studies 
by Gao’s group (2005) have shown that treatment with glucose-insulin-potassium (GIK) at 
reperfusion recruited the same Akt-dependent and NO-mediated pathway of protection (Ma 
et al., 2006).  Recent studies by Smart et al. involving pre-treatment of cardiomyocytes 
with interleukin-6 (IL-6) have similarly induced a PI3K and NO-dependent pathway of 
protection with an increase in expression of iNOS (Smart et al., 2006). 
We went on further to analyse the effects of I/R and H/R on iNOS expression in isolated 
perfused hearts and ventricular rat cardiomyocytes, respectively. Artemisinin (4.3µM) and 
L-NAME (100µM) were administered together during reperfusion/reoxygenation. 
Similarly, we were able to attribute the nitric oxide dependent protection to iNOS isoform 
expression, whereby artemisinin administered alone reduced infarct size/cellular viability 
following I/R or H/R injury and more importantly the observed protection was abrogated 
by aminoguanidine, a highly specific iNOS inhibitor. Despite the increase in eNOS/iNOS 
expression with drug treatment, aminoguanidine/L-NAME did not significanty decrease 
eNOS/iNOS levels compared to H/R control. Our findings are supported by Li et al. (2003) 
who demonstrated iNOS overexpression (through adenovirally encoded human iNOS) to 
be greatly protective against I/R injury in mice (Li et al., 2003). Heger et al. (2002) have 
also analysed mice with constitutively expressed cardiac-specific overexpression of iNOS 
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and found that the overexpression of iNOS conferred protection following ischaemia-
reperfusion in isolated hearts (Heger et al., 2002). Furthermore, Zingarelli et al. confirmed 
that the absence of the iNOS gene leads to the development of tissue damage in ischemic 
hearts after early reperfusion (Zingarelli et al., 2002) thus concluding that iNOS plays a 
beneficial role in modulating the early defensive inflammatory response against 
reperfusion injury through regulation of signal transduction. These finding offers an 
explanation to the artemisinin-mediated protection observed in the I/R model which we 
associated with the nitric oxide-dependent pathway, in particular the upregulation of iNOS. 
Also in the cleaved caspase-3 assay, isolated ventricular rat myocytes were stained using 
an intracellular Alexa Fluor® 488 labelled caspase-3 antibody which detects myocyte 
cleaved caspase 3 activity. Our results demonstrated that H/R caused an upregulation of 
activated caspase-3 levels when compared to normoxic controls whereby treatment with 
artemisinin caused a decrease in caspase-3 activity. During the activation of the caspases, 
firstly, an initiator caspase is activated as a result of hypoxia is then cleaved and in turn 
activates the effector caspases leading to a proteolytic cascade that initiates cell death as 
picked up in this assay. The levels of cleaved caspase-3 activity were measured via flow 
cytometry in this study indicate cells potentially committed to apoptosis (Jovanovic et al., 
2002). Feng et al. (2005) using bradykinin similary showed that preconditioning the heart 
with bradykinin would improve survival via upregulation in antiapoptotic proteins and 
inhibition of myocardial apoptosis in rabbit hearts subjected to 30 minutes simulated heart 
arrest using cardiopegia ischaemia. This study relates apoptosis to cleaved caspase-3 
activity and showed the decrease in the levels of activated caspase-3 shows a decrease in 
the number of cells committed to apoptosis while associating it to protection. 
Due to its ubiquitous role, nitric oxide has also been associated with inducing apoptosis in 
cardiac myocytes in a dose-dependent manner. In high concentrations, nitric oxide can 
induce caspase activation, DNA fragmentation and cell death (Choi et al., 2010; Jovanovic 
et al., 2002). Our results also suggests that upregulation of nitric oxide, induced by 
administering artemisinin at reperfusion, is involved in inhibiting caspase-3. This is evident 
in the use of inihibitors of nitric oxide such as L-NAME and aminoguanidine. It is well 
documented in human endothelial cells that nitric oxide completely abrogates apoptosis by 
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interfering with the activation of the caspase cascade (Dimmeler et al., 1997). In in vivo 
studies, nitric oxide was shown to inhibit caspase-3 through S-nitrosation (Rossig et al., 
1999). 
Mitochondrial studies have also suggested that mitochondrial damage may be potentiated 
by nitric oxide, which leads to activation of the apoptotic-signalling cascade. Whilst 
mitochondria appear to be a target for nitric oxide-mediated injury, the mitochondria may 
also be a potential target for protection (Borutaite et al., 2000). Due to the vast advances in 
understanding the role of nitric oxide in the ischaemic biology of the heart, it is well 
established that nitric oxide prevents I/R, although the mechanism is debatable (Ferdinandy 
et al., 2003). However, studies have suggested that nitric oxide functions via the inhibition 
of the respiratory chain depolarization of the mitochondrial membrane or from the 
prevention of ROS generation and calcium uptake in cells (Gao et al., 2008; Camara et al., 
2010) which explains the protective properties it displays. Which we postulate may equally 
explain artemisinin’s mediated protection we have observed. 
Ferdinandy et al. (2007) determined that increase in ROS may significantly disrupt major 
cytoprotective signalling pathways (Ferdinandy et al., 2007) with nitric oxide being a 
critical mediator of myocardial homeostasis such as vasodilation and adaption to stress 
(Jones and Bolli 2006). Nitric oxide is sufficient to confer cardioprotection as research has 
established, with growing studies suggesting that nitric oxide bioavailability is necessary 
in eliciting several protective interventions (Jones et al., 2003). In this chapter, we have 
successfully shown an increase in nitric oxide with artemisinin treatment in the different 
assays employed. These findings are similar to a study by Salloum et al. (2003) which 
showed that sildenafil increased eNOS and iNOS proteins in the heart (Salloum et al., 
2003) and cardiomyocytes via the opening of the mitochondria opening of mitochondrial 
ATP-dependent K+ channels. Das et al., (2005) have also shown that sildenafil protects 
against necrosis and apoptosis through Nitric oxide signalling pathway which has a 
possible therapeutic potential in preventing myocyte cell death following I/R. This has a 
direct effect on protection against myocardial infarction (Salloum et al., 2003) and 
simulated I/R injury and apoptosis in cardiomyocytes (Das et al., 2005; Kukreja 2007). 
Evidence from cultured endothelial cell obtained from male Sprague Dawley rat subjected 
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Insulin treatment following I/R has also affirmed that phosphorylation of eNOS via 
PI3K/Akt pathway increases nitric oxide production (Gao et al., 2002). This therefore 
elucidates the importance of nitric oxide signalling pathway and its anti-apoptotic effect 
following myocardial ischaemia and reperfusion. 
eNOS is essential in determining the vascular tone and platelet activity in cells.  However, 
it’s most important in the modulation of myocardial metabolism by nitric oxide (Trochu et 
al., 2000). Our results show artemisinin stimulates p-eNOS, supported by Bell and Yellon 
(2003) who have shown by using bradykinins in an isolated perfused rat model of 
ischaemia reperfusion that the recruitment of PI3K and Akt leads to the phosphorylation of 
eNOS which attenuates reperfusion injury (Bell and Yellon 2003). The presence of nitric 
oxide in our artemisinin treated cells has been previously attributed to cardioprotective 
properties in different models. Evidence from research has also shown a decrease in the 
amount of basal nitric oxide following inducing ischaemia (Maulik et al., 1995) this 
suggests the increase amounts seen in comparison to the I/R control group was as a result 
of the drug treatment. Bell and Yellon 2003 have shown that the presence of eNOS is a 
prerequisite to the drug-mediated salvaging effect in reperfusion injury implying a role of 
nitric oxide in the observed protection. Additionally, Liu et al. (2002) have emphasised and 
highlighted the important role of eNOS in limiting post infarction cardiac hypertrophy. 
Other studies have also confirmed exposure to hypoxia causes a reduction in eNOS levels 
due to the generation of reactive oxygen species, lipid peroxidation, protein denaturation 
and DNA damage (Cacciutolo et al., 1993). Likewise, increased phosphorylation of eNOS 
in our artemisinin treatment groups significantly improved/restored myocardial function, 
which is in line with previous studies on eNOS upregulation (Kukreja 2007; Farah et al., 
2013). This may be due to the blocking of nitric oxide synthase and superoxide formation 
caused by eNOS, (Pou et al., 1992) hence resulting in cardioprotective effect.  
Other analytical techniques have also been used to quantitate the major metabolites of nitric 
oxide i.e. nitrite and nitrate, in a variety of biological fluids (Tsikas 2007). To quantitatively 
measure nitrite and nitrate levels (which are the oxidation products of nitric oxide), Griess 
reagent has been exclusively used for decades now to measure nitrite levels. To quantify 
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nitrate, nitrate is enzymatic reduced to nitrite which is inidicative of nitric oxide production 
(Chartterjee et al., 2002). 
Our results show artemisinin treatment led to an increase in the levels of nitrate and nitrite 
in a dose-dependent manner. Laboratory studies mimicking myocardial infarction have 
shown an increased induction of iNOS, eNOS, and nitric oxide in the heart, followed by 
increased plasma concentrations of nitrate and nitrite (Feng et al., 2001). Nevertheless such 
studies emphasised that the balance between the cytostasis and cytotoxicity of nitric oxide 
is dependent on the amount of nitric oxide synthase available within the tissue as well as 
the interactions with free radicals such as the superoxide (Rakhit and Marber 2001). 
Interestingly, our results showed an increase in iNOS with artemisinin treatment. 
Upregulation of nitric oxide by iNOS however has been previously linked to myocardial 
dysfunction and results in higher mortality after myocardial infarction (Feng et al., 2001). 
Contrastingly, Aldieri et al. (2003), showed that iNOS upregulation in cells of neonatal rats 
was not followed by any associated toxicity as it is usually following the reaction with 
superoxide to form peroxynitrate which supports the findings in rat cardiomyocytes. By 
altering mitochondrial permeability, there is an increase in the pro apoptotic Bcl-2 family 
(e.g. Bax), which then stimulates apoptosis (Haunstetter and Izumo 1998; Mashimo and 
Goyal 1999). 
However, studies by other researchers such as Xiong et al. (2010) have supported our 
findings and shown that artemisinin can ameliorate cardiac hypertrophy after aortic 
banding. Due to artemisinin’s low toxicity profile, it is a favourable drug of choice in anti-
malarial therapy and with great potential in a variety of settings. Furthermore, studies have 
shown artemisinin and its derivatives are increasingly being used due to their reliable and 
consistent pharmacokinetic profiles (Pasvol 2005). 
5.5 CONCLUSION 
Developing pharmacological approaches to attenuate the incidence of I/R and delaying the 
onset of apoptosis and necrosis is of great clinical importance (Ferdinandy et al., 2007). 
We can therefore conclude the pharmacological agents such as artemisinin, widely used in 
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the clinical setting as an anti-malarial agent; in the myocardium has the ability to reduce 
infarct size and ischaemia-reperfusion injury in a nitric oxide-dependent manner.  
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Chapter 6 
 
6 ARTEMISININ PROTECTS AGAINST 
DOXORUBICIN-INDUCED CARDIOTOXICITY 
AND ENHANCES CYTOTOXICITY IN HL-60 
CANCER CELLS VIA THE NITRIC OXIDE 
SIGNALLING PATHWAYS 
6.1 INTRODUCTION 
The use of anthracyclines alone or in combination with other anti-cancer treatments remains 
the most viable chemotherapy treatment for a range of cancers, including breast cancer, 
leukaemia, lymphomas and sarcomas (Vejpongsa and Yeh, 2013). Cancer chemotherapy has 
made remarkable advances over the years in the treatment of solid and haematologic 
malignancies such as using immunoconjugates (which are cytotoxic effectors covalently 
linked to monoclonal antibodies that enable a more targeted cell-surface receptor 
recognition delivery system) (Wessels and OW, 2014). Encouraging results have also been 
yielded with the use of immunotherapies particularly immune checkpoint inhibitors in 
several cancer types, however immunotherapies are not here to replace chemotherapy or use 
of anthracyclines which has undoubtedly revolutionised cancer therapy (Volkova and 
Russell, 2011; Armand 2015). Anthracyclines have emerged as one of the most effective 
anticancer treatments ever developed. Unfortunately, their clinical use is limited due to their 
associated cardiotoxicity (van Dalen et al., 2008). 
Doxorubicin, a widely used anthracycline, is used in treatment against leukaemia, 
lymphoma, and breast and prostate cancer (Liu et al., 2008; Torres and Simic 2012). 
Doxorubicin has been shown to have a cumulative dose-dependent cardiotoxicity, with the 
risk of heart failure increasing significantly after the cumulative dose increases above 
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400 mg/m2 (Vejpongsa and Yeh, 2013). Doxorubicin therapy is therefore limited due to 
acute or chronic toxicity to the heart, with the acute toxicity being transient and clinically 
manageable while the chronic toxicity evolves into progressive cardiomyopathy, thus 
limiting its clinical use (Minotti et al., 2001). Studies have shown that treatment with 
doxorubicin often results in increased risks of cardiomyopathies, congestive heart failure 
and subsequently an increased risk of mortality in cancer patients (Koti et al., 2008; Vergely 
et al., 2007). This has led to several deaths as a result of non cancer causes especially in 
patients with pre-existing cardiac conditions such as ventricular dysfunction (Takemura and 
Fujiwara 2007; Adams and Lipshultz 2005; Tacar et al. 2013). Other risk factors that may 
increase the risk of anthracycline induced cardiotoxicity that have been identified as being 
age, female gender, prior mediastinal radiation therapy, hypertension, myopathy and or heart 
failure (Hoff et al., 1979; Volkova and Rusell 2011). 
Cardiac toxicity is one of most detrimental side effects of anticancer therapies, so the gain 
in life expectancy due to anticancer therapy might be countered by increased mortality due 
to cardiac problems such as heart failure, myocardial ischaemia, arrhythmias, hypertension 
or thromboembolism (Metens et al., 2008, Bovelli et al., 2010). Several studies have 
confirmed that cancer patients treated with doxorubicin develop adverse cardiac side effects 
that often led to the termination of doxorubicin treatment (Kalyanaraman et al., 2002; Singal 
et al., 2001). Statistical evidence gathered by oncologists assessing the risk of cancer relapse 
suggest using adjuvant therapy such as chemotherapy, radiation therapy, hormone therapy 
or an adjuvant anthracycline in addition to primary treatment maximises efficiency of 
treatment thus improving survival and limiting specific side effects (Handa 2014; Peters 
1993; Bonadona and Valagussa 1981). Although, limited data is available of the 
reoccurrence of cancers and of the benefits of adjuvant treatments (Sargent et al., 2008). 
Adjuvant chemotherapy has been shown to provide several benefits for example 
Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor 
receptor 2 (HER2) protein (Slamon et al., 2001). Trastuzumab is approved for patients with 
HER2-positive breast cancer and is given for treatment of metastatic cancers and very often 
as an adjunctive therapy for breast cancer treatment (Romond et al., 2005). Initial studies 
on trastuzumab showed that it improved survival in the late-stage of HER2-positive breast 
cancer (Hudis 2007). If treatment is started at the early stages trastuzumab also reduces the 
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risk of cancer recurring after remission from 9.5% to 3% however studies have also shown 
that it increases the risk of cardiovascular events (Moja et al., 2012). Another clinical trial 
also showed that administering doxorubicin and cyclophosphamide followed by adjuvant 
trastuzumab resulted in an increased incidence of congestive heart failure due to the 
adjunctive treatment (Russell et al., 2010). This further emphasises the urgent need to 
develop a safe and effective treatment against the different malignancies without 
compromising on the antineoplastic efficacy of doxorubicin (Scott et al., 2011).  
The mechanism of doxorubicin induced cardiotoxicity appears to be multifactorial and has 
been shown to involve a variety of processes such as oxidative stress, nitrosative stress, and 
ROS. In addition to ROS formation, RNS are also implicated in doxorubicin cardiotoxicity 
(Mukhopadhyay et al., 2007). The stress placed on the cardiomyocytes by the free radicals 
involves doxorubicin and its metabolites such as doxorubicinol which has been implicated 
in cardiotoxicity (Romana et al., 2008, Giorgio et al., 2004). Treatment with doxorubicin 
has also been previously shown to form complexes with iron which forms radicals (Stefano 
et al., 2004).  
Research has suggested the cardiotoxicity is also linked to disruption of cardiomyocyte 
integrity and loss of cardiac function. Nitric oxide, an important radical gas is involved in 
cellular signalling, normal homeostasis as well as pathophysiology of heart (Hummel et al., 
2006).  
Previous chapters have associated artemisinin with nitric oxide and mentioned the potential 
of artemisinin to be effective against a variety of cancer types. It remains an imperative need 
to develop anti-cancer agents that are free from adverse cardiac side effects or the 
development of adjunctive therapies that protect the heart from cardiotoxicity. We therefore 
focused this chapter on the effects of artemisinin on HL-60 cells and in the myocardium as 
well as artemisinin’s effect when co-administered with the severely cardiotoxic doxorubicin. 
Studies have previously implicated nitric oxide in anthracycline toxicity, with nitric oxide 
playing a key role in the pathogenesis of diseases (Fogli et al., 2014). Conversely, the 
beneficial nature of nitric oxide is well documented and has also been shown in a previous 
chapter (chapter 5) where nitric oxide was implicated in artemisinin mediated 
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cardioprotection. This conforms to the understanding that nitric oxide is a ubiquitous 
signalling molecule involved in a variety of physiological, biological and molecule events 
within cells (Hummel et al., 2006, Jones and Bolli 2006). 
Due to the claims made by previous researchers in terms of the implication of doxorubicin 
and nitric oxide compounded with our earlier observed association of artemisinin mediated 
nitric oxide protection, we investigated the possible involvement of nitric oxide in 
doxorubicin’s toxicity as well as that of artemisinin when used as an adjunctive therapy to 
doxorubicin in the myocardium and in HL-60 cell lines. We proposed that, artemisinin a 
known cardioprotective compound could potentially reverse doxorubicin induced toxicity 
by recruiting targets of the nitric oxide pathway without negatively impacting on its 
cytotoxicity in HL-60 cancer cells. 
In this chapter, we therefore administered artemisinin at as an adjunctive therapy in HL-60 
cells. This is with the aim of improving the doxorubicin associated toxicity due to 
artemisinins cardioprotective effect and its potential against several cancer types (Ho et al., 
2012; Qaderi et al., 2013). Artemisinin has been shown to be effective against 66 cancer 
cell types without the risk of exacerbating any cardiovascular conditions (Sun et al., 2007; 
Kinoshita et al., 2010). We administered artemisinin in combination with doxorubicin and 
in the presence and absence of nitric oxide inhibitors (L-NAME and aminoguanidine) to 
conduct investigations in the different myocardial models previously tested as well as in 
HL-60 cells.  
Aims of the current study were to investigate:  
(a) the effect of artemisinin and doxorubicin administered during reperfusion in isolated 
perfused rat hearts and isolated ventricular cardiomyocytes subjected to I/R or H/R 
respectively. The study also investigated cell signalling pathway associated with the 
observed effect in the myocardium; 
(b) the effect of co-administering artemisinin with doxorubicin in HL-60 cells while 
investigating the cell signalling pathway associated with the observed effect in the 
HL-60 cells; 
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Adult male Sprague Dawley rats (350-400g) were obtained from Charles River (Margate, 
UK). The care and use of animals were in accordance with the Guidance on the Operation 
of the Animals (Scientific Procedures Act 1986). The study was carried out upon obtaining 
ethical approval from Coventry University Research ethics committee which was regularly 
assessed throughout the project. 
6.2.2 Preparation of drugs 
Artemisinin, L-NAME and aminoguanidine hydrochloride both supplied from Sigma-
Aldrich (Poole, UK) and dissolved in DMSO making sure the final concentration of DMSO 
was less than 0.02%  (a concentration shown not to affect haemodynamics or infarct size) 
(unpublished paper) and stored at -20 °C. Doxorubicin Hydrochloride purchased from 
Tocris Cookson (Bristol, UK) and was dissolved in ultrapure water aliquoted and stored at 
-20. MTT was purchased from Sigma (Poole, UK). Cleaved Caspase-3 (Asp175) Antibody 
(Alexa Fluor® 488 Conjugate), iNOS, phospho-eNOS (Ser 1177), total-eNOS and HRP 
conjugated Rabbit monoclonal antibodies and antibiotin were purchased from New England 
Biolabs (Hertfordshire, UK). SuperSignal West Femto® enhanced chemoluminescent 
substrates were purchased from Pierce (UK). The nitric oxide Assay was purchased from 
Cell Biolabs Inc (San Diego, USA). HL-60 cells were obtained from ECACC. 
6.2.3 Isolated perfused rat heart model 
Briefly, following sacrifice, the hearts were rapidly excised and cannulated as described in 
detai in chapter 2. Subsequent retrograde perfusion with KH buffer, saturated with 95% O2, 
5% CO2, maintained at a temperature of 37 ± 0.5oC and pH 7.4 using a water-jacketed heat 
exchange coil. 
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Balloon of a diastolic pressure of 8-10mmHg was inserted into the left atrium allowing 
LVDP to be measured. A physiological pressure transducer was connected to a bridge amp 
and a power lab (AD Instruments Ltd, Chalgrove, UK) which allows the LVDP, HR using 
ECG leads. CF was measured by collecting the perfusate at regular intervals.  
The experiment was conducted for 175 minutes in total. 20 minutes stabilisation followed 
by 35 minutes ischaemia and 120 minutes reperfusion as described in chapter 2 (Figure 52). 
Doxorubicin (1µM) and/or artemisinin (4.3µM) was administered throughout reperfusion 
in the presence and absence of either L-NAME (100µM) or aminoguanidine. TTC solution 
in 8ml of phosphate buffer 2 (100mM NaH2PO4) and 2ml phosphate buffer 1 (100mM 
NaH2PO4.2H2O for 10–12 minutes and fixed in 10% formaldehyde for at least 4 hours to 
enhance the staining prior to analysis.  
The heart slices were then removed from formaldehyde and traced onto acetate film using 
different coloured markers to differentiate between the viable, at risk and infarct tissue 
which was scanned into a computer to allow calculation of Infarct to risk ratio from the 
differentiated tissues traced. Areas of viable, at risk and infarct tissue were measured using 
the Image Tool program as developed by UTHSCSA, Version 8.1. 
6.2.4 Adult Rat Ventricular Myocytes Isolation 
Adult ventricular rat myocytes were isolated from Sprague Dawley rats (350-400g) by 
enzymatic dissociation method (Maddock et al., 2002). Method described in detail in 
chapter 2. Hearts were mounted onto a modified Langendorff apparatus and perfused with 
modified Krebs buffer containing (in mM) ; 116 NaCl, 5.4  KCl, 0.4 MgSO4.7H20, 10 
glucose, 20 taurine, 5 pyruvate, 0.9 Na2HPO4. 12H2O and 25 NaHCO3 25 dissolved in RO 
water. The buffer was then oxygenated with 95% O2 and 5% CO2 and maintained at 37oC, 
pH 7.4 using NaOH. The hearts were then perfused with a collagenase digestion buffer 
(containing Collagenase 0.075% (Worthingtons Type II) and 4.4M CaCl2, pH 7.4) at a rate 
of 7.5ml/minutes. During perfusion with collagenase the effluent was collected and re-used. 
Following digestion, the ventricles were mechanically disrupted and incubated for 10 
minutes in 15ml of digestion buffer in an orbital shaker and oxygenated with 95% O2 and 
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5% CO2.  Cells were then centrifuged at 400rpm for 2 minutes, supernatant discarded and 
the pelleted cells re-suspended in RB (in mM 116 NaCl, 5.4 KCL , 0.4 MgSO4, 10 glucose, 
20 taurine, 5 Pyruvate, 0.9 NaHPO4 , 5 Creatine, 2% BSA, 50µM CaCl2  and 1% PenStrep 
pH 7.4 at 37o C) where the calcium concentration was gradually brought to 1.25mM to avoid 
calcium overload. The isolated myocytes were incubated in RB (at 37oC, 5% CO2 for 24 
hours before being used (Maddock et al., 2002).                                                         
The cells were incubated in 15 mls of hypoxic buffer (12 mM KCL, 0.49 mM MgCl2, 0.9 
mM CaCl2, 4 mM HEPES, 10 mM Deoxyglucose and 20 mM lactate and placed into a 
hypoxic chamber , Galaxy 48R (New Brunswick) pre-heated at 37 °C with 95% O2 and 5% 
CO2.. Myocytes were then assigned to the different treatment groups and were incubates 
with either: doxorubicin (1µM), artemisinin (4.3µM), doxorubicin (1µM) ± artemisinin 
(4.3µM), doxorubicin (1µM) ± artemisinin (4.3µM) ± L-NAME (100µM), doxorubicin 
(1µM) ± artemisinin (4.3µM) ± aminoguanidine (100µM) throughout the reoxygenation 
period. The myocytes then underwent reoxygenation for 2 hours. Upon completing 
reoxygenation the cells were then assessed either for cellular viability using MTT or 
underwent flow cytometric analysis for iNOS, p-eNOS (Ser 1177), total-eNOS or cleaved 
caspase-3 activity as described below. 
6.2.5 Cellular viability assay based on MTT reductase activity using isolated 
ventricular cardiomyocytes 
The cells were subjected to MTT assay which measures viable cells by reducing MTT 
tetrazolium dye from yellow to purple. The isolated myocytes were counted using a using a 
nucleo counter (Chemometec, Sartorius, Surrey, UK) and resuspended in restoration buffer 
(RB) to a density of 100,000 cells/ml. 1ml of the cells was pipetted to be used as normoxic 
control while the remaining cells were centrifuged and the pellet re-suspended in Esumi 
hypoxic buffer (in mM 137 NaCl, 12 KCL, 0.49 MgCl2, 0.9 CaCl2, 4 HEPES, 20 Na lactate, 
10 deoxy-D-glucose). The myocytes were then incubated in a hypoxic chamber, Galaxy 48R 
(New Brunswick) for 120 minutes with atmosphere 5% CO2 95% N2 at 37oC.  
Some wells were used as normoxic control which contained 100µl of restoration buffer only. 
The remaining wells were randomly allocated to the different treatment groups which 
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contained 50µl of cells and 50µl of drug treatment. Drugs used for this study were diluted 
with restoration buffer to a final concentration of 4.3µM in the artemisinin treated group, 
100µM in L-NAME treated group and 100µM in aminoguanidine treated group.  The 
drugs were administered at the start of reoxygenation and cells incubated for an additional 
120 minutes with 20µl of MTT (MTT solution consisting of 5mg.ml-1 in PBS (10g for 10-4 
cells/well) was added at reoxygenation except for the blanks which contained restoration 
buffer and MTT solution only which were then incubated in the dark at 370C for 120 
minutes. Myocytes were subsequently lysed with 100µl of lysis buffer (20% SDS in 50% 
dimethylformamide) and incubated on an orbital shaker and incubated overnight at 37o C. 
Colorimetric analysis of the plate was done to measure the fluorescence emission at 450nm 
(Thermo Scientific, UK) using a plate reader (Anthos 2001). The absorbance was measured 
for the different treatment groups. The effect of the artemisinin treatment was obtained by 
subtracting the absorbance from the control values.  Graphs were made using the mean 
absorbance of the drug treated group as a percentage of the mean absorbance of the control 
group. 
6.2.6 Quantitative analysis for cleaved caspase-3, iNOS and eNOS (Ser 1177) using 
FACS analysis 
Following the cardiomyocyte isolation, the myocytes were harvested and centrifuged at 
1200 rpm for 2 minutes. The pellet was then resuspended in PBS and fixed with 3% 
formaldehyde for 10 minutes at room temperature. The cells were then put on ice for 1 
minute before centrifuging at 1200 rpm for 2 minutes following aspiration of the 
supernatant. 250 µl of ice cold methanol (90%) was added and the samples were incubated 
on ice for 30 minutes before being washed twice in incubation buffer (0.5% BSA in PBS) 
following a 10 minutes (at 37°C) incubation of the samples each time followed by 
centrifugation of the samples (at 1200rpm, 2 minutes). The antibody was prepared to 1:100 
final dilution in incubation buffer for the analysis of cleaved caspase-3 activity or iNOS and 
eNOS.  
6.2.7 Quantitative analysis of cleaved caspase-3 activity 
Cleaved caspase-3 (Asp175) antibody (Alexa Fluor 488 conjugate) was used to detect the levels 
of activated caspase-3 in the different experimental groups. For the analysis of cleaved 
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caspase-3 activity, the cells were incubated for 1 hour in cleaved caspase-3(Asp175) secondary 
rabbit monoclonal antibody (Alexa Fluor ® 488 conjugate) (New England Biolabs, 
Hertfordshire,UK) diluted at 1:1000. At the end of the incubation period, the cells were 
centrifuged and the supernatant was removed the cells resuspended in 500µl PBS and 
analysed using flow cytometer (Becton Dickinson, Oxford, UK) using the on the FL1 
channel to count 10,000 events  (Vermes et al., 2002; Hussain et al., 2014). 
6.2.8 Quantitative analysis of iNOS, p-eNOS (Ser 1177) and eNOS  
To quantify iNOS levels, FACS analysis was used to assess the differential protein levels 
for iNOS and GAPDH. Following centrifugation, the harvested cells samples were probed 
for 1 hour with iNOS or GAPDH rabbit monoclonal antibody diluted at 1:100 dilution in 
incubation buffer followed by incubating in Alexa Fluor® 488 goat anti-rabbit IgG antibody 
at a dilution of 1:1000 for 1 hour. 
For p-eNOS and e-NOS the samples were also probed for 1 hour with p-eNOS and eNOS 
rabbit monoclonal antibody diluted at 1:100 dilution in incubation buffer followed by 
incubation in Alexa Fluor® 488 goat anti-rabbit IgG antibody at a dilution of 1:1000 for 1 
hour. 
At the end of the incubation period, the cells were centrifuged and the supernatant was 
removed the cells resuspended in 500µl PBS and analysed using flow cytometer (Becton 
Dickinson, Oxford, UK)  on the FL1 channel to count 10,000 events  (Vermes et al., 
2002; Maddock et al.2002).  
6.2.9 MTT cell viability assay using HL-60 cell line 
Human leukaemia cancer cell lines HL-60 were obtained from the ECACC. The cells were 
cultured in RPMI 1640 media without L-Glutamine (Biosera, Ringmer, UK) which was 
supplemented with 10% fetal bovine serum, 2mM L-glutamine, HEPES and 0.1% antibiotic 
solution (100 U/ml penicillin, 0.1mg/ml streptomycin from Invitrogen). The cells were 
maintained at 37°C under a humidified atmosphere and 5% CO2. 50µL of the cells 
containing (1x105cells/well) were plated in 96-well flat-bottomed microtitre plates, and 
treated with varying concentrations of artemisinin (0.4mM), doxorubicin (1µM), 
artemisinin (0.4mM) ± doxorubicin (1µM), artemisinin (0.4mM) ± doxorubicin (1µM) ± L-
P a g e  | 172 
NAME (100µM), doxorubicin (1µM), artemisinin (0.4mM) ± doxorubicin (1µM) ± 
aminoguanidine (100µM) for 24 hours. At the end of the incubation period, the cells were 
terminated by adding MTT solution (20µl of 5mg/ml MTT to each well) and further 
incubated for 2 hours at 37°C. 100µl of lysis buffer (20% sodium dodecyl sulfate in 50% 
dimethyl formamide) was then added to each well containing treatment and control samples.  
Incubation was at 37°C and its duration was based on results of 24 hours assay optimization 
experiments from previous experiments in the lab (data not presented in this study). The 
plates were incubated overnight to solubilise the cells. The absorbing intensity of each well 
was determined at 492nm using a plate reader (Anthos 2001) which measures the percentage 
of cell growth calculated using the following formula;  
% Cell Growth = (average absorbance of treated wells for Artemisinin/average 
absorbance of untreated control wells) x 100%. 
Each experiment was repeated three times and the values estimated using the 4-parametric 
logistic analysis (Grafit Software, Erithacus, UK). Dose–response was plotted for 
artemisinin, doxorubicin and the combination of the two using inhibitors. 
6.2.10 Nitric oxide Assay using the OxiSelect™ In Vitro Nitric Oxide Calorimetric 
Assay 
In this assay, the nitrate (NO3-) in the sample is converted to nitrite (NO2-) by nitrate 
reductase enzyme which is absorbed at 540nm according to manufacturer’s instructions 
6.2.10.1 Experimental protocol using the Nitric Oxide assay 
Adult ventricular rat myocytes were isolated from Sprague Dawley rats by enzymatic 
dissociation method as described previously in chapter 2. The isolated myocytes were 
counted using a using a nucleo counter (Chemometec, Sartorius, Surrey, UK) and 
resuspended in restoration buffer (RB) to a density of 100,000 cells/ml. 
Preparation of Samples and standards were according to manufacturer’s instructions. Nitrite 
and nitrate standards were prepared by making a dilution series of concentration range 0-
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140µM from a standard 14mM of the nitrite. Triplicate wells were used for measuring the 
nitrate concentration. 
6.2.10.2 Measurement of Total/Nitrate levels 
Nitrate levels in the samples were measured by subtracting nitrite only from total nitrite and 
nitrate. 
Nitrate = (Total nitrite + nitrate) - Nitrite only. 
To measure the nitrite levels, 50µL of nitrite standards, samples or blanks were added to a 
96 well plate. Followed by 50µL of PBS and 50µL of Griess Reagent A were added to each 
well. The plate was then incubated for 10 minutes allowing the colour to develop. 
Absorbance was then read at 540nm on a microplate reader. The concentration of nitrite was 
calculated by comparing sample absorbance to standards. Negative controls without nitrate 
were subtracted from reading. Each nitrite standard and sample was assayed in duplicate. 
6.2.10.3 Measurement of Total/Nitrate via Nitrate Reduction 
To measure nitrate levels, 50µL of nitrate standard, samples or blanks to the 96 well plate. 
Drug treated cells were subjected to artemisinin (4.3µM) and/or doxorubicin (1µM) 
treatment. The enzyme reaction mixture was also prepared for the number of tests to be 
performed. The diluted enzyme cofactor was added to the mixture (1:100 dilution in 
deionized water) and vortexed. 50µL of the enzyme reaction mixture was then added to the 
wells containing the sample/nitrate and covered with foil. The plates were then incubated 
for 1 hour at room temperature on an orbital shaker. 50µL of Greiss Reagent A was also 
added and vortexed followed by Greiss Reagent B. The plate was then incubated for a 
further 10 minutes for colour development absorbance was then read at 540nm. The 
sample’s absorbance was then calculated by comparing the Nitrate and standard curve and 
comparing our drug treatment to control.  
 
Statistical Analysis  
Results were expressed as Mean ± SEM for infarct/risk ratio, cell viability, cleaved caspase-
3 analysis, iNOS, p-eNOS (Ser 1177) and nitric oxide assay. Infarct size was tested for group 
differences using one way ANOVA with LSD post hoc tests. P values of P<0.05 were 
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considered statistically significant. Haemodynamics: LVDP, HR and CF were assessed for 
statistical difference using two way ANOVA at the different time points. 
6.3 RESULTS 
6.3.1 Exclusion Criteria 
Three rat hearts were excluded from this experimental study; two due to low viability of 
live cells following isolation (≤70%) and the other due to a tear in the ventricular wall while 
tightening the snare during ischaemia. All other groups have been included. 
6.3.2 Haemodynamics 
LVDP, HR and CF were assessed for statistical difference using two-way ANOVA at the 
different time points. 
 
In the doxorubicin (1µM)  treated hearts there was  a significant decrease in LVDP 
compared to time matched I/R control hearts, a marked decreased was seen at 145 minutes 
(73.9±3.5% vs. 52.0±2.2%, P<0.01) and at 175 minutes (70.7±2.9% vs 50.7±3.5%, P<0.01 
in doxorubicin treatment groups, Figure 52). There was no significant effect on HR and CF 
when comparing the different treatment groups. 
 
Hearts treated with artemisinin (4.3µM) showed no significant increase in LVDP compared 
to I/R control as shown in chapter 3. However, it can be seen that artemisinin co-treatment 
with doxorubicin artemisinin reversed doxorubicin induced decreases in LVDP. At 145 
minutes into reperfusion treatment administration or artemisinin with doxorubin 
significantly reversed doxorubicin induced decreases in LVDP add time point (72.0±5.2% 
vs. 52.0±2.2% in doxorubicin treatment, P<0.01, Figure 52) this effect remained significant 
until the experiment was terminated at 175 minutes (70.7±4.5% vs. 50.7±3.5%, P<0.01, 
Figure 52). 
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Figure 52. The effects of artemisinin, doxorubicin and the co-administration of artemisinin and doxorubicin 
on LVDP. Hearts underwent 20 minutes of stabilisation, 35 minutes of ischaemia and 120 minutes of 
reperfusion, during which the drugs were administered at the onset of reperfusion. Data is expressed as 
Mean±sem. **P<0.01 vs. I/R control, *P<0.05 vs. I/R, #P<0.05 vs. Dox, ##P<0.05 vs. Dox (n=4-8) 
6.3.3 Treatment using artemisinin and doxorubicin confers protection from I/R and 
against doxorubicin induced injury. 
Artemisinin (4.3µM) administered throughout reperfusion significantly decreased 
infarct size to risk ratio compared to the I/R control (38.0±2.5% vs. 55.8±1.7%, 
P<0.001, Figure 53). Doxorubicin administered at reperfusion significantly increased 
infarct size to risk ratio compared to the I/R control (71.3±3.2% vs. 55.8±1.7%, 
P<0.001, Figure 53) 
Co-administering artemisinin (4.3µM) with doxorubicin (1µM) significantly reversed 
doxorubin mediated increase in infarct size to risk ratio (%) (45.7±2.5% vs. 71.3±3.2%, 
P<0.001, Figure 53). 
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Figure 53. The effects of doxorubicin (1µM) in the presence/absence of artemisinin (4.3µM) administered at 
reperfusion in an isolated perfused heart model subjected to I/R. Results are shown as Mean±SEM. 
***P<0.001 vs. IR, ###P<0.001 vs. Art, #P<0.05 vs. Art, $$$P<0.001 vs. Dox. (n=3-8) 
 
To elucidate the mechanistic basis of artemisinin induced protection against the 
doxorubicin-induced cardiotoxicity earlier established in our ischaemia reperfusion studies, 
we also evaluated the effect of the nitric oxide cell survival pathway in cardiomyocytes 
subjected to H/R injury. 
6.3.4 Artemisinin reverses doxorubicin and H/R induced injury in isolated 
cardiomyocyte via the activation of the nitric oxide cell survival pathway.  
Cardiomyocytes previously isolated were subjected to 2 hours of hypoxia and 2 hours of 
reoxygenation and the drug treatments were administered throughout the reoxygenation 
period. 
Treating the isolated cardiomyocytes with artemisinin (4.3µM) upon reoxygenation 
significantly improved cellular viability compared to the H/R group (66.5±6.3% vs. 
29.3±6.1 % respectively, P<0.01, Figure 54). However, upon administering doxorubicin 
(1µM) during reoxygenation following hypoxia cellular viability was decreased by a further 
10% compared to H/R however this did not reach statistical significance (19.2±2.4% vs. 
29.3±6.1 % respectively, P>0.05, Figure 54).  
Co-administration of artemisinin (4.3µM) with doxorubicin (1µM) upon reoxygenation 
significantly reversed doxorubicin mediated cytotoxicity (48.2±4.8% vs. 19.2±2.4%, 
P<0.001, Figure 54).  
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However, to determine the role of nitric oxide signalling in artemisinin mediated 
cytoprotection against doxorubicin induced injury in cardiomyocytes, we co-administered 
the non-specific nitric oxide synthase inhibitor L-NAME (100µM) in combination with 
artemisinin (4.3µM) and doxorubicin (1µM).  Co-administering artemisinin (4.3µM) and 
doxorubicin (1µM) in the presence of L-NAME significantly increased viability compared 
to the artemisinin + doxorubicin group (72.0±0.7% vs. 48.2±4.8%, (P<0.01), Figure 54).  
Whereas comparing the results obtained from artemisinin + doxorubicin + L-NAME 
(100µM) group compared to doxorubicin alone (1µM) similarly showed significance 
(72.0±0.7% vs. 19.2±2.4%, P<0.001, Figure 54,). However, L-NAME (100µM) 
administered alone did not have an effect on myocyte viability compared to H/R control 
(47.0±7.1% vs. 29.3 ± 6.1% respectively, Figure 54). 
Upon treatment with the specific iNOS inhibitor aminoguanidine (100µM), results showed 
a significant increase in cardiomyocytes viability compared to H/R control (46.4 ± 6.4 % 
vs. 29.3±6.1% respectively, P<0.05, Figure 54).  
Interestingly, aminoguanidine (100µM) when administered in combination with artemisinin 
(4.3µM) and doxorubicin (1µM) during reoxygenation also showed a significant 
improvement in viability compared to doxorubicin treatment alone (43.5±7.1% vs. 
19.2±2.4%, P<0.01, Figure 54). However, the combination of aminoguanidine (100µM), 
artemisinin (4.3µM) and doxorubicin (1µM) compared to artemisinin (4.3µM) alone was 
found not to be significant (43.5±7.1% vs. 48.1± 4.8%, Figure 54). 
 
 
Figure 54: MTT reductase activity used in assessing cellular viability in isolated ventricular cardiomyocytes 
subjected to two hours of hypoxia and two hours of reoxygenation. Dox (1µM) was administered in the 
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presence/absence of Art, L-NAME (100µM) and aminoguanidine (100µM). ### P<0.001 vs. Norm, 
**P<0.01 vs. HR, *P<0.05 vs. Art, ***P<0.001 vs. Dox, **P<0.05 vs. L-NAME, ##P<0.01 vs. Dox+Art 
(n=3-8) (D+A+L=Dox+Art+L-NAME and D+A+Ag= Dox+Art+Ag) (n=3-6) 
 
Results obtained from the myocyte cell viability assay, were used to evaluate the 
involvement of nitric oxide pathway in doxorubicin mediated cytotoxicity. Doxorubicin 
(1µM) was administerd in the presence of non selective NOS synthase inhibitor L-NAME 
or the selective iNOS inhibitor aminoguanidine.  
 
Results showed doxorubicin (1µM) administered in the presence of L-NAME (100µM) had 
no significant effect on cellular viability compared to H/R (25.7±8.25 vs. 29.3±6.8% 
respectively, Figure 55). Similarly, doxorubicin (1µM) administered with L-NAME 
(100µM) compared to L-NAME was also not significant (25.7±8.25% vs. 47.0±7.1% 
respectively, Figure 55). 
 
Cardiomyocytes were treated with doxorubicin (1µM) were also investigated in the 
presence of the iNOS inhibitor aminoguanidine (100µM) which showed no significant 
difference in cellular viability compared to aminoguanidine (100µM) treatment alone 
(45.7±8.1% vs. 50.1±7.4%, Figure 55). Cells treated with doxorubicin (1µM) and 
aminoguanidine (100µM) significantly reversed doxorubicin mediated decrease in cellular 
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Figure 55. The effects of doxorubicin and inhibition of the nitric oxide pathway on cellular viability in 
cardiomyocytes. Doxorubicin (1µM) was administered alone in the presence and absence of L-NAME 
(100µM) or aminoguanidine (100µM). ## P<0.001 vs. Norm, **P<0.01 vs. Dox, *P<0.05 vs. HR. (n=3-6). 
6.3.5 Artemisinin reverses doxorubicin mediated increases in cleaved-caspase-3  
We assessed the levels of cleaved caspase-3 activity via flow cytometric analysis in isolated 
cardiomyocytes subjected to 2 hours of hypoxia and 2 hours of reoxygenation. Drug 
treatments were administered throughout reoxygenation as follows: artemisinin (4.3µM) 
alone, doxorubicin (1µM) treatment alone, artemisinin (4.3µM) ± doxorubicin (1µM), 
artemisinin (4.3µM) ± doxorubicin (1µM) ± L-NAME (100µM), artemisinin (4.3µM) ± 
doxorubicin (1µM) ± aminoguanidine (100µM). 
By administering artemisinin (4.3µM) during reoxygenation, there was a significant 
decrease in cleaved caspase-3 activity compared to the H/R group (17.1±2.0% vs. 
26.8±2.0% respectively, P<0.05, Figure 56). However, treatment with doxorubicin alone 
(1µM) significantly increased the levels of cleaved caspase 3 compared to H/R (48.0±2.15% 
vs. 26.8±2.0% respectively, P<0.001, Figure 56).  
Co-administration of artemisinin (4.3µM) with doxorubicin (1µM) however significantly 
reversed the increase in cleaved caspase 3 activity observed in the doxorubicin treated group 
(24.0±2.5% vs. 48.0±2.15%, P<0.001, Figure 56).  
Whereas by administering the combination of artemisinin (4.3µM) with doxorubicin (1µM) 
in the presence of the inhibitor of NOS, L-NAME (100µM), the results showed a reversal 
in the anti-caspase 3 activity of artemisinin, shown as an increase in cleaved caspase-3 levels 
compared to artemisinin treatment alone (33.0±1.4% vs. 17.14±2.0%, P<0.01, Figure 56). 
The combined treatment with artemisinin (4.3µM) with doxorubicin (1µM) in the presence 
of the inhibitor of NOS, L-NAME (100µM) compared to doxorubicin alone a showed 
significant decrease (33.0±1.4% vs. 48.0±2.15%, P<0.001, Figure 56). 
Co-treating with a combination of artemisinin (4.3µM) with doxorubicin (1µM) in the 
presence of aminoguanidine (100µM) compared to artemisinin reversed the effect (4.3µM) 
(30.7 ± 1.1 % vs. 17.1 ± 2.0 %, P<0.01, Figure 56). Treatment with L-NAME showed, L-
NAME had no significant effect compared to H/R control (29.9±0.7% vs. 26.8±2.0%, 
P>0.05, Figure 56). No significant effect was observed with aminoguanidine administered 
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alone throughout reoxygenation too compared to H/R control (28.0±2.1 vs.  26.8±2.0%, 
P>0.05, Figure 56). 
 
Figure 56. Effect of administering doxorubicin (Dox) (1µM), artemisinin (Art) (4.3µM), both drugs 
combined and in the presence and absence of L-NAME (100µM) and aminoguanidine (Amg) (100µM) on 
cleaved caspase-3 activity in isolated adult rat cardiomyocytes after two hours of hypoxia followed by two 
hours of reoxygenation (HR) as analysed using Flow Cytometry. Results are shown as Mean±SEM. 
***P<0.001 vs. Norm, *P<0.05 vs. HR, ***P<0.001 vs. HR, ^^^P<0.001 vs. Dox, **P<0.01 vs. Art (n=4-
6). (D+A+L=Dox+Art+L-NAME) and (D+A+Ag=Dox+Art+Aminoguanidine). 
6.3.6 Effect of cleaved caspase-3 in isolated cardiomyocytes treated with doxorubicin 
alone and their involvement with nitric oxide pathway. 
As described in section 6.3.6 doxorubicin (1µM) administration significantly increased 
cleaved caspase 3 activity compared to non-treated H/R control (48.0±2.15% vs. 26.8±2.0% 
respectively, P<0.001, Figure 56). We therefore further analysed the involvement of 
doxorubicin in nitric oxide signalling in relation to their effect on cleaved caspase-3 activity 
in isolated adult cardiomyocytes. Doxorubicin (1µM) administered with L-NAME (100µM) 
showed no significant difference compared to doxorubicin alone (34.3±8.7% vs. 48±2.1%, 
Figure 57). L-NAME alone partially reversed the combined effect of doxorubicin (1µM) 
with L-NAME (100µM) but did not reach significance (29.9±0.7% vs. 34.3±8.7%, Figure 
57) and neither did it have an effect on cleaved caspase-3 activity (29.9±0.7% vs. 
26.8±2.0%, Figure 57).  
Co-treating the cardiomyocytes with doxorubicin (1µM) and aminoguanidine (100µM) was 
partialy reversed by aminoguanidine (100µM) but did not reach significance (36.7 ± 5.2 % 
vs 28.0 ± 2.1 %, Figure 57).  






























Figure 57. Effect of doxorubicin (Dox) (1µM), artemisinin (Art) (4.3µM), both drugs combined and in the 
presence and absence of L-NAME (100µM) and aminoguanidine (Ag) (100µM) on cleaved caspase-3 
activity in isolated adult rat cardiomyocytes after two hours of hypoxia followed by two hours of 
reoxygenation (HR) as analysed using Flow Cytometry. Results are shown as MEAN±SEM. ###P<0.001 vs. 
Norm, ***P<0.001 vs. HR. (n=4-6). 
 
6.3.7 Co-treatment with artemisinin (4.3µM) and doxorubicin (1µM) against 
doxorubicin (1µM) induced cytotoxicity in isolated cardiomyocytes shows 
involvement of eNOS (Ser 1177) as analysed using FACS analysis.  
Isolated ventricular cardiomyocytes were subjected to 2 hours hypoxia and 2 hours 
reoxygenation with artemisinin (4.3µM) treatment to determine the levels of p-eNOS 
expression using FACS analysis. Untreated cardiomyocytes subjected to H/R showed a 
decrease in the expression of p-eNOS compared to the untreated normoxic control 
(46.3±2.0% vs. 100.0±0%, P<0.001, Figure 58a). Upon treating the cardiomyocytes 
with artemisinin, a significant (P<0.001) increase in the level of p-eNOS compared H/R 
control was observed (156.3± 31.0% vs. 46.3±2.0% respectively, Figure 58a). Also 
administering artemisinin (4.3µM) significantlly (P<0.001) increased the level of p-
eNOS compared H/R control (156.3± 31.0% vs. 46.3±2.0% respectively, P<0.001, 
Figure 58a). 
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Administration of doxorubicin (1µM) with artemisinin (4.3µM), significantly increased 
levels of eNOS (Ser 1177) compared to doxorubicin treatment alone (223.0±11.35% vs. 
63.5±7.2%, P<0.001, Figure 58a).  
Treatment with artemisinin (4.3µM), doxorubicin (1µm) and a non-selective inhibitor 
of NOS, L-NAME (100µM), upon reoxygenation showed a significant decrease 
compared to L-NAME treated cardiomyocytes (149.7±23.2% vs. 51.0±10.6%, 
P<0.001, Figure 58a). Administering artemisinin (4.3µM), doxorubicin (1µm) and a 
non-selective inhibitor of NOS, L-NAME (100µM) showed a partial decrease in eNOS 
(Ser 1177) expression levels compared to artemisinin (4.3µM) and doxorubicin (1µm) but 
this did not reach statistical significance (149.7±23.2% vs 223.0±11.35% respectively, 
P>0.05, Figure 58a).L-NAME alone decreased expression of compared to H/R although 
it did not reach statistical significance (51.0±10.6% vs. 46.3±2.0%, Figure 58a).  
Isolated cardiomyocytes treated with artemisinin (4.3µM), doxorubicin (1µm) and a 
non-selective inhibitor of NOS, L-NAME (100µM) showed a significant increase in 
eNOS(Ser 1177) expression levels compared to untreated H/R control (149.7±23.2% vs. 
46.3±2.0% respectively, P<0.01, Figure 58a). 
The combination of doxorubicin and artemisinin treated cardiomyocytes expressed a 
partial increase in the expression of eNOS(Ser 1177) which did not reach statistical 
significance compared to artemisinin treatment (223.0±11.35% vs. 156.3±31.0% 
respectively, P>0.05, Figure 58a).  
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Figure 58a. Effect of administering doxorubicin (Dox) (1µM) and artemisinin (Art) (4.3µM) throughout 
reoxygenation in the presence and absence of L-NAME (100µM) on eNOS (Ser 1171), expressions as 
analysed using Flow Cytometry. ***P<0.001 vs. Normoxia (Norm), **P<0.01 vs. HR, ###P<0.001 vs. Dox, 
##P<0.01 vs. L-NAME (n=4-6) (D+A+L=Dox+Art+L-NAME).  
6.3.8 Effect on p-eNOS expression in cardiomyocytes subjected to H/R injury 
followed by doxorubicin treatment in the presence/absence of NOS inhibitor L-
NAME 
 
p-eNOS expression was significantly down regulated in the H/R group compared to 
normoxic control (46.3±2.0% vs 100.0±0%, P<0.001 respectively, Figure 58c). 
Administration of Doxorubicin (1uM) throughout reoxygenation had no significant effect 
on p-eNOS expression compared with H/R control group (63.5 ± 11.5% vs. 46.3±2.0%, 
P>0.05, Figure 58c).  
 
Co-administration of doxorubicin (1µM) with L-NAME (100µM), also expressed similar 
levels of p-eNOS (Ser 1177) compared to doxorubicin alone when analysed using FACS 
analysis (63.3±15.2% vs. 63.5 ± 11.5%, P>0.05, Figure 58b). L-NAME (100µM), alone 
showed no significance in p-eNOS expression compared to H/R control (51.0±10.6% vs. 
46.3±2.0%, P>0.05, respectively, Figure 58b). 
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Figure 58b. Effect of administering doxorubicin (1µM) throughout reoxygenation in the presence and 
absence of L-NAME (100µM) on eNOS expressions as analysed using Flow Cytometry. ***P<0.001 vs. 
Normoxia (Norm) (n=4-6). 
 
6.3.9 Doxorubicin used in combination with artemisinin in isolated cardiomyocytes 
subjected to H/R show elevation in iNOS expression with artemisinin and 
combination treatment. 
Treatment with artemisinin (4.3µM) led to a significant increase in iNOS expression 
compared to H/R control (150.5±14.4% vs. 69.9±7.2%, respectively, P<0.01, Figure 
59a). An increase in iNOS was also observed from using doxorubicin (1µM) and 
artemisinin (4.3µM) combined compared to H/R group (108.6±12.0% vs. 69.9±7.2%, 
P<0.01, respectively, Figure 59a). 
 
6.3.10 Effect of iNOS expression upon treatment with a combination of doxorubicin 
and artemisinin in isolated cardiomyoctes subjected to HR in the 
presence/absence of L-NAME and aminoguanidine. 
Adjunctive treatment with L-NAME showed significant upregulation in iNOS 
expression compared to L-NAME (83.6±7.4% vs 69.9±7.2%, P<0.05, Figure 59a). 
Treatment with doxorubicin (1µM) and artemisinin (4.3µM) and aminoguanidine 
(100µM) compared to doxorubin and artemisinin alone showed a significance decrease 
(76±5.4% vs. 108±12.0%, P<0.01, Figure 59a). 
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Figure 59a. Effect of doxorubicin (1µM) and artemisinin (Art) (4.3µM) on iNOS expression in the presence 
and absence of L-NAME (100µM) and aminoguanidine (Ag) (100µM) analysed using FACS analysis. 
*P<0.05 vs. Normoxia (Norm), **P<0.01 vs. HR, ##P<0.01 vs. Dox, $P<0.05 vs.L-NAME, #P<0.05 vs. 
Dox+Art. Data expressed as mean± SEM (n=4-6). 
 
6.3.11 Effect of iNOS expression in cardiomyocytes subjected to H/R followed by 
treatment with doxorubicin at reoxygenation in the presence/absence of L-
NAME or aminoguanidine. 
We also looked into the effect of doxorubicin on the nitric oxide pathway where we 
administered inhibitor L-NAME and aminoguanidine, as in the adjunctive treatment 
Treatment with doxorubicin (1µM) alone compared to H/R showed a partial decrease in 
iNOS expression but this did not reach significance (54.4±6.9% vs. 69.9±7.2%, P>0.05, 
Figure 59b). Co-treatment of doxorubicin (1µM) with inhibitor L-NAME (100µM) also 
showed no significant effect compared to doxorubicin alone (1µM) (68.2±9.8% vs. 
54.4±6.3%, Figure 59b); neither did aminoguanidine treatment (67.5±4.9% vs. 54.4±6.3%, 
Figure 59b). 
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Figure 59b. Effect of doxorubicin (1µM) on iNOS expression in the presence and absence of L-NAME 
(100µM) and Aminoguanidine (Ag) (100µM) analysed using FACS analysis. *P<0.05 vs. Normoxia (Norm) 
(n=4-6) 
 
6.3.12 Involvement of nitric oxide in doxorubicin induced cytotoxicity in HL-60 cells 
and attenuation it’s via artemisinin administration. 
In chapter 3, we established that artemisinin (0.4mM) possesses cytotoxic properties against 
HL-60 cells. In order to investigate the effect of co-administering artemisinin (0.4mM) and 
doxorubicin (1µM) in HL-60 cells, we used MTT analysis and compared the drug treatment 
groups to the control. Both artemisinin and doxorubicin administered alone were 
significantly cytotoxic against HL-60 cells, with artemisinin showing (58.6±2.0% vs. 
100±0%, P<0.001) and doxorubicin (43.2±8.6% vs. 100%±0%, P<0.001, Figure 60) 
compared to control. Co-treatment with artemisinin (0.4mM) nearly doubled doxorubicin’s 
(1µM) anti-cancer properties (28.2±3.6% vs. 43.2±8.6%, P<0.001, Figure 60). We further 
used the non-selective inhibitor of nitric oxide L-NAME (100µM) against HL-60 cells: L-
NAME (100µM) alone did not cause any effect compared to control (97.7±4.7% vs. 
100±0%). Using L-NAME (100µM) together with a combination of artemisinin (0.4mM) 
and doxorubicin (1µM) significantly (P<0.05) increased cytoxicity compared to artemisinin 
(71.7±6.1% vs. 58.6±2.0%) or (71.7±6.1% vs. 43.2±8.6%, P<0.05) compared to 
doxorubicin treatment. L-NAME blocked the observed effect of artemisinin, co-treated with 
doxorubicin and L-NAME (71.7±6.1% vs. 97.7±6.6%, P<0.05, Figure 60). Comparing 
doxorubicin and artemisinin treated HL-60 to L-NAME also showed significance (28.2 
±3.6% vs 97.7±6.6%, P<0.001, Figure 60) 
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6.3.13 Effect of adjunctive treatment with inhibitors (L-NAME and aminoguanidine) 
in HL-60 cells analysed using MTT reductase activity. 
 
Figure 60. The effects of artemisinin (0.4mM), doxorubicin (1µM), L-NAME (100µM) and various 
combinations of the three drugs on the cytotoxicity of HL-60 cancer cells. ***P<0.001 vs. control, #P<0.05 
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  MTT   iNOS   eNOS   Caspase-3   HL-60   
Norm 
100 ± 
0 %   100 ± 0 %   100 ± 0 %   8.8 ± 1.2 %   
100 ± 
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% 
 NS vs. 
H/R 
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8.6 % *** vs. Norm 









































* vs. Dox/Art 
L-NAME 
47 ± 
7.1 %  NS vs H/R 
72.8 ± 
14.0 % 
 NS vs. 
H/R 
51.0 ± 10.6 
% 
 NS vs. 
H/R 
29.9 ± 0.7 
% 
 * vs. 
H/R 
97.7 ± 
6.6 % NS vs. H/R 
Dox+Art+Amg 
43.5 ± 
7.1 % ** vs. Dox 
76.1 ± 5.4 
% 
 ** vs. 
Dox+Art     
30.7 ± 1.1 
% 
** vs. 
Art     
Amg 
46.4 ± 
6.4 % * vs H/R 
73.3  ± 
8.0 % 
 NS vs. 
H/R     
28.0 ± 2.1 
% 
 NS vs. 
H/R     
Art + L-NAME 
48.1 ± 
5.5 % * vs. Art 
71.5 ± 5.8 
% 
** vs. 
Art 59.6±8.1%  
** vs. 
Art 











 NS vs. 
H/R 
70.0 ± 8.7 
% 
 NS vs. 
Dox 
63.3 ± 15.2 
% 
 NS vs. 
Dox 
34.3 ± 8.7 
% 









6.3 % ** vs. H/R 
67.5 ± 4.9 
% 
 ** vs 
H/R     
36.7 ± 5.2 
% 
 *** vs. 
Art     
Table 5. Summary table showing the effect of adjunctive treatment with inhibitors (L-NAME and aminoguanidine) in cardiomyocytes and in HL-60 cells analysed 
using MTT reductase activity, FACS analysis and caspase 3 assay. *P<0.05, **P<0.01 and ***P<0.001. Results are expressed as MEAN±SEM
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6.4 DISCUSSION 
Despite the advances in chemotherapy, presently administered anticancer therapies are not 
without their complications (Volkova and Rusell 2011). One of the most common 
therapeutic anticancer agent is the anthracyclines, with doxorubicin being the most effective 
and frequently administered anthracycline (Rahman et al., 2007). The effect of doxorubicin 
that has been observed clinically and is not limited to tumour cells only; this is because 
doxorubicin’s efficacy in treating cancer is limited by its cumulative dose-dependent 
cardiotoxicity (Volkova and Rusell 2011). 
Deleterious effects of doxorubicin were also observed from our haemodynamic effects, 
where doxorubicin significantly decreased LVDP during reperfusion in isolated hearts. Our 
findings are in concordance with previous studies that have also associated the drop in LVDP 
with administering doxorubicin (Cai et al., 2010; Ramond et al., 2008; Gharanei et al., 
2014). Concurrent administration of artemisinin at reperfusion significantly reversed the 
myocardial changes in terms of both haemodynamics (LVDP) and the cellular changes 
induced by doxorubicin treatment.  
Doxorubicin has been shown to affect various tissues/cells other than the targeted tumour 
cells, which may lead to serious consequences to the healthy tissues in other organs. Some 
of the documented effects vary from bone marrow toxicity, which causes cells to rapidly 
divide, to more serious cellular apoptosis/necrosis (Minotti et al., 2004). Cardiac myocytes, 
when affected by doxorubicin toxicity, can lead to serious consequences due to their limited 
capacity to regenerate (Minotti et al., 2004). Cardiac apoptosis induced by doxorubicin has 
been related to the production of excessive reactive oxygen species by the mitochondrial 
NADPH dehydrogenase (Gilleron et al., 2009). Doxorubicin treatment of HL-60 has been 
observed to trigger increases in caspase-3-like activity, which is a common feature of 
apoptosis (Crespo-Ortiz and Wei 2012; Childs et al., 2002). 
Doxorubicin induced cardiotoxicity has been linked to an increase in cleaved caspase-3 
activity as shown in our study as well as in previous studies (Khan et al., 2006). In addition 
to this, Khan et al. (2006) also showed an increase in the expression of Bax protein and the 
release of cytochrome c which are known to mediate cell death. This supports our findings 
P a g e  | 190 
of infarct size increasing with doxorubicin treatment and increase in activated caspase-3, 
which is a known marker for apoptosis. Doxorubicin’s cytotoxicity has been associated with 
the generation of free radicals, which cause lipid peroxidation, mainly in the cell membrane, 
leading to cell damage (Banfi et al., 1992; Fukuda et al., 1992). Our results show that 
doxorubicin induces more cardiotoxicity in isolated perfused rat hearts subjected to I/R 
compared to control and to H/R, which we suggest is via the manifestation of oxidative 
stress caused by the generation of free radicals. Gilleron et al. (2009) showed that 
doxorubicin administration was accompanied by increased superoxide production through 
NADPH oxidase activation in rat cardiomyoblasts. Inhibiting these enzymes leads to a 
reduction in doxorubicin-induced reactive oxygen species production and caspase-3 like 
activity (Gilleron et al., 2009).  
Doxorubicin treatment also greatly decreased cellular viability in the cardiomyocyte 
subjected to H/R injury. Mitochondria also plays a central role in the cardiotoxic effect of 
doxorubicin by regulating the implicating cytochrome c, Bax, caspase-3 and so on. Gharanei 
et al. (2014) also showed doxorubicin induced cardiotoxicity affcets mitochondrial activity 
and integrity which leads to mitochondrial dysfunction and eventually death. This was 
suggested to be as a result of the accumulation of ROS and calcium overload which leads 
to oxidative stress, causes a depletion in ATP, mitochondrial dysfunction (as a result of 
change in mitochondrial permeability), cellular necrosis and initiation of apoptosis 
(Halestrap et al., 2004; Hausenloy et al., 2002, Minotti et al., 2004). Minotti et al. (2004) 
have shown that off-target effects of doxorubicin treatment can manifest into serious 
cardiovascular complications; however, the mechanisms of action still remain unknown, 
although they have been found to be multifactorial. Gharanei et al., (2014) have identified 
one of the potential ways of attenuating doxorubicin-induced cardiotoxicity is by the inhibition 
of the mPTP which is a novel adjunctive therapy route to reducing the manifestations of 
doxorubicin-induced cardiotoxicity. We postulate that the use of an adjunctive drug regimen 
may be effective in reversing the doxorubicin induced cardiac toxicity in the isolated 
perfused heart as well as well as in cardiomyocytes. The effects of using the adjunctive 
therapy treatment will then be tested in a cancer cell line in order to investigate the effect of the 
co-treatment on anti-cancer properties of doxorubicin. 
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Previous research similarly administered C-phycocyanin, which protects against I/R injury 
and ameliorates doxorubicin induced oxidative stress and apoptosis in rat cardiomyoctes 
(Khan et al., 2006). Doxorubicin has been shown to induce DNA fragmentation, apoptosis, 
increase Bax expression, increase cytochrome c and also increase caspase-3 activity. The 
aforementioned deleterious effects were markedly attenuated by C-phycocyanin which was 
shown to ameliorate I/R induced cardiac dysfunction through its antioxidant and 
antiapoptotic actions and also via the modulation of p38 MAPK and ERK1/2 (Khan et al., 
2006) 
With the aim of reducing the known cardiotoxic effect of doxorubicin, this study used 
artemisinin as an adjuvant therapy. It is imperative to assess the effects in previous settings 
such as isolated perfused hearts, isolated cardiomyocytes subjected to I/R or H/R injury and 
also in cell viability/caspase-3 assays. The effects of adjunctive therapy in a cancer line were 
also established in order to investigate whether co-treatment with artemisinin will affect the 
cytotoxicity of doxorubicin against cancer cells. This study further supports the crucial role 
of artemisinin as a cardioprotective agent and its potential against doxorubicin induced 
cardiotoxicity. 
With recent medical interventions and research development, cancer patients are able to 
survive much longer but with higher chances of developing or exacerbating other pre-
existing conditions most popularly, cardiomyopathies (Civelleri et al., 2000). Previous 
studies as well as previous chapters have shown doxorubicin exacerbates I/R injury in both 
naïve and stressed hearts. By administering artemisinin, it was therefore necessary to 
investigate the off target effects of the potential adjuvant therapy both in naïve and diseased 
conditions (simulated reperfusion injury). 
In our previous chapters, we have established that artemisinin’s mediated cardioprotective 
effects is via the nitric oxide cell survival pathway. We therefore investigated whether 
artemisinin’s protection against doxorubicin-induced toxicity is via the same pathway 
described earlier. Artemisinin has been shown to structurally possess an endoperoxide 
bridge and in antimalarial treatment, the endoperoxide bridge has been shown to play a key 
role in the inihibition of the parasite (Wang et al., 2010). A study by Wang et al. (2010) 
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showed the accompanied dysregulation in the malarial mitochondria was responsible for 
impairing functions which was usually followed by a rapid burst in ROS levels. Rapid short 
burst of ROS are not necessarily deleterious, in a different setting of I/R injury, short burst 
of ROS generated from preconditioning (short cycles of ischaemia/reperfusion prior to the 
onset of ischaemia) has been shown to decrease infarction and resulted in an upregulation 
of potentially protective proteins in different modes including rats and pigs (Heusch et al., 
2008). 
This chapter, however, the focus aim was to establish the effect of artemisinin in 
doxorubicin-induced cardiotoxicity via infarct analysis, their combined effect in cellular 
viability assays and in activated caspase-3 levels in cardiomyocytes, furthermore we it 
investigated the cell signalling pathway involved in the observed effect in the 
cardiomyocytes as well as upon co-administering artemisinin and doxorubicin in on HL-60 
cells using MTT assay. 
In the isolated perfused hearts, doxorubicin decreased haemodynamic functions and 
increased infarct to risk ratio in I/R tissue as shown in Figure 52. By administering 
artemisinin at reperfusion, artemisinin reverses this effect. Artemisinin has a dose dependent 
decrease in I/R and improves viability in the MTT assay. Our results also show an increase 
in nitric oxide synthesis via eNOS and iNOS synthesis with co-treatment using artemisinin 
and doxorubicin in cardiomyocytes. 
Our results showed an increase in p-eNOS expression with adjunctive treatment. This data 
suggests that nitric oxide may be upregulated via the eNOS pathway with administering 
adjunctive treatment of artemisinin and doxorubicin. Upregulation in eNOS expression has 
been associated with cardioprotection in rat models of I/R injury (Felaco et al., 2000). p-
eNOS was downregulated by co-treating the cardiomyocytes with doxorubicin, artemisinin 
and the non selective inhibitor, L-NAME resulting in a decrease in eNOS expression. This 
effect was implicated with adjunctive treatment as treating the cells with doxorubicin or L-
NAME alone showed a down-regulation of eNOS expression. Previous studies have shown 
L-NAME decreases eNOS activity in several models including I/R models in rats, memory 
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models using rats and several cancer models (Boultadakis and Pitsikas 2010; Hussain et al., 
2013; Johansson et al., 1998; Klamer et al., 2001) 
Artemisinin has previously been been identified in telemore protection study using Swiss 
mice as an inhibitor of NOS and an inducer of nitric oxide (Zeng and Zhang, 2011; Zeng et 
al., 2011). This supports our findings that artemisinin mediates protection via NO cell 
signalling pathway.  Pharmacokinetic research has also shown that at concentrations of 
50µM, artesunate (a derivative of artemisinin) simulated NOS induction and nitric oxide 
production in hepatoma cell line (Zeng and Zhang 2011). Concentrations above 100µM 
however, led to abrogation of nitric oxide generation (Zeng and Zhang 2011). In other 
studies however, artesunate was shown to inhibit nitric oxide synthesis in bacterial 
proliferation studies (Zeng et al., 2011). In the present study, adjunctive treatment with 
doxorubicin and artemisinin implicated the nitric oxide pathway which was shown to be 
independent of doxorubicin treatment in our study. Interestingly, a study using human colon 
cancer HT29 cells showed NOS induction increases doxorubicin efficacy using simvastatin 
(sodha et al., 2008). 
However, another study using bovine aortic endothelial cells, contradicted our findings by 
by showing that doxorubicin-induced apoptosis is linked to the redox activation of 
doxorubicin by eNOS (Kalivendi et al., 2009). Kalivendi et al. (2009), however, explained 
that the cardiovascular toxicity of doxorubicin was solely attributed to the enzymatic switch 
in the activity of eNOS to a superoxide generating enzyme (i.e. NADPH oxidase activity). 
Vasquez-vivar et al. (1997) explained that this phenomenon of eNOS upregulation by 
doxorubicin (5µM) is a result of the reduction of doxorubicin reductase domain of eNOS 
observed to generate peroxynitrite and hydrogen peroxide, both potent oxidants that are 
implicated in several vascular pathologies.  
Research has shown a difference in the nitric oxide generated in non-
preconditioned/unstressed myocardium compared to nitric oxide in preconditioned 
myocardium, which explains the phenomenon whereby the heart displays a defensive 
phenotype in response to stress conditions (Bolli 2001). We also believe that there is a 
difference in the nitric oxide generation in artemisinin’s cardioprotection and its 
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cytotoxicity. Bolli (2001) explained that eNOS has a well-established and immediate 
cytoprotective function, which is, however, short term, while iNOS has a delayed but long 
term defence function, which distinguishes protection in the unstressed/non-preconditioned 
myocardium and the late preconditioned myocardium. Our findings showing cytoprotection 
implicated the upregulation of iNOS expressions with adjunctive treatment. This was 
supported by Smart et al. who similarly showed pre-treating cardiomyocytes with 
interleukin-6 (IL-6) was cardioprotective via the PI-3 kinase and NO-dependent pathway of 
cytoprotection through the upregulation of iNOS (Smart et al., 2006). 
In our studies, we assessed the cardiomyocytes for p-eNOS expression, where a non 
selective nitric oxide inhibitor L-NAME was administered in the study results showed an 
upregulation of over 4 fold increase in p-eNOS levels with adjunctive treatment compared 
to H/R control. Upregulation in eNOS expression as previously described is well established 
in cytoprotective agents (Bolli 2001). However, we also observed an increase in iNOS 
expression using combined drug treatment, with a nearly 2 fold increase compared to H/R 
control, administering aminoguanidine (a selective iNOS inhibitor aborageted the observed 
effect suggesting involvement of iNOS. Despite iNOS reported to have detrimental effects 
with iNOS knock out mice (mice were of C57BL/6 strain bred into the B6C3 background) 
shown to exhibit mitochondrial damage such as cytoplasmic swelling and degeneration of 
the mitochondria when compared to wildtype mice (Cole et al., 2006, Kang et al., 1997). 
Studies have also reported slight increase in nitric oxide to show protection in adriamycin 
induced cardiotoxicity where adriamycin was shown to induce cardiac injury via the 
generation of superoxide (Cole et al., 2006, Pacher et al., 2003). In the study by Cole et al. 
(2006), structural improvements to the mitochondria as well as improvements in cardiac 
function and decrease in biochemical injury markers such as cardiac troponin, creatine 
phosphokinase, and lactate dehydrogenase in transgenic manganese superoxide dismutase 
(MnSOD) overexpressing animals crossed with iNOS null mic were observed.  This 
suggested that nitric oxide produced by iNOS may contribute to protection of normal tissue 
by adriamycin induced injury in vivo which further suggests a slight increase in iNOS 
expression upon administering artemisinin and doxorubicin against doxorubicin induced 
injury is protective. Cole et al. (2006) further suggested that reduction in nitric oxide levels 
mediated by adriamycin treatment has led to an increase in cardiac mitochondrial injury can 
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be attenuated by a compensatory increase in MnSOD which supports increase in iNOS 
expression levels.  
Furthermore studies using artemisinin have shown an upregulation in iNOS expression in 
the treatment for allergic asthma (Ho et al., 2012). Majority of studies reviewed by Bolli 
(2001) also examined the role of nitric oxide in vivo and in vitro and concluded that both 
endogenous and exogenous nitric oxide have a protective role, with a small minority 
reporting a detrimental effect suggesting a ying-yang effect with nitric oxide upregulation 
(Palcher et al., 2007; Bolli 2001). Upregulation of nitric oxide synthesis has been associated 
with a cytoprotective function in the heart, especially in preconditioning, where the heart 
attempts to protects itself (Bolli, 2007). 
 
In the present study, we were able to show that artemisinin has the ability to salvage 
cardiomyocytes damaged as a result of H/R followed by doxorubicin treatment. The 
observed protection was linked with the nitric oxide-dependent pathway of protection, seen 
as an increase in iNOS and eNOS in isolated ventricular myocytes. Gene transfer of eNOS 
and iNOS have been shown to present infarct-sparing actions in ischaemic preconditioning 
models, thus implicating both in the protection of the heart against ischaemia/reperfusion 
injury (Bolli 2001).  
Studies have postulated several different molecular mechanisms responsible for 
anthracycline induced cardiomyopathy, cardiotoxicity is mainly associated to redox 
recycling, ROS generation, a disturbance of Ca2+ homeostasis, altering nucleic acid by 
intercalation into DNA and modulate intracellular signalling, which may lead to disruption 
in homeostatic process, development of sacropenia or even cell death (Kim et al., 2006; 
Zhang et al., 2012; Geisberg and Sawyer 2010; Chen et al., 2007).  Despite over four 
decades of investigating anthracylines, the pathogenic mechanisms responsible for their 
cardiotoxicity has not been completely elucidated (Gianni et al., 2008). Anthracyclines 
structurally consist of a tetracyclic aglycone linked with an amino sugar. The quinone 
moiety of anthracycline could serve as an electron acceptor, which contributes to the 
production of ROS (Vejpongsa and Yeh, 2013). In studies using HL-60 cell lines, 
artemisinin has been shown to induce damage via the generation of ROS, which was found 
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to activate apoptosis (Michaelis et al., 2010). Doxorubicin induced free radical generation 
can interact with oxygen to form superoxide hydroxyl radicals which can lead to DNA 
damage (Eliot et al., 1984; Benchekroun et al., 1993). 
Our results showed artemisinin significantly improved cellular viability in cardiomyocytes, 
protected the myocardium against doxorubicin-induced cardiac injury and exacerbated 
doxorubicin’s cytotoxicity against HL-60 cells. Previous research by Efferth et al. (2007) 
showed that artesunate (an artemisinin derivative) improved efficacy of doxorubicin against 
tumour cells, with the synergistic effect largely explained by the fact that artesunate and 
doxorubicin use different killing mechanisms. Doxorubicin has also been shown to 
stimulate nitric oxide production in Ehrlich ascites carcinoma (EAC) cells as well as in 
murine breast cancer cell line (Sayed-Ahmad et al., 2001; Bani et al., 1995). These studies 
proposed nitric oxide may contribute to doxorubicin’s antitumour activity in the two cell 
lines they have tested. Sayed-Ahmad et al. (2001) showed treatment with L-NAME or 
aminoguanidine (both inhibitors of nitric oxide) significantly decreased doxorubicin 
induced nitric oxide production and attenuated the effect on tumour cells (Sayed-Ahmad et 
al., 2001). Furthermore, research by Haywood et al., (1996) and Vejlstrup et al.,(1998) 
showed that the high levels of nitric oxide was as a result of the inducible nitric oxide 
generated however, Sayed-Ahmad et al., (2001) in their study suggested the increased in 
nitric oxide is as a result of eNOS transcription in the EAC cells as shown in our results.  
Artemisinin induces apoptosis in leukemic T cells mainly through the intrinsic 
mitochondrial pathway via generation of reactive oxygen species (ROS) while doxorubicin 
kills cancer cells via DNA intercalation (Efferth et al., 2007). In our results we observed 
adjunctive treatment with doxorubicin and artemisinin reversed the increase in caspase-3 
activity with doxorubicin treatement. Treatment with doxorubicin alone increased the level 
of caspase-3 activity compared to control. This was similarly observed in previous studies 
investigating the apoptotic sensitivities of neonatal and adult mouse hearts. Doxorubicin 
was shown to induce myocardial apoptosis in both neonatal and adult cardiomyocytes with 
a dose dependent cardiotoxicity that was shown to be caspase dependent (Shi et al., 2012).  
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In our studies using HL-60 cells, artemisinin was shown to be cytotoxic against HL-60 cells 
with its observed cytotoxicity implicating the nitric oxide pathway as shown in our MTT 
assay where treatment with artemisinin showed an effect that was reversed by the non 
selective NOS inhibitor, L-NAME. 
This suggests that artemisinin in cardiomyocytes and in HL-60 cancer cells implicates the 
nitric oxide pathway in different ways. In our HL-60 assay, treatment with aminoguanidine 
was shown to have an effect on cytotoxicity thus did not inhibit nitric oxide expression in 
our study. Previous studies have reported hydroxyguanidine, thiosemicarbazide, and 
substituted benzohydroxamic acid all express promising antitumor activities by inhibiting 
DNA synthesis as a consequence of inhibiting ribonucleotide reductase (Saiho et al., 2010). 
HL-60 cell lines have extensively been used by our group and others to investigate the effect 
of different drug treatments. With adjunctive treatment, our results showed an increase in 
iNOS and eNOS with HL-60 cell line, investigating the cell cycle regulators, downstream 
of checkpoint kinase activation will have provided a greater insight into adjunctive 
treatment. Previous studies have reported that artemisinin markedly increases the degree of 
differentiation in HL-60 cells when combined with low doses of 1, α 25-dihydoxyvitamin 
D3 [1, 25-(OH) 2D3] or all-trans retinoic acid (all-trans RA) (Kim et al., 2003). This study 
showed by using 10µM of artemisinin alone, artemisinin presented weak effects in terms of 
differentiation in HL-60 cells where ERK inhibitors were shown to block this effect. 
The artemisinin’s are currently undergoing widespread investigation as potential 
chemotherapeutic agents to be used in the treatment of a variety of cancers. They are known 
to generally inhibit tumour growth, induce growth cycle arrest, promote apoptosis, negate 
angiogenesis and prevent tissue invasion and metastasis (Crespo-Ortiz and Wei, 2012; Ho 
et al., 2014). Our results show artemisinin exerts additive or synergistic effects on HL-60 
viability which agrees with previous research.  
In contrast to presently prescribed anthracyclines, clinical toxicology studies involving 
malaria patients, where the artemisinins have been extensively researched, have shown 
minimal side effects and resistance has been observed, although some presented slight 
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neurotoxicity (Efferth & Kaina, 2010; Liang and Albrecht, 2003; Dondorp et al., 2010; 
McGready et al., 2012). 
Clinical trials have reported that use of the iron-chelating dexrazoxane, a cardioprotective 
agent, will effectively prevent the cumulative anthracyline induced cardiotoxicity from 
doxorubicin and epirubicin treatment in patients with metastatic or advanced breast cancer 
(Minotti et al., 2001). Minotti et al. (2001) have documented that changes in iron 
homeostasis are major players in cardiotoxicity induced by doxorubicin, leading to the 
generation of by-products such as the secondary alcohol doxorubicinol or ROS, which act 
independently or as part of the same mechanism. Doxorubicinol and ROS have both been 
shown to contribute to cardiotoxicity by inactivating iron regulatory proteins (IRP) and 
altering the function of cytoplasmic aconitase/IRP-1, leading to the accumulation of excess 
iron within the cells. Excess iron undoubtedly causes a cluster formation of IRP-1 in cells, 
which generates null proteins that prevents miRNA binding, leading to a switch to aconitase. 
This prevents iron uptake for normal metabolic use and also prevents iron homeostasis, 
which induces the severe cardiotoxicity observed in treatment (Minotti et al., 2001). 
For this reason, dexrazoxane, despite being a cardioprotective agent, is now contraindicated 
in children and young adolescents, as it causes severe myelosuppression and serious 
infection (Schwartz et al., 2009). Its use has been limited to adults with advanced or 
metastatic breast cancer who have previously received a minimum cumulative dose of 300 
mg/m2 doxorubicin or 540 mg/m2 epirubicin (Schwartz et al., 2009; Swain et al., 1997). As 
such, deferasirox is unable to provide cardioprotection against anthracycline-induced 
cardiotoxicity (Simunek et al., 2009). Although several agents have been identified to be 
cardioprotective against doxorubicin-induced cardiotoxicity, such as the beta-blocker 
carvedilol (Carreira et al., 2006), curcumin (Srivastava and Mehta, 2009), flavonoids (Bast 
et al., 2007), erythropoietin (Kim et al., 2008), antioxidants (Koti et al., 2008) and many 
others, the molecular pathogenesis of anthracycline cardiotoxicity remains highly 
controversial, making the possible effectiveness of the anthracycline cardioprotective agent 
complex highly debatable depending on the nature of the compound. Many anthracyclines 
may promote the formation of ROS through redox cycling of their aglycones. These free 
radicals can also cause lipid peroxidation which can lead to cell damage (Banfi et al., 1992). 
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Doxorubicin induced ROS which is found to activate cell death pathways which explains 
doxorubicin induced cardiotoxicity in cardiomyocytes (Montaigne et al., 2012; Sawyer et 
al., 2010). Elbaky et al. (2010) co-administered simvastatin with doxorubicin in a 
cardiovascular rat model and demonstrated that simvastatin protects against myocardial 
injury and decreases doxorubicin induced stress. With decades of research, artemisinin has 
shown much promise, with reports showing very minimal or no side effects with its clinical 
use, especially in the malaria setting, where there are tight measures to contain artemisinin 
resistance in malaria endemic areas (Nakase et al., 2008; WH0 2011). Therefore, there is a 
great potential in developing arteminin as a cardioprotective agent against doxorubicin 
induced cardiotoxicity. There is also evidence that the antitumour effect of certain cancer 
chemotherapy agents may be augmented by the presence of nitric oxide (Wink et al., 1991). 
Nitric oxide can therefore enhance the effect of doxorubicin, and with artemisinin shown in 
chapter 5 to generate nitric oxide via eNOS. The synergistic anticancer activity may be 
enhanced by using the combination of artemisinin and doxorubicin in cancer treatment. 
 
Based on the results from the studies above, we have successfully established that by using 
the inhibitors of nitric oxides (L-NAME and aminoguanidine), we can now suggest  that 
artemisinin’s reversal of doxorubicin induced cardiotoxicity in the H/R setting may be 
associated with the nitric oxide cell survival siganalling pathway. This pathway is a known 
cardioprotective pathway (Heusch et al., 2008; Wang et al., 2008) and one that can be 
attributed to artemisinin’s cardioprotection in our previous chapter. This finding allows us 
to implicate nitric oxide involvement in cardioprotection. Previous studies have howerever 
established in HL-60 cells the involvement of ERK in their differentiation to granulocytic 
and monocytic lineage known as MAPK in HL-60 and NB4 cells (Kim et al., 2003) 
 
Furthermore findings from this study have suggested a dual role for artemisinin in 
cardiomyocytes as well as in HL-60 cell, both involving nitric oxide pathway. However, 
further studies could investigate the effect of iNOS and eNOS expression on HL-60 cells 
using FACS analysis. The study proposes artemisinin has powerful cardioprotective effect 
against I/R injury and doxorubicin induced cardiomyopathy in a variety of settings, as well 
as artemisinin being a potent cytotoxic agent against HL-60 cells with both effects 
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implicating the nitric oxide synthase pathway. Previous studies have implicated nitric oxide 
in mediating anti-hypertrophic effects, with artemisinin showing anti-hypertrophy in a dose-
dependent manner in cardiomyocytes (Wollert et al., 2002; Xiong et al., 2010). Kukreja 
(2007) similarly showed using a cardioprotective agent against I/R, doxorubicin induced 
cardiomyopathy and anti-hypertensive effect was induced by the chronic nitric oxide 
synthase pathway in animals which agrees with our findings in isolated perfused hearts and 
cardiomyocytes. 
 
We can therefore suggest artemisinin’s profound anti-cancer activity to be via the mediation 
of nitric oxide in HL-60 cells. This study showed promising cytotoxicity using artemisinin 
treatment against HL-60 cells. This is supported by research by Aldieri et al. (2003) who 
showed artemisinin inhibited nitric oxide synthesis in cytokine-stimulated human 
astrocytoma T67 cells and activated the nuclear factor NF-kB (Aldieri et al., 2003). A study 
has suggested that artemisinin is responsible for the cytotoxic effects in HL-60 cells by the 
release of the highly alkylating carbon-centered radicals and ROS (Uysal, Sahna, Ozguler, 
Burma, & Ilhan, 2014) which causes cellular necrosis in HL-60 cells. Another study 
suggested artemisinin is a possible treatment in leukaemic disease as shown by their 
promising results (Kim et al., 2003). Tumour cells are more prone to ROS damage as they 
exhibit very low expression of antioxidant enzymes such as superoxide dismutase, 
glutathione peroxidase, catalase as compared to the function and damage done in normal 
cells. Hence, increasing oxidative stress to allow an antitumor mechanism to become active 
is common in the anticancer medication procedures. Furthermore we have shown upon 
addition of doxorubicin, artemisinin’s mediated protection against I/R and doxorubicin 
induced injury as well as its combined cytotoxicity implicate the nitric oxide pathway as 
summarised in the schematic representation in Figure 61. 
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Figure 61: Hypothetical schematic representation of the adjunctive therapy using artemisinin and 
doxorubicin in isolated cardiomyocytes and isolated perfused heart subjected to HR injury and I/R respectively 
via the downstream targets of PI3K-Akt kinase cascade, Nitric oxide. Administering Artemisinin (4.3µM)and 
doxorubicin (1µM) at reperfusion initiated cardioprotection by protecting against reperfusion-induced cell 
death in cardiomyocytes. The scheme portrays the important anti-apoptotic mechanisms that have been 
implicated in mediating cellular survival associated with the recruitment of nitric oxide shown to reverse the 
activation of caspases and increase nitrite and nitrate production. Doxorubicin (1µM) and artemisinin 
(0.4mM) nearly doubled doxorubicin cytotoxicity in HL-60 cell line. 
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6.5 CONCLUSION  
We have successfully shown, by co-administering artemisinin and doxorubicin at 
reperfusion, that artemisinin attenuates and protects against both I/R injury and doxorubicin-
induced injury in isolated perfused rat hearts in a nitric oxide dependent manner. Co-treating 
the isolated cardiomyocytes with artemisinin and doxorubicin reversed the H/R and 
doxorubicin induced injury decreased the levels of cleaved caspase 3 compared to the H/R 
control group. Artemisinin was shown to confer protection via activation of nitric oxide 
synthase pathways in both the I/R setting as well as in H/R setting shown to upregulates p-
eNOS protein significantly compared with time matched controls. Nitric oxide was also 
generated via iNOS expression with artemisinin treatment. 
  
Additionallly, this study investigated the effect of artemisinin alone in HL-60 cancer cells 
and upon co-treating with doxorubicin in HL-60 cells and in cardiomyocytes. Artemisinin 
was shown to confer protection in the isolated perfused heart model and in isolated 
cardiomyocytes subjected to H/R injury and doxorubicin induced injury. Cleaved caspase-
3 levels were shown to decrease and cellular viability to improve. Co-treatment with L-
NAME and aminoguanidine implicated the nitric oxide pathway in cardioprotection. In HL-
60 cells, we also achieved treatment efficacy in terms of cytotoxicity using artemisinin as 
an adjuvant to doxorubicin without compromising on doxorubicin’s effectiveness against 
HL-60 cells. In the process, we established that artemisinin and doxorubicin administered 
together present an enhanced cytotoxicity in a nitric oxide dependent manner. We also found 
that by administering the two together doubled artemisinins cytotoxicity while implicating 
the nitric oxide pathway in HL-60 cells. 
The result from this study demonstrated the value of adjuvant treatment and identified that 
artemisinin augments the cytotoxicity of doxorubicin in HL-60 cells. The study also 
provided valuable information about the cell signalling pathway involved in co-
administering artemisinin and doxorubicin in cardiomyocytes and in HL-60 cells which is 
suggested to occur via a nitric oxide dependent manner. The use of artemisinin as an 
adjuvant regimen to doxorubicin treatment although warrants further investigation shows a 
new opportunity to enhance the effectiveness of doxorubicin treatment in cancer treatment.
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Chapter 7 
7 GENERAL DISCUSSION 
7.1 DISCUSSION 
Summary of main findings 
In this study we have shown that: 
• Treatment with artemisinin resulted in a decrease myocardial infarction, increase 
in cellular viability, decrease in levels of cleaved caspase-3 in isolated perfused 
hearts and isolated cardiomyocytes subjected to I/R and H/R respectively. 
• Hearts treated with artemisinin showed a decrease in the expression of miRNA 
associated with apoptosis and myocardial injury. 
• Artemisinin limits myocardial reperfusion injury via the recruitment of PI3K-Akt-
p70s6k/BAD cell survival pathway which may offer a novel strategy for 
cardioprotection in a clinical setting. 
• Artemisinin treatment led to an increase in the levels of iNOS and eNOS in 
isolated cardiomyocytes. This study implied the presence of eNOS may be 
associated with artemisinin’s protective effect against myocardial reperfusion 
injury. It furthermore associated the treatment with increase in nitrate and nitrite in 
a dose dependent manner thus implying the role of nitric oxide in the observed 
protection. 
• Artemisinin was shown to have profound anticancer activity against HL-60 cells. 
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• Co-treating artemisinin with doxorubicin showed artemisinin confers protection 
against I/R injury and doxorubicin induced injury in isolated perfused hearts in a 
nitric oxide dependent manner. 
• Combined treatment of artemisinin and doxorubicin showed a decrease in cleaved 
caspase 3 levels, improvement in cardiomyocytes viability and enhanced cytotoxic 
efficacy against HL-60 cells. Furthermore establishing the enhanced cytotoxicity is 
associated with nitric oxide pathway. 
• The findings generally suggest artemisinin is pro-apoptotic in HL-60 cells and 
anti-apoptotic in the myocardium which suggests the potential of artemisinin 
particularly in cancer patients with underlying comorbities such as IHD. 
• Findings also suggest artemisinin to be a promising remedy in combating a variety 
of diseases beyond malaria.  
Previous research has shown no evidence of cardiotoxicity with artemisinin or its 
derivatives when administered alone in antimalarial patients (Vugt et al., 1996; Gupta et al., 
2005). However, a controversial study recently published that by administering artesunate-
amodiaquine in the treatment of uncomplicated malaria, in a study involving Ghanian 
children, patients presented incidences of sinus bradycardia (Adjei et al., 2012). This was 
however concluded that the rhythmic disturbances may well be associated with amodiaquine 
rather than artesunate (Adjei et al., 2012). 
Several studies have confirmed artemisinin, which contains an endoperoxide bridge is the 
structure responsible for its mechanism of action in antimalarial treatment (Posner & O'Neill, 
2004). As well as being used as an antimalarial drug, artemisinin has a great potential in the 
treatment of several cancer types (Efferth et al., 2011). However in this thesis we focused 
on the effect of artemisinin in the myocardium, a popular off-target of drug toxicity. 
As described in previous chapters, upon reperfusing an occluded organ (after a transient 
period of ischaemia), reperfusion injury often occurs. This is described as one of the major 
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causes of damage to tissues (Uysal et al., 2014). During ischaemia, hearts also undergo 
inflammation of vascular tissues, oxidative damage, cellular apoptosis and necrosis leading 
to ischaemia reperfusion injury (Wang et al., 2007). There is a lot of recent developments 
in the field of oxidative stress research, highlighting the role of ROS, inflammation and I/R 
injury. Toxic oxidative reaction such as lipid peroxidation, inhibition of mitochondrial 
respiratory chain enzymes, inactivation of membrane sodium channels, and other oxidative 
modifications of proteins have been related to named pathophysiologies. Several novel 
findings have identified novel pharmacological agents such as peroxynitrite decomposition 
catalysts and selective superoxide dismutase mimetics (SODm) in shock, I/R, and 
inflammation. Treatment with peroxynitrite decomposition catalysts inhibits peroxynitrate 
while SODm selectively mimics the activity of the human superoxide dismutase enzymes. 
In vivo studies have been shown that this treatment helps to cellular energetic failure 
associated with shock, inflammation, and I/R injury. ROS has also previously been 
associated with initiating DNA single-strand breakage and activation of the nuclear enzyme 
poly (ADP-ribose) synthetase thus leading to severe energy depletion of the cells and 
necrotictype cell death. Treatment with antioxidant has been shown to inhibit the activation 
of poly(ADP-ribose) synthetase thus preventing organ injury associated with shock, 
inflammation, and I/R (Cuzzocrea et al., 2001). Studies like ours also show the potential of 
artemisinin as a pharmacological agent capable of salvaging cardiomyocytes subjected to 
I/R and H/R injury. The study ahs identified potenatial mechanisms of artemisinin mediated 
cardioprotection which will undoubtedly help in developing artemisinin as a potential 
treatment against I/R injury.  
This project investigated the effects of artemisinin treatment in stressed conditions. It also 
looked at the intracellular mechanism associated with the observed cardioprotective effect. 
Previous study by Gu et al. (2012) which supports the cardioprotective properties of 
artemsinin we have similar shown suggests that the protection observed is via the down 
regulation of NFkB pathway although the study failed to investigate the effect of artemisinin 
treated sham group which would have clearly elucidated the effects of artemisinin treatment 
thus making their results more convincing. Furthermore, studies by Purcell et al. (2001) and 
Gupta et al. (2002) suggest that the activation of the NFkB pathway is usually a causal effect 
in cardiac hypertrophy response (Gu et al., 2012).  
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 Several assays using cardiomyocytes were used for the screening of artemisinin in order 
to determine its mechanistic basis in cardiomyocytes such as MTT assay, cleaved-caspase-
3, nitric oxide assay and flow cytometric analysis. The effects on cell proliferation (in HL-
60 cells) was also investigated using MTT assay to investigate artemisinin’s direct cytotoxic 
effects against HL-60. Understanding of the intracellular signalling involved in artemisinin 
mediated cardioprotection will provide an insight and inform future development of non 
toxic cancer therapies. This project also, investigated the differential expression of some 
popular miRNA’s associated with I/R. We furthermore investigated the potential of 
administering artemisinin as an adjunct therapy to the cardiotoxic doxorubicin in isolated 
cardiomyocytes and HL-60 cancer cells. 
Our data showed a dose dependent decrease in infarct size which is consistent with Sun et 
al., (2007) who showed artemisinin at 10µM and 100µM alleviated myocardial injury in 
experimental Wistar rats which they believe may be associated with its functions of anti-
oxidation and scavenging of free radicals. The ability of artemisinin to alleviate the 
simulated I/R injury by attenuating and preventing cellular damage proves artemisinin is an 
agent with great potential. However, we also showed artemisinin improves myocytes 
viability as well as offers protection via an anti-apoptotic process. This study, further 
investigated the intracellular signalling pathways involved in this observed protection by 
co-administering inhibitors of PI3K pathway (wortmannin) and inhibitor of p70S6K 
(rapacymin) where both inhibitors abolished the observed protection thus suggesting the 
involvement of the PI3K-Akt-BAD/p70s6K pathway. Studies have previously shown, Akt 
in the mitochondria translocates to sites where it modulates signalling for either cell death 
or cell survival (Yang et al., 2009 and Abel and Doenst 2011).  
Our results show a significant increase in the level phosphorylated Akt with artemisinin 
treatment and a subsequent decrease was observed by co-administering artemisinin with the 
inhibitor of PI3k-Akt, wortmannin. This suggests the involvement of PI3k-Akt pathway of 
mediation in artemisinin’s cardioprotection. We also investigated the downstream targets of 
Akt such as BAD and p70S6K.  
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Using Western blotting and flow cytometric analysis, we confirmed that artemisinin 
protected the isolated perfused heart and the ventricular myocytes from the ischaemia 
reperfusion injury via the recruitment of PI3K-Akt-BAD/p70s6K cell survival pathway.  
It is well established in research that the activation of PI3K-Akt-BAD/p70s6K cell survival 
pathway is associated with the activation of other pro-survival factors (such as G-protein-
coupled receptor ligands, bradykinin) and inhibition of pro-apoptotic factors such as BAX, 
p53 which can be investigated in further studies (Li and Sato, 2001; Al khouri et al., 2005; 
Hausenloy and Yellon, 2004). Hausenloy and Yellon (2004) also showed signalling through 
PI3K-Akt-BAD pathway confers protection against I/R injury, through the activation of the 
serine–threonine kinase, Akt (Hausenloy and Yellon 2004) thus supporting our findings. 
Studies have confirmed the association of PI3K-Akt-p70s6K in cardioprotection in the past, 
in studies using pharmacological agents such as cordyceps which similarly has an anticancer, 
anti-inflammatory, and antioxidant function and was shown to alleviate myocardial I/R 
injury in Sprague Dawley rats (Park et al., 2014). The PI3K-Akt-p70s6K is well established 
as a cardioprotective pathway as previously described. 
We also investigated another downstream target of PI3K pathway, nitric oxide and found 
artemisinin attenuates I/R injury via the upregulation of eNOS. There is overwhelming 
evidence that shows nitric oxide is an important cardioprotective molecule due to its 
vasodilator, antioxidant, antiplatelet, and anti-neutrophil actions making it essential for 
normal cellular homeostasis (Ferdinandy 2006). 
Myocardial function remained relatively stable in both our ischaemic and normoxic model. 
The IC50 used in a previous study by Hara et al., (2007) which was 30µM (nearly 15 times 
higher than the normal plasma concentration used in a clinical setting for antimalarial 
treatment which is 2.1µM after an oral administration of 500mg) (Alin et al.,1996) 
expressed anticholinergic toxicities. The possible anti cholinergic toxicities that maybe 
observed with the use of artemisinin may only be evident at a concentration 15 times the 
plasma concentration presently administered according to the aforementioned study. This 
further suggests artemisinin at lower concentrations and at clinical concentrations will not 
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influence heart function. Other studies have also verified the influence of artemisinin in the 
heart may only appear at doses higher than normal plasma concentrations. 
Artemisinin in the heart counteracts the apoptotic effect induced by H/R injury enabling less 
myocytes to be committed to apoptosis. Our results implied the process is mediated by the 
joint effect of the phosphorylation of Akt in the cardiac cells as well as the suppression of 
caspase-3 activation. Experimental studies have shown that by administering 
cardioprotective agents such as erythropoietin (shown to be anti-apoptotic), PI3K-γ/δ 
inhibitors (shown to be anti-inflammatory), intracoronary aqueous oxygen, and ischaemic 
post condiitoning (shown to be anti-apoptotic and anti-inflammatory) have shown 
promising results of limiting acute myocardial infarction. An acute therapeutic window is 
also reported to exist in patients with STEMI whereby administering a pharmacological 
intervention few hours after PPCI procedure might provide an additional therapeutic 
window to target late into the reperfusion phase (Hausenloy and Yellon, 2013). This may be 
a great investigational area of interest whereby artemisinin can be studies and developed as 
a novel treatment to limit myorcardial injury.  
Cleaved caspase-3, is also a pivotal effector caspase in apoptotic signalling which has been 
associated with I/R and cellular damage leading to apoptosis (Sakamaki and Satou 2009; Lu 
and Chen 2011). Artemisinin administered during re-oxygenation also showed 
improvement in the viability of isolated ventricular myocytes and it was able to decrease a 
cleaved caspase-3 activity in the isolated perfused heart. This is indicative of the potential 
of artemisinin to salvage H/R induced injured adult ventricular myocytes and suggest the 
action artemisinin’s action is via anti-apoptotic mechanisms. Artemisinin in cancer cells also 
creates free radicals that are carbon-centered and this may facilitate lysosomal disturbance 
and generate ROS which results in mitochondrial impairment, activation of caspases, and 
cell death (Wang et al., 2007). In the mitochondrion, these adducts interfere with the 
electron transfer chain (ETC) by interacting with heme or heme-bound proteins leading to 
generation of ROS and apoptosis (Uysal et al., 2014). 
A recent study has confirmed the generation of ROS in artesunate-treated HL-60 cells after 
16hrs of treatment suggesting the mechanism of artemisinin induced damage in cancer cells 
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(Uysal et al., 2014). This study also showed administering artemisinin reverses the 
doxorubicin induced toxicity by decreasing the infarct sizes in isolated perfused rat hearts 
subjected to I/R injury and in cardiomyocytes.  
In the MTT assay using HL-60 cancer cells, artemisinin expressed profound cytotoxicity 
due to its ability to react with iron in cancer cells to form free radicals (Lai et al., 2005). In 
most of the systems, artemisinin’s cytotoxicity is often aggravated by the cancer cells that 
have an exaggerated iron expression which increases artemisinin’s activity around 100-fold 
compared to other normal cell lines, as we observed in our artemisinin treated HL-60 cancer 
cells compared to control (Posner and O’Neill, 2004). Cancer cells exhibit a rise in 
transferrin receptors (TfR) which are responsible for intracellular concentration levels and 
the uptake in iron levels in the system. The different levels of TfR in the cancer cells may 
be variable depending on the cell line (Lai et al., 2013). A theory suggested that iron-
activated artemisinin is responsible for the damage caused by the release of the highly 
alkylating carbon-centered radicals and ROS (Uysal et al., 2014). Tumor cells are more 
prone to ROS damage as they exhibit very low expression of antioxidant enzymes such as 
superoxide dismutase, glutathione peroxidase, catalase as compared to the function and 
damage done in normal cells (Uysal et al., 2014). 
The drug concentrations which are required to produce damage in cancer cells are often 
higher than the amounts required to induce toxicity in malaria parasites. As we have shown 
in our study also the concentration required to be protective in cardiomyocytes is 100 fold 
less than in cancer cells. Artemisinin, artemether, DHA and artesunate exhibit IC50s (fifty 
percent inhibitory concentration) up to 15 nM in malaria parasites. Microscopy analyses in 
artesunate-treated cells have displayed early oncosis-like morphological changes which 
activate the ROS generation in the subcellular structures (Uysal et al., 2014). 
In spite of the growing indication of the damage affected by ROS system in many cells, cell 
damage is also related with oxidative stress. The novel artemisinin dimers are able to incur 
damage in the cancer cells without being dependent on the generation of ROS, however, the 
underlying mechanism of cytotoxicity is another matter. It is also not proven whether 
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artemisinin’s-induced cell death may or may not be a ROS-independent mechanism of the 
death of cancer cells. 
Doxorubicin was shown to cause cardiac injury and increased the infarct size in both during 
ischaemia/reperfusion injury and in naive conditions. Studies have also associated 
doxorubicin with adverse cardiac effects, including progressive heart failure and 
cardiomyopathy (Gharanei et al., 2013). Artemisinin was used as an adjunctive therapeutic 
agent which reverses doxorubicin induced injury in ischaemia reperfusion setting. In 
addition to this findings, our study showed by administering the adjunctive treatment, data 
showed a profound anti-cancer effect (nearly doubling their individual cytotoxic effect). 
Results also showed this effect is in a nitric oxide dependent manner. Previous studies have 
implicated Nitric oxide in preventing cancer metastasis and inhibition of cell adhesion 
molecules (CAMs) (Efferth et al., 2011). 
In our miRNA study, we investigated the miRNA expression changes in response to 
treatment with artemisinin. Despite artemisinin showing protection in animal studies, 
artemisinin needs to be fully studied in clinical trial setting and the development of miRNAs 
as reliable biomarkers for early assessment of potential drug induced cardiotoxicity 
especially in patients with comorbidities or at risk of developing cardiac myopathies is 
highly important. As this could allow the detection of subclinical cardiac injury (Sandhu 
and Maddock 2014). 
Furthermore, this study showed that artemisinin alleviated I/R injury and doxorubicin 
induced cardiotoxicity in isolated perfused hearts, doxorubicin decreased haemodynamic 
functions and increased infarct to risk ratio in I/R tissue which artemisinin was shown to 
reverse. This study has also showed that artemisinin has a dose dependent decrease in I/R 
and improves viability in the MTT assay shown as an increase in nitric oxide synthesis via 
p-eNOS and iNOS synthesis with adjunctive treatment. High levels of nitric oxide produced 
via eNOS synthesis are well established as cardioprotective where studies in the past have 
implicated the PI3K-eNOS pathway in protection as show in our study (Bell and Yellon 
2002). Other studies have also shown low levels of nitric oxide generated via iNOS 
P a g e  | 211 
synthesis may present cardioprotection (Cole et al., 2006). Both studies although contrasting 
in view support our findings. 
7.2 STUDY LIMITATIONS/FUTHER SUGGESTIONS 
In the current study we observed some effects on haemodynamic function of the heart 
following artemisinin and doxorubicin administration. However, it will be worth 
investigating the effect of reduction in function. The langendorff model itself exposes the 
excised heart to several vulnerabilities such as injury due to instrumentation although 
accounted for by the control hearts which could also increase the possibility of 
preconditioning due to cannulation of the heart. Research has shown that generation of free 
radicals in ischaemic heart diseases have a akinetic effect on the heart muscle, there is a 
limitation and discrepancy in findings in a controlled environment (laboratory) and that 
found in clinical trials and upon administration in clinics. 
Speculations have also been made about reaching a therapeutic ceiling with current 
reperfusion treatment. Reperfusion has been shown to limit infarct size by approximately 
50%, in a review by Miura and Miki (2008) using a consensus of over 10 studies reported 
patients showed more than 75% infarction despite coronary reperfusion suggesting 
mortality and morbidity is increased when more than 20% of the left ventricle is infarcted 
thus suggesting effective reperfusion treatment has to reduce infarction to below the 20% 
target (Miura and Miki 2008). However, with research by Hausenloy and colleagues which 
suggested ,a mediator pathway that is activated in reperfusion, have revealed in their study 
that cardioprotection occur as a result of remote preconditioning by inhibiting transition 
pores at reperfusion however, half of the dead cells were killed by transition pores in early 
reperfusion (Zhoa et al., 2003). Many strategies for activating preconditioning have been 
developed based on this and using several off patent compounds such as GSK blockers, 
erythropoietin, cyclosporine A, nitric oxide donors and so on. This in my opinion is because 
there is very little interest in cardioprotectants by the big pharmaceutical companies due to 
several failed trials and too many off patent compounds leaving the larger trails to be 
government sponsored such as the cyclosporine A trail by Ovize et al (2011). In a review by 
King (2010), he reported Ovize et al (2011) had shown that infarct size in patient undergoing 
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reperfusion therapy alone was strongly correlated with risk zone which we evaluated in our 
study. Identifying the risk can easily identify the 25% that needs treatment (Piot et al., 2008). 
Animal models respond well to preconditioning based interventions but whether the lack of 
a clear end point as shown in experimental studies will limit the development remains a 
concern (Piot et al., 2008). 
Large scale clinical trials such as the AMISTAD I have produced positive results via 
subgroup analysis whereas applying the same analysis to a larger trails AMISTAD II failed 
to show similar results (Ross et al., 2005) this raises concerns of reproducibility and clinical 
trials often not as robust as experimental studies those questioning the suitability in clinical 
appications.  
UO126 should be used in further study to identify whether the increase in the p42/p44 extra-
cellular signal-regulated kinases (ERK 1/2) protein levels thus investigating both branches 
of the RISK pathway for possible association. ERK 1/2 is also known to confer powerful 
cardioprotective responses. These two pathways (PI3K-Akt and Erk 1/2) can however either 
work together or independently and at the moment is outside the scope of our research. 
Myocardial I/R injury is undoubtedly a multifactorial phenomenon resulting in damage 
inflicted on the myocardium. This is shown to range from atherosclerotic plaque rupturing, 
formation of plugins in the microcirculation upon restoring blood flow across the obstructed 
site, neutrophil aggregation, tissue oedema and more. The therapies being used include 
mechanical opening of the vessel followed by pharmacological intervention such as 
adjuvant use of anti coagulants in reducing ischaemic injury and therapies aimed at limiting 
the extent of necrosis have proven quite successful in limiting ischeamic injury (Ibáñez et 
al., 2015). The time has come to focus on therapies to reduce reperfusion injury, few studies 
have been relatively successful, we proposed the use of pharmacological agents such as 
artemisinin shown to have multiple effects such as anti inflammatory effects in addition to 
the previously discussed might be a viable way of reducing infiltration of myocardial tissue 
by inflammatory cells which is known to induce an additional damage to the myocardium. 
However, until sufficiently reviewed, artemisinin remains a potential therapy requiring 
development in the filed of I/R. 
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Although no unfavourable effects were observed with artemisinin treatment, additional 
experiments with various treatment timings are desirable. The effect of continuous 
administration is similarly as important as using different dosages as we did in the present 
study. In order to increase the impact of this study, using an aged population where 
comorbidities are more likely to occur will significantly enhance the impact.  
Furthermore, artemisinin in malarial treatment has been shown to involve the parasites 
mitochondria where it causing dysfunction and eventually death due to mitochondrial 
mediation. Investigating mPTP in cardiomyocytes woud have provided a better insight into 
our study as they may be changes in the respiratory chain depolarization of the 
mitochondrial membrane or from the prevention of ROS generation and calcium uptake in 
cells however investigating nitric oxide via mPTP is problematic due to the ubiquitous role 
of nitric oxide and the fact that the mitochondria appear to be a target for nitric oxide-
mediated injury (Borutaite et al., 2000).  
7.3 CONCLUSION 
This study demonstrated the protective effects of artemisinin in stressed conditions such as 
I/R and/or doxorubicin induced injuries. To our knowledge this is the first study to elucidate 
the intracellular signalling involved in artemisinin’s cardioprotectiveness involves PI3K-
AKT-BAD/p70S6K in an ex vivo model of the myocardium subjected to I/R injury as well 
as the first study to implicate the generation of nitric oxide via eNOS and iNOS synthesis 
in artemisinin in cardiomyocytes. 
It also demonstrated that artemisinin can not only reverse I/R injury but also doxorubicin 
induced toxicity in isolated perfused hearts and isolated cardiomyocytes subjected to HR 
injury. Co-administration of artemisinin and doxorubicin also more than double the anti-
cancer effect of both drugs HL-60 cells. 
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